

WO04018428

Publication Title:

WO04018428

Abstract:

Abstract not available for WO04018428 Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018428 A1

(51) International Patent Classification⁷: **C07D 213/82**,
209/42, 405/12, 413/12, 401/12, 409/12, 417/12, 471/04,
231/14, A61P 31/00, A61K 31/415, 31/44, 31/4745, C07D
261/20, 413/04, 261/08, 261/10, 241/24, 333/38, 487/08,
495/04, 277/68, 279/02

(US). NORTHUIS, JILL, M. [US/US]; 10420 Roger Street,
Portage, MI 49002 (US).

(21) International Application Number:

PCT/US2003/024796

(74) Agent: O'BRIEN, Jonathan, P.; Global Intellectual Prop-
erty, Pharmacia & Upjohn Company, 301 Henrietta Street,
Kalamazoo, MI 49001 (US).

(22) International Filing Date: 22 August 2003 (22.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:

60/405,429 23 August 2002 (23.08.2002) US
60/430,592 3 December 2002 (03.12.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PHAR-
MACIA & UPJOHN COMPANY [US/US]; 301 Henri-
etta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): THORARENSEN,
Atli [IS/US]; 5657 W. Heverly, Portage, MI 49024 (US).
RUBLE, Craig, J. [US/US]; 56881 County Road 653,
Paw Paw, MI 49079 (US). FISHER, Jed, F. [US/US];
3517 Old Colony Road, Kalamazoo, MI 49008-2913 (US).
ROMERO, Donna, L. [US/US]; 6629 Morningstar Way,
Kalamazoo, MI 49009 (US). BEAUCHAMP, Thomas,
J. [US/US]; 7277 Leawood Street, Portage, MI 49024

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTIBACTERIAL BENZOIC ACID DERIVATIVES

(57) Abstract: The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

WO 2004/018428 A1

ANTIBACTERIAL BENZOIC ACID DERIVATIVES

FIELD OF THE INVENTION

The present invention relates to antibacterial agents that are useful for
5 sterilization, sanitation, antisepsis, and disinfection.

BACKGROUND

The inappropriate growth of a variety of bacteria has been a problem for many
years. Bacteria have caused degradation of natural product materials, infection in
10 humans and other animals, and spoilage of foods.

Sterilization denotes the use of either physical or chemical agents to eliminate
all viable bacteria from a material, while disinfection generally refers to the use of
germicidal chemical agents to destroy the potential infectivity of a material. Sanitizing
refers to procedures used to simply lower the bacterial content of utensils used for
15 food. Antisepsis refers to the topical application of chemicals to a body surface to kill
or inhibit pathogenic microbes. Disinfectants are widely used for skin antisepsis in
preparation for surgery.

Bacteria are the smallest organisms that contain all the machinery required for
growth and self-replication. A bacterium includes a rigid cell wall surrounding the
20 cytoplasmic membrane, which itself encloses a single naked chromosome without a
nuclear membrane. The cytoplasmic membrane consists primarily of a bi-layer of lipid
molecules.


The fundamental criterion of bactericidal action is loss of the ability of the
organism to propagate indefinitely, when placed in a suitable environment.
25 Bactericidal action suggests microbe damage of various types, including the triggering
of irreversible damage to the cytoplasmic cell membrane or irreversible impairment of
the DNA (or viral RNA replication. Accordingly, sterilization is not identical with
destruction of microbes. Additionally, it is understood that damage to nucleic acids
(DNA or RNA) is not always irreversible, as it is known that ultraviolet light-induced
30 damage to viral nucleic acids can be repaired by enzymatic and genetic mechanisms.

SUMMARY OF THE INVENTION

The invention relates to antibacterial agents that are useful for sterilization,
sanitation, antisepsis, and disinfection.

In one aspect, the invention features methods of using antibacterial agents of formula I for sterilizing, sanitizing, antiseptis, or disinfecting. The method includes applying the antibacterial agent to a location in need of sterilization, sanitation, antiseptis, and disinfection.

5 In general, the antibacterial agents have the formula



wherein

10 X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group; and

15 R₄ is an optionally substituted HET.

DETAILED DESCRIPTION OF THE INVENTION

The term "halo" refers to a halogen atom selected from Cl, Br, I, and F.

20 The term "alkyl" refers to both straight- and branched-chain moieties. Unless otherwise specifically stated alkyl moieties include between 1 and 9 carbon atoms.

The term "alkenyl" refers to both straight- and branched-chain moieties containing at least one -C=C-. Unless otherwise specifically stated alkenyl moieties include between 1 and 9 carbon atoms.

25 The term "alkynyl" refers to both straight- and branched-chain moieties containing at least one -C≡C-. Unless otherwise specifically stated alkynyl moieties include between 1 and 9 carbon atoms. between 1 and 6 carbon atoms

The term "alkoxy" refers to -O-alkyl groups.

The term "cycloalkyl" refers to a cyclic alkyl moiety. Unless otherwise specifically stated cycloalkyl moieties will include between 3 and 9 carbon atoms.

The term "cycloalkenyl" refers to a cyclic alkenyl moiety. Unless otherwise specifically stated cycloalkyl moieties will include between 3 and 9 carbon atoms and at least one $-C=C-$ group within the cyclic ring.

The term "amino" refers to $-NH_2$.

5 The term "aryl" refers to phenyl and naphthyl.

The term "het" refers to mono- or bi-cyclic ring systems containing at least one heteroatom selected from O, S, and N. Each mono-cyclic ring may be aromatic, saturated, or partially unsaturated. A bi-cyclic ring system may include a mono-cyclic ring containing at least one heteroatom fused with an cycloalkyl or aryl group. A bi-
10 cyclic ring system may also include a mono-cyclic ring containing at least one heteroatom fused with another het, mono-cyclic ring system.

Examples of "het" include, but are not limited to, pyridine, thiophene, furan, pyrazoline, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl,
15 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 1,2,3-oxathiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl,
20 1,2,3-oxathiazole-1-oxide, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 3-oxo-1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-1,3,4-thiadiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-5-yl, 5-oxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1,3,4-oxadiazole, 4-oxo-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, thiazolodione, 1,2,3,4-thiatriazole, 1,2,4-dithiazolone, phthalimide, quinoliny, morpholiny, benzoxazolyl,
25 diaziny, triaziny, quinoliny, quinoxaliny, naphthyridiny, azetidiny, pyrrolidiny, hydantoinyl, oxathiolanyl, dioxolanyl, imidazolidiny, and azabicyclo[2.2.1]heptyl.

The term "heteroaryl" refers to a mono- or bicyclic het in which at least one cyclic ring is aromatic.

30 The term "substituted alkyl" refers to an alkyl moiety including 1-4 substituents selected from halo, het, cycloalkyl, cycloalkenyl, aryl, $-OQ_{10}$, $-SQ_{10}$, $-S(O)_2Q_{10}$, $-S(O)Q_{10}$, $-OS(O)_2Q_{10}$, $-C(=NQ_{10})Q_{10}$, $-C(=N-O-Q_{10})Q_{10}$, $-S(O)_2-N=S(O)(Q_{10})_2$, $-S(O)_2-N=S(Q_{10})_2$, $-NQ_{10}Q_{10}$, $-C(O)Q_{10}$, $-C(S)Q_{10}$, $-C(O)OQ_{10}$, $-OC(O)Q_{10}$,

-C(S)NQ₁₀Q₁₀, -N(Q₁₀)C(S)NQ₁₀Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀,
 -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀,
 -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, and -SNQ₁₀Q₁₀.

Each of the het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-

5 4 substituents independently selected from halo and Q₁₅.

The term "substituted aryl" refers to an aryl moiety having 1-3 substituents selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀,

10 -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, -NQ₁₀C(O)Q₁₀, -N(Q₁₀)C(S)NQ₁₀Q₁₀, -N(Q₁₀)C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, alkenyl, alkynyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, and aryl being optionally substituted
 15 with 1-3 substituents selected from halo and Q₁₅.

The term "substituted het" refers to a het moiety including 1-4 substituents selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀,
 20 -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

25 The term "substituted alkenyl" refers to a alkenyl moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀,
 30 -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

The term "substituted alkoxy" refers to an alkoxy moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀,
 5 -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

10 The term "substituted cycloalkenyl" refers to a cycloalkenyl moiety including 1-3 substituents -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)Q₁₀,
 15 -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

The term "substituted amino" refers to an amino moiety in which one or both
 20 of the amino hydrogens are replaced with a group selected from -OQ₁₀, -SQ₁₀, -S(O)₂Q₁₀, -S(O)Q₁₀, -OS(O)₂Q₁₀, -C(=NQ₁₀)Q₁₀, -C(=NOQ₁₀)Q₁₀, -S(O)₂-N=S(O)(Q₁₀)₂, -S(O)₂-N=S(Q₁₀)₂, -NQ₁₀Q₁₀, -C(O)Q₁₀, -C(S)Q₁₀, -C(O)OQ₁₀, -OC(O)Q₁₀, -C(O)NQ₁₀Q₁₀, -C(S)NQ₁₀Q₁₀, -C(O)C(Q₁₆)₂OC(O)Q₁₀, -CN, =O, =S, -NQ₁₀C(O)Q₁₀,
 25 -NQ₁₀C(S)Q₁₀, -NQ₁₀C(O)NQ₁₀Q₁₀, -NQ₁₀C(S)NQ₁₀Q₁₀, -S(O)₂NQ₁₀Q₁₀, -NQ₁₀S(O)₂Q₁₀, -NQ₁₀S(O)Q₁₀, -NQ₁₀SQ₁₀, -NO₂, -SNQ₁₀Q₁₀, alkyl, substituted alkyl, het, halo, cycloalkyl, cycloalkenyl, and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₅.

Each Q₁₀ is independently selected from -H, alkyl, cycloalkyl, het, cycloalkenyl,
 30 and aryl. The het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substituents selected from halo and Q₁₃.

Each Q_{11} is independently selected from -H, halo, alkyl, aryl, cycloalkyl, and het. The alkyl, aryl, cycloalkyl, and het being optionally substituted with 1-3 substituents independently selected from halo, $-\text{NO}_2$, $-\text{CN}$, $=\text{S}$, $=\text{O}$, and Q_{14} .

Each Q_{13} is independently selected from Q_{11} , $-\text{O}Q_{11}$, $-\text{SQ}_{11}$, $-\text{S}(\text{O})_2Q_{11}$,
 5 $-\text{S}(\text{O})Q_{11}$, $-\text{OS}(\text{O})_2Q_{11}$, $-\text{C}(=\text{NQ}_{11})Q_{11}$, $-\text{S}(\text{O})_2\text{N}=\text{S}(\text{O})(Q_{11})_2$, $-\text{S}(\text{O})_2\text{N}=\text{S}(Q_{11})_2$,
 $-\text{SC}(\text{O})Q_{11}$, $-\text{NQ}_{11}Q_{11}$, $-\text{C}(\text{O})Q_{11}$, $-\text{C}(\text{S})Q_{11}$, $-\text{C}(\text{O})\text{O}Q_{11}$, $-\text{OC}(\text{O})Q_{11}$, $-\text{C}(\text{O})\text{NQ}_{11}Q_{11}$,
 $-\text{C}(\text{S})\text{NQ}_{11}Q_{11}$, $-\text{C}(\text{O})\text{C}(Q_{16})_2\text{OC}(\text{O})Q_{10}$, $-\text{CN}$, $=\text{O}$, $=\text{S}$, $-\text{NQ}_{11}\text{C}(\text{O})Q_{11}$, $-\text{NQ}_{11}\text{C}(\text{S})Q_{11}$,
 $-\text{NQ}_{11}\text{C}(\text{O})\text{NQ}_{11}Q_{11}$, $-\text{NQ}_{11}\text{C}(\text{S})\text{NQ}_{11}Q_{11}$, $-\text{S}(\text{O})_2\text{NQ}_{11}Q_{11}$, $-\text{NQ}_{11}\text{S}(\text{O})_2Q_{11}$,
 $-\text{NQ}_{11}\text{S}(\text{O})Q_{11}$, $-\text{NQ}_{11}\text{SQ}_{11}$, $-\text{NO}_2$, and $-\text{SNQ}_{11}Q_{11}$.

Each Q_{14} is -H or a substituent selected from alkyl, cycloalkyl, phenyl, or
 naphthyl, each optionally substituted with 1-4 substituents independently selected from
 $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O}Q_{16}$, $-\text{SQ}_{16}$, $-\text{S}(\text{O})_2Q_{16}$, $-\text{S}(\text{O})Q_{16}$, $-\text{OS}(\text{O})_2Q_{16}$, $-\text{NQ}_{16}Q_{16}$, $-\text{C}(\text{O})Q_{16}$,
 $-\text{C}(\text{S})Q_{16}$, $-\text{C}(\text{O})\text{O}Q_{16}$, $-\text{NO}_2$, $-\text{C}(\text{O})\text{NQ}_{16}Q_{16}$, $-\text{C}(\text{S})\text{NQ}_{16}Q_{16}$, $-\text{CN}$, $-\text{NQ}_{16}\text{C}(\text{O})Q_{16}$,
 $-\text{NQ}_{16}\text{C}(\text{S})Q_{16}$, $-\text{NQ}_{16}\text{C}(\text{O})\text{NQ}_{16}Q_{16}$, $-\text{NQ}_{16}\text{C}(\text{S})\text{NQ}_{16}Q_{16}$, $-\text{S}(\text{O})_2\text{NQ}_{16}Q_{16}$, and
 15 $-\text{NQ}_{16}\text{S}(\text{O})_2Q_{16}$. The alkyl, cycloalkyl, and cycloalkenyl being further optionally
 substituted with $=\text{O}$ or $=\text{S}$.

Each Q_{15} is H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or
 naphthyl, each optionally substituted with 1-4 substituents independently selected from
 $-\text{F}$,
 20 $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O}Q_{16}$, $-\text{SQ}_{16}$, $-\text{S}(\text{O})_2Q_{16}$, $-\text{S}(\text{O})Q_{16}$, $-\text{OS}(\text{O})_2Q_{16}$, $-\text{C}(=\text{NQ}_{16})Q_{16}$,
 $-\text{S}(\text{O})_2\text{N}=\text{S}(\text{O})(Q_{16})_2$, $-\text{S}(\text{O})_2\text{N}=\text{S}(Q_{16})_2$, $-\text{SC}(\text{O})Q_{16}$, $-\text{NQ}_{16}Q_{16}$, $-\text{C}(\text{O})Q_{16}$, $-\text{C}(\text{S})Q_{16}$,
 $-\text{C}(\text{O})\text{O}Q_{16}$, $-\text{OC}(\text{O})Q_{16}$, $-\text{C}(\text{O})\text{NQ}_{16}Q_{16}$, $-\text{C}(\text{S})\text{NQ}_{16}Q_{16}$, $-\text{C}(\text{O})\text{C}(Q_{16})_2\text{OC}(\text{O})Q_{16}$, $-\text{CN}$,
 $-\text{NQ}_{16}\text{C}(\text{O})Q_{16}$, $-\text{NQ}_{16}\text{C}(\text{S})Q_{16}$, $-\text{NQ}_{16}\text{C}(\text{O})\text{NQ}_{16}Q_{16}$, $-\text{NQ}_{16}\text{C}(\text{S})\text{NQ}_{16}Q_{16}$, -
 $\text{S}(\text{O})_2\text{NQ}_{16}Q_{16}$, $-\text{NQ}_{16}\text{S}(\text{O})_2Q_{16}$, $-\text{NQ}_{16}\text{S}(\text{O})Q_{16}$, $-\text{NQ}_{16}\text{SQ}_{16}$, $-\text{NO}_2$, and $-\text{SNQ}_{16}Q_{16}$.
 25 The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with $=\text{O}$ or
 $=\text{S}$.

Each Q_{16} is independently selected from -H, alkyl, and cycloalkyl. The alkyl
 and cycloalkyl optionally including 1-3 halos.

Mammal denotes human and animals.

Each Q_{17} is independently selected from -H, -OH, and alkyl optionally
 30 including 1-3 halos and -OH.

The term "electron withdrawing group" refers to the ability of a substituent to
 withdraw electrons relative to that of hydrogen if the hydrogen atom occupied the

same position on the molecule. The term "electron withdrawing group" is well understood by one skilled in the art and is discussed in Advanced Organic Chemistry by J. March, John Wiley & Sons, New York, New York, (1985) and the discussion therein is incorporated herein by reference. Electron withdrawing groups include, but are not limited to, groups such as halo, nitro, carboxy, cyano, aryl optionally substituted, aromatic het (excluding pyridine) optionally substituted, $-\text{OC}(\text{Z}_n)_3$, $-\text{C}(\text{Z}_n)_3$, $-\text{C}(\text{Z}_n)_2-\text{O}-\text{C}(\text{Z}_m)_3$, $-(\text{CO})-\text{Q}_{17}$, $-\text{SO}_2-\text{C}(\text{Z}_n)_3$, $-\text{SO}_2\text{-aryl}$, $-\text{C}(\text{NQ}_{17})\text{Q}_{17}$, $-\text{CH}=\text{C}(\text{Q}_{17})_2$, $-\text{C}\equiv\text{C}-\text{Q}_{17}$, in which each Z_n and Z_m is independently H, halo, $-\text{CN}$, $-\text{NO}_2$, $-\text{OH}$, or C_1 -alkyl optionally substituted with 1-3 halo, $-\text{OH}$, NO_2 , and provided that at least one of Z_n is halo, $-\text{CN}$, or NO_2 , and further provided that Q_{17} is not $-\text{OH}$ when the electron withdrawing group is $-(\text{CO})-\text{Q}_{17}$.

It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein.

In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, use of the compounds as pharmaceutically acceptable salts may be appropriate. Examples of pharmaceutically acceptable salts which are within the scope of the present invention include organic acid addition salts formed with acids which form a physiological acceptable anion and inorganic salts. Examples of pharmaceutically acceptable salts include, but are not limited to, the following acids: acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium edetate, camsyllic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycolylarsanilic, hexamic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic toluenesulfonic, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-

ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like.

5 Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

10 The antibacterial agents of this invention have useful activity against a variety of organisms. The in vitro activity of compounds of this invention can be assessed by standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilution as described in "Approved Standard. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically",
15 3rd. ed., published 1993 by the National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania, USA.

 The antibacterial agents described herein are useful for sterilization, sanitation, antiseptis, and disinfection. The antibacterial agents can be applied to a location in need of sterilization, sanitation, antiseptis, or disinfection, by methods known to those
20 skilled in the art. For instance, the antibacterial agents may be incorporated into a cleaning solution that is applied, such as by spraying or pouring, to an item in need of sterilization, sanitation, antiseptis, or disinfection. The antibacterial agents may be used alone or in combination, e.g., agents disclosed herein with one another or agent(s) disclosed herein with other antibacterial agents. The antibacterial agents may be
25 applied in varying concentrations depending upon the bacterial susceptibility to antibacterial agent(s) being applied and the desired level of sterilization, sanitation, antiseptis, or disinfection.

 In other embodiments, certain antibacterial agents described herein are useful for treating microbial infections in mammals, such as by administering an effective
30 amount of the antibacterial agent compound to the mammal.

 Examples of compounds useful as antimicrobial agents for the treatment of microbial infections mammals, include, but are not limited to,
5-bromo-2-({[3-chloro-5-(trifluoromethyl)-2-pyridinyl]carbonyl} amino)benzoic acid

- 2-({[4-({[2-(4-aminophenyl)ethyl]amino}sulfonyl)-3-methylthien-2-yl]carbonyl}amino)-5-bromobenzoic acid
- 5-bromo-2-({[4-({[3-(1H-imidazol-1-yl)propyl]amino}sulfonyl)-3-methylthien-2-yl]carbonyl}amino)benzoic acid
- 5 5-bromo-2-({[5-({[3-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-3-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[3-methyl-4-({[3-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-methyl-4-({[3-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)thien-2-yl]carbonyl}amino)benzoic acid
- 10 2-({[4-({[1-benzylpiperidin-4-yl]amino]sulfonyl}-3-methylthien-2-yl)carbonyl]amino}-5-bromobenzoic acid
- 2-({[4-({[1-benzylpiperidin-4-yl]amino]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}-5-bromobenzoic acid
- 15 5-bromo-2-({[5-({[3-(dibutylamino)propyl]amino}sulfonyl)thien-3-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[4-({[3-(dibutylamino)propyl]amino}sulfonyl)-3-methylthien-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[4-({[3-(dibutylamino)propyl]amino}sulfonyl)-5-methylthien-2-yl]carbonyl}amino)benzoic acid
- 20 5-chloro-2-({[5-chloro-2-(methylsulfonyl)pyrimidin-4-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-chloro-2-(methylthio)pyrimidin-4-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-chloro-2-morpholin-4-ylpyrimidin-4-yl]carbonyl}amino)benzoic acid
- 2-({[1-benzyl-5-methoxy-1H-pyrazol-3-yl]carbonyl]amino}-5-bromobenzoic acid
- 25 2-({[5-(benzyloxy)-1-methyl-1H-pyrazol-3-yl]carbonyl}amino)-5-bromobenzoic acid
- 2-({[2-[4-(acetyloxy)phenyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]carbonyl]amino)-5-bromobenzoic acid
- 2-({[5-({[2-(4-aminophenyl)ethyl]amino}sulfonyl)thien-3-yl]carbonyl}amino)-5-bromobenzoic acid
- 30 5-bromo-2-({[5-({[2,3-dihydro-1H-inden-2-ylamino]sulfonyl]thien-3-yl]carbonyl]amino)benzoic acid
- 2-({[5-({[1-benzylpiperidin-4-yl]amino]sulfonyl}thien-3-yl)carbonyl]amino}-5-bromobenzoic acid

- 5-bromo-2-({[(5-({[4-(4-chlorophenyl)piperazin-1-yl]sulfonyl}thien-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[5-({[4-(dimethylamino)benzyl]amino}sulfonyl)thien-3-yl]carbonyl}amino)benzoic acid
- 5 5-bromo-2-({[4-({[4-(dimethylamino)benzyl]amino}sulfonyl)-5-methylthien-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[(5-({[4-(4-chlorophenyl)(methyl)amino]sulfonyl}thien-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[5-(2,3-dihydro-1H-indol-1-ylsulfonyl)thien-3-yl]carbonyl}amino)benzoic acid
- 10 5-bromo-2-({[5-({(2,3-dihydro-1,4-benzodioxin-6-ylamino)sulfonyl}thien-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[4-({(2,3-dihydro-1,4-benzodioxin-6-ylamino)sulfonyl}-3-methylthien-2-yl)carbonyl]amino}benzoic acid
- 15 5-bromo-2-({[4-({[(3-chloro-4-fluorophenyl)amino]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[(3-methyl-4-({[4-morpholin-4-ylphenyl]amino]sulfonyl}thien-2-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[4-({[4-(diethylamino)phenyl]amino}sulfonyl)-3-methylthien-2-yl]carbonyl}amino)benzoic acid
- 20 5-bromo-2-({[5-({(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl}thien-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[4-({(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 25 2-({[5-({(5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)sulfonyl}thien-3-yl)carbonyl]amino}-5-bromobenzoic acid
- 2-({[4-({(5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)sulfonyl}-3-methylthien-2-yl)carbonyl]amino}-5-bromobenzoic acid
- 2-({[4-({(5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)sulfonyl}-5-methylthien-2-yl)carbonyl]amino}-5-bromobenzoic acid
- 30 5-bromo-2-(2-furoylamino)benzoic acid
- 5-bromo-2-[(5-bromo-2-furoyl)amino]benzoic acid
- 5-bromo-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoic acid

- 5-bromo-2-(3-furoylamino)benzoic acid
- 5-bromo-2-(((3-methylthien-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((5-methylthien-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-((thien-3-ylcarbonyl)amino)benzoic acid
- 5 5-bromo-2-[(1H-indol-3-ylcarbonyl)amino]benzoic acid
- 2-[(1,3-benzodioxol-5-ylcarbonyl)amino]-5-bromobenzoic acid
- 2-[(1-benzofuran-2-ylcarbonyl)amino]-5-bromobenzoic acid
- 5-bromo-2-(((2-chloropyridin-3-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzoic acid
- 10 5-bromo-2-(((5-butylpyridin-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((2-phenylquinolin-4-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-[(quinolin-2-ylcarbonyl)amino]benzoic acid
- 5-bromo-2-[(quinolin-4-ylcarbonyl)amino]benzoic acid
- 5-bromo-2-((2-(methylthio)pyridin-3-yl)carbonyl)amino)benzoic acid
- 15 5-bromo-2-[(quinoxalin-2-ylcarbonyl)amino]benzoic acid
- 5-bromo-2-(((3-methyl-1H-inden-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((7-methoxy-1-benzofuran-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((5-methylpyrazin-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((5,6-dichloropyridin-3-yl)carbonyl)amino)benzoic acid
- 20 5-bromo-2-(((10,10-dioxido-9-oxo-9H-thioxanthen-3-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((2,6-dimethoxypyridin-3-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((5-bromothien-2-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-[(2,5-dimethyl-3-furoyl)amino]benzoic acid
- 5-bromo-2-(((6-bromopyridin-2-yl)carbonyl)amino)benzoic acid
- 25 5-bromo-2-([5-(4-nitrophenyl)-2-furoyl]amino)benzoic acid
- 5-bromo-2-([5-(4-chlorophenyl)-2-furoyl]amino)benzoic acid
- 5-bromo-2-[(2,6-dichloroisonicotinoyl)amino]benzoic acid
- 5-bromo-2-([5-[3-(trifluoromethyl)phenyl]-2-furoyl]amino)benzoic acid
- 5-bromo-2-([(4-[(3-chloro-4-fluorophenyl)amino]sulfonyl)-3-methylthien-2-yl)carbonyl]amino)benzoic acid
- 30 5-bromo-2-([(5-methyl-4-[(2-methyl-1,3-benzothiazol-5-yl)amino]sulfonyl)thien-2-yl)carbonyl]amino)benzoic acid

- 5-bromo-2-[(4-[(4-[(diethoxyphosphoryl)methyl]phenyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5-bromo-2-[(4-[(4-chlorophenyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5 5-bromo-2-[(5-[(4-(diethylamino)phenyl)amino)sulfonyl]thien-3-yl)carbonyl]amino]benzoic acid
- 5-bromo-2-[(4-[(2,3-dihydro-1H-inden-2-ylamino)sulfonyl]-3-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5-bromo-2-[(4-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 10 2-[(4-[(2-(4-aminophenyl)ethyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-bromobenzoic acid
- 5-bromo-2-[(4-[(4-chlorophenyl)piperazin-1-yl)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 15 5-bromo-2-[(4-[(2,3-dihydro-1H-inden-2-ylamino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 2-[(3-benzoylpyridin-2-yl)carbonyl]amino]-5-bromobenzoic acid
- 5-bromo-2-[(2-isobutyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbonyl]amino]benzoic acid
- 20 5-bromo-2-[(1,3-dioxo-2-(tetrahydrofuran-2-ylmethyl)-2,3-dihydro-1H-isoindol-5-yl)carbonyl]amino]benzoic acid
- 2-[(6-(benzylthio)pyridin-3-yl)carbonyl]amino)-5-cyanobenzoic acid hydrochloride
- 5-bromo-2-[(2-(methylsulfonyl)-5-morpholin-4-ylpyrimidin-4-yl)carbonyl]amino]benzoic acid
- 25 2-[(2-(4-chlorophenyl)-1,1-dioxido-3,4-dihydro-2H-1,2-benzothiazin-7-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(6-(methylthio)pyridin-3-yl)carbonyl]amino]benzoic acid hydrochloride
- 5-cyano-2-[(6-(ethylthio)pyridin-3-yl)carbonyl]amino]benzoic acid hydrochloride
- 2-[(6-chloropyridin-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 30 5-cyano-2-[(3-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-(3-furoylamino)benzoic acid
- 5-cyano-2-[(3-methyl-1H-inden-2-yl)carbonyl]amino]benzoic acid
- 2-[(6-bromopyridin-2-yl)carbonyl]amino)-5-cyanobenzoic acid

- 5-cyano-2-[(2,5-dimethyl-3-furoyl)amino]benzoic acid
- 5-cyano-2-[(thien-3-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-[(pyridin-2-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-[(2,6-dimethoxypyridin-3-yl)carbonyl]amino} benzoic acid
- 5 2-[(1,3-benzodioxol-5-ylcarbonyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-[(quinolin-2-ylcarbonyl)amino]benzoic acid
- 2-[(5-bromopyridin-3-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-[(6-methoxypyridin-3-yl)carbonyl]amino} benzoic acid
- 5-cyano-2-([5-(1-methyl-1H-pyrrol-2-yl)pyridin-3-yl]carbonyl) amino)benzoic acid
- 10 5-cyano-2-([5-(4-methoxyphenyl)pyridin-3-yl]carbonyl) amino)benzoic acid
- 5-cyano-2-[(5-pyrazin-2-ylpyridin-3-yl)carbonyl]amino} benzoic acid
- 2-[(2,3'-bipyridin-5'-ylcarbonyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-([5-(2-furyl)pyridin-3-yl]carbonyl) amino)benzoic acid
- 5-cyano-2-([5-(2-methylphenyl)pyridin-3-yl]carbonyl) amino)benzoic acid
- 15 5-cyano-2-([5-[2-(trifluoromethyl)phenyl]pyridin-3-yl]carbonyl)amino]benzoic acid
- 2-([5-(4-tert-butylphenyl)pyridin-3-yl]carbonyl) amino)-5-cyanobenzoic acid
- 2-([5-(4-chlorophenyl)pyridin-3-yl]carbonyl) amino)-5-cyanobenzoic acid
- 5-cyano-2-([6-(propylthio)pyridin-3-yl]carbonyl) amino)benzoic acid hydrochloride
- 5-cyano-2-[(1H-indol-2-ylcarbonyl)amino]benzoic acid
- 20 2-[(1-benzofuran-2-ylcarbonyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-[(pyrazin-2-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-[(5-phenoxy pyridin-3-yl)carbonyl]amino} benzoic acid
- 2-([6-(butylthio)pyridin-3-yl]carbonyl) amino)-5-cyanobenzoic acid
- 2-([6-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]pyridin-3-yl]carbonyl)amino]-5-
- 25 cyanobenzoic acid
- 5-cyano-2-([5-(3-hydroxyprop-1-ynyl)pyridin-3-yl]carbonyl) amino)benzoic acid
- 5-cyano-2-([6-[(1-phenylethyl)thio]pyridin-3-yl]carbonyl) amino]benzoic acid
- 5-cyano-2-([6-(isopropylthio)pyridin-3-yl]carbonyl) amino)benzoic acid
- 5-cyano-2-([6-(cyclopentylthio)pyridin-3-yl]carbonyl) amino)benzoic acid
- 30 5-cyano-2-[(2-pyridin-3-yl-1,3-thiazol-4-yl)carbonyl]amino} benzoic acid
- 2-([2-(benzylthio)-4-ethoxypyrimidin-5-yl]carbonyl) amino)-5-cyanobenzoic acid
- 2-([5-(benzylthio)-1,3,4-thiadiazol-2-yl]carbonyl) amino)-5-cyanobenzoic acid
- 5-cyano-2-[(2-phenylquinolin-4-yl)carbonyl]amino} benzoic acid

- 5-cyano-2-(2-furoylamino)benzoic acid
- 5-cyano-2-[(4-[(2,6-dimethylmorpholin-4-yl)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(4-[(cyclohexyl(methyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 2-[(4-[(4-(4-acetylphenyl)piperazin-1-yl)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(4-[(3-[(diethylamino)carbonyl]piperidin-1-yl)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 2-[(4-[(allyl(cyclopentyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(4-[(diisobutylamino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-methyl-4-[(4-pyrimidin-2-yl)piperazin-1-yl)sulfonyl]thien-2-yl)carbonyl]amino]benzoic acid
- 2-[(4-[(benzyl(2-cyanoethyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(4-[(benzyl(2-hydroxyethyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(4-(azepan-1-ylsulfonyl)-5-methylthien-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(5-methyl-4-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)sulfonyl]thien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-methyl-4-[(2-(pyrrolidin-1-yl)methyl)pyrrolidin-1-yl)sulfonyl]thien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-methyl-4-(morpholin-4-ylsulfonyl)thien-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-methyl-4-[(4-(4-nitrophenyl)piperazin-1-yl)sulfonyl]thien-2-yl)carbonyl]amino]benzoic acid
- 2-[(4-[(butyl(ethyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(4-[(2-hydroxy-2-phenylethyl)(methyl)amino)sulfonyl]-5-methylthien-2-yl)carbonyl]amino]benzoic acid

- 5-cyano-2-{{(4-{{2-(methoxymethyl)pyrrolidin-1-yl}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(4-{{(4-cyano-4-phenylpiperidin-1-yl)sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5 5-cyano-2-{{(4-{{(3,5-dimethylpiperidin-1-yl)sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(4-{{2-(diethylamino)ethyl}(ethyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 2-{{(4-{{benzyl(isopropyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 10 2-{{(4-{{benzyl(isopropyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-{{(5-methyl-4-{{(4-phenylpiperazin-1-yl)sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(5-methyl-4-{{(2-methylpyrrolidin-1-yl)sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 15 5-cyano-2-{{(4-{{(4-(4-fluorophenyl)piperazin-1-yl)sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(5-methyl-4-{{(4-pyridin-2-yl)piperazin-1-yl)sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(5-methyl-4-{{(4-methylpiperidin-1-yl)sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 20 5-cyano-2-{{(4-{{(2,3-dihydro-1H-inden-5-ylamino)sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(5-methyl-4-{{methyl(2-phenylethyl)amino}sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 25 2-{{(4-{{(azocan-1-yl)sulfonyl}-5-methylthien-2-yl)carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-{{(4-{{(2-hydroxy-1-methyl-2-phenylethyl)(methyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(5-methyl-4-{{(3-methylpiperidin-1-yl)sulfonyl}thien-2-yl)carbonyl}amino}benzoic acid
- 30 5-cyano-2-{{(4-{{(3-hydroxy-3-phenylpropyl)(methyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}benzoic acid
- 2-{{(4-{{butyl(cyanomethyl)amino}sulfonyl}-5-methylthien-2-yl)carbonyl}amino}-5-cyanobenzoic acid

- 5-cyano-2-({[5-methyl-4-(pyrrolidin-1-ylsulfonyl)thien-2-yl]carbonyl}amino)benzoic acid
- 2-({[4-({[4-benzylpiperazin-1-yl]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5 5-cyano-2-({[4-({[(2-cyanoethyl)(methyl)amino]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 5-cyano-2-({[4-({[(2-hydroxy-1-methyl-2-phenylethyl)(methyl)amino]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 5-cyano-2-({[4-({[4-hydroxypiperidin-1-yl]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 10 5-cyano-2-({[5-methyl-4-(octahydroquinolin-1(2H)-ylsulfonyl)thien-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[(5-methoxy-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 2-({[5-(benzyloxy)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 15 5-cyano-2-({[5-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[(5-quinolin-3-yl)pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[5-[4-(trifluoromethyl)phenyl]pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[5-[3-(trifluoromethyl)phenyl]pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[5-(2,4-dimethoxypyrimidin-5-yl)pyridin-3-yl]carbonyl}amino)benzoic acid
- 20 acid
- 5-cyano-2-({[(5-phenylpyridin-3-yl)carbonyl]amino}benzoic acid
- 2-({[2-(benzylthio)-1,3-thiazol-5-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-isocyano-2-({[(5-phenyl-1,2,4-oxadiazol-3-yl)carbonyl]amino}benzoic acid
- 5-isocyano-2-({[(2-phenyl-1,3-oxazol-4-yl)carbonyl]amino}benzoic acid
- 25 2-({[(2-tert-butyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-bromo-2-({[(2-tert-butyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)carbonyl]amino}benzoic acid
- 5-cyano-2-({[4-({[2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}benzoic acid
- 30 2-({[4-({[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]sulfonyl}-5-methylthien-2-yl)carbonyl]amino}-5-cyanobenzoic acid

- 2-(((4-((butyl(2-hydroxyethyl)amino)sulfonyl)-5-methylthien-2-yl)carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-(((5-quinolin-8-ylpyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((6-morpholin-4-ylpyridin-3-yl)carbonyl)amino)benzoic acid
- 5 5-cyano-2-(((5-(1H-pyrazol-4-ylethynyl)pyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((5-((2,4-dimethoxypyrimidin-5-yl)ethynyl)pyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((5-ethynylpyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((4-((2-ethylpiperidin-1-yl)sulfonyl)-5-methylthien-2-yl)carbonyl)amino)benzoic acid
- 10 5-cyano-2-(((4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-5-methylthien-2-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((4-(3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-5-methylthien-2-yl)carbonyl)amino)benzoic acid
- 15 2-(((6-(benzylsulfonyl)pyridin-3-yl)carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-(((6-piperidin-1-ylpyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((5-((3,5-dimethylisoxazol-4-yl)ethynyl)pyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((5-(phenylethynyl)pyridin-3-yl)carbonyl)amino)benzoic acid
- 20 5-cyano-2-(((5-((2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-oxoethyl)pyridin-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((5-phenylisoxazol-3-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-(((6-(tetrahydro-2H-pyran-4-ylthio)pyridin-3-yl)carbonyl)amino)benzoic acid
- 25 5-cyano-2-(((5-(ethylthio)pyridin-3-yl)carbonyl)amino)benzoic acid
- 2-(((2-(benzylthio)-1,3-thiazol-4-yl)carbonyl)amino)-5-cyanobenzoic acid
- 5-bromo-2-(((5-phenylisoxazol-3-yl)carbonyl)amino)benzoic acid
- 2-(((6-((3-(4-bromophenoxy)propyl)thio)pyridin-3-yl)carbonyl)amino)-5-cyanobenzoic acid
- 30 5-cyano-2-(((6-((cyclopropylmethyl)thio)pyridin-3-yl)carbonyl)amino)benzoic acid
- 5-bromo-2-(((6-(isopropylthio)pyridin-3-yl)carbonyl)amino)benzoic acid
- 2-(((5-(benzylthio)pyrazin-2-yl)carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-(((5-methoxy-1-benzofuran-2-yl)carbonyl)amino)benzoic acid

- 5-cyano-2-({[(7-methoxy-1-benzofuran-2-yl)carbonyl]amino}benzoic acid
5-cyano-2-({[(1-methyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
5-cyano-2-({[6-(cyclohexylthio)pyridin-3-yl]carbonyl}amino)benzoic acid
2-({[5-(benzylthio)isoxazol-3-yl]carbonyl}amino)-5-bromobenzoic acid
5 5-bromo-2-({[6-(cyclohexylthio)pyridin-3-yl]carbonyl}amino)benzoic acid
2-({[5-(benzylthio)isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
2-({[5-(benzylthio)pyrazin-2-yl]carbonyl}amino)-5-bromobenzoic acid
2-({[6-(sec-butylthio)pyridin-3-yl]carbonyl}amino)-5-cyanobenzoic acid
5-cyano-2-({[6-(pentylthio)pyridin-3-yl]carbonyl}amino)benzoic acid
10 2-({[5-(benzylthio)-1,3,4-oxadiazol-2-yl]carbonyl}amino)-5-bromobenzoic acid
2-({[6-(benzyloxy)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
N-[4-bromo-2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]-5-phenylisoxazole-3-carboxamide
2-({[(7-chloro-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid
15 5-cyano-2-({[(4-methoxy-1H-indol-2-yl)carbonyl]amino}benzoic acid
5-bromo-2-({[(1-methyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
2-({[(6-chloro-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid
2-({[(1-benzyl-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid
5-cyano-2-({[(1-ethyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
20 5-cyano-2-({[7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
5-cyano-2-({[(5-phenyl-1,3-oxazol-2-yl)carbonyl]amino}benzoic acid
2-({[5-(benzylthio)-1,3,4-thiadiazol-2-yl]carbonyl}amino)-5-bromobenzoic acid
5-cyano-2-({[(2-phenylfuro[2,3-c]pyridin-5-yl)carbonyl]amino}benzoic acid
5-cyano-2-({[6-(hexylthio)pyridin-3-yl]carbonyl}amino)benzoic acid
25 5-cyano-2-({[6-[(3-ethoxy-3-oxopropyl)thio]pyridin-3-yl]carbonyl}amino)benzoic acid
2-({[6-(benzylthio)pyrazin-2-yl]carbonyl}amino)-5-cyanobenzoic acid
2-({[6-(benzylthio)pyrazin-2-yl]carbonyl}amino)-5-bromobenzoic acid
2-({[5-(3-chlorophenyl)-1,3-thiazol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
5-cyano-2-({[(5-phenyl-1,3-thiazol-2-yl)carbonyl]amino}benzoic acid
30 5-cyano-2-({[(4-phenyl-1,3-thiazol-2-yl)carbonyl]amino}benzoic acid
2-[(1,3-benzothiazol-2-ylcarbonyl)amino]-5-cyanobenzoic acid
5-cyano-2-[(thieno[2,3-b]pyridin-2-ylcarbonyl)amino]benzoic acid
5-cyano-2-({[(3-methylfuro[2,3-c]pyridin-5-yl)carbonyl]amino}benzoic acid

- 5-bromo-2-({[5-(pentylthio)-1,3,4-oxadiazol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[6-({[3-(2-methoxyethoxy)propyl]thio}pyridin-3-yl)carbonyl]amino}benzoic acid
- 5-chloro-2-({[5-phenyl-1,3-oxazol-2-yl]carbonyl]amino}benzoic acid
- 5 5-bromo-2-({[6-(tetrahydro-2H-pyran-4-ylthio)pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-(nonylthio)pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-({[3,5-dimethylisoxazol-4-yl)methyl]thio}pyridin-3-yl)carbonyl]amino}benzoic acid
- 10 5-cyano-2-({[5-methylisoxazol-3-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-({[2-methoxy-2-oxoethyl]thio}pyridin-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[6-(hexylthio)pyridin-3-yl]carbonyl]amino}benzoic acid
- 5-chloro-2-({[6-(hexylthio)pyridin-3-yl]carbonyl]amino}benzoic acid
- 15 5-bromo-2-({[6-({[3-(2-methoxyethoxy)propyl]thio}pyridin-3-yl)carbonyl]amino}benzoic acid
- 2-({[(1-allyl-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-({[1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 20 5-cyano-2-({[(1-pentyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 2-({[(1-butyl-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-({[(1-propyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 5-chloro-2-({[(1-propyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 2-({[(1-butyl-1H-indol-2-yl)carbonyl]amino}-5-chlorobenzoic acid
- 25 5-chloro-2-({[(1-pentyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 5-chloro-2-({[1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-chloro-2-({[1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 2-({[(1-allyl-1H-indol-2-yl)carbonyl]amino}-5-chlorobenzoic acid
- 2-({[(1-allyl-1H-indol-2-yl)carbonyl]amino}-5-bromobenzoic acid
- 30 5-bromo-2-({[1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-bromo-2-({[1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-bromo-2-({[(1-pentyl-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-({[(1-butyl-1H-indol-2-yl)carbonyl]amino}benzoic acid

- 5-bromo-2-{{{1-(1-propyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 2-({[4-(benzyloxy)pyridin-2-yl]carbonyl}amino)-5-bromobenzoic acid
 2-{{{1-(1-benzyl-1H-indol-2-yl)carbonyl}amino}-5-chlorobenzoic acid
 2-{{{1-(1-benzyl-1H-indol-2-yl)carbonyl}amino}-5-bromobenzoic acid
 5 5-bromo-2-{{{1-(1-isopropyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 5-cyano-2-{{{1-(1-isopropyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 5-chloro-2-{{{1-(1-methyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 5-chloro-2-{{{1-(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 5-bromo-2-{{{1-(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 10 5-cyano-2-{{{1-(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid
 5-cyano-2-({[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-chloro-2-({[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-bromo-2-({[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-chloro-2-{{{6-{{3-(2-methoxyethoxy)propyl}thio}pyridin-3-yl}carbonyl}amino}benzoic acid
 15 5-cyano-2-{{{4,5-dichloroisothiazol-3-yl}carbonyl}amino}benzoic acid
 2-{{{4-chloro-5-phenylisothiazol-3-yl}carbonyl}amino}-5-cyanobenzoic acid
 5-bromo-2-{{{4-chloro-1-oxidopyridin-2-yl}carbonyl}amino}benzoic acid
 5-cyano-2-{{{3-phenylisoxazol-5-yl}carbonyl}amino}benzoic acid
 20 5-chloro-2-[(E)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoic acid
 5-cyano-2-[(E)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoic acid
 2-({[4-(benzyloxy)pyridin-2-yl]carbonyl}amino)-5-cyanobenzoic acid
 2-{{{6-{{5-(5-chloro-1,2,4-thiadiazol-3-yl)methyl}thio}pyridin-3-yl}carbonyl}amino}-5-cyanobenzoic acid
 25 5-cyano-2-{{{6-{{1,2,4-oxadiazol-3-ylmethyl}thio}pyridin-3-yl}carbonyl}amino}benzoic acid
 2-({[4-(benzyloxy)-1-oxidopyridin-2-yl]carbonyl}amino)-5-bromobenzoic acid
 2-({[4-(benzylthio)-1-oxidopyridin-2-yl]carbonyl}amino)-5-bromobenzoic acid
 5-cyano-2-({[5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 30 5-cyano-2-({[5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl}amino)benzoic acid
 2-({[5-(2-chlorophenyl)isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
 5-cyano-2-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 2-{{{6-{{4-(acetyloxy)butyl}thio}pyridin-3-yl}carbonyl}amino}-5-cyanobenzoic acid

- 5-cyano-2-({[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)carbonyl]amino}benzoic acid
 5-cyano-2-({[6-[(4-hydroxybutyl)thio]pyridin-3-yl}carbonyl)amino]benzoic acid
 5-chloro-2-({[7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-bromo-2-({[7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5 5-cyano-2-({[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-cyano-2-({[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
 5-cyano-2-({[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
 5-bromo-2-({[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
 5-chloro-2-({[5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 10 5-cyano-2-({[5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
 2-({[(5-tert-butylisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoic acid
 5-cyano-2-({[(3,5-dimethyl-4,5'-biisoxazol-3'-yl)carbonyl]amino}benzoic acid
 5-cyano-2-({[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino}benzoic acid
 5-bromo-2-({[5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
 15 5-chloro-2-({[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino}benzoic acid
 5-chloro-2-({[5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
 5-bromo-2-({[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino}benzoic acid
 5-bromo-2-({[5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
 5-bromo-2-({[5-(4-({[(5-methylisoxazol-3-yl)amino]sulfonyl}phenyl)isoxazol-3-
 20 yl]carbonyl}amino)benzoic acid
 5-chloro-2-({[(5-phenylisoxazol-3-yl)carbonyl]amino}benzoic acid
 5-chloro-2-({[5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
 5-bromo-2-({[5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 5-cyano-2-({[5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 25 5-cyano-2-({[5-(3-phenylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 5-cyano-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
 5-bromo-2-({[(5-phenyl-1,3-oxazol-2-yl)carbonyl]amino}benzoic acid
 5-bromo-2-({[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
 2-({[5-(1,3-benzodioxol-5-yl)-1,3-oxazol-2-yl]carbonyl}amino)-5-bromobenzoic acid
 30 5-bromo-2-({[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-chloro-2-({[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
 5-cyano-2-[(isoquinolin-3-ylcarbonyl)amino]benzoic acid
 5-cyano-2-({[7-[(phenylacetyl)amino]-1H-indol-2-yl]carbonyl)amino]benzoic acid

- 2-({[7-(benzoylamino)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 2-{{{7-}[(acetyloxy)acetyl]amino}-1H-indol-2-yl}carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-{{{7-}[(cyclopentylcarbonyl)amino]-1H-indol-2-yl}carbonyl]amino]benzoic acid
- 2-{{{7-}amino-1H-indol-2-yl}carbonyl]amino}-5-cyanobenzoic acid
- 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-({[5-(4-fluorophenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 10 5-bromo-2-({[5-(3-phenylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-chloro-2-({[5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-chloro-2-({[5-(3-phenylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-chloro-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 15 5-cyano-2-{{{6-}[(1-methylpentyl)thio]pyridin-3-yl}carbonyl]amino]benzoic acid
- 5-cyano-2-{{{6-}[(1-ethylpropyl)thio]pyridin-3-yl}carbonyl]amino]benzoic acid
- 5-bromo-2-({[5-(2-chlorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl}amino)benzoic acid
- 20 5-bromo-2-{{{5-}[(2-(trifluoromethyl)phenyl)-1,3-oxazol-2-yl]carbonyl]amino]benzoic acid
- 2-{{{7-}[(6-chloropyridin-3-yl)carbonyl]amino}-1H-indol-2-yl}carbonyl]amino}-5-cyanobenzoic acid
- 5-chloro-2-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 25 5-chloro-2-({[5-(2-chlorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(2-methylphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(triisopropylsilyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-{{{7-}[(isoxazol-5-ylcarbonyl)amino]-1H-indol-2-yl}carbonyl]amino]benzoic acid
- 30 5-cyano-2-{{{7-}[(2,4-difluorobenzoyl)amino]-1H-indol-2-yl}carbonyl]amino]benzoic acid
- 5-cyano-2-{{{7-}[(fluoroacetyl)amino]-1H-indol-2-yl}carbonyl]amino]benzoic acid
- 2-({[7-(acetylamino)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid

- 2-{{(7-{{(4-chlorophenyl)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-{{(7-{{(4-methoxyphenyl)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5 5-cyano-2-{{(7-{{(cyclopentylacetyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(3-fluorobenzoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(3-cyanobenzoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(cyclohexylcarbonyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 10 acid
- 5-cyano-2-((7-(propionylamino)-1H-indol-2-yl)carbonyl)amino)benzoic acid
- 5-cyano-2-{{(7-{{(5-methoxy-5-oxopentanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 2-((7-(butyrylamino)-1H-indol-2-yl)carbonyl)amino)-5-cyanobenzoic acid
- 15 2-{{(7-{{(4-bromobenzoyl)amino}-1H-indol-2-yl}carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-{{(7-{{(3-phenylpropanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(phenoxyacetyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(3-cyclopentylpropanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 20 5-cyano-2-{{(7-{{(3-methoxy-3-oxopropanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(2-ethylhexanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(3,4-dimethoxyphenyl)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 25 5-cyano-2-{{(7-{{(3,5,5-trimethylhexanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(cyclopropylcarbonyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 30 5-cyano-2-{{(7-{{(methoxyacetyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(3-methylbutanoyl)amino}-1H-indol-2-yl}carbonyl}amino}benzoic acid
- 5-cyano-2-((7-(pentanoylamino)-1H-indol-2-yl)carbonyl)amino)benzoic acid

- 5-cyano-2-{{(7-{{(4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]hept-1-yl)carbonyl}amino}-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 2-{{(7-{{chloro(phenyl)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5 2-{{(7-{{(benzyloxy)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(3-ethoxy-3-oxopropanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 2-[(7-[(1-adamantylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 10 acid
- 5-cyano-2-((7-(hexanoylamino)-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 5-cyano-2-{{(7-{{(2-phenylcyclopropyl)carbonyl}amino}-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-[(7-[(2-phenylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 15 acid
- 5-cyano-2-((7-(heptanoylamino)-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 2-{{(7-{{(acetyloxy)(phenyl)acetyl}amino}-1H-indol-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(thien-2-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 20 acid
- 5-cyano-2-[(7-[(2-methylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-[(8-methoxy-8-oxooctanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 25 5-cyano-2-[(7-[(2-ethylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-((7-(octanoylamino)-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 5-cyano-2-[(7-[(cyclobutylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- acid
- 5-cyano-2-((7-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 30 2-((7-((2-(benzylthio)-1,3-thiazol-4-yl)carbonyl)amino)-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid

- 5-cyano-2-{{(7-{{(3-(morpholin-4-ylsulfonyl)benzoyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(1H-indol-2-ylcarbonyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5 5-cyano-2-{{(7-{{(1-methyl-1H-indol-2-yl)carbonyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(5-phenylisoxazol-3-yl)carbonyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(5-phenylpentanoyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 10 acid
- 5-cyano-2-{{(7-{{(4-phenylbutanoyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(4-(4-methoxyphenyl)butanoyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 15 5-cyano-2-{{(6-{{(1-methylbutyl)thio}pyridin-3-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(5-{{(3-methylthien-2-yl)isoxazol-3-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(5-{{(3-methoxyphenyl)-1,3-oxazol-2-yl)carbonyl)amino} benzoic acid
- 2-{{(7-{{(2-chlorophenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino}-5-cyanobenzoic acid
- 20 5-cyano-2-{{(7-{{(2,4-dichlorophenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(3,4-dichlorophenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 2-{{(7-{{(3-chlorophenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino}-5-cyanobenzoic acid
- 25 5-cyano-2-{{(7-{{(3-(trifluoromethyl)phenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 5-cyano-2-{{(7-{{(3-methylphenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid
- 30 2-{{(7-{{(4-tert-butylphenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino}-5-cyanobenzoic acid
- 5-cyano-2-{{(7-{{(3-methoxyphenyl)acetyl)amino}}-1H-indol-2-yl)carbonyl)amino} benzoic acid

- 5-cyano-2-{{(7-{{(2-methoxyphenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(2-methylphenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5 5-cyano-2-{{(7-{{(4-(trifluoromethyl)phenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(4-isopropylphenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(4-methylphenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 10 5-cyano-2-{{(7-{{(4-fluorophenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 2-{{(5-(butylthio)pyrazin-2-yl)carbonyl}amino}-5-cyanobenzoic acid
- 5-cyano-2-{{(7-{{(2-(trifluoromethyl)phenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 15 5-cyano-2-{{(7-{{(3-fluorophenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(phenylthio)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 20 5-cyano-2-{{(7-{{(2-naphthylacetyl)amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(1-naphthylacetyl)amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(2-naphthyloxy)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(2-propoxybenzoyl)amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 25 acid
- 5-cyano-2-{{(7-{{(tetrahydrofuran-3-ylcarbonyl)amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 5-cyano-2-{{(7-{{(1-methylcyclopropyl)carbonyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 30 5-cyano-2-{{(7-{{(4-ethoxyphenyl)acetyl}amino})-1H-indol-2-yl)carbonyl}amino}benzoic acid
- 2-{{(7-{{(1-benzothien-3-ylacetyl)amino})-1H-indol-2-yl)carbonyl}amino}-5-cyanobenzoic acid

- 2-[(7-[(1,1'-biphenyl-4-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(7-[(4-butoxybenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(2-(2-phenylethyl)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 5 2-[(7-[(1,1'-biphenyl-2-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(4-(ethylthio)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 10 5-cyano-2-[(7-[(2-(methylsulfonyl)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-[(7-[(2,6-dichlorophenyl)acetyl]amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 2-[(7-[(1,1'-biphenyl-4-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 15 2-[(7-[(1,3-benzodioxol-5-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(3,3-dimethylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 20 5-cyano-2-[(7-[(thien-2-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 5-bromo-2-[(5-(4-cyanophenyl)-1,3-oxazol-2-yl)carbonyl]amino)benzoic acid
- 5-bromo-2-[(5-methoxypyrazin-2-yl)carbonyl]amino)benzoic acid
- 2-[(5-(1,3-benzodioxol-5-yl)-1,3-oxazol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-bromo-2-[(5-(sec-butylthio)pyrazin-2-yl)carbonyl]amino)benzoic acid
- 25 5-bromo-2-[(5-(butylthio)pyrazin-2-yl)carbonyl]amino)benzoic acid
- 2-[(5-(butylthio)pyrazin-2-yl)carbonyl]amino)-5-chlorobenzoic acid
- 5-cyano-2-[(E)-2-(1-methyl-1H-indol-2-yl)ethenyl]benzoic acid
- 5-bromo-2-[(1-methyl-3-phenyl-1H-pyrazol-5-yl)carbonyl]amino)benzoic acid
- 5-bromo-2-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)carbonyl]amino)benzoic acid
- 30 5-bromo-2-[(5-(4-methoxyphenyl)-1-methyl-1H-pyrazol-3-yl)carbonyl]amino)benzoic acid
- 5-bromo-2-[(3-phenyl-1H-pyrazol-5-yl)carbonyl]amino)benzoic acid
- 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-bromobenzoic acid

- 5-cyano-2-[(5-[2-(trifluoromethyl)phenyl]-1,3-oxazol-2-yl)carbonyl]amino]benzoic acid
- 2-[(6-[(4-aminobutyl)thio]pyridin-3-yl)carbonyl]amino]-5-cyanobenzoic acid trifluoroacetate
- 5 5-bromo-2-([5-(pentylthio)pyrazin-2-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-([5-(hexylthio)pyrazin-2-yl]carbonyl)amino]benzoic acid
- 2-([5-(sec-butylthio)pyrazin-2-yl]carbonyl)amino]-5-cyanobenzoic acid
- 5-cyano-2-([5-(2-furyl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-([5-(2-furyl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 10 5-bromo-2-([3-(2,6-difluorophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-[(7-[(3-methyl-5-phenylisoxazol-4-yl)carbonyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-[(2-(2-methoxyethoxy)ethoxy)acetyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid
- 15 5-cyano-2-[(7-[(2-hydroxybenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-[(4-(trifluoromethoxy)phenyl)sulfonyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid
- 20 5-cyano-2-[(7-(proplylamino)-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-[(7-[(3-methylisoxazol-5-yl)acetyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid
- 5-bromo-2-([5-(4-fluorophenyl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(4-cyanophenyl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 25 5-bromo-2-([5-(1-methyl-1H-pyrrol-2-yl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-([5-(3-cyanophenyl)-1,3-oxazol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(pentylthio)pyrazin-2-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-[(5-[(3-(2-methoxyethoxy)propyl)thio]pyrazin-2-yl]carbonyl]amino]benzoic acid
- 30 5-chloro-2-[(5-[(3-(2-methoxyethoxy)propyl)thio]pyrazin-2-yl]carbonyl]amino]benzoic acid

- 5-cyano-2-[(5-[2-([4-(trifluoromethoxy)phenyl]sulfonyl)amino]phenyl)isoxazol-3-yl]carbonyl]amino]benzoic acid
- 5-chloro-2-[(5-[2-([4-(trifluoromethoxy)phenyl]sulfonyl)amino]phenyl)isoxazol-3-yl]carbonyl]amino]benzoic acid
- 5 2-([5-(1,3-benzodioxol-5-yl)isoxazol-3-yl]carbonyl]amino)-5-cyanobenzoic acid
- 2-([5-(1,3-benzodioxol-5-yl)isoxazol-3-yl]carbonyl]amino)-5-bromobenzoic acid
- 5-cyano-2-([(5-nitro-1,2-benzisoxazol-3-yl)carbonyl]amino)benzoic acid
- 2-([(1-acetyl-1H-indazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(1,3-benzoxazol-2-ylcarbonyl)amino]-5-cyanobenzoic acid
- 10 2-[(7-[(benzylsulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-([(1-methyl-7-([3-(morpholin-4-ylsulfonyl)benzoyl]amino)-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-([(7-([(4-fluorophenyl)acetyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 15 5-cyano-2-[(7-[(fluoroacetyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-([(1-methyl-7-([(1-methyl-1H-indol-2-yl)carbonyl]amino)-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-([(5-([3-(2-methoxyethoxy)propyl]thio)pyrazin-2-yl)carbonyl]amino)benzoic acid
- 20 5-chloro-2-([5-(pentylthio)pyrazin-2-yl]carbonyl]amino)benzoic acid
- 5-cyano-2-([5-(hexylthio)pyrazin-2-yl]carbonyl]amino)benzoic acid
- 5-chloro-2-([5-(hexylthio)pyrazin-2-yl]carbonyl]amino)benzoic acid
- 5-cyano-2-([5-(1-methyl-1H-pyrrol-2-yl)-1,3-oxazol-2-yl]carbonyl]amino)benzoic acid
- 25 2-([5-(sec-butylthio)pyrazin-2-yl]carbonyl]amino)-5-chlorobenzoic acid
- 5-cyano-2-([5-(3-cyanophenyl)-1,3-oxazol-2-yl]carbonyl]amino)benzoic acid
- 5-bromo-2-[(2-[(3R)-3,4-dihydroxybutyl]-1,3-oxazol-4-yl)carbonyl]amino]benzoic acid
- 30 5-cyano-2-([5-[(phenylacetyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
- 2-([5-[(benzylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino)-5-cyanobenzoic acid

- 2-({[6-(benzyloxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[6-methoxy-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(2-isopropoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-7-[(morpholin-4-ylcarbonyl)amino]-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-7-({[(tetrahydrofuran-2-ylmethyl)amino]carbonyl}amino)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[7-hydroxy-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[2-{2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}-1,3-oxazol-4-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(2-phenylethyl)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[5-({(E)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethenyl}pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(isopentylthio)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(isobutylthio)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-methoxypyrazin-2-yl]carbonyl}amino)benzoic acid
- 2-({[7-({[(benzylamino)carbonyl]amino)-1-methyl-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[7-({[(2,3-dihydroxypropyl)amino]carbonyl}amino)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 1-[({[2-({[(2-carboxy-4-cyanophenyl)amino]carbonyl}-1-methyl-1H-indol-7-yl)amino]carbonyl}(methyl)amino)-1-deoxyhexitol
- 5-cyano-2-({[7-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-{2-[2-(2-ethoxyethoxy)ethoxy]phenyl}isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-[2-(hexyloxy)phenyl]isoxazol-3-yl]carbonyl}amino)benzoic acid
- 2-({[5-[2-(allyloxy)phenyl]isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[5-[2-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)phenyl]isoxazol-3-yl]carbonyl}amino)benzoic acid
- 2-({[7-(benzyloxy)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[1-methyl-7-(3-phenoxypropoxy)-1H-indol-2-yl]carbonyl}amino)benzoic acid

- 5-cyano-2-([5-(hydroxymethyl)isoxazol-3-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-(hexyloxy)pyrazin-2-yl]carbonyl)amino)benzoic acid
- 2-([5-(acetylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-([5-[(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-([5-[2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 2-([5-(benzoylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-([5-[(phenylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(2-ethoxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-[2-(tetrahydro-2H-pyran-2-ylmethoxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([7-(cyclobutylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-[2-(3-phenoxypropoxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([7-(2-furylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([7-([(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([7-([(2R)-2,3-dihydroxypropyl]oxy)-1-methyl-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(2-hydroxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-[2-(tetrahydrofuran-3-yloxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-[2-(cyclobutyloxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-[2-(tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(2-([(1S,2R)-2-methylcyclopentyl]oxy)phenyl]isoxazol-3-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-[2-(2-methoxy-1-methylethoxy)phenyl]isoxazol-3-yl]carbonyl)amino]benzoic acid

- 5-cyano-2-[(5-[2-(1-methylbutoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-[2-(cyclobutylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-(cyclobutylloxy)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5 5-cyano-2-[(7-(2-methoxy-1-methylethoxy)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-isopropoxy-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 2-[(7-(benzyloxy)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(6-chloro-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 10 5-bromo-2-[(6-chloro-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-[2-(cyclohex-2-en-1-ylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(2-(3-[(2-carboxy-4-cyanophenyl)amino]carbonyl)isoxazol-5-yl)phenoxy]acetyl]amino)-5-cyanobenzoic acid
- 15 5-cyano-2-[(5-[2-(1-ethylpropoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-{2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-[2-(1-cyclohexylethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 20 2-[(6-sec-butoxy-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(6-butoxy-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(5-{[(4-fluorophenyl)sulfonyl]amino}-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-[2-(trifluoromethyl)phenyl]pyrazin-2-yl)carbonyl]amino]benzoic acid
- 25 5-cyano-2-[(5-[2-(2-oxobutoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-[2-(2-oxo-2-phenylethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(5-(2-bromophenyl)isoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(5-(1,1'-biphenyl-2-yl)isoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 30 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(5-{[(4-methoxybenzyl)thio]pyrazin-2-yl}carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-(3-methoxyphenyl)isoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-(2-fluorophenyl)pyrazin-2-yl)carbonyl]amino]benzoic acid

- 5-bromo-2-{{[(5-{{(E)-2-[(2S)-1,4-dioxaspiro[4.5]dec-2-yl]ethenyl}}pyrazin-2-yl)carbonyl]amino}benzoic acid
- 2-{{[(5-bromo-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoic acid
- 2-[[{6-[(benzylsulfonyl)amino]-1,2-benzisoxazol-3-yl}carbonyl]amino]-5-
- 5 cyanobenzoic acid
- 5-cyano-2-[[{6-[(phenylsulfonyl)amino]-1,2-benzisoxazol-3-yl}carbonyl]amino]benzoic acid
- 5-cyano-2-({[7-(cyclohexylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 10 5-cyano-2-({[7-(cyclopropylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-7-(tetrahydro-2H-pyran-2-ylmethoxy)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-7-(pentyloxy)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 15 2-({[5-(chloromethyl)isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[5-(morpholin-4-ylmethyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-{{[(5-phenyl-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid
- 5-bromo-2-{{[(5-bromo-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid
- 2-{{[(5-{2-[(5-chloropentyl)oxy]phenyl}isoxazol-3-yl)carbonyl]amino}-5-cyanobenzoic acid
- 20 acid
- 2-({[4,5-bis(methoxymethyl)isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-[[{5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl}carbonyl]amino]benzoic acid
- 5-cyano-2-({[5-(2-methylphenyl)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 25 5-cyano-2-({[5-(2,3,4-trimethoxyphenyl)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[7-(2-methoxyethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[7-(2-hydroxy-3-isopropoxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 30 5-cyano-2-{{[(6-phenyl-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid
- 5-cyano-2-[[{6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl}carbonyl]amino]benzoic acid
- 2-[[{5-[(benzylamino)methyl]isoxazol-3-yl}carbonyl]amino]-5-cyanobenzoic acid

- 2-{{{5-[[bis(2-hydroxyethyl)amino]methyl]isoxazol-3-yl}carbonyl]amino}-5-cyanobenzoic acid
- 2-([5-(azidomethyl)isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
- 5-cyano-2-([5-(nonylthio)pyrazin-2-yl]carbonyl)amino)benzoic acid
- 5 5-cyano-2-([1-methyl-7-[2-(methylthio)ethoxy]-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([(5-phenyl-4,5-dihydroisoxazol-3-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-[(4,5-dihydronaphtho[2,1-d]isoxazol-3-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-[(pyrrolo[1,2-c]pyrimidin-3-ylcarbonyl)amino]benzoic acid
- 10 2-[(4-azido-3-iodobenzoyl)amino]-1-methyl-1H-indol-2-yl}carbonyl)amino]-5-cyanobenzoic acid
- 2-([5-[(4-azido-3-iodobenzoyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid
- 2-[(E)-2-(1,2-benzisoxazol-3-yl)ethenyl]-5-cyanobenzoic acid
- 15 5-cyano-2-([(5-[(pyridin-4-ylmethyl)amino]methyl]isoxazol-3-yl)carbonyl]amino)benzoic acid trifluoroacetate
- 5-cyano-2-([5-[(pyridin-4-ylthio)methyl]isoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([6-(hexylthio)pyridazin-3-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([5-(octylthio)pyrazin-2-yl]carbonyl)amino)benzoic acid
- 20 5-cyano-2-([5-(6-methoxypyridin-3-yl)pyrazin-2-yl]carbonyl)amino)benzoic acid
- 5-cyano-2-([(5-phenylpyrazin-2-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-[(4,5,6,7-tetrahydro-1,2-benzisoxazol-3-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-([5-[4-(methylsulfonyl)phenyl]pyrazin-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-(3,5-dimethylisoxazol-4-yl)pyrazin-2-yl]carbonyl)amino)benzoic acid
- 25 2-[(2,1-benzisoxazol-3-ylcarbonyl)amino]-5-cyanobenzoic acid
- 2-([5-([amino(imino)methyl]amino)methyl]isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
- 2-[(2,1-benzisoxazol-3-ylcarbonyl)amino]-5-bromobenzoic acid
- 5-cyano-2-([6-[(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 30 5-cyano-2-([(6-[(4-fluorophenyl)sulfonyl]amino)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 2-[(6-amino-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid

- 5-cyano-2-({[5-(2-fluorophenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[6-[2-(trifluoromethyl)phenyl]pyridazin-3-yl]carbonyl}amino)benzoic acid
- 2-({[(2-benzyl-1,1-dioxido-3,4-dihydro-2H-1,2-benzothiazin-5-yl)carbonyl]amino}-5-bromobenzoic acid
- 5 2-({[(2-benzyl-1,1-dioxido-3,4-dihydro-2H-1,2-benzothiazin-5-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-({[1-methyl-6-[2-(trifluoromethyl)phenyl]-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-6-(2,3,4-trimethoxyphenyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 10 5-iodo-2-({[1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-iodo-2-({[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-7-(pyridin-3-ylmethoxy)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 15 2-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)-5-iodobenzoic acid
- 5-iodo-2-({[5-(2-methylphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
- 5-iodo-2-({[5-phenylisoxazol-3-yl]carbonyl}amino)benzoic acid
- 4-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)-2'-(trifluoromethyl)-1,1'-biphenyl-3-carboxylic acid
- 20 2-({[5-(2-({(2R)-3-bromo-2-methylpropyl]oxy}phenyl)isoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[6-(heptylthio)pyridazin-3-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[5-(heptylthio)pyrazin-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[6-(3,5-dimethylisoxazol-4-yl)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 25 2-({[(5-chloropyrazin-2-yl)carbonyl]amino}-5-cyanobenzoic acid
- 5-cyano-2-({[1-methyl-6-(2-methylphenyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-bromo-2-({[6-(hexylthio)pyridazin-3-yl]carbonyl}amino)benzoic acid
- 30 5-cyano-2-({[6-(pentylthio)pyridazin-3-yl]carbonyl}amino)benzoic acid
- 2-({[(5-chloropyrazin-2-yl)carbonyl]amino}-5-iodobenzoic acid
- 2-({[5-(benzylthio)pyrazin-2-yl]carbonyl}amino)-5-iodobenzoic acid

- 2-[(5-[(benzyloxy)carbonyl]-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(7-amino-4,6-dibromo-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5 5-cyano-2-[(5-(2-fluorophenyl)isoxazol-3-yl)carbonothioyl]amino)benzoic acid
- 2-[(5-[2-(1,1'-biphenyl-4-yloxy)phenyl]isoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(5-[2-(1,1'-biphenyl-3-yloxy)phenyl]isoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 10 5-cyano-2-[(5-(3,4-dihydroxybutyl)isoxazol-3-yl)carbonyl]amino)benzoic acid
- 5-cyano-2-[(4,6-dibromo-1-methyl-7-[(phenylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 2-[(6-(acetyloxy)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(6-hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino)benzoic acid
- 15 2-[(5-[2-(1,1'-biphenyl-2-yloxy)phenyl]isoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(5-(hexylthio)pyrimidin-2-yl)carbonyl]amino)benzoic acid
- 2-[(6-(benzyloxy)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(6-methoxy-1,2-benzisoxazol-3-yl)carbonyl]amino)benzoic acid
- 20 2-[(6-[(benzylsulfonyl)oxy]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(6-[(phenylsulfonyl)oxy]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(7-amino-4-bromo-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 25 2-[(7-(benzyloxy)-3-bromo-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(1H-benzimidazol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-bromo-2-[(5-{2-[(2R)-1,4-dioxaspiro[4.5]dec-2-yl]-2-hydroxyethyl}pyrazin-2-yl)carbonyl]amino)benzoic acid
- 2-[(6-[(acetyloxy)acetyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 30 cyanobenzoic acid
- 2-[(5-(anilinosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(5-[(diethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid

- 2-[[{(7-amino-6-bromo-1-methyl-1H-indol-2-yl)carbonyl}amino]-5-cyanobenzoic acid
- 5-cyano-2-[[{(1-methyl-7-[(phenylacetyl)amino]-4,6-bis[2-(trifluoromethyl)phenyl]-1H-indol-2-yl)carbonyl}amino]benzoic acid
- 5-bromo-2-[[{6-(heptylthio)pyridazin-3-yl}carbonyl}amino]benzoic acid
- 5 5-cyano-2-[[{(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl}amino]benzoic acid
- 2-[[{7-(benzyloxy)-3-bromo-1-methyl-1H-indol-2-yl}carbonyl}amino]-5-cyanobenzoic acid
- 2-[[{(4-bromo-1-methyl-7-[(phenylacetyl)amino]-1H-indol-2-yl)carbonyl}amino]-5-cyanobenzoic acid
- 10 5-cyano-2-[[{(1-methyl-6-[(quinolin-8-ylsulfonyl)amino]-1H-indol-2-yl)carbonyl}amino]benzoic acid
- 5-cyano-2-[[{(5-(morpholin-4-ylsulfonyl)-1,2-benzisoxazol-3-yl)carbonyl}amino]benzoic acid
- 15 5-cyano-2-[[{(6-(cyclobutylmethoxy)-1-methyl-1H-indol-2-yl)carbonyl}amino]benzoic acid
- 2-[[{(6-(butyrylamino)-1-methyl-1H-indol-2-yl)carbonyl}amino]-5-cyanobenzoic acid
- 5-cyano-2-[[{(6-[(methoxyacetyl)amino]-1-methyl-1H-indol-2-yl)carbonyl}amino]benzoic acid
- 20 5-bromo-2-[[{(6-(pentylthio)pyridazin-3-yl)carbonyl}amino]benzoic acid
- 5-cyano-2-[[{(7-methyl-1H-indol-2-yl)carbonyl}amino]benzoic acid
- 5-cyano-2-[[{(6-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl}amino]benzoic acid
- 2-[[{(5-(acetylamino)-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl}amino]-5-cyanobenzoic acid
- 25 5-cyano-2-[[{(5-[(dimethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl}amino]benzoic acid
- 5-cyano-2-[[{(5-[(methoxyacetyl)amino]-1,2-benzisoxazol-3-yl)carbonyl}amino]benzoic acid
- 30 5-cyano-2-[[{(5-[(cyclobutylcarbonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl}amino]benzoic acid
- 5-cyano-2-[[{(6-(2-furoylamino)-1-methyl-1H-indol-2-yl)carbonyl}amino]benzoic acid

- 5-cyano-2-({[1-methyl-6-({[methyl(phenyl)amino]carbonyl}amino)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 2-({[6-(acetyl-amino)-1-methyl-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[1-methyl-6-({[4-(trifluoromethoxy)benzoyl]amino}-1H-indol-2-yl)carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-(2-fluorophenyl)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[6-(cyclopropylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-1H-indol-3-yl]carbonyl}amino}benzoic acid
- 2-({[7-bromo-1-methyl-1H-indol-2-yl]carbonyl]amino}-5-cyanobenzoic acid
- 5-bromo-2-({[5-{2-[(2R)-1,4-dioxaspiro[4.5]dec-2-yl]-2-methoxyethyl}pyrazin-2-yl]carbonyl]amino}benzoic acid
- 5-bromo-2-({[5-{(3R)-2,3,4-trihydroxybutyl}pyrazin-2-yl}carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-methoxy-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-hydroxy-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[6-phenoxy-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[1-methyl-7-[2-(trifluoromethyl)phenyl]-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-cyano-2-({[1-methyl-7-phenyl-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 2-({[7-(4-tert-butylphenyl)-1-methyl-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid
- 5-cyano-2-({[1-methyl-7-(5-methylthien-2-yl)-1H-indol-2-yl]carbonyl}amino)benzoic acid
- 5-cyano-2-({[1-methyl-6-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]amino}benzoic acid
- 5-bromo-2-({[5-{(3R)-2,3,4-trimethoxybutyl}pyrazin-2-yl}carbonyl]amino}benzoic acid
- 5-bromo-2-({[5-{(3R)-3,4-dihydroxy-2-methoxybutyl}pyrazin-2-yl]carbonyl]amino}benzoic acid

- 2-[(5-[3,4-bis(methoxymethoxy)butyl]isoxazol-3-yl)carbonyl)amino]-5-bromobenzoic acid
- 5-cyano-2-([6-([[(2,5-dimethoxyphenyl)amino]carbonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 5 5-cyano-2-([6-[(isoxazol-5-ylcarbonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 5-cyano-2-([[(1-methyl-6-[(pentylamino)carbonyl]amino)-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-([1-methyl-7-[4-(methylsulfonyl)phenyl]-1H-indol-2-yl)carbonyl)amino]benzoic acid
- 10 5-cyano-2-([7-(2-methoxyphenyl)-1-methyl-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([7-(2-fluorophenyl)-1-methyl-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([1-methyl-7-(2-methylphenyl)-1H-indol-2-yl]carbonyl)amino]benzoic acid
- 15 acid
- 5-cyano-2-([6-[(pyridin-4-ylmethyl)thio]pyridazin-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([6-([[(3,5-dimethylisoxazol-4-yl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-([5-(dimethylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 20 5-cyano-2-([5-(ethylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-[(cyclopropylmethyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-[(2-methoxyethyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 25 5-cyano-2-([5-[(2-hydroxyethyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-([5-[(2,3-dihydroxypropyl)amino]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-bromo-2-([5-[(3R)-2-methoxy-3,4-bis(methoxymethoxy)butyl]pyrazin-2-yl]carbonyl)amino]benzoic acid
- 30 2-([6-([bis(butylsulfonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl)amino]-5-cyanobenzoic acid

- 2-[(6-[bis(phenylsulfonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(6-[(2-methoxyethoxy)acetyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5 5-cyano-2-[(1H-indazol-3-ylcarbonyl)amino]benzoic acid
- 5-cyano-2-[(5-(hexylthio)pyridin-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(6-[(2E)-5-hydroxypent-2-enyl]thio)pyridazin-3-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(6-[(2-oxo-2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-6-yl)ethyl]thio)pyridazin-3-yl)carbonyl]amino]benzoic acid
- 10 5-cyano-2-[(5-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-bromo-2-[(5-[(3R)-3-hydroxy-2-methoxy-4-(methoxymethoxy)butyl]pyrazin-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 15 5-cyano-2-[(5-[(dipropylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(5-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 20 5-cyano-2-[(1-methyl-1H-indazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(5-(anilinosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-bromobenzoic acid
- 5-bromo-2-[(5-(morpholin-4-ylsulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 5-bromo-2-[(5-(hexylthio)pyridin-2-yl)carbonyl]amino]benzoic acid
- 25 5-cyano-2-[(1-methyl-6-[(thien-2-ylsulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(1-methyl-6-[(methylamino)carbonyl]amino)-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(6-[(isopropylamino)carbonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 30 5-cyano-2-[(5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid compound with N,N-diethylamine (1:1)

- 2-({(5-{[bis(2-hydroxyethyl)amino]sulfonyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
- 2-({[6-(bis{[4-(acetyl)amino]phenyl}sulfonyl)amino]-1-methyl-1H-indol-2-yl}carbonyl)amino)-5-cyanobenzoic acid
- 5 2-({[6-{bis(thien-2-ylsulfonyl)amino]-1-methyl-1H-indol-2-yl}carbonyl)amino)-5-cyanobenzoic acid
- 5-bromo-2-({[5-{(dimethylamino)sulfonyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 5-bromo-2-({[5-{(diethylamino)sulfonyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 10 2-({[5-{(benzylamino)sulfonyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]-5-bromobenzoic acid
- 2-({[5-(acetyl)amino]-6-[4-(acetyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]-5-bromobenzoic acid
- 15 2-({[5-{3-(acetyl)amino]phenyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]-5-cyanobenzoic acid or 5-Cyano-2-({[5-(3-acetamidophenyl)-benzisoxazole-3-carbonyl]amino}benzoic acid
- 5-cyano-2-({[5-{4-(methylsulfonyl)phenyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 20 5-bromo-2-({[5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 5-bromo-2-({[5-{(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 2-({[5-(aminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-bromobenzoic acid
- 25 5-cyano-2-({[1-methyl-6-[(morpholin-4-ylcarbonyl)amino]-1H-indol-2-yl}carbonyl)amino]benzoic acid
- 5-cyano-2-({[5-{4-(morpholin-4-ylcarbonyl)phenyl]-1,2-benzisoxazol-3-yl}carbonyl)amino]benzoic acid
- 2-({[5-(2-acetylphenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
- 30 5-cyano-2-({[5-(2,5-dimethoxyphenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
- 5-cyano-2-({[5-(2-phenoxyphenyl)isoxazol-3-yl]carbonyl)amino]benzoic acid

- 2-[(7-[3-(acetylamino)phenyl]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-({6-(2-methylphenyl)-1,2-benzisoxazol-3-yl}carbonyl)amino)benzoic acid
- 5-bromo-2-[(5-[(3S)-3,4-dihydroxybutyl]pyrazin-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-({6-(3,5-dimethylisoxazol-4-yl)-1,2-benzisoxazol-3-yl}carbonyl)amino)benzoic acid
- 2-[(5-[2-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(ethylsulfonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 2-[(7-[bis(methylsulfonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(1-methyl-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 2-[(7-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 2-[(7-[(butylsulfonyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(7-[(3-chloropropyl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(7-[(3,5-dimethylisoxazol-4-yl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid
- 2-[(7-[(5-bromo-6-chloropyridin-3-yl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid
- 5-cyano-2-[(1-methyl-7-[(methylsulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(6E)-6-(methoxyimino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino)benzoic acid
- 2-[(6E)-6-[(benzyloxy)imino]-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(6E)-6-(phenoxyimino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino)benzoic acid

- 5-cyano-2-[(1-methyl-7-[(propylsulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5 5-cyano-2-[(1-methyl-7-[(methylsulfonyl)methyl]sulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 2-[(7-[3-(butylamino)-2-hydroxypropoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid hydrochloride
- 5-cyano-2-[(7-[2-hydroxy-3-(2-phenoxyethoxy)propoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 10 5-cyano-2-[(7-[2-hydroxy-3-[(3-methylbut-2-enyl)oxy]propoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 5-cyano-2-[(7-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid
- 15 2-[(7-[3-(but-3-ynloxy)-2-hydroxypropoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(5-[acetyl(ethyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(5-[ethyl(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 20 5-cyano-2-[(5-[(dimethylamino)sulfonyl]amino)-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
- 2-[(6-bromo-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 2-[(6-[2-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 25 cyanobenzoic acid
- 2-[(6-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(6E)-6-(ethoxyimino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino]benzoic acid
- 30 2-[(6E)-6-(tert-butoxyimino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino]-5-cyanobenzoic acid
- 5-cyano-2-[(6E)-6-(hydroxyimino)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2-yl)carbonyl]amino]benzoic acid

- 5-bromo-2-{{[(1,1-dioxido-1,2-benzisothiazol-3-yl)carbonyl]amino} benzoic acid
 2-[(1,2-benzisothiazol-3-ylcarbonyl)amino]-5-bromobenzoic acid
 5-cyano-2-({[7-(2-hydroxy-3-methoxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid
 5 5-cyano-2-({[7-(3-ethoxy-2-hydroxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid
 2-({[7-(3-chloro-2-hydroxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)-5-cyanobenzoic acid
 5-cyano-2-[(1-methyl-7-[(pyridin-4-ylacetyl)amino]-1H-indol-2-yl]carbonyl)amino]benzoic acid trifluoroacetate
 10 5-cyano-2-[(5-[2-(hydroxymethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
 5-cyano-2-[(6-[3-(hydroxymethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
 15 5-cyano-2-[(5-[(methylsulfonyl)amino]-6-[4-[(methylsulfonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
 5-bromo-2-[(6-[(dipropylamino)sulfonyl]-3-pyridinyl]carbonyl)amino]benzoic acid
 5-bromo-2-[(4-[4-chloro(methyl)anilino]sulfonyl]-2-thienyl)carbonyl]amino} benzoic acid
 20 5-bromo-2-[(5-[(4-chloro(methyl)anilino]sulfonyl)-2-thienyl)carbonyl]amino} benzoic acid
 5-bromo-2-[(5-[(4-chloro(methyl)anilino]sulfonyl)-2-furoyl)amino]benzoic acid
 2-({[2-(benzylsulfanyl)-1H-imidazol-4-yl]carbonyl} amino)-5-bromobenzoic acid
 5-bromo-2-[(4-[4-chloro(methyl)anilino]sulfonyl]-5-methyl-2-thienyl)carbonyl]amino} benzoic acid
 25 5-bromo-2-[(4-[4-chloro(methyl)anilino]sulfonyl]-3-methyl-2-thienyl)carbonyl]amino} benzoic acid
 5-bromo-2-[(5-[(4-chloro(methyl)anilino]sulfonyl)-3-thienyl)carbonyl]amino} benzoic acid
 30 5-bromo-2-[(2-thienylcarbonyl)amino]benzoic acid
 2-([2-(benzylsulfanyl)isonicotinoyl]amino)-5-bromobenzoic acid
 5-bromo-2-[(5-[(4-chloro(methyl)anilino]sulfonyl)-3-pyridinyl)carbonyl]amino} benzoic acid

5-bromo-2-{{[(5-{{[4-chloro(methyl)anilino]sulfonyl}-1-oxido-3-pyridinyl)carbonyl]amino}benzoic acid

2-({[4-(benzylsulfanyl)-2-pyridinyl]carbonyl} amino)-5-bromobenzoic acid

2-({[6-(benzylsulfanyl)-2-pyridinyl]carbonyl} amino)-5-bromobenzoic acid.

5 The antibacterial agent may be incorporated into a pharmaceutical composition.

The pharmaceutical compositions of this invention may be prepared by combining the compounds of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

20 Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compound according to this invention.

The quantity of active component, that is the compound according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

In therapeutic use for treating, or combatting, bacterial infections in warm-blooded animals, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about

0.1 to about 100, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered
5 may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., 2-4 four times per day.

10 The compounds according to this invention may be administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound or a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid
15 carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compound of this invention generally will be
20 dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/mL to about 400 mg/mL of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds according to this invention are advantageously administered
25 orally in solid and liquid dosage forms.

As a topical treatment an effective amount of Formula I is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Preparation of such creams and gels is well known in the art and can include penetration enhancers.

30 The antibacterial agents of this invention have useful activity against a variety of organisms. The in vitro activity of compounds of this invention can be assessed by standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilution as described in "Approved Standard. Methods

for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically", 3rd. ed., published 1993 by the National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania, USA.

In some embodiments, the antibacterial compounds are prodrugs of the compounds of formula I. The expression "prodrug" denotes a derivative of a known direct acting drug, which is transformed into the active drug by an enzymatic or chemical process. Prodrugs of the compounds of formula I are prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include, but are not limited to, compounds of structure (I) wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to the animal, cleaves to form the free hydroxyl, amino or sulfhydryl group, respectively. Representative examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups. See Notari, R. E., "Theory and Practice of Prodrug Kinetics," Methods in Enzymology, 112:309-323 (1985); Bodor, N., "Novel Approaches in Prodrug Design," Drugs of the Future, 6(3):165-182 (1981); and Bundgaard, H., "Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities," in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, N.Y. (1985).


The antibacterial compounds of this invention may be synthesized by various methods known to those skilled in the art. Non-limiting examples of synthetic schemes for producing the antibacterial agents are described below.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

Example: 1 R₄ as an INDOLE or Derivative thereof:

Preparation of 7-(benzyloxy)-1H-indole-2-carboxylic acid



- 5 Ethyl 7-(benzyloxy)-1H-indole-2-carboxylate (645 mg, 2.18 mmol) and LiOH•H₂O (480 mg, 11.4 mmol) were combined in THF (10 mL) and H₂O (5 mL) and staken at 45°C overnight. When the reaction was complete, the solution was diluted with MTBE, washed with 2 N HCl and brine, dried (MgSO₄), and concentrated in vacuo to afford 554 mg (95%) of the acid.


10

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.84 (s, 1 H), 11.84 (s, 1 H), 7.65 (d, *J* = 6.97 Hz, 2 H), 7.40 (t, *J* = 6.97 Hz, 2 H), 7.33 (d, *J* = 7.16 Hz, 1 H), 7.22 (d, *J* = 7.91 Hz, 1 H), 7.09 (d, *J* = 2.26 Hz, 1 H), 6.97 (t, *J* = 7.72 Hz, 1 H), 6.86 (d, *J* = 7.15 Hz, 1 H), 5.27 (s, 2 H).

15

Preparation of



20 **Preparation of**



- 25 Ethyl 7-(benzyloxy)-1H-indole-2-carboxylate (10.22 g, 34.6 mmol) was dissolved in DMF (100 mL). NaH (60% dispersion, 2 g) was added and the reaction was stirred for 30 min at rt. MeI (25 mL) was added and solution stirred overnight. The reaction

was diluted with MTBE, washed with H₂O x5, dried (MgSO₄), concentrated to afford 12.16 g (114%) Ethyl 7-(benzyloxy)-1-methyl-1H-indole-2-carboxylate as a yellow solid. The crude material was carried on as is.

- 5 The yellow solid product (7.5 g, 24.2 mmol) and LiOH•H₂O (9 g, 214 mmol) were combined in THF (100 mL) and H₂O (10 mL) and stirred at 45°C overnight. When hydrolysis was complete, the solution was diluted with CH₂Cl₂, washed with 2 N HCl, dried (MgSO₄), and concentrated to afford 5.62 (83%) of the title compound as a white solid.


10

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.85 (br s, 1 H), 7.54 (d, *J* = 6.9 Hz, 2 H), 7.43 (t, *J* = 7.38 Hz, 2 H), 7.36 (d, *J* = 7.08 Hz, 1 H), 7.22 (d, *J* = 6.96 Hz, 1 H), 7.17 (s, 1 H), 6.99 (t, *J* = 7.83 Hz, 1 H), 6.91 (d, *J* = 6.93 Hz, 1 H), 5.25 (s, 2 H), 4.30 (s, 3 H).

15

Example 1.1: *tert*-Butyl 2-([7-(benzyloxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoate



- 7-(Benzyloxy)-1-methyl-1H-indole-2-carboxylic acid (5.62 g, 20.0 mmol) and 4 drops
20 of DMF were combined in CH₂Cl₂ (150 mL). Oxalyl chloride (2.0 mL) was added and the suspension was stirred until clear, 4 hrs. The volatiles were removed in vacuo and the resulting acid chloride was placed under high-vac for 30 minutes to ensure removal of the oxalyl chloride. The acid chloride was re-dissolved in CH₂Cl₂ (70 mL), added to a solution of *tert*-butyl-2-amino-5-cyanobenzoate (4.15 g, 19.0 mmol) in CH₂Cl₂ (70
25 mL) and pyridine (6 mL), and stirred at rt overnight. The solution was diluted with CH₂Cl₂, washed with 2 N HCl, dried (MgSO₄), concentrated, and triturated with MeOH to afford 7.25 g (75%) of the title compound as yellow solid.


Analytical data

- ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.85 (s, 1 H), 8.63 (d, *J* = 8.79 Hz, 1 H), 8.34 (d, *J* = 2.01 Hz, 1 H), 8.08 (dd, *J* = 8.64, 2.07 Hz, 1 H), 7.55 (d, *J* = 6.96 Hz, 2 H), 7.44

30

(t, $J = 7.53$ Hz, 2 H), 7.37 (d, $J = 7.10$ Hz, 1 H), 7.33 (d, $J = 7.35$ Hz, 1 H), 7.22 (s, 1 H), 7.05 (t, $J = 7.92$ Hz, 1 H), 6.95 (d, $J = 7.35$ Hz, 1 H), 5.28 (s, 2 H), 4.29 (s, 3 H), 1.59 (s, 9 H).

5 **Example 1.2: 5-Cyano-2-([(7-hydroxy-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid**




The compound from Example 1.1 (152 mg, 0.316 mmol) was dissolved in CH_2Cl_2 (5 mL). TiCl_4 (1.0 M in CH_2Cl_2 , 10 mL) was added slowly and the reaction was stirred
10 for 20 min. The reaction was quenched with MeOH, concentrated, and triturated with MeOH for afford 63 mg (59%) of the title compound as a white solid.

Analytical data

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.31 (s, 1 H), 9.95 (s, 1 H), 8.82 (d, $J = 6.63$ Hz, 1 H), 8.41 (d, $J = 1.56$ Hz, 1 H), 8.08 (dd, $J = 6.60, 1.59$ Hz, 1 H), 7.15 (s, 1 H), 7.12 (d, $J = 5.52$ Hz, 1 H), 6.90 (t, $J = 5.79$ Hz, 1 H), 6.67 (d, $J = 5.64$ Hz, 1 H), 4.32 (s, 3 H).
15

20 **Example 1.3: 5-Cyano-2-([(1-methyl-7-(3-phenoxypropoxy)-1H-indol-2-yl)carbonyl]amino)benzoic acid**




General method A: The compound of Example 1.1 (500 mg, 1.28 mmol), PPh_3 (677 mg, 2.58 mmol), and 3-phenoxy-1-propanol (388 mg, 2.55 mmol) were combined in THF (10 mL) and cooled in an ice bath. DIAD (570 μL , 2.89 mmol) was added over
25 1 min. The reaction was shaken overnight on an orbital shaking block at rt. The

reaction was absorbed on SiO₂ and purified using silica gel chromatography (EtOAc/Hep: 1/19, 1/4) to afford 261 mg (39%) of the t-Bu ester, 36883-bdw-33. In some occasions a DIAD product co-eluted with the product, in which case the co-elutants were triturated with MeOH to afford the clean desired ester. The ester (255 mg, 485 mmol) and LiOH•H₂O (262 mg, 624 mmol) were dissolved in THF (10 mL) and H₂O (1 mL) and shaken at 45°C overnight. When the hydrolysis was complete, the reaction was diluted with CH₂Cl₂, washed with 2 N HCl, dried (MgSO₄), concentrated and triturated with MeOH to afford 73 mg (32%) of the title compound as a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.81 (d, *J* = 8.80 Hz, 1 H), 8.41 (d, *J* = 2.06 Hz, 1 H), 8.08 (dd, *J* = 8.78, 2.11 Hz, 1 H), 7.31-7.26 (m, 3 H), 7.18 (s, 1 H), 7.06-6.85 (m, 5 H), 4.31-4.29 (m, 5), 4.21 (t, *J* = 6.17 Hz, 2 H), 2.36-2.29 (m, 2 H).


Example 1.4: 2-([7-(Benzyloxy)-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid



General procedure B: The acid, 7-(benzyloxy)-1H-indole-2-carboxylic acid (146 mg, 0.546 mmol) and 2 drops of DMF were combined in CH₂Cl₂ (10 mL). Oxalyl chloride (300 μL) was added and the reaction was stirred for 4 hrs. Heptane was added and the volatiles were removed in vacuo. The resulting acid chloride was dissolved in CH₂Cl₂ (10 mL), added to a solution of tert-butyl 2-amino-5-cyanobenzoate (118 mg, 0.541 mmol) in CH₂Cl₂ (10 mL) and pyridine (1 mL), and the reaction was shaken overnight at rt. The solution was then diluted with MTBE, washed with 2 N HCl and brine, dried (MgSO₄), concentrated, and triturated with MeOH to afford 142 mg (56%) of the title compound as a white solid.

Analytical data


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.48 (s, 1 H), 12.10 (s, 1 H), 8.84 (d, *J* = 8.80 Hz, 1 H), 8.42 (d, *J* = 2.08 Hz, 1 H), 8.10 (dd, *J* = 8.76, 2.09 Hz, 1 H), 7.65 (d, *J* = 7.00, Hz, 2 H), 7.41 (t, *J* = 7.64 Hz, 2 H), 7.34 (d, *J* = 7.36 Hz, 1 H), 7.30 (d, *J* = 7.96 Hz, 1 H), 7.17 (d, *J* = 2.16 Hz, 1 H), 7.02 (t, *J* = 7.88 Hz, 1 H), 6.90 (d, *J* = 7.44 Hz, 1 H), 5.30 (s, 2 H).

Example 1.5: 5-Cyano-2-([7-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid

Prepared according to method A: The compound from example 1.1 (401 mg, 1.02 mmol) and 2,3-dihydro-1,4-benzodioxin-2-ylmethanol (350 mg, 2.11 mmol) afforded 237 mg (42%) of the *t*-Bu ester. The ester (234 mg, 4.34 mmol) was hydrolyzed to afford 125 mg (56%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.41 (s, 1 H), 8.81 (d, *J* = 8.88 Hz, 1 H), 8.41 (d, *J* = 2.08 Hz, 1 H), 8.08 (dd, *J* = 8.88, 2.04 Hz, 1 H), 7.31 (d, *J* = 8.08 Hz, 1 H), 7.20 (s, 1 H), 7.05 (t, *J* = 7.88 Hz, 1 H), 6.94-6.85 (m, 5 H), 4.74-4.68 (m, 1 H), 4.52 (dd, *J* = 11.60, 2.28 Hz, 1 H), 4.44 (dd, *J* = 10.60, 4.10 Hz, 1 H), 4.37 (dd, *J* = 10.36, 5.56 Hz, 1 H), 4.30 (s, 3 H), 4.23 (dd, *J* = 11.40, 7.04 Hz, 1 H).

Example 1.6: 5-Cyano-2-([7-(cyclobutylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid

Prepared according to method A: The compound of example 1.1 (384 mg, 0.981 mmol) and cyclobutane methanol (200 μ L, 2.12 mmol) afforded 299 mg (66%) of the *t*-Bu ester. The ester (242 mg, 0.527 mmol) was hydrolyzed to afford 171 mg (80%) of a white solid following recrystallization with MeOH/CH₂Cl₂.


5

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.81 (d, *J* = 8.80 Hz, 1 H), 8.41 (d, *J* = 2.08 Hz, 1 H), 8.08 (dd, *J* = 8.84, 2.12 Hz, 1 H), 7.26 (d, *J* = 7.48 Hz, 1 H), 7.19 (s, 1 H), 7.02 (t, *J* = 7.80 Hz, 1 H), 6.82 (d, *J* = 7.36 Hz, 1 H), 4.31 (s, 3 H), 4.08 (d, *J* = 6.52 Hz, 2 H), 2.90-2.83 (m, 1 H), 2.14-2.11 (m, 2 H), 1.95-1.89 (m, 4 H).

10

Example 1.7: 5-Cyano-2-[(7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid




15 Prepared according to method A: The compound of example 1.1 (709 mg, 1.81 mmol) and (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol (450 mg, 3.62 mmol) afforded 467 mg (51%) of the *t*-Bu ester. The ester (202 mg, 400 μ mol) was hydrolyzed to afford 127 mg (71%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

20 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.81 (d, *J* = 8.80 Hz, 1 H), 8.41 (d, *J* = 2.04 Hz, 1 H), 8.09 (dd, *J* = 8.80, 2.12 Hz, 1 H), 7.29 (d, *J* = 7.52 Hz, 1 H), 7.20 (s, 1 H), 7.03 (t, *J* = 7.88 Hz, 1 H), 6.86 (d, *J* = 7.40 Hz, 1 H), 4.54 (quintet, *J* = 5.80 Hz, 1 H), 4.31 (s, 3 H), 4.19-4.13 (m, 3 H), 3.89 (dd, *J* = 8.36, 6.04 Hz, 1 H), 1.39 (s, 3 H), 1.33 (s, 3 H).

25


Example 1.8: 5-Cyano-2-([7-(2,3-dihydroxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid

The compound of Example 1.7 (150 mg, 0.334 mmol) was dissolved in CH₂Cl₂ (4 ml),
 5 TFA (3 mL), and H₂O (3 drops) and shaken at rt for 20 min. Heptane was added to
 the solution and the volatiles were removed *in vacuo*. The crude product was purified
 by recrystallization from MeOH/CH₂Cl₂ to afford 74 mg (54%) of a white solid.

Analytical data

10 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.82 (d, *J* = 8.80 Hz, 1 H), 7.41 (d,
J = 2.08 Hz, 1 H), 8.09 (dd, *J* = 8.72, 2.08 Hz, 1 H), 7.26 (d, *J* = 7.96 Hz, 1 H), 7.19
 (s, 1 H), 7.03 (t, *J* = 7.88 Hz, 1 H), 6.82 (d, *J* = 7.64 Hz, 1 H), 4.33 (s, 3 H), 4.15 (dd,
J = 9.76, 4.16 Hz, 1 H), 4.03 (dd, *J* = 9.72, 5.60 Hz, 1 H), 3.91 (quintet, *J* = 5.40 Hz,
 1 H), 3.53 (d, *J* = 5.76 Hz, 2 H).

15

Example 1.9: 5-Cyano-2-([7-(cyclobutyloxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid


Prepared according to method A: The compound of example 1.1 (402 mg, 1.03 mmol)
 20 cyclobutyl alcohol (161 μL, 2.06 mmol) afforded 240 mg (52%) of the *t*-Bu ester.
 The ester (240 mg, 0.539 mmol) was hydrolyzed to afford 154 mg (73%) of a white
 solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

25 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.35 (s, 1 H), 8.81 (d, *J* = 8.80 Hz, 1 H), 8.41 (d,
J = 2.12 Hz, 1 H), 8.08 (dd, *J* = 8.80, 2.12 Hz, 1 H), 7.25 (d, *J* = 7.44 Hz, 1 H), 7.18

(s, 1 H), 7.00 (t, $J = 7.88$ Hz, 1 H), 6.66 (d, $J = 7.44$ Hz, 1 H), 4.84 (quintet, $J = 7.08$ Hz, 1 H), 4.32 (s, 3 H), 2.51-2.48 (m, 2 H), 2.19-2.12 (m, 2 H), 1.90-1.82 (m, 1 H), 1.74-1.68 (m, 1 H).

5 **Example 1.10: 5-Cyano-2-({[7-(2-methoxy-1-methylethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid**




Prepared according to method A: The compound of example 1.1 (428 mg, 1.09 mmol) and 2-hydroxy-1-methoxypropane (220 μ L, 2.25 mmol) afforded 249 mg (49%) of the *t*-Bu ester. The ester (246 mg, 0.531 mmol) was hydrolyzed to afford 138 mg (63%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.40 (s, 1 H), 8.82 (d, $J = 8.82$ Hz, 1 H), 8.41 (d, $J = 2.07$ Hz, 1 H), 8.08 (dd, $J = 8.79, 2.10$ Hz, 1 H), 7.26 (d, $J = 7.50$ Hz, 1 H), 7.18 (s, 1 H), 7.03 (t, $J = 7.86$ Hz, 1 H), 6.91 (d, $J = 7.56$ Hz, 1 H), 4.76 (sextet, $J = 4.55$ Hz, 1 H), 4.29 (s, 3 H), 3.63-3.54 (m, 2 H), 3.32 (s, 3 H), 1.33 (d, $J = 6.21$ Hz, 3 H).


20 **Example 1.11: 5-Cyano-2-({[7-isopropoxy-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid**



Prepared according to method A: The compound of example 1.1 (409 mg, 1.04 mmol) and isopropanol (300 μ L) afforded 291 mg (65%) of the *t*-Bu ester. The ester (288 mg, 0.664 mmol) was hydrolyzed to afford 158 mg (63%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.35 (s, 1 H), 8.81 (d, *J* = 8.82 Hz, 1 H), 8.40 (d, *J* = 2.04 Hz, 1 H), 8.07 (dd, *J* = 8.82, 2.10 Hz, 1 H), 7.24 (d, *J* = 7.92 Hz, 1 H), 7.17 (s, 1 H), 7.02 (t, *J* = 7.89 Hz, 1 H), 6.86 (d, *J* = 7.62 Hz, 1 H), 4.76 (septet, *J* = 6.06 Hz, 1 H), 4.29 (s, 3 H), 1.37 (d, *J* = 6.00 Hz, 6 H).

Example 1.12: 2-({[7-(Benzyloxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid

Prepared according to method B: 7-(benzyloxy)-1-methyl-1H-indole-2-carboxylic acid (7.80 g, 27.7 mmol) and methyl 5-cyanoanthranilate (4.80 g, 27.2 mmol) afforded 8.37 g (70%) of the methyl ester. The ester (398 mg, 0.906 mmol) was hydrolyzed to afford 327 mg (85%) of a white solid.

15 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.39 (s, 1 H), 8.80 (d, *J* = 8.71 Hz, 1 H), 8.40 (d, *J* = 2.08 Hz, 1 H), 8.07 (dd, *J* = 8.71, 2.08 Hz, 1 H), 7.56 (d, *J* = 7.05 Hz, 2 H), 7.44 (t, *J* = 7.26 Hz, 2 H), 7.36 (t, *J* = 7.25 Hz, 1 H), 7.29 (d, *J* = 7.67 Hz, 1 H), 7.19 (s, 1 H), 7.04 (t, *J* = 7.67 Hz, 1 H), 6.94 (d, *J* = 7.47 Hz, 1 H), 5.27 (s, 2 H), 4.30 (s, 3 H).

20 **Example 1.13: 5-Cyano-2-({[7-(cyclopropylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid**


Prepared according to method A: The compound of example 1.1 (399 mg, 1.02 mmol) and cyclopropyl alcohol (180 μL, 2.22 mmol) afforded 249 mg (55%) of the *t*-Bu

ester. The ester (246 mg, 0.552 mmol) was hydrolyzed to afford 154 mg (70%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

- 5 ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.39 (s, 1 H), 8.82 (d, *J* = 8.86 Hz, 1 H), 7.41 (d, *J* = 2.07 Hz, 1 H), 8.08 (dd, *J* = 8.67, 2.07 Hz, 1 H), 7.26 (d, *J* = 7.54 Hz, 1 H), 7.18 (s, 1 H), 7.01 (t, *J* = 6.79 Hz, 1 H), 6.80 (d, *J* = 7.35 Hz, 1 H), 4.35 (s, 3 H), 3.98 (d, *J* = 6.79 Hz, 2 H), 1.41-1.27 (m, 1 H), 0.65-0.59 (m, 2 H), 0.43-0.37 (m, 2 H).

- 10 **Example 1.14: 5-Cyano-2-({[7-(cyclohexylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid**




- Prepared according to method A: The compound of example 1.1 (413 mg, 1.06 mmol) and cyclohexane methanol (150 μL) afforded 261 mg (52%) of the *t*-Bu ester. The
15 ester (257 mg, 0.543 mmol) was hydrolyzed to afford 173 mg (75%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

- 20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.39 (s, 1 H), 8.81 (d, *J* = 8.92 Hz, 1 H), 8.41 (d, *J* = 2.07 Hz, 1 H), 8.08 (dd, *J* = 8.71, 2.07 Hz, 1 H), 7.26 (d, *J* = 7.67 Hz, 1 H), 7.18 (s, 1 H), 7.02 (t, *J* = 7.88 Hz, 1 H), 6.83 (d, *J* = 7.67 Hz, 1 H), 4.30 (s, 3 H), 4.13 (dd, *J* = 6.64, 6.42 Hz, 2 H), 2.06-1.95 (m, 1 H), 1.89-1.77 (m, 4 H), 1.64-1.50 (m, 4 H), 1.22-1.15 (m, 2 H).

- 25 **Example 1.15: 5-Cyano-2-({[7-(2-methoxyethoxy)-1-methyl-1H-indol-2-yl]carbonyl}amino)benzoic acid**




Prepared according to method A: The compound of example 1.1 (411 mg, 1.05 mmol) and 2-methoxy ethanol (170 μ L, 2.16 mmol) afforded 323 mg (68%) of the *t*-Bu ester. The ester (319 mg, 0.638 mmol) was hydrolyzed to afford 228 mg (81%) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.37 (s, 1 H), 8.81 (d, *J* = 8.71 Hz, 1 H), 8.40 (d, *J* = 2.28 Hz, 1 H), 8.07 (dd, *J* = 8.91, 2.07 Hz, 1 H), 7.27 (d, *J* = 8.08 Hz, 1 H), 7.18 (s, 1 H), 7.03 (t, *J* = 7.88 Hz, 1 H), 6.84 (d, *J* = 7.67 Hz, 1 H), 4.31 (s, 3 H), 4.26-4.23 (m, 2 H), 3.79-3.76 (m, 2 H) 3.36 (s, 3 H).

Example 1.16: 5-Cyano-2-((1-methyl-7-(tetrahydro-2H-pyran-2-ylmethoxy)-1H-indol-2-yl)carbonyl)amino)benzoic acid




Prepared according to method A: The compound of example 1.1 (410 mg, 1.05 mmol) and 2-methanol tetrahydropyran (250 μ L) afforded the *t*-Bu ester. The ester was hydrolyzed to afford 180 mg (40% 2-steps) of a white solid following recrystallization with MeOH/CH₂Cl₂.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.37 (s, 1 H), 8.80 (d, *J* = 8.59 Hz, 1 H), 8.39 (d, *J* = 2.53 Hz, 1 H), 8.06 (dd, *J* = 9.10, 2.02 Hz, 1 H), 7.26 (d, *J* = 7.57 Hz, 1 H), 7.17 (s, 1 H), 7.01 (t, *J* = 8.09 Hz, 1 H), 6.81 (d, *J* = 7.58 Hz, 1 H), 4.30 (s, 3 H), 4.06 (d,

$J = 5.05$ Hz, 2 H), 3.96-3.92 (m, 1 H), 3.75-3.71 (m, 1 H), 3.47-3.40 (m, 1 H), 1.87-1.84 (m, 1 H), 1.74-1.70 (m, 1 H), 1.59-1.40 (m, 4 H).

Example 1.17: 5-Cyano-2-([1-methyl-7-(oxiran-2-ylmethoxy)-1H-indol-2-yl]carbonyl)amino)benzoic acid




Prepared according to method A: The compound of example 1.1 (406 mg, 1.04 mmol) and glycidol (170 μ L) afforded 52 mg (11%) the *t*-Bu ester which was hydrolyzed to afford the title compound.

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 11.79 (s, 1 H), 8.62 (d, $J = 8.71$ Hz, 1 H), 8.34 (d, $J = 2.08$ Hz, 1 H), 8.09 (dd, $J = 8.71, 2.08$ Hz, 1 H), 7.33 (d, $J = 7.47$ Hz, 1 H), 7.22 (s, 1 H), 7.04 (t, $J = 7.88$ Hz, 1 H), 6.86 (d, $J = 7.88$ Hz, 1 H), 4.49 (dd, $J = 11.20, 2.49$ Hz, 1 H), 4.30 (s, 3 H), 4.02 (dd, $J = 11.20, 6.22$ Hz, 1 H), 3.49-3.44 (m, 1 H), 2.79 (dd, $J = 4.98, 4.35$ Hz, 1 H), 2.79 (dd, $J = 4.97, 2.69$ Hz, 1 H), 1.58 (s, 9 H).

Example 1.18: 5-Cyano-2-([7-(2-hydroxy-3-isopropoxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid




The epoxide, 5-Cyano-2-([1-methyl-7-(oxiran-2-ylmethoxy)-1H-indol-2-yl]carbonyl)amino)benzoic acid, (50 mg, 0.112 mmol), isopropanol (2 mL), and $\text{Yb}(\text{OTf})_3$ (52 mg), and CH_2Cl_2 (2 mL) were combined and shaken at 45°C overnight. The reaction was diluted with CH_2Cl_2 , washed with H_2O , dried (MgSO_4),

concentrated, and triturated with MeOH to afford 20 mg (36 %) of the *t*-Bu ester, 36883-bdw-108. The ester (20 mg, 0.0399 mmol) was dissolved in THF (10 mL) and H₂O (1 mL) with LiOH (50 mg, 1.19 mmol) and shaken at 45°C overnight. The acid was diluted with CH₂Cl₂, washed with 2 N HCl, dried (MgSO₄), concentrated, and
5 triturated with MeOH to afford 11 mg (61%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.43 (s, 1 H), 8.82 (d, *J* = 8.92 Hz, 1 H), 8.41 (d, *J* = 2.08 Hz, 1 H), 8.09 (dd, *J* = 8.91, 2.07 Hz, 1 H), 7.27 (d, *J* = 7.47 Hz, 1 H), 7.19
10 (s, 1 H), 7.03 (t, *J* = 7.88 Hz, 1 H), 6.82 (d, *J* = 7.47 Hz, 1 H), 4.33 (s, 3 H), 4.12 (dd, *J* = 9.53, 3.94 Hz, 1 H), 4.07-3.99 (m, 2 H), 3.59 (quintet, *J* = 6.22 Hz, 1 H), 3.54-3.46 (m, 2 H), 1.09 (dd, *J* = 6.02, 3.11 Hz, 6 H).

Example 1.19: 5-Cyano-2-([7-(2-furylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl)amino)benzoic acid
15




Prepared according to method A: The compound of example 1.1 (437 mg, 1.16 mmol) and 2-methanol furan (200 μL, 2.31 mmol) afforded 75 mg (14%) of the *t*-Bu ester. The ester (72 mg, 0.157 mmol) was hydrolyzed to afford 19 mg (28%) of a white
20 solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.35 (s, 1 H), 8.80 (d, *J* = 8.80 Hz, 1 H), 8.41 (d, *J* = 2.04 Hz, 1 H), 8.08 (dd, *J* = 8.80, 2.08 Hz, 1 H), 7.74 (s, 1 H), 7.32 (dd, *J* = 7.00, 1.84 Hz, 1 H), 7.19 (s, 1 H), 7.08-7.04 (m, 2 H), 6.65 (d, *J* = 3.16 Hz, 1 H), 6.50 (dd, *J* = 3.12, 1.88 Hz, 1 H), 5.23 (s, 2 H), 4.23 (s, 3 H).
25

Example 1.20: 5-Cyano-2-({[1-methyl-7-(pentyloxy)-1H-indol-2-yl]carbonyl}amino)benzoic acid















Prepared according to method A: The compound of example 1.1 (215 mg, 0.549 mmol) and 1-pentanol (120 μ L, 1.11 mmol) afforded 58 mg (23%) of the *t*-Bu ester. The ester (55 mg, 0.119 mmol) was hydrolyzed to afford 7.0 mg (14%) of a white solid.







Example 1.21-1.121







The following compounds were produced by making non-critical variations to the methods described above.







1.21	
1.23	






1.24	
1.25	
1.26	
1.27	
1.28	
1.29	







1.30	
1.31	
1.32	
1.33	
1.34	
1.35	






1.36	
1.37	
1.38	
1.39	
1.40	
1.41	






1.43	
1.44	
1.45	
1.46	
1.47	
1.48	







1.49	
1.50	
1.51	
1.52	
1.54	
1.55	







1.56	
1.57	
1.58	
1.59	
1.61	







1.62	
1.63	
1.64	
1.65	
1.66	
1.67	







1.68	
1.69	
1.70	
1.71	
1.72	







1.73	
1.74	
1.75	
1.76	
1.77	







1.78	
1.79	
1.80	
1.81	
1.82	
1.83	







1.84	
1.85	
1.86	
1.87	
1.88	
1.89	



1.90	
1.91	
1.92	
1.93	
1.94	
1.95	

1.96	
1.97	
1.98	
1.99	
1.100	
1.101	

1.102	
1.103	
1.104	
1.105	
1.106	
1.107	


1.108	
1.109	
1.110	
1.111	
1.112	
1.113	

1.114	
1.115	
1.116	
1.117	
1.118	
1.119	

1.120	
1.121	

Example 2: R₄ as Benzothiazine and Derivatives thereof


Preparation of 2-(4-Chlorophenyl)-3,4-dihydro-2H-1,2-benzothiazine-7-carboxylic acid 1,1-dioxide



Chlorosulfonic acid (25 mL, 380 mmol, Aldrich) was added to a flask containing 4-(2-chloroethyl)benzoic acid (5.00 g, 27.1 mmol, Lancaster), and the mixture was heated in an 80 °C oil bath for 4.3 hours. The mixture was then poured over ice. The precipitate was extracted into 2 X 200 mL of CH₂Cl₂ to which a small amount of THF was added to help solubility. The organics were dried over MgSO₄ and evaporated leaving 6.82 g of brown solid. To 3.95 g of this sulfonyl chloride was added 4-chloro-N-methylaniline (3.65 g, 28.6 mmol) and toluene (60 mL). Triethylamine (2.0 mL, 14 mmol, Aldrich) was added, and the mixture was heated in a 100 °C oil bath for 4.25 hours. A solution of 3 M aqueous sodium hydroxide (25 mL) was added, and the mixture was heated for a further 15 minutes. The mixture was then added to a separatory funnel with 50 mL of water and 50 mL of MTBE. The aqueous layer was washed with an additional 100 mL of MTBE and then made acidic with concentrated


HCl. Product was extracted into 2 X 150 mL of CH₂Cl₂. The combined CH₂Cl₂ was dried over MgSO₄ and evaporated leaving 1.75 g of brown solid that was carried on without further purification. For the purposes of characterization, 340 mg of the product was recrystallized from hot toluene/THF. The crystals were washed with toluene and dried at 105 °C under vacuum yielding 76 mg of light brown solid.

Example 2.1 Methyl 2-({[2-(4-chlorophenyl)-1,1-dioxido-3,4-dihydro-2H-1,2-benzothiazin-7-yl]carbonyl}amino)-5-cyanobenzoate



To 2-(4-chlorophenyl)-3,4-dihydro-2H-1,2-benzothiazine-7-carboxylic acid 1,1-dioxide (705 mg, 2.09 mmol) in CH₂Cl₂ (30 mL) was added DMF (20 µL) and oxalyl chloride (300 µL, 3.4 mmol). The mixture was stirred for 3.5 hours, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂ (15 mL), and methyl 2-amino-5-cyanobenzoate (310 mg, 1.76 mmol) in pyridine (6 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 mL of 1 M aqueous HCl and 100 mL of brine. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with CH₂Cl₂ as eluent. Yield was 372 mg of white solid.

Example 2.2 2-({[2-(4-Chlorophenyl)-1,1-dioxido-3,4-dihydro-2H-1,2-benzothiazin-7-yl]carbonyl}amino)-5-cyanobenzoic acid



To a mixture of the corresponding methyl ester (276 mg, 0.556 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (1.0 mL). The mixture was stirred at

room temperature for 1.5 hours and then at 50 °C for 20 minutes. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of EtOAc with a small amount of THF added. The organics were washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. They were then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol and then dried at 100 °C under vacuum yielding 116 mg of white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.53 (s, 1 H), 8.78 (d, *J* = 8.8 Hz, 1 H), 8.40 (d, *J* = 2.1 Hz, 1 H), 8.32 (d, *J* = 1.8 Hz, 1 H), 8.18 (dd, *J* = 8.2, 1.9 Hz, 1 H), 8.11 (dd, *J* = 8.8, 2.1 Hz, 1 H), 7.75 (d, *J* = 8.2 Hz, 1 H), 7.46 (d, *J* = 8.8 Hz, 2 H), 7.28 (d, *J* = 8.8 Hz, 2 H), 4.23 (t, *J* = 6.3 Hz, 2 H), 3.29 (t, *J* = 6.3 Hz, 2 H).


Example 3: R₄ as Pyridine or Derivatives thereof


15 Pyridine Synthesis

The synthesis of the pyridine derivative is outlined in Scheme 1. The amide 1 was easily prepared by acylation of 4-chloronicotinic acid. The displacement of the chloride with a thiol nucleophile could be achieved with thioacetate in refluxing methanol affording the desired thiol in modest yield. The conversion of the thiol to a sulfonamide and subsequent hydrolysis afforded the desired acid.

Scheme 1


25



Preparation of 5-Phenoxynicotinonitrile

5 5-Bromonicotinonitrile (915 mg, 5 mmol) and sodium phenoxide (697 mg, 6 mmol, Aldrich) were suspended in dry DMSO (10 mL) and heated to 120 °C for 10 hours. The reaction had stalled at this point and was diluted with EtOAc (200 mL). The organic mixture was washed 2x with 1.0M HCl, 1x with 1.0M NaOH, 1x with water and 1x with brine (175 mL each). The organic layer was dried over MgSO₄, filtered
10 and evaporated. The resultant dark oil was purified on a Biotage Flash 40M (90 g) silica cartridge using 100% CH₂Cl₂. After evaporation the resultant milky oil became a solid and was dried under vacuum at 100 °C to afford 225 mg (23%) of an off-white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.60 (dd, *J* = 6.3, 2.2 Hz, 2 H), 7.42-7.48 (m, 3 H), 7.25-7.30 (m, 1 H), 7.05-7.09 (m, 2 H).

15


Preparation of 5-Phenoxynicotinic acid

20

5-Phenoxynicotinonitrile (196 mg, 1.0 mmol) was dissolved in EtOH (2 mL), and the solution was treated with NaOH (800 mg, 20.0 mmol) in water (10 mL). The colorless solution was refluxed for one hour then stirred at RT overnight. After evaporating the EtOH, the aqueous solution was diluted to 100 mL with water and the solution washed
25 2x with CH₂Cl₂. The aqueous layer was made acidic with concentrated HCl to afford a white precipitate, which was collected by vacuum filtration, washed with water and heptane and dissolved in a mixture of CH₂Cl₂ and THF. The organic solution was dried over MgSO₄, filtered and evaporated. The resultant product was dried at 100 °C

under vacuum to afford 79g (37%) of a white solid. ^1H NMR (400 MHz, $\text{CD}_3\text{OD} + \text{CHCl}_3$) δ 8.93 (s, 1 H), 8.52 (s, 1 H), 7.96 (d, $J = 1.5$ Hz, 1 H), 7.40-7.46 (m, 2 H), 7.22-7.27 (m, 1 H), 7.07-7.10 (m, 2 H), 4.30 (br s, 1 H).

5 **Example 3.1: Methyl 5-cyano-2-[[[(5-phenoxy)pyridin-3-yl]carbonyl]amino]benzoate**




10 5-Phenoxynicotinic acid (75 mg, 0.35 mmol) was suspended in dry CH_2Cl_2 (10 mL) under N_2 and treated with DMF (15 μL) followed by oxalyl chloride (60 μL , 0.70 mmol). Gas evolved as the mixture rapidly became homogenous. After stirring for one hour at RT, the solvent and excess oxalyl chloride were evaporated and the resultant yellowish residue was taken up in dry CH_2Cl_2 (10 mL). Methyl 2-amino-5-

15 cyanobenzoate (61 mg, 0.35 mmol) was added as a solution in dry pyridine (3 mL) and the dark amber solution was stirred at RT overnight. The reaction was poured into CH_2Cl_2 (100 mL) and washed 2x with 1.0M HCl and 1x with brine (75 mL each). The solvents were evaporated and the crude product was purified on a Biotage Flash 40M (90 g) silica cartridge using a step gradient of CH_2Cl_2 to 5% EtOAc in CH_2Cl_2 . After

20 evaporation the resultant solid was dried under vacuum at 100 $^\circ\text{C}$ to afford 68 mg (52%) of a white solid. ^1H NMR (400 MHz, CDCl_3) δ 12.37 (s, 1 H), 9.02 (d, $J = 8.9$ Hz, 1 H), 8.99 (br s, 1 H), 8.61 (br s, 1 H), 8.41 (d, $J = 1.9$ Hz, 1 H), 7.83-7.88 (m, 2 H), 7.45 (t, $J = 7.9$ Hz, 2 H), 7.25 (t, $J = 7.4$ Hz, 1 H), 7.12 (d, $J = 7.7$ Hz, 2 H), 4.01 (s, 3 H).


25

Example 3.2: 5-Cyano-2-[[[(5-phenoxy)pyridin-3-yl]carbonyl]amino]benzoic acid




The corresponding methyl ester (example 3.1, 54 mg, 0.14 mmol) was dissolved in dioxane (10 mL), and the solution was treated with 1.0M LiOH (1.0 mL, 1.0 mmol) turning the solution a light yellow color. After stirring overnight at RT, the reaction was complete by HPLC and the solution was poured into EtOAc (100 mL). The organic layer was washed 2x with 1.0M HCl, 4x with water and 1x with brine (75 mL each). The organic layer was dried over Na₂SO₄ and following evaporation of solvent the resultant white solid was re-crystallized from hot CH₃OH/THF. A second crop of crystals was similarly obtained from the mother liquor. The resultant products were combined and dried at 100 °C under vacuum to afford 17 mg (33%) of straw colored crystals. (~2.5% HCl salt). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.41 (s, 1 H), 8.90 (d, *J* = 1.2 Hz, 1 H), 8.72 (d, *J* = 8.7 Hz, 1 H), 8.65 (d, *J* = 2.7 Hz, 1 H), 8.40 (d, *J* = 1.9 Hz, 1 H), 8.11 (dd, *J* = 8.7, 1.9 Hz, 1 H), 7.79 (t, *J* = 2.1 Hz, 1 H), 7.48 (t, *J* = 7.9 Hz, 2 H), 7.27 (t, *J* = 7.4 Hz, 1 H), 7.18 (d, *J* = 7.7 Hz, 2 H).


15 Preparation of 5-(Ethylthio)nicotinonitrile



5-Bromonicotinonitrile1 (1.83 g, 10 mmol), sodium ethanethiolate (799 mg, 9.5mmol, Aldrich) and a dash of sodium ethoxide were suspended in dry DMF (20 mL) and stirred at RT. A moderate exotherm was noted after five minutes and the reaction was judged complete after 2 hours. The reaction was poured into MTBE (200 mL), and was washed 6x with water, 1x with 1.0M NaOH, 1x with 1.0M HCl, and 1x with brine (175 mL each). The organic layer was evaporated and the resultant oil was purified on a Biotage Flash 40M (90 g) silica cartridge using 0.75% EtOAc in CH₂Cl₂. After evaporation the resultant colorless oil became a solid and was dried under vacuum at RT to afford 848 mg (54%) of an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.79 (d, *J* = 1.9 Hz, 1 H), 8.77 (d, *J* = 2.3 Hz, 1 H), 8.28-8.40 (m, 1 H), 3.13 (q, *J* = 7.3 Hz, 2 H), 1.26 (t, *J* = 7.4 Hz, 3 H).

Preparation of 5-(Ethylthio)nicotinic acid


5-(Ethylthio)nicotinonitrile (569 mg, 3.47 mmol) was dissolved in EtOH (10 mL), and the solution was treated with NaOH (2.77 g, 69.3 mmol) in water (20 mL). The colorless solution was refluxed for one hour during which time the solution became straw colored. After evaporating the EtOH, the aqueous solution was diluted to 175 mL with water and the solution washed 2x with CH₂Cl₂ (200 mL each). The aqueous layer was made acidic with concentrated HCl and extracted 3x with EtOAc. The combined organics were dried over MgSO₄, filtered and evaporated. The resultant white solid was dried at 100 °C under vacuum to afford 561 g (88%) of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.57 (s, 1 H), 8.85 (d, *J* = 1.9 Hz, 1 H), 8.72 (d, *J* = 2.3 Hz, 1 H), 8.11 (t, *J* = 2.2 Hz, 1 H), 3.10 (q, *J* = 7.3 Hz, 2 H), 1.25 (t, *J* = 7.3 Hz, 3 H).

Example 3.3: 5-Cyano-2-([5-(ethylthio)pyridin-3-yl]carbonyl)amino)benzoic acid

5-(Ethylthio)nicotinic acid, (1.95 g, 10.6 mmol) was suspended in dry CH₂Cl₂ (30 mL) under N₂ and treated with DMF (25 μL) followed by oxalyl chloride (1.86 mL, 21.3 mmol). Gas evolved as the mixture rapidly became homogenous. After stirring for one hour at RT, the solvent and excess oxalyl chloride were evaporated and the resultant residue was taken up in CH₂Cl₂ (30 mL). *tert*-Butyl-2-amino-5-cyanobenzoate (2.23 g, 10.7 mmol) was added as a solution in 5 mL dry pyridine and the dark gold solution was stirred at RT for four hours. The cloudy reaction was diluted with CH₂Cl₂ (200 mL), and the organic layer was washed 2x with 1.0M HCl, and 1x with brine (200 mL each). The organic layer was evaporated, and then purified

on a Biotage Flash 40M (90g) silica cartridge using 5% EtOAc in CH₂Cl₂. The solvent was evaporated and the resultant product dried under vacuum at 100 °C to afford 2.89 g (71%) of white solid as the *t*-butyl ester. The *t*-butyl ester (1.0g, 2.61 mmol) was dissolved dry CH₂Cl₂ (10 mL) and was treated with TFA (5.0 mL) turning the mixture yellow. After stirring 24 hours at RT, the reaction was complete by HPLC. The crude product was precipitated by diluting the reaction with CH₃OH and collected by vacuum filtration thru #42 filter paper. The product was washed with CH₃OH, THF, and heptane. The crude product was dried on the filter paper at 100 °C under vacuum to afford 626 mg (73%) of bone white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.39 (s, 1 H), 8.89 (d, *J* = 2.1 Hz, 1 H), 8.76 (d, *J* = 8.5 Hz, 1 H), 8.76 (d, *J* = 2.3 Hz, 1 H), 8.41 (d, *J* = 2.1 Hz, 1 H), 8.18 (t, *J* = 2.1 Hz, 1 H), 8.12 (dd, *J* = 8.7, 2.1 Hz, 1 H), 3.13 (q, *J* = 7.4 Hz, 2 H), 1.29 (t, *J* = 7.3 Hz, 3 H).


Example 3.4: 5-Cyano-2-[[[(6-morpholin-4-yl)pyridin-3-yl]carbonyl]amino]benzoic acid



t-butyl 2-[[[(6-chloropyridin-3-yl)carbonyl]amino]-5-cyanobenzoate (100 mg, 0.28 mmol), morpholine (73 mg, 0.84 mmol) and AgNO₃ (51 mg, 0.28 mmol) were refluxed in Ethanol (30 ml) for 24 h. The resulting mixture was filtrated through celite. The solvent was removed and the residue was loaded on silica gel to be purified by flash chromatography (DCM/MeOH= 50:1) to afford 110 mg (95%) of advanced *t*-butyl ester, 105 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 81 mg (89%) of a yellow solid.

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.28 (s, 1 H), 8.84 (d, *J* = 8.9 Hz, 1 H), 8.72 (d, *J* = 2.3 Hz, 1 H), 8.39 (d, *J* = 2.1 Hz, 1 H), 8.07 (dd, *J* = 2.1, 8.9 Hz, 1 H), 8.02 (dd, *J* = 2.6, 9.1 Hz, 1 H), 7.0 (d, *J* = 8.9 Hz, 1 H), 3.67 (m, 8H);

Example 3.5: 5-Cyano-2-[[[(6-piperidin-1-yl)pyridin-3-yl]carbonyl]amino]benzoic acid

t-butyl 2-[[[(6-chloropyridin-3-yl)carbonyl]amino]-5-cyanobenzoate (100 mg, 0.28 mmol) and piperidine (73 mg, 0.84 mmol) afforded 86 mg (76%) of advanced t-butyl ester, 105 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 62 mg (90%) of a yellow solid.

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.23 (s, 1 H), 8.84 (d, *J* = 9.0 Hz, 1 H), 8.67 (d, *J* = 2.4 Hz, 1 H), 8.38 (d, *J* = 2.0 Hz, 1 H), 8.05 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.95 (dd, *J* = 2.5, 9.1 Hz, 1 H), 6.95 (d, *J* = 9.2 Hz, 1 H), 3.68 (t, *J* = 5.4 Hz, 4 H), 1.65 (m, 2 H), 1.55 (m, 4 H).

Example 3.6: Methyl 2-[[[4-(benzyloxy)pyridin-2-yl]carbonyl]amino]-5-bromobenzoate

To sodium 4-(benzyloxy)pyridine-2-carboxylate, as described by Clark-Lewis et al. in *J. Chem. Soc.* 1961, 189-201, (2.02 g, 8.04 mmol) in CH₂Cl₂ (100 mL) was added DMF (50 μL) and oxalyl chloride (1.4 mL, 16 mmol). The mixture was stirred for 1 hour, and the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was suspended in CH₂Cl₂ (75 mL), and methyl 2-amino-5-bromobenzoate (1.50 g, 6.52 mmol, Avocado) in pyridine (20 mL) was added. The mixture was stirred overnight and then concentrated by rotary evaporation. The residue was added to a separatory funnel with 150 mL of CH₂Cl₂, and this solution was washed with 100 mL of saturated NaHCO₃, 100 mL of 4% aqueous acetic acid, 100 mL of saturated NaHCO₃, and 100 mL of brine. The CH₂Cl₂ was evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica


cartridge with a gradient from 50 % CH₂Cl₂ in heptane to 75% CH₂Cl₂ in heptane as eluent. Yield was 1.52 g of white solid.

Example 3.7: 2-([4-(Benzyloxy)pyridin-2-yl]carbonyl)amino)-5-bromobenzoic acid



To a mixture of the methyl ester from example 3.6 (356 mg, 0.807 mmol) in dioxane (20 mL) was added 1 M aqueous sodium hydroxide (2.0 mL). The mixture was stirred at room temperature for 4 hours and then in a 50 °C oil bath for 1 hour. The reaction mixture was added to a separatory funnel with 100 mL of 1 M aqueous HCl, and the product was extracted into 100 mL of EtOAc. The EtOAc was washed with an additional 100 mL of 1 M aqueous HCl followed by 100 mL of water. It was then dried over MgSO₄ and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 249 mg of white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.00 (s, 1 H), 8.81 (d, *J* = 9.1 Hz, 1 H), 8.56 (d, *J* = 5.8 Hz, 1 H), 8.13 (d, *J* = 2.5 Hz, 1 H), 7.87 (dd, *J* = 9.1, 2.5 Hz, 1 H), 7.76 (d, *J* = 2.5 Hz, 1 H), 7.50 (d, *J* = 6.8 Hz, 2 H), 7.43 (t, *J* = 7.2 Hz, 2 H), 7.37 (t, *J* = 7.2 Hz, 1 H), 7.32 (dd, *J* = 5.7, 2.6 Hz, 1 H), 5.33 (s, 2 H).


Example 3.8: 2-([4-(Benzyloxy)-1-oxidopyridin-2-yl]carbonyl)amino)-5-bromobenzoic acid



To a solution of methyl 2-([4-(benzyloxy)pyridin-2-yl]carbonyl)amino)-5-bromobenzoate (262 mg, 0.593 mmol) in 1,2-dichloroethane (10 mL) was added solid *m*-CPBA (225 mg, 1.30 mmol, Aldrich). The mixture was stirred at room temperature for 3 hours, at 55 °C for 6.5 hours, and then at 75 °C for 8.5 hours. An additional portion of *m*-CPBA (302 mg, 1.75 mmol) was added, and the mixture was heated at

75 °C for an additional 15 hours. The solution was diluted with 100 mL of CH₂Cl₂ and then washed with 100 mL of saturated NaHCO₃. The CH₂Cl₂ was dried over MgSO₄ and evaporated. The residue was dissolved in CH₂Cl₂ and loaded onto a 1" plug of silica gel. Unreacted starting material was eluted with CH₂Cl₂, and the desired N-oxide was eluted with EtOAc. Yield was 137 mg of white solid as the methyl ester. To a solution of the corresponding methyl ester (137 mg, 0.300 mmol) in THF (30 mL) in a 50 °C oil bath was added sodium hydroxide (0.50 mL of 1.0 M solution in water). A precipitate formed within minutes. An additional portion of sodium hydroxide solution (1.0 mL) was added after 1 hour. Heat was removed after an additional 4.2 hours. The reaction mixture was stirred overnight with 100 mL of 1.0 M aqueous HCl and 100 mL of CH₂Cl₂, but the solids did not dissolve. The solids were then filtered, washed with water followed by heptane, and dried at 100 °C under vacuum. Yield was 63 mg of white solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 5.31 (s, 2 H) 7.40 (m, 4 H) 7.49 (m, 2 H) 7.81 (dd, *J*=8.98, 2.59 Hz, 1 H) 7.89 (d, *J*=3.65 Hz, 1 H) 8.01 (d, *J*=2.74 Hz, 1 H) 8.39 (d, *J*=7.00 Hz, 1 H) 8.54 (d, *J*=8.83 Hz, 1 H) 13.68 (s, 1 H) 14.73 (s, 1 H).

Example 3.9: 2-([4-(Benzyloxy)pyridin-2-yl]carbonyl)amino)-5-cyanobenzoic acid



20


To a slurry of sodium 4-(benzyloxy)pyridine-2-carboxylate (2.58 g, 10.3 mmol) in CH₂Cl₂ (100 mL) was added DMF (50 µL) followed by oxalyl chloride (1.8 mL, 21 mmol). It became a solution. Solvent and excess oxalyl chloride were removed by rotary evaporation after 1 hour. The residue was dissolved in CH₂Cl₂ (75 mL), and methyl 2-amino-5-cyanobenzoate (1.61 g, 9.14 mmol) in pyridine (15 mL) was added. The mixture was stirred for 2 days and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 of 1.0 M citric acid and 100 mL of brine. Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using a gradient from 50% CH₂Cl₂ in heptane to 100% CH₂Cl₂. Product was collected as 296 mg of white solid as the methyl ester. To a mixture of

30

the corresponding methyl ester (134 mg, 0.346 mmol) in dioxane (10 mL) was added 1 M aqueous sodium hydroxide (1.0 mL). The mixture was stirred at room temperature for 7 hours and then added to a separatory funnel with 100 mL of 1 M aqueous HCl. The product was extracted into 100 mL of EtOAc. The EtOAc was washed with 100 mL of water. It was then dried over MgSO_4 and evaporated. The residue was recrystallized from hot ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 68 mg of white solid. ^1H NMR (400 MHz, DMSO-D_6) δ ppm 5.34 (s, 2 H) 7.34 (dd, $J=5.85, 2.63$ Hz, 1 H) 7.38 (d, $J=7.31$ Hz, 1 H) 7.43 (t, $J=7.16$ Hz, 2 H) 7.50 (d, $J=7.02$ Hz, 2 H) 7.78 (d, $J=2.63$ Hz, 1 H) 8.11 (dd, $J=8.77, 2.05$ Hz, 1 H) 8.41 (d, $J=2.05$ Hz, 1 H) 8.57 (d, $J=5.55$ Hz, 1 H) 9.00 (d, $J=8.77$ Hz, 1 H) 13.29 (s, 1 H) 14.16 (s, 1 H)


Example 4: R_4 as Nalidixic Acid or Derivative Thereof

Preparation of Nalidixic Acid Chloride (27)




To a solution nalidixic acid (26, 5.8 g, 0.025 mol dissolved 250 mL of CH_2Cl_2) was added DMF (2 drops) and oxalyl chloride (25 mL of a 2 M solution in CH_2Cl_2 , 50 mmol) under a nitrogen atmosphere. After stirring for 20 h, the acid chloride was concentrated to dryness, azeotroped with toluene (2 x 25 mL), dried on a high vacuum overnight, and used in situ for the following reactions.

Example 4.1: Solid Phase Synthesis of 5-Cyano-2-[(1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carbonyl)-amino]benzoic Acid (28)




Resin-bound 5-cyano anthranilic acid (5, 0.5 g, 1.0 mmol/g loading, 500 μ mol) was suspended in pyridine (100 mL) in a 250-mL serum flask equipped with an overhead stirrer. After the addition of nalidixic acid chloride (27, 5 mL of a 1 M solution in CH_2Cl_2 , 10 equiv), the flask was purged with nitrogen and stirred at room temperature for 20 h. The reaction mixture was then drained and the resin washed (CH_3CN , DMF, CH_3CN , DMF, CH_3CN , DMF, H_2O , THF, H_2O , THF, H_2O , THF, CH_3CN , CH_2Cl_2 , CH_3CN , CH_2Cl_2 , CH_2Cl_2 , CH_2Cl_2 , 50 mL each wash). The product was then cleaved from the resin using 50% TFA/ CH_2Cl_2 for 3 h to yield 28 (60 mg, 32%) in 78% reaction purity as determined by HPLC/MS analysis.

Example 4.2: Solution Phase Synthesis of 5-Cyano-2-[(1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carbonyl)-amino]benzoic Acid (28)



To a 250-mL round bottom flask containing *t*-butyl-2-amino-5-cyano-benzoate⁸ (29, 100 mg, 459 μ mol, PHA-561053, lot 34629-tjb-145) was added nalidixic acid chloride (27, 6 mL of a 1 M solution in CH_2Cl_2 , 1.2 equiv) and pyridine (75 mL). Additional nalidixic acid chloride (~0.5 equiv) was added until the aniline was completely consumed as determined by HPLC analysis of the reaction mixture. The reaction mixture was concentrated to a dark brown solid and dried on a high vacuum for 4 h. The solid was dissolved in CH_2Cl_2 (250 mL) and extracted with 2 N NaOH (3 x 250 mL). The combined organic layers were dried over MgSO_4 and concentrated to yield a brown solid. The crude product was dissolved in CH_2Cl_2 (100 mL) and stirred with a 50% TFA/ CH_2Cl_2 solution (50 mL) for 24 h. The reaction mixture was then concentrated and the crude solid triturated with CH_2Cl_2 (5 mL) to yield 67.3 mg (39%) of the corresponding amide (28) in 96% purity: ^1H NMR ($\text{DMSO}-d_6$) δ 13.20 (s, 1H), 9.11 (s, 1H), 8.82 (d, J = 8.84 1H), 8.27 (d, J = 2.08, 1H), 8.01 (dd, J = 2.08, 8.82, 1H), 7.51 (d, J = 8.17, 1H), 4.61 (q, J = 6.87), 2.68 (s, 3H), 1.43 (t, J = 7.03).

Example 5: R4 as Pyrazole or Derivatives Thereof**Pyrazole Synthesis****JFF Scheme 4**

Preparation of 1-Methyl-5-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester [10199-51-6] and 1-Methyl-3-phenyl-1H-pyrazole-5-carboxylic acid ethyl ester [10250-63-2].

- 5 To a mixture of [98-86-2] (50 mL, 0.42 mol) and NaH (60% oil dispersion, 17.5 g, 0.44 mol) in EtOH (1 L) is added diethyloxalate (36.5 mL, 0.42 mol). The reaction mixture is stirred overnight at rt. It is concentrated to give 85 g (92%) of a yellow powder. To a solution of this powder (3.15 g, 14.3 mmol) in a mixture of EtOH (50 mL) and aqueous 3 M HCl (5 mL) is added methylhydrazine (0.76 mL, 14.3 mmol).
- 10 The reaction mixture is stirred overnight. It is concentrated, and the residue is purified by silica chromatography to give the two pyrazole products. [10199-51-6]: R_f = 0.8 (4:1 hexanes/EtOAc); ^1H NMR (CDCl_3 , 400 MHz) δ 7.84 (2H), 7.45 (2H), 7.35 (1H), 4.42 (2H), 4.28 (3H), 1.45 (3H); MS (ESI+) m/z 231.2. [10250-63-2]: R_f = 0.3 (4:1 hexanes/EtOAc); ^1H NMR (CDCl_3 , 400 MHz) δ 7.4 (5H), 6.90 (1H), 4.62 (2H), 4.00
- 15 (3H), 1.44 (3H); MS (ESI+) m/z 231.4.

Preparation of 1-Methyl-5-phenyl-1H-pyrazole-3-carboxylic acid [10199-53-8].

- Using 1.2 g of [10199-51-6], and the procedure described for the preparation of
- 20 [10250-64-3], acid [10199-53-8] is isolated as a powder: MS (ESI-) m/z 185.2.

Preparation of 1-Methyl-3-phenyl-1H-pyrazole-5-carboxylic acid [10250-64-3].

- A mixture of ester [10250-63-2] (1.7 g, 7.4 mmol) and aqueous 1 M KOH (10 mmol)
- 25 in EtOH (20 mL) is stirred for 6 h. The reaction mixture is concentrated, and the residue is partitioned between cold aqueous 1 M HCl and EtOAc. The EtOAc solution is separated. The aqueous solution is further extracted with EtOAc. The combined EtOAc extracts are dried and concentrated to give [10250-64-3] as a powder: MS (ESI-) m/z 185.5.

30

Preparation of 5-Bromo-2-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)carbonyl]amino]benzoic acid methyl ester (JFF-4b).

- To a suspension of acid [10250-64-3] (150 mg, 0.74 mmol) in CH_2Cl_2 is added oxalyl
- 35 chloride (65 μL , 0.74 mmol) and DMF (1 drop). The reaction mixture is stirred at rt for 90 min. It is concentrated to give an oil. The oil is dissolved in CH_2Cl_2 (5 mL), and methyl 5-bromoanthranilate (17 mg, 0.74 mmol), NEt_3 (207 μL , 1.48 mmol), and DMAP (10 mg, 0.074 mol) are added. The reaction mixture is stirred at rt for 72h. It is

quenched with aqueous 1 M HCl (10 mL). The aqueous mixture is extracted with EtOAc. The EtOAc extracts are dried and concentrated to give an oil. The oil is dissolved in CH₂Cl₂, and **4b** is precipitated as a solid by the addition of hexanes: MS (ESI+) *m/z* 415.3.

5

Preparation of 5-Bromo-2-[[[(1-methyl-5-phenyl-1*H*-pyrazol-3-yl)carbonyl]amino]benzoic acid methyl ester (JFF-4a).

Compound **4a** is prepared from [10199-53-8], using the procedure given for JFF-4b:

10 MS (ESI+) *m/z* 415.5.

Example 5.1: 5-Bromo-2-[[[(1-methyl-5-phenyl-1*H*-pyrazol-3-yl)carbonyl]amino]benzoic acid (Example JFF-4).

15 **Example JFF-4** is prepared from **4a** using the procedure given for **Example JFF-5**:MS (ESI+) *m/z* 399.2.

Example 5.2: 5-Bromo-2-[[[(1-methyl-3-phenyl-1*H*-pyrazol-5-yl)carbonyl]amino]benzoic acid (Example JFF-5).

20


To a solution of ester **JFF-4b** (75 mg, 0.18 mmol) in 2:1 MeOH/CH₂Cl₂ (3 mL) is added aqueous 1 M KOH (200 μ L). The reaction mixture is stirred for 4 h. It is concentrated. The residue is partitioned between aqueous 1 M HCl and EtOAc. The EtOAc solution is separated, and the aqueous solution is extracted further with EtOAc.

25 The combined EtOAc extracts are dried and concentrated to give **Example JFF-5** as a solid: MS (ESI-) *m/z* 399.2.

30

35

JFF Scheme 5



Preparation of (\pm)-4-(2,6-Difluorophenyl)-4-hydroxybut-2-ynoic acid ethyl ester (JFF-5a).

A solution of LDA (2.0 M, 17.5 mL) is added to a solution of ethyl propiolate (3.6 mL, 0.035 mol) in THF (0.3 L) at -78°C . The reaction mixture is stirred for 30 min, at which time [437-81-0] (3.8 mL, 0.035 mol) is added. The reaction mixture is stirred at -78°C for 30 min, and then is warmed to rt. It is poured into aqueous 5% CuSO_4 (0.2 L). The aqueous mixture is extracted with EtOAc (2 x 0.1 L). The combined EtOAc extracts are dried and concentrated to give an oil, that is purified by silica flash chromatography (9:1 hexanes:EtOAc) to give 5A: TLC R_f = 0.2 (9:1 hexanes/EtOAc); ^1H NMR (CDCl_3 , 400 MHz) δ 7.4 (1H), 7.0 (2H), 5.91 (1H), 4.3 (2H), 2.81 (1H), 1.35 (3H).

Preparation of 4-(2,6-Difluorophenyl)-4-oxobut-2-ynoic acid ethyl ester (JFF-5B).

To a solution of 5A (4.2 g, 17.5 mmol) in acetone (0.2 L) at 0°C is added dropwise Jones' reagent (2.7 M Cr, 0.54 equiv). The reaction mixture separates into two layers. When the reaction is determined as complete by TLC (30 min), the reaction mixture is diluted with Et_2O and brine. The Et_2O extract is dried and concentrated to give an oil, that is purified by silica chromatography (4:1 hexanes:EtOAc) to give 5B.

Preparation of 3-(2,6-Difluorophenyl)-1-methyl-1H-pyrazole-5-carboxylic acid ethyl ester (JFF-5C, $\text{C}_{13}\text{H}_{12}\text{F}_2\text{N}_2\text{O}_2$).

A mixture of methylhydrazine (228 μL , 4.28 mmol) and 5B (680 mg, 2.86 mmol) in EtOH (30 mL) is refluxed for 4 h. The reaction mixture is evaporated, and the residue is purified by silica chromatography (2:1 hexanes:EtOAc) to give 5C: ^1H NMR (CDCl_3 , 400 MHz) δ 7.3 (1H), 7.2 (1H), 7.0 (2H), 4.4 (2H), 4.3 (3H), 1.4 (3H); MS (FAB) m/z 267.0949; Anal.C 58.64, H 4.56, N 10.06.

Preparation of 3-(2,6-Difluorophenyl)-1-methyl-1H-pyrazole-5-carboxylic acid (JFF-5D).

A mixture of ester 5C (200 mg, 0.75 mmol) and aqueous 1 M KOH (2 mL) in EtOH (3 mL) is stirred for 2 h at rt. The reaction mixture is concentrated, and the residue is partitioned between aqueous 1 M HCl and EtOAc. The EtOAc solution is separated, and the aqueous solution is further extracted with EtOAc. The combined EtOAc


extracts are dried and concentrated to give **5D**: ^1H NMR (CD_3OD , 400 MHz) δ 7.43 (1H), 7.10 (3H), 4.24 (3H).


5-Bromo-2-[[[3-(2,6-difluorophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]-benzoic acid (Example JFF-6, $\text{C}_{18}\text{H}_{12}\text{BrF}_2\text{N}_3\text{O}_3$).

To a suspension of acid **5D** (100 mg, 0.42 mmol) in CH_2Cl_2 (5 mL) is added oxalyl chloride (73 μL , 0.84 mmol). After 2 h the reaction mixture is concentrated, and the residue is dissolved in CH_2Cl_2 (5 mL). Methyl 5-bromoanthranilate (145 mg, 0.63 mmol), Et_3N (176 μL , 1.26 mmol), and DMAP (10 mg, 0.084 mmol) are added. The reaction mixture is stirred at rt for 24 h. It is poured into aqueous 1 M HCl (10 mL). The aqueous mixture is extracted with EtOAc. The EtOAc solution is dried and concentrated. The residue is purified by silica chromatography (4:1 hexanes/EtOAc) to give **5E**, the methyl ester: ^1H NMR (CDCl_3 , 400 MHz) δ 11.97 (1H), 8.78 (1H), 8.26 (1H), 7.73 (1H), 7.35 (1H), 7.23 (1H), 7.06 (2H), 4.38 (3H), 4.02 (3H); MS (ESI+) m/z 451.3. A mixture of **5E** (50 mg) and aqueous 1 M KOH (2 mL) in 2:1 MeOH/ CH_2Cl_2 (3 mL) is stirred at rt for 2 h. The reaction mixture is concentrated, and the residue is partitioned between aqueous 1 M HCl and EtOAc. The EtOAc solution is separated, and the aqueous solution is further extracted with EtOAc. The combined EtOAc extracts are dried and concentrated to give **Example JFF-6**: ^1H NMR (CDCl_3 , 400 MHz) δ 12.29 (1H), 8.65 (1H), 8.2 (1H), 7.61 (1H), 7.25 (1H), 7.14 (1H), 6.95 (2H), 4.27 (3H); MS (FAB) m/z 436.0105.

Example 6: R_4 as Benzisoxazolyl of Derivatives Thereof


Benzisoxazolyl Synthesis



Preparation of 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-cyanobenzoic acid


5 1,2-benzisoxazole-3-carboxylic acid (200 mg, 1.23 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). tert-butyl 2-amino-5-cyanobenzoate (270 mg, 1.23 mmol) was added dropwise as a
10 solution in THF/ pyridine (5 mL/1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by chromatography (1% MeOH in CHCl_3) to give 100 mg of the desired amide (22%). This amide was
15 dissolved in 10 mL CH_2Cl_2 /TFA (1/1) and stirred for 10 hrs at room temperature. The solvent was then removed *in vacuo* and the resulting solid was washed with MeOH, providing 80 mg of the title compound (95%). ^1H NMR (400 MHz, DMSO) 7.59 (t, 1H), 7.81 (t, 1H), 7.96 (d, 1H), 8.16 (dd, 1H), 8.24 (d, 1H), 8.90 (d, 1H), 12.92 (s, 1H).

20

Example 6.1: 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-bromobenzoic acid


1,2-benzisoxazole-3-carboxylic acid (815 mg, 5.0 mmol) was suspended in
25 dichloroethane (DCE) (10 mL). Oxalyl chloride (0.545 mL, 6.25 mmol) was added followed by a catalytic amount of DMF. The reaction was stirred at room temperature for 5 hrs. The solvent was removed *in vacuo*, and the resulting oil was redissolved in

DCE (10 mL). Methyl 2-amino-5-bromobenzoate was added dropwise as a solution in THF/pyridine (5 mL/2 mL). The mixture was stirred for 48 hrs. The resulting solid was filtered and washed with MeOH, giving 925 mg (50%) of the desired amide. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by
 5 acidification to give 608 mg (68%) of the title compound. ¹H NMR (400 MHz, DMSO) 7.58 (t, 1H), 7.78 (t, 1H), 7.92 (dd, 1H), 7.95 (d, 1H), 8.16 (d, 1H), 8.24 (d, 1H), 8.71 (d, 1H), 12.60 (s, 1H).



Preparation of tert-butyl 2-(((5-amino-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoate

10




5-Nitro-1,2-benzisoxazole-3-carboxylic (2.08 g, 10 mmol) was suspended in CH₂Cl₂ (50 mL). Oxalyl chloride (1.1 mL, 12.5 mmol) was added followed by a catalytic amount of DMF. The reaction was stirred at room temperature for 5 hrs. The solvent
 15 was removed *in vacuo*, and the resulting residue was redissolved in CHCl₃ (50 mL). tert-Butyl 2-amino-5-cyanobenzoate was added dropwise as a solution in THF/pyridine (40 mL/10 mL). The mixture was stirred for 12 hrs at room temperature. The resulting solid was filtered and washed with MeOH, giving 2.9 g (72%) of the desired nitro-amide. The nitro-amide was reduced with 10% Pd/C in 100 mL (THF/MeOH,
 20 1/1) with ammonium formate (4.7 g, 75 mmol) as H₂ source. After stirring for 10 hr at

room temperature the mixture was filter and the resulting solids washed with THF.


Excess solvent was removed *in vacuo* and the residue purified by chromatography (1% MeOH in CHCl₃) to give 2.61 g of the title compound (96%). ¹H NMR (400 MHz, CDCl₃) 1.69 (s, 9H), 3.90 (bs, 2H), 7.04 (dd, 1H), 7.49 (m, 2H), 7.84 (dd, 1H), 8.37 (d, 1H), 9.06 (d, 1H), 12.76 (s, 1H).

Example 6.2: 2-([5-(acetylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid



tert-Butyl 2-{[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl₃ (10 ml). Pyridine (1 mL) and acetyl chloride (57 μ L, 0.8 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl₃) to give 203 mg (73%) of the desired acetamide. This amide was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was recrystallized from THF/MeOH to give 170 mg (96%) of the title compound. ¹H NMR (400 MHz, DMSO) 2.10 (s, 3H), 7.86 (m, 2H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.63 (d, 1H), 8.91 (d, 1H), 10.32 (s, 1H), 12.86 (s, 1H).


Example 6.3: 2-([5-(benzoylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid



tert-Butyl 2-{[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl₃ (10 ml). Pyridine (1 mL) and benzoyl


chloride (175 μ L, 1.5 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl_3) to give 214 mg (67%) of the desired phenylamide. This amide was dissolved in 10 mL $\text{CH}_2\text{Cl}_2/\text{TFA}$ (1/1) and stirred for 10
 5 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was recrystallized from THF/MeOH to give 168 mg (88%) of the title compound. ^1H NMR (400 MHz, DMSO) 7.60 (m, 3H), 7.95 (d, 1H), 8.02 (m, 2H), 8.12 (dd, 1H), 8.17 (dd, 1H) 8.45 (d, 1H), 8.81 (d, 1H), 8.92 (d, 1H), 10.62 (s, 1H), 12.92 (s, 1H).

10 **Example 6.4: 5-cyano-2-[(5-[(phenylacetyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid**




tert-Butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl_3 (10 ml). Pyridine (1 mL) and phenylacetyl
 15 chloride (200 μ L, 1.5 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl_3) to give 151 mg (46%) of the desired phenylacetamide. This amide was dissolved in 10 mL $\text{CH}_2\text{Cl}_2/\text{TFA}$ (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining
 20 solid was recrystallized from THF/MeOH to give 92 mg (68%) of the title compound. ^1H NMR (400 MHz, DMSO) 3.70 (s, 2H), 7.30 (m, 5H), 7.89 (m, 2H), 8.16 (dd, 1H), 8.44 (d, 1H) 8.63 (s, 1H), 8.89 (d, 1H), 10.57 (s, 1H), 12.89 (s, 1H).

25 **Example 6.5: 5-cyano-2-[(5-[(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl] amino]benzoic acid**



tert-Butyl 2-(((5-amino-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl_3 (10 mL). Pyridine (1 mL) and methanesulfonyl chloride (116 μL , 1.5 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl_3) to give 234 mg (73%) of the desired methanesulfonamide. This amide was dissolved in 10 mL $\text{CH}_2\text{Cl}_2/\text{TFA}$ (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was recrystallized from THF/MeOH to give 194 mg (95%) of the title compound. ^1H NMR (400 MHz, DMSO) 3.02 (s, 3H), 7.62 (dd, 1H), 7.95 (d, 1H), 8.08 (d, 1H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.63 (d, 1H), 8.91 (d, 1H), 10.09 (s, 1H), 12.87 (s, 1H). MS (CI) m/z (rel. intensity) 418 ($\text{M}+\text{NH}_4$, 100), 260 (7), 241 (9), 230 (10), 180 (33), 152 (19), 136 (87), 118 (64), 88 (19), 74 (43). Anal. Calcd for $\text{C}_{17}\text{H}_{12}\text{N}_4\text{O}_6\text{S}$: C, 51.00; H, 3.02; N, 13.99; S, 8.01. Found: C, 49.27; H, 3.19; N, 13.38.

Example 6.6: 5-cyano-2-(((5-[(phenylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




tert-Butyl 2-(((5-amino-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl_3 (10 mL). Pyridine (1 mL) and benzenesulfonyl chloride (191 μL , 1.5 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl_3) to give 242 mg (67%) of the desired phenylamide. This amide was dissolved in 10 mL $\text{CH}_2\text{Cl}_2/\text{TFA}$ (1/1) and stirred for 10

hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was recrystallized from THF/MeOH to give 201 mg (93%) of the title compound. ¹H NMR (400 MHz, DMSO) 7.55 (m, 4H), 7.76 (m, 2H), 7.85 (d, 1H), 7.95 (d, 1H), 8.16 (dd, 1H) 8.43 (d, 1H), 8.88 (d, 1H), 10.65 (s, 1H), 12.85 (s, 1H).

5


Example 6.7: 2-[(5-[(benzylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid



tert-Butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl₃ (10 ml). Pyridine (1 mL) and α-toluenesulfonyl chloride (200 μL, 1.5 mmol) were then added and the reaction stirred for 10 hrs at room temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl₃) to give 169 mg (48%) of the desired phenylacetamide. This amide was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was recrystallized from THF/MeOH to give 102 mg (68%) of the title compound. ¹H NMR (400 MHz, DMSO) 4.52 (s, 2H), 7.30 (m, 5H), 7.55 (dd, 1H), 7.92 (d, 1H), 8.07 (d, 1H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.93 (d, 1H), 10.21 (s, 1H), 12.94 (s, 1H).

20

Example 6.8: 2-[(6-Chloro-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoic acid




A solution of concentrated sulfuric acid (15 mL) and water (5 mL) was added to a flask containing ethyl 6-chloro-1,2-benzisoxazole-3-carboxylate, as described in *Chem. Pharm. Bull.* 1998, 46, 84-96, (1.99 g, 8.82 mmol), and the resulting mixture was

stirred in an 80 °C oil bath for 1 hour. A thick precipitate had formed which prevented stirring, so another 20 mL of the acid solution was added, and the mixture was stirred for an additional 2 hours at 80 °C. The reaction mixture was then added to water.

The resulting precipitate was washed with water and then dried briefly on a frit with a flow of air. It was then suspended in CH₂Cl₂ (60 mL) and treated with DMF (20 µL) and oxalyl chloride (1.4 mL, 16 mmol). An additional portion of oxalyl chloride (0.4 mL) was added after 35 minutes. After a further 40 minutes, the solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂ (50 mL) and treated with *tert*-butyl 2-amino-5-cyanobenzoate (1.50 g, 6.87 mmol) and pyridine (15 mL). The mixture was stirred overnight and then added to a separatory funnel with CH₂Cl₂ (150 mL). This solution was washed with 1.0 M HCl (2 X 100 mL) and brine (100 mL). Product was adsorbed onto silica gel, divided into two lots, and purified on Biotage Flash 40 M silica gel cartridges using 70% CH₂Cl₂ in heptane as eluent. Product was collected as 2.46 g (70%) of white solid as the *t*-butyl ester. The corresponding *tert*-butyl ester (435 mg, 1.09 mmol) was stirred for 15.5 hours in a mixture of CH₂Cl₂ (30 mL) and TFA (20 mL). The solvents were removed by rotary evaporation, and the residue was recrystallized from ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 250 mg of white solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 7.64 (dd, *J*=8.50, 1.66 Hz, 1 H) 8.16 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.20 (d, *J*=8.71 Hz, 1 H) 8.22 (d, *J*=1.66 Hz, 1 H) 8.44 (d, *J*=2.07 Hz, 1 H) 8.87 (d, *J*=8.92 Hz, 1 H) 12.91 (s, 1 H).


Example 6.9: 5-Bromo-2-[[[(6-chloro-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



A solution of concentrated sulfuric acid (15 mL) and water (5 mL) was added to a flask containing ethyl 6-chloro-1,2-benzisoxazole-3-carboxylate (680 mg, 3.01 mmol), and the resulting mixture was stirred in an 80 °C oil bath for 3.3 hours. The reaction

mixture was then added to water (50 mL). The resulting precipitate was washed with water and then dried briefly on a frit with a flow of air. It was then suspended in CH_2Cl_2 (40 mL) and treated with DMF (20 μL) and oxalyl chloride (0.50 mL, 5.7 mmol). Solvent and excess oxalyl chloride were removed by rotary evaporation after 5 50 minutes. The residue was dissolved in CH_2Cl_2 (30 mL) and treated with *tert*-butyl 2-amino-5-bromobenzoate (528 mg, 1.94 mmol) and pyridine (10 mL). The mixture was stirred overnight and then added to a separatory funnel with CH_2Cl_2 (150 mL). This solution was washed with 1.0 M HCl (2 X 100 mL) and brine (100 mL). Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge 10 using 40% CH_2Cl_2 in heptane as eluent. Product was collected as 690 mg (51%) of white solid as the *t*-butyl ester. The corresponding *tert*-butyl ester (497 mg, 1.10 mmol) was stirred for 6 hours in a mixture of CH_2Cl_2 (15 mL) and TFA (15 mL). Solvents were removed by rotary evaporation, and the residue was recrystallized from THF. The solids were washed with THF followed by heptane and then dried at 100 15 $^\circ\text{C}$ under vacuum yielding 286 mg of white solid. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 7.63 (dd, $J=8.50$, 1.66 Hz, 1 H) 7.91 (dd, $J=9.02$, 2.59 Hz, 1 H) 8.15 (d, $J=2.49$ Hz, 1 H) 8.20 (m, $J=8.91$ Hz, 2 H) 8.67 (d, $J=8.91$ Hz, 1 H) 12.60 (s, 1 H).


Preparation of (5-Bromo-2-fluorophenyl)(hydroxy)acetic acid



20 Trimethylsilyl cyanide (17.5 mL, 131 mmol, Aldrich) was added by syringe to a solution of 5-bromo-2-fluorobenzaldehyde (24.7 g, 122 mmol, Lancaster) and 1,4-diazabicyclo[2.2.2]octane (1.0 g, 8.9 mmol, Aldrich) in CH_2Cl_2 (60 mL) at such a rate that the mixture maintained a moderate reflux. After 20 minutes of stirring, the 25 mixture was diluted with CH_2Cl_2 (150 mL) and washed with water (3 X 150 mL) and brine (150 mL). The organics were dried over Na_2SO_4 and evaporated leaving the silylated cyanohydrin as 35 g of golden oil. This material was treated with concentrated HCl (75 mL) in water (25 mL) and then heated to reflux for 2 hours. The mixture was allowed to cool and then made basic with 6.0 M NaOH. The mixture 30 was diluted with water (300 mL) and washed with CH_2Cl_2 (2 X 250 mL). It was then


made acidic with concentrated HCl, and the product was extracted into CH₂Cl₂ (2 X 250 mL). The organics were dried over Na₂SO₄ and evaporated leaving the product as 21.5 g (71%) of white solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 5.22 (s, 1 H) 6.18 (br s, 1 H) 7.21 (dd, *J*=9.74, 8.91 Hz, 1 H) 7.55 (ddd, *J*=8.71, 4.56, 2.70 Hz, 1 H) 7.62 (dd, *J*=6.32, 2.59 Hz, 1 H) 12.92 (br s, 1 H).

Preparation of Ethyl (5-bromo-2-fluorophenyl)(hydroxy)acetate



- 10 Sulfuric acid (1.0 mL) was added to a solution of 5-bromo-2-fluorophenyl)(hydroxy)acetic acid (20.0 g, 80.3 mmol) in ethanol (150 mL), and the solution was heated at reflux for 22 hours. The ethanol was removed by rotary evaporation, and the residue was dissolved in EtOAc. This solution was washed with saturated NaHCO₃ (2 X 200 mL) and brine (200 mL) and then dried over Na₂SO₄.
- 15 Evaporation yielded the product as 20.6 g (93 %) of golden oil. ¹H NMR (400 MHz, ¹⁹F Decoupled, CHLOROFORM-D) δ ppm 1.24 (t, *J*=7.15 Hz, 3 H) 3.55 (d, *J*=4.98 Hz, 1 H) 4.25 (m, 2 H) 5.35 (d, *J*=4.56 Hz, 1 H) 6.97 (d, *J*=8.92 Hz, 1 H) 7.43 (dd, *J*=8.71, 2.49 Hz, 1 H) 7.53 (d, *J*=2.49 Hz, 1 H).


20 Preparation of Ethyl (5-bromo-2-fluorophenyl)(oxo)acetate



- Acetic anhydride (8.0 mL, 85 mmol, Mallinckrodt) was added dropwise to a solution of ethyl (5-bromo-2-fluorophenyl)(hydroxy)acetate (19.1 g, 68.7 mmol) in DMSO (30 mL) with stirring in a 90 °C oil bath. The heat was removed after 3 hours. Water (10 mL) was added, and the mixture was stirred for 30 minutes before being added to a separatory funnel with EtOAc (100 mL). This mixture was washed with brine (3 X 100 mL) and then dried over MgSO₄. Solvent was removed by rotary evaporation, and the residue was purified by chromatography on a Biotage Flash 75 L silica cartridge using 50 % CH₂Cl₂ in heptane as eluent. Yield was 14.0 g (74%) of white


solid. ^1H NMR (400 MHz, ^{19}F Decoupled, CHCl_3 -D) δ ppm 1.40 (t, $J=7.15$ Hz, 3 H) 4.44 (q, $J=7.26$ Hz, 2 H) 7.08 (d, $J=8.91$ Hz, 1 H) 7.73 (dd, $J=8.81, 2.59$ Hz, 1 H) 8.03 (d, $J=2.70$ Hz, 1 H).

5 **Preparation of Ethyl (5-bromo-2-fluorophenyl)(hydroxyimino)ethanoate**



Hydroxylamine hydrochloride (3.57 g, 51.4 mmol, Mallinckrodt) and sodium acetate (4.39 g, 53.5 mmol, Mallinckrodt) were added as solids to a solution of ethyl (5-bromo-2-fluorophenyl)(oxo)acetate (12.8 g, 46.4 mmol) in ethanol (30 mL). The mixture was stirred at room temperature for 3 hours and then at 50 °C for 1 hour. The mixture was allowed to cool and was then filtered. The precipitate was washed with ethanol, and these washings were added to the filtrate. The filtrate was concentrated to an oil. Water (200 mL) was added, and the product was extracted into EtOAc. The EtOAc was washed with an additional portion of water (100 mL) and then dried over MgSO_4 . Evaporation left the product as 13.6 g (101%) of oil that was used without further purification. NMR and HPLC indicated a mixture of isomers. ^1H NMR (Major Isomer, 400 MHz, ^{19}F Decoupled, $\text{DMSO}-d_6$) δ ppm 1.24 (t, $J=6.95$ Hz, 3 H) 4.24 (q, $J=7.05$ Hz, 2 H) 7.29 (d, $J=8.91$ Hz, 1 H) 7.61 (d, $J=2.49$ Hz, 1 H) 7.68 (dd, $J=8.81, 2.59$ Hz, 1 H) 12.98 (s, 1 H).

20 **Preparation of Ethyl 5-bromo-1,2-benzisoxazole-3-carboxylate**




A mixture of ethyl (5-bromo-2-fluorophenyl)(hydroxyimino)ethanoate (2.15 g, 7.41 mmol) and potassium carbonate (1.13 g, 8.18 mmol, Mallinckrodt) in DMSO (10 mL) was heated in a 100 °C oil bath for 50 minutes. The mixture was diluted with MTBE (100 mL) and washed with water (2 X 100 mL). The organics were evaporated in the presence of silica gel, and the product was purified by chromatography using a Biotage Flash 40 M silica cartridge with 50 % CH_2Cl_2 in heptane as eluent. Yield was 1.44 g


(72%) of white solid. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.40 (t, $J=7.15$ Hz, 3 H) 4.50 (q, $J=7.12$ Hz, 2 H) 7.94 (m, 2 H) 8.19 (m, 1 H).

Example 6.10: 2-[[[(5-Bromo-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-


5 cyanobenzoic acid




A solution of sulfuric acid (37.5 mL) in water (12.5 mL) was added to a flask containing ethyl 5-bromo-1,2-benzisoxazole-3-carboxylate (1.26 g, 4.67 mmol), and the mixture was heated in an 80 °C oil bath for 3.75 hours. The mixture was then added to 150 mL of water. The precipitate was collected, washed with water, and briefly air dried. The resulting white solid (711 mg) was sluried in CH_2Cl_2 (30 mL) and treated with DMF (20 μL) and oxalyl chloride (1.0 mL, 12 mmol). The solvent and excess oxalyl chloride were removed by rotary evaporation after 1.7 hours. The residue was dissolved in CH_2Cl_2 (20 mL) and treated with *tert*-butyl 2-amino-5-cyanobenzoate (547 mg, 2.51 mmol) and pyridine (8 mL). The mixture was stirred overnight and then added to a separatory funnel with 100 mL of EtOAc. A few mL of THF were added to improve solubility. This mixture was washed with 1.0 M HCl (2 X 100 mL) and brine (100 mL). Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using a gradient from 50% CH_2Cl_2 to 75 % CH_2Cl_2 in heptane as eluent. Product was collected as 647 mg (31%) of white solid as the *t*-butyl ester. *tert*-Butyl 2-[[[(5-bromo-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (435 mg, 0.984 mmol) was stirred for 23 hours in a mixture of CH_2Cl_2 (10 mL) and TFA (10 mL). The solvents were removed by rotary evaporation, and the residue was recrystallized from THF/heptane. Yield was 89 mg of white solid. The mother liquor was concentrated, and the residue was recrystallized from EtOH/THF yielding an additional 162 mg of white solid. Total yield was 251 mg (66%). ^1H NMR (DMSO- d_6) δ 12.90 (s, 1 H), 8.86 (d, $J=8.9$ Hz, 1 H), 8.43 (d, $J=2.1$ Hz, 1 H), 8.31-8.32 (m, 1 H), 8.16 (dd, $J=8.8, 2.2$ Hz, 1 H), 7.93-7.98 (m, 2 H).

Example 6.11: 2-[(2,1-Benzisoxazol-3-ylcarbonyl)amino]-5-cyanobenzoic acid

- To a slurry of 2,1-benzisoxazole-3-carboxylic acid, as described in *J. Chem. Soc. (C)* 1970, 2660-2661, (1.01 g, 6.19 mmol) in CH_2Cl_2 (50 mL) was added DMF (20 μL) and oxalyl chloride (2.0 mL, 23 mmol). Solvent and excess oxalyl chloride were removed by rotary evaporation after 2.5 hours of stirring. The residue was dissolved in CH_2Cl_2 (30 mL), and *tert*-butyl 2-amino-5-cyanobenzoate (1.07 g, 4.90 mmol) in pyridine (20 mL) was added. After 3.5 hours, the mixture was diluted with CH_2Cl_2 (100 mL) and washed with 1 M HCl (2 X 100 mL) followed by brine (100 mL). The product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica cartridge using a gradient from 60% to 75% CH_2Cl_2 in heptane as eluent. Product was isolated as 1.16 g of white solid as the *t*-butyl ester. To a solution of the corresponding *tert*-butyl ester (809 mg, 2.23 mmol) in CH_2Cl_2 (25 mL) was added TFA (15 mL). The solvents were removed by rotary evaporation after 23 hours. Methanol was added and then removed by rotary evaporation to remove residual TFA. The residue was then recrystallized from 50 mL of 4:1 ethanol/THF. The collected solids were washed with methanol, CH_2Cl_2 , and heptane and then dried at 100 °C under vacuum yielding 258 mg of pale yellow solid. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 7.39 (dd, $J=8.81, 6.32$ Hz, 1 H) 7.57 (dd, $J=9.12, 6.43$ Hz, 1 H) 7.85 (d, $J=9.12$ Hz, 1 H) 8.03 (d, $J=8.71$ Hz, 1 H) 8.15 (dd, $J=8.71, 2.07$ Hz, 1 H) 8.44 (d, $J=2.28$ Hz, 1 H) 8.86 (d, $J=8.71$ Hz, 1 H) 12.95 (s, 1 H).

Synthesis of 5- and 6- substituted 1,2-benzisoxazole-3-carboxylic acids



Such as described by in JACS 1975 97 7305.

Example 6.13 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-cyanobenzoic acid

1,2-benzisoxazole-3-carboxylic acid (200 mg, 1.23 mmol) was suspended in CH_2Cl_2 (10 mL) and $(\text{COCl})_2$ added (725 mg, 0.5 mL, 5.7 mmol). A catalytic amount of DMF was then added and the mixture stirred for 4 hrs. The solvent was then removed *in vacuo* to give the acid chloride as an oil. The oil was dissolved in CHCl_3 (10 mL). tert-butyl 2-amino-5-cyanobenzoate (270 mg, 1.23 mmol) was added dropwise as a solution in THF/ pyridine (5 mL/1 mL). The solution was stirred at room temperature for an additional 12 hrs then poured into 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried over Na_2SO_4 and concentrated *in vacuo*. The resulting residue was purified by chromatography (1% MeOH in CHCl_3) to give 100 mg of the desired amide (22%). This amide was dissolved in 10 mL CH_2Cl_2 /TFA (1/1) and stirred for 10 hrs at room temperature. The solvent was then removed *in vacuo* and the resulting solid was washed with MeOH, providing 80 mg of the title compound (95%).

20


¹H NMR (400 MHz, DMSO) 7.59 (t, 1H), 7.81 (t, 1H), 7.96 (d, 1H), 8.16 (dd, 1H), 8.24 (d, 1H), 8.90 (d, 1H), 12.92 (s, 1H)

MS (EI) m/z (rel. intensity) 307 (M^+ , 0), 171 (81), 119 (59), 115 (46), 91 (99), 90 (30), 78 (31), 65 (26), 64 (59), 62 (46), 61 (68).

25

HRMS (FAB) calcd for $\text{C}_{16}\text{H}_9\text{N}_3\text{O}_4 + \text{H}$ 308.0671, found 308.0665.


Example 6.14: 2-[(1,2-benzisoxazol-3-ylcarbonyl)amino]-5-bromobenzoic acid



30


- 1,2-benzisoxazole-3-carboxylic acid (815 mg, 5.0 mmol) was suspended in dichloroethane (DCE) (10 mL). Oxalyl chloride (0.545 mL, 6.25 mmol) was added followed by a catalytic amount of DMF. The reaction was stirred at room temperature for 5 hrs. The solvent was removed *in vacuo*, and the resulting oil was redissolved in DCE (10 mL). Methyl 2-amino-5-bromobenzoate was added dropwise as a solution in THF/pyridine (5 mL/2 mL). The mixture was stirred for 48 hrs. The resulting solid was filtered and washed with MeOH, giving 925 mg (50%) of the desired amide. The ester was treated with LiOH in 1:1:1 THF/MeOH/H₂O for 12 hrs followed by acidification to give 608 mg (68%) of the title compound.
- 10 H NMR (400 MHz, DMSO) 7.58 (t, 1H), 7.78 (t, 1H), 7.92 (dd, 1H), 7.95 (d, 1H), 8.16 (d, 1H), 8.24 (d, 1H), 8.71 (d, 1H), 12.60 (s, 1H)

Scheme 8



15

Example 6.16: tert-butyl 2-[[[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate



20

5-Nitro-1,2-benzisoxazole-3-carboxylic (2.08 g, 10 mmol) was suspended in CH₂Cl₂ (50 mL). Oxalyl chloride (1.1 mL, 12.5 mmol) was added followed by a catalytic

amount of DMF. The reaction was stirred at room temperature for 5 hrs. The solvent was removed *in vacuo*, and the resulting residue was redissolved in CHCl₃ (50 mL).


tert-Butyl 2-amino-5-cyanobenzoate was added dropwise as a solution in THF/pyridine (40 mL/10 mL). The mixture was stirred for 12 hrs at room temperature. The

5 resulting solid was filtered and washed with MeOH, giving 2.9 g (72%) of the desired nitro-amide. The nitro-amide was reduced with 10% Pd/C in 100 mL (THF/MeOH, 1/1) with ammonium formate (4.7 g, 75 mmol) as H₂ source. After stirring for 10 hr at room temperature the mixture was filter and the resulting solids washed with THF.

Excess solvent was removed *in vacuo* and the residue purified by chromatography (1%
10 MeOH in CHCl₃) to give 2.61 g of the title compound (96%).

H NMR (400 MHz, CDCl₃) 1.69 (s, 9H), 3.90 (bs, 2H), 7.04 (dd, 1H), 7.49 (m, 2H), 7.84 (dd, 1H), 8.37 (d, 1H), 9.06 (d, 1H), 12.76 (s, 1H).


15 **Example 6.17:** 2-({[5-(acetylamino)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-cyanobenzoic acid



tert-Butyl 2-{{[5-amino-1,2-benzisoxazol-3-yl]carbonyl}amino}-5-cyanobenzoate (250 mg, 0.66 mmol) was dissolved in CHCl₃ (10 mL). Pyridine (1 mL) and acetyl chloride (57 μL, 0.8 mmol) were then added and the reaction stirred for 10 hrs at room
20 temperature. The resulting mixture was absorbed onto silica and purified by chromatography (2% MeOH in CHCl₃) to give 203 mg (73%) of the desired acetamide. This amide was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was
25 recrystallized from THF/MeOH to give 170 mg (96%) of the title compound.

H NMR (400 MHz, DMSO) 2.10 (s, 3H), 7.86 (m, 2H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.63 (d, 1H), 8.91 (d, 1H), 10.32 (s, 1H), 12.86 (s, 1H)


Example 6.18: 2-({[5-(benzoylamino)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid



5 The title compound, 168 mg, was synthesized as above from tert-butyl 2-({[5-amino-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate (250 mg, 0.66 mmol) and benzoyl chloride (175 μ L, 1.5 mmol). H NMR (400 MHz, DMSO) 7.60 (m, 3H), 7.95 (d, 1H), 8.02 (m, 2H), 8.12 (dd, 1H), 8.17 (dd, 1H), 8.45 (d, 1H), 8.81 (d, 1H), 8.92 (d, 1H), 10.62 (s, 1H), 12.92 (s, 1H).

10


Example 6.19: 5-cyano-2-[(5-[(phenylacetyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



15 Synthesized as above from tert-butyl 2-({[5-amino-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate (250 mg, 0.66 mmol) and phenylacetyl chloride (200 μ L, 1.5 mmol) to give 92 mg of the title compound. H NMR (400 MHz, DMSO) 3.70 (s, 2H), 7.30 (m, 5H), 7.89 (m, 2H), 8.16 (dd, 1H), 8.44 (d, 1H), 8.63 (s, 1H), 8.89 (d, 1H), 10.57 (s, 1H), 12.89 (s, 1H).


20

Example 6.20: 5-cyano-2-[(5-[(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




Synthesized as above from tert-butyl 2-[[5-amino-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoate (250 mg, 0.66 mmol) and methanesulfonyl chloride (116 μ L, 1.5 mmol) to give 194 mg of the title compound. ¹H NMR (400 MHz, DMSO) 3.02 (s, 3H), 7.62 (dd, 1H), 7.95 (d, 1H), 8.08 (d, 1H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.63 (d, 1H), 8.91 (d, 1H), 10.09 (s, 1H), 12.87 (s, 1H).

Example 6.21: 5-cyano-2-[[5-[(phenylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid




Synthesized as above from tert-butyl 2-[[5-amino-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoate (250 mg, 0.66 mmol) and benzenesulfonyl chloride (191 μ L, 1.5 mmol) to give 201 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.55 (m, 4H), 7.76 (m, 2H), 7.85 (d, 1H), 7.95 (d, 1H), 8.16 (dd, 1H), 8.43 (d, 1H), 8.88 (d, 1H), 10.65 (s, 1H), 12.85 (s, 1H).

Example 6.22: 2-[[5-[(benzylsulfonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoic acid




Synthesized as above from tert-butyl 2-([(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoate (250 mg, 0.66 mmol) and α -toluenesulfonyl chloride (200 μ L, 1.5 mmol) to give 102 mg of the title compound. ¹H NMR (400 MHz, DMSO) 4.52 (s, 2H), 7.30 (m, 5H), 7.55 (dd, 1H), 7.92 (d, 1H), 8.07 (d, 1H), 8.16 (dd, 1H), 8.45 (d, 1H), 8.93 (d, 1H), 10.21 (s, 1H), 12.94 (s, 1H).

Example 6.23: 5-cyano-2-([(5-([(4-fluorophenyl)sulfonyl]amino)-1,2-benzisoxazol-3-yl)carbonyl]amino) benzoic acid




Synthesized as above from tert-butyl 2-([(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoate (250 mg, 0.66 mmol) and 4-fluorobenzenesulfonyl chloride (200 mg, 1.0 mmol) to give 205 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.40 (m, 2H), 7.49 (dd, 1H), 7.80 (m, 2H), 7.87 (d, 1H), 7.94 (d, 1H), 8.16 (dd, 1H), 8.44 (d, 1H), 8.88 (d, 1H), 10.66 (s, 1H), 12.91 (s, 1H).

Example 6.24: 5-cyano-2-([(5-[(methoxyacetyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino) benzoic acid




Synthesized as above from tert-butyl 2-[[[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (150 mg, 0.44 mmol) and methoxyacetyl chloride (40 μ L, 0.44 mmol) to give 106 mg of the title compound. ¹H NMR (400 MHz, DMSO) 3.41 (s, 3H), 4.07 (s, 2H), 7.90 (d, 1H), 7.96 (dd, 1H), 8.17 (dd, 1H), 8.45 (d, 1H), 8.72 (d, 1H), 8.91 (d, 1H), 10.19 (s, 1H), 12.89 (s, 1H)

Example 6.25: 5-cyano-2-[[[(5-[(cyclobutylcarbonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



Synthesized as above from tert-butyl 2-[[[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (150 mg, 0.44 mmol) and cyclobutylcarbonyl chloride (50 μ L, 0.44 mmol) to give 112 mg of the title compound. ¹H NMR (400 MHz, DMSO) 1.85 (m, 1H), 1.95 (m, 1H), 2.14 (m, 2H), 2.26 (m, 2H), 3.27 (m, 1H), 7.88 (d, 1H), 8.17 (dd, 1H), 8.45 (d, 1H), 8.66 (d, 1H), 8.90 (d, 1H), 10.11 (s, 1H), 12.89 (s, 1H).

Example 6.26: 5-cyano-2-[[[(6-[(methylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




Synthesized as above from tert-butyl 2-[(6-amino-1,2-benzisoxazol-3-yl)carbonylamino]-5-cyanobenzoate (250 mg, 0.66 mmol) and methanesulfonyl

5 chloride (100 μ L, 1.28 mmol) to give 220 mg of the title compound.

¹H NMR (400 MHz, DMSO) 3.19 (s, 3H), 7.35 (dd, 1H), 7.65 (d, 1H), 8.14 (d, 1H), 8.16 (d, 1H), 8.45 (d, 1H), 8.89 (d, 1H), 10.59 (s, 1H), 12.87 (s, 1H)


Example 6.27: 5-cyano-2-[(6-[(phenylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonylamino]benzoic acid



Synthesized as above from tert-butyl 2-[(6-amino-1,2-benzisoxazol-3-yl)carbonylamino]-5-cyanobenzoate (250 mg, 0.66 mmol) and benzenesulfonyl

15 chloride (150 μ L, 1.17 mmol) to give 252 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.29 (dd, 1H), 7.55 (m, 4H), 7.88 (m, 2H), 8.05 (d, 1H), 8.15 (dd, 1H), 8.43 (d, 1H), 11.14 (s, 1H), 12.79 (s, 1H).


Example 6.28: 5-cyano-2-[(6-[(4-fluorophenyl)sulfonyl]amino)-1,2-benzisoxazol-3-yl)carbonylamino]benzoic acid



Synthesized as above from tert-butyl 2-[[6-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (250 mg, 0.66 mmol) and 4-

- 5 fluorobenzenesulfonyl chloride (200 mg, 1.0 mmol) to give 256 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.29 (dd, 1H), 7.42 (m, 2H), 7.57 (d, 1H), 7.94 (m, 2H), 8.07 (d, 1H), 8.16 (dd, 1H), 8.43 (d, 1H), 8.85 (d, 1H), 11.15 (s, 1H), 12.80 (s, 1H).


- 10 **Example 6.29:** 2-[(6-[(benzylsulfonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino-5-cyanobenzoic acid



Synthesized as above from tert-butyl 2-[[6-amino-1,2-benzisoxazol-3-


- 15 yl)carbonyl]amino]-5-cyanobenzoate (250 mg, 0.66 mmol) and α -toluenesulfonyl chloride (200 μ L, 1.5 mmol) to give 140 mg of the title compound. ¹H NMR (400 MHz, DMSO) 5.17 (s, 2H), 7.00 (d, 1H), 7.50 (m, 5H), 7.78 (d, 1H), 8.16 (dd, 1H), 8.43 (d, 1H), 8.87 (d, 1H), 10.21 (s, 1H), 12.78 (s, 1H).

Example 6.30: 2-[[[(6-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid




- 5 Synthesized as above from tert-butyl 2-[[[(6-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (250 mg, 0.66 mmol) to give 165 mg of the title compound. ¹H NMR (400 MHz, DMSO) 6.73 (d, 1H), 6.80 (1H, dd), 7.78 (d, 1H), 8.14 (dd, 1H), 8.43 (d, 1H), 8.87 (d, 1H), 12.70 (s, 1H).

- 10 **Example 6.31:** 5-cyano-2-([5-(ethylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid



- 15 **General Procedure:**




- tert-Butyl 2-[[[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate (150 mg, 0.44 mmol) was suspended in 5 mL of THF/MeOH (1/1). To the suspension was added acetaldehyde (22 μ L, 0.4 mmol), sodium cyanoborohydride (NaCNBH₃) (25 mg, 0.4 mmol) and 0.1 mL of acetic acid (AcOH). The reaction was monitored by HPLC and was diluted with 50 mL of CH₂Cl₂ when complete. The organic solution was washed with brine, dried over Na₂SO₄ and concentrated to a yellow solid. This solid was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 10 hrs at room

temperature. Solvent was removed *in vacuo* and the remaining solid was washed with MeOH to give 60 mg of the title compound. ¹H NMR (400 MHz, DMSO) 1.23 (t, 3H), 3.08 (q, 2H), 7.06 (d, 1H), 7.13 (dd, 1H), 7.65 (d, 1H), 8.13 (dd, 1H), 8.42 (d, 1H), 8.90 (d, 1H), 12.79 (s, 1H)

5

Example 6.32: 5-cyano-2-[(5-[(cyclopropylmethyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




10

Synthesized as above from tert-butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (150 mg, 0.44 mmol) and cyclopropyl carboxaldehyde (33 μ L, 0.45 mmol) to give 58 mg of the title compound. ¹H NMR (400 MHz, DMSO) 0.27 (m, 2H), 0.52 (m, 2H), 1.09 (m, 1H), 2.96 (d, 2H), 7.14 (s, 1H), 7.22 (d, 1H), 7.68 (d, 1H), 8.15 (dd, 1H), 8.44 (d, 1H), 8.91 (d, 1H), 12.80 (s, 1H).

15

Example 6.33: 5-cyano-2-[(5-[(2-methoxyethyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




20

Synthesized as above from tert-butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (150 mg, 0.44 mmol) and methoxyacetaldehyde (40 mg, 0.45 mmol) to give 75 mg of the title compound. ¹H NMR (400 MHz, DMSO) 3.25 (t, 2H), 3.31 (s, 3H), 3.56 (t, 2H), 7.10 (d, 1H), 7.20 (dd, 1H), 7.66 (d, 1H), 8.15 (dd, 1H), 8.44 (d, 1H), 8.92 (d, 1H), 12.79 (s, 1H).

25

Example 6.34: 5-cyano-2-[(5-[(2-hydroxyethyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




5

Synthesized as above from tert-butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (150 mg, 0.44 mmol) and tert-butyl dimethylsiloxyacetaldehyde (85 μ L, 0.45 mmol) to give 111 mg of the title compound. H NMR (400 MHz, DMSO) 3.15 (t, 2H), 3.63 (t, 2H), 7.09 (d, 1H), 7.18 (dd, 1H), 7.65 (d, 1H), 8.15 (dd, 1H), 8.43 (d, 1H), 8.91 (d, 1H), 12.79 (s, 1H).

10

Example 6.35: 5-cyano-2-[(5-[(2,3-dihydroxypropyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




15

Synthesized as above from tert-butyl 2-[(5-amino-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoate (150 mg, 0.44 mmol) and glyceraldehyde dimer (40 mg, 0.21 mmol) to give 91 mg of the title compound. H NMR (400 MHz, DMSO) 2.96 (dd, 1H), 3.22 (dd, 1H), 3.42 (m, 3H), 3.70 (m, 1H), 7.09 (d, 1H), 7.21 (dd, 1H), 7.65 (d, 1H), 8.15 (dd, 1H), 8.43 (d, 1H), 8.92 (d, 1H), 12.81 (s, 1H).


20

Example 6.36a: 5-cyano-2-[(5-(dimethylamino)-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



Synthesized as above from tert-butyl 2-({[5-amino-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate (150 mg, 0.44 mmol), formaldehyde (0.5 mL, 6.25 mmol) and NaCNBH₃ (95 mg, 1.5 mmol) to give 85 mg of the title compound. H NMR (400 MHz, DMSO) 2.99 (s, 6H), 7.24 (d, 1H), 7.35 (dd, 1H), 7.77 (d, 1H), 8.15 (dd, 1H), 8.43 (d, 1H), 8.91 (d, 1H), 12.84 (s, 1H).

Example 6.36b: tert-butyl 2-({[6-(acetyloxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate




6-Hydroxy-1,2-benzisoxazole-3-carboxylic acid (4.5 g, 25 mmol) was dissolved in 25 mL of acetic anhydride. Several drops of concentrated sulfuric acid were added and the solution stirred at room temperature. After 4 h the reaction was poured onto ice and then extracted with CH₂Cl₂. The organic solution was dried over Na₂SO₄ and concentrated to give 6-acetoxy-1,2-benzisoxazole-3-carboxylic acid as white solid. This solid (2.8 g, 12.7 mmol) was suspended in 100 mL CH₂Cl₂ and 2.5 mL of oxalyl chloride was added followed by 10 drops of DMF. The reaction was stirred at room temperature for 3 h. The solution was concentrated to an off white solid and then redissolved in 100 mL CHCl₃. To this solution was added tert-butyl 2-amino-5-cyanobenzoate as a solution in THF/pyridine (40 mL/10 mL). After stirring for 12 h at room temperature the solution was concentrated to a pink solid. The solid was dissolved in EtOAc and washed with 1N HCl. The organic solution was dried over Na₂SO₄ and then concentrated to a white solid which was washed with MeOH to give

2.55 g of the title compound. ¹H NMR (300 MHz, CDCl₃) 1.69 (s, 9H), 2.40 (s, 3H), 7.25 (dd, 1H), 7.53 (d, 1H), 7.86 (dd, 1H), 8.30 (d, 1H), 8.38 (d, 1H), 9.05 (d, 1H), 12.84 (s, 1H).

Example 6.37: 2-({[6-(acetyloxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid

tert-Butyl 2-({[6-(acetyloxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate (250 mg, 0.59 mmol) was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 3 h at room temperature. Solvent was removed *in vacuo* and the remaining solid was washed with MeOH to give 206 mg of the title compound. ¹H NMR (400 MHz, DMSO) 2.35 (s, 3H), 7.39 (dd, 1H), 7.85 (d, 1H), 8.16 (dd, 1H), 8.22 (d, 1H), 8.44 (d, 1H), 8.89 (d, 1H), 12.87 (s, 1H)

Example 6.38a: tert-butyl 5-cyano-2-{{[6-(hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoate




tert-Butyl 2-({[6-(acetyloxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoate (1.93 g, 4.58 mmol) was suspended in 100 mL THF/MeOH (1/1). A solution of K₂CO₃ in 50 mL of H₂O and stirred for 3 h at room temperature. 50 mL of 1 N HCl was added and the resulting precipitate was filtered and dried overnight at 50 C in a vacuum oven to give 1.61 g of the title compound. ¹H NMR (400 MHz, DMSO) 1.60 (s, 9H), 7.04 (dd, 1H), 7.14 (d, 1H), 7.97 (d, 1H), 8.16 (dd, 1H), 8.39 (d, 1H), 8.77 (d, 1H), 10.73 (s, 1H), 12.32 (s, 1H).

Example 6.38b: 5-cyano-2-{{[6-(hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid

tert-Butyl 5-cyano-2-{{[6-(hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoate (250 mg, 0.60 mmol) was dissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 4 h at room temperature. Solvent was removed *in vacuo* and the remaining solid was

washed with MeOH to give 213 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.03 (dd, 1H), 7.13 (d, 1H), 7.99 (d, 1H), 8.16 (dd, 1H), 8.44 (d, 1H), 8.89 (d, 1H), 10.73 (s, 1H), 12.87 (s, 1H)


5 **Example 6.39:** 2-({[6-(benzyloxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid



10


tert-Butyl 5-cyano-2-({[6-(4-hydroxyphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoate (250 mg, 0.66 mmol) was dissolved in 10 mL of THF. To this solution was added
 15 benzyl alcohol (155 μ L, 1.5 mmol), triphenyl phosphine (393 mg, 1.5 mmol) and diethylazodicarboxylate (236 μ L, 1.5 mmol). After stirring at room temperature for 12 h the reaction was diluted with 50 mL of CH₂Cl₂ and filtered through SiO₂. The organic solution was concentrated to a oil and redissolved in 10 mL CH₂Cl₂/TFA (1/1) and stirred for 4 h at room temperature. Solvent was removed *in vacuo* and the remaining
 20 solid was washed with MeOH to give 35 mg of the title compound. ¹H NMR (400 MHz, DMSO) 5.27 (s, 2H), 7.24 (dd, 1H), 7.37 (m, 1H), 7.43 (m, 2H), 7.51 (m, 2H), 7.61 (d, 1H), 8.06 (d, 1H), 8.15 (dd, 1H), 8.44 (d, 1H), 8.89 (d, 1H), 12.84 (s, 1H).

25 **Example 6.40:** 5-cyano-2-({[6-(methoxy)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid



Synthesized as above from tert-butyl 5-cyano-2-[[6-(6-hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate (250 mg, 0.66 mmol) and MeOH (60 μ L, 1.5 mmol) to give 154 mg of the title compound. ¹H NMR (400 MHz, DMSO) 3.91 (s, 3H), 7.17 (dd, 1H), 7.51 (d, 1H), 8.04 (d, 1H), 8.15 (dd, 1H), 8.44 (d, 1H), 8.89 (d, 1H), 12.81 (s, 1H).


Example 6.41: 2-[(6-[(benzylsulfonyl)oxy]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid



tert-Butyl 5-cyano-2-[[6-(6-hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate (250 mg, 0.66 mmol) was dissolved in CHCl_3 (10 mL). Pyridine (1 mL) and α -toluenesulfonyl chloride (400 mg, 2.1 mmol) were then added and the reaction stirred for 12 h at 50 $^\circ\text{C}$. The solvent was removed *in vacuo* and the resulting solid washed with MeOH. This solid was dissolved in 10 mL CH_2Cl_2 /TFA (1/1) and stirred for 10 hrs at room temperature. Solvent was removed *in vacuo* and the remaining solid was


washed with MeOH to give 240 mg of the title compound. ¹H NMR (400 MHz, DMSO) 5.14 (s, 2H), 7.45 (m, 3H), 7.54 (m, 2H), 7.92 (d, 1H), 8.17 (dd, 1H), 8.27 (d, 1H), 8.45 (d, 1H), 8.89 (d, 1H), 12.91 (s, 1H).

- 5 **Example 6.42:** 5-cyano-2-[(6-[(phenylsulfonyl)oxy]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



- 10 Synthesized as above from tert-butyl 5-cyano-2-[(6-hydroxy-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate (250 mg, 0.66 mmol) and benzenesulfonyl chloride (400 μ L, 3.1 mmol) to give 235 mg of the title compound. ¹H NMR (400 MHz, DMSO) 7.24 (dd, 1H), 7.70 (t, 2H), 7.80 (d, 1H), 7.86 (t, 1H), 7.92 (m, 2H), 8.17 (dd, 1H), 8.19 (d, 1H), 8.45 (d, 1H), 8.85 (d, 1H), 12.86 (s, 1H).


- 15 **Example 6.43:** Methyl 5-bromo-2-([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoate



- 20 Ethyl-1,2-benzisoxazole-3-carboxylate (10 g, 52 mmol) was dissolved in 100 mL of chlorosulfonic acid and heated to 80 C. After 16 h the reaction was cooled to room temperature, poured onto ice and then extracted with EtOAc. The organic solution was dried over Na₂SO₄ and then concentrated to a brown oil. This oil was dissolved in

60 mL of thionyl chloride and heated to 50 C. After 6 h excess reagent was removed *in vacuo* and the remaining residue dissolved in 300 mL CHCl₃. Methyl-2-amino-5-bromobenzoate was added as a solution in 100 mL CHCl₃ and 10 mL pyridine. After stirring overnight at room temperature the resulting precipitate was filtered providing
5 3.96 g of the title compound. ¹H NMR (400 MHz, CDCl₃) 3.80 (s, 3H), 7.77 (dd, 1H), 7.92 (d, 1H), 8.27 (d, 1H), 8.32 (dd, 1H), 8.82 (d, 1H), 9.12 (d, 1H), 12.63 (s, 1H)


Example 6.44: 5-bromo-2-({[5-(morpholin-4-ylsulfonyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid



10

Methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoate (250 mg, 0.53 mmol) was suspended in 5 mL of THF. Morpholine (0.5 mL, 5.7 mmol) was added and the reaction warmed to 50 C. Solvent was
15 removed *in vacuo* and the resulting solid washed with MeOH. This solid was suspended in 5 mL THF and 1 mL water and 50 mg LiOH was added. After 5 h the reaction was acidified with 1 N HCl and extracted with EtOAc. The organic solution was dried over Na₂SO₄ and concentrated to a white solid which was suspended in MeOH and filtered giving 140 mg of the title compound. ¹H NMR (400 MHz, DMSO)
20 2.94 (m, 4H), 3.65 (m, 4H), 7.93 (dd, 1H), 8.11 (dd, 1H), 8.16 (d, 1H), 8.23 (d, 1H), 8.54 (d, 1H), 8.69 (d, 1H), 12.68 (s, 1H).


Example 6.45: 2-({[5-(anilinosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-bromobenzoic acid



25

Synthesized as above from methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)benzoate (250 mg, 0.53 mmol) and aniline (0.5 mL, 5.3 mmol) to give 99 mg of the title compound. H NMR (400 MHz, DMSO) 7.04 (t, 1H), 7.11 (d, 2H), 7.23 (2H), 7.93 (dd, 1H), 8.07 (dd, 1H), 8.12 (d, 1H), 8.16 (d, 1H), 8.64 (d, 1H), 8.67 (d, 1H), 10.52 (s, 1H), 12.68 (s, 1H).

Example 6.46: 2-({[5-(dimethylaminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-bromobenzoic acid




10

Synthesized as above from methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)benzoate (250 mg, 0.53 mmol) and dimethylamine (1.0 mL, 2.0 mmol) to give 130 mg of the title compound. H NMR (400 MHz, DMSO) 2.67 (s, 6H) 7.93 (dd, 1H), 8.13 (dd, 1H), 8.16 (d, 1H), 8.21 (d, 1H), 8.54 (d, 1H), 8.69 (d, 1H), 12.67 (s, 1H).

15

Example 6.47: 2-({[5-(diethylaminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-bromobenzoic acid




20

Synthesized as above from methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)benzoate (250 mg, 0.53 mmol) and diethylamine (0.2 mL, 1.94 mmol) to give 150 mg of the title compound. H NMR (400 MHz, DMSO) 1.07 (t, 3H), 3.22 (q, 2H), 7.93 (dd, 1H), 8.16 (m, 3H), 8.58 (t, 1H), 8.69 (d, 1H), 12.66 (s, 1H).

25

Example 6.48: 2-({[5-(benzylaminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-bromobenzoic acid




5

Synthesized as above from methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)benzoate (250 mg, 0.53 mmol) and benzylamine (0.2 mL, 1.83 mmol) to give 131 mg of the title compound. H NMR (400 MHz, DMSO) 4.04 (d, 2H), 7.19 (m, 5H), 7.93 (dd, 1H), 8.11 (d, 1H), 8.17 (d, 1H), 8.46 (t, 1H), 8.58 (t, 1H), 8.69 (d, 1H), 12.66 (s, 1H).

10

Example 6.49: 2-({[5-(aminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-bromobenzoic acid




15

Synthesized as above from methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)benzoate (250 mg, 0.53 mmol) and ammonia (4.0 mL, 2.0 mmol) to give 220 mg of the title compound. H NMR (400 MHz, DMSO) 7.63 (s, 2H), 7.93 (dd, 1H), 8.16 (m, 3H), 8.69 (dd, 1H), 12.67 (s, 1H).


20

Example 6.50: 2-({[5-(methylaminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl} amino)-5-bromobenzoic acid




Synthesized as above from methyl 5-bromo-2-((5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl) amino)benzoate (250 mg, 0.53 mmol) and methylamine (5.0 mL, 10
5 mmol) to give 300 mg of the title compound. ¹H NMR (400 MHz, DMSO) 2.45 (d, 3H), 7.75 (q, 1H), 7.93 (dd, 1H), 8.16 (m, 3H), 8.64 (d, 1H), 8.69 (d, 1H), 12.65 (s, 1H).

Example 6.51: 2-((5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl)carbonyl) amino)-5-bromobenzoic acid
10




Synthesized as above from methyl 5-bromo-2-((5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl) amino)benzoate (250 mg, 0.53 mmol) and pyrrolidine (.125 mL, 1.5
15 mmol) to give 260 mg of the title compound. ¹H NMR (400 MHz, DMSO) 1.67 (m, 4H) 3.20 (m, 4H), 7.93 (dd, 1H), 8.13 (dd, 1H), 8.16 (d, 1H), 8.19 (m, 2H), 8.58 (t, 1H), 8.69 (d, 1H), 12.67 (s, 1H).

Example 6.52: 5-Cyano-2-((6-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl) amino)benzoic acid
20



Preparation Pa: Ethyl 6-(2-methylphenyl)benzoisoxazole-3-carboxylate.




- 5 A mixture of ethyl 6-bromobenzoisoxazole-3-carboxylate (550 mg, 1.39 mmol), *o*-tolylboronic acid (377 mg, 1.5 eq), Pd(PPh₃)₄ (171 mg, 0.08 eq), toluene (10 mL), ethanol (1.5 mL), and 1 M Na₂CO₃ (1.5 mL) is stirred at reflux for 3.5 h. The reaction mixture is diluted with CH₂Cl₂ (0.1 L) and H₂O (0.1 mL). The CH₂Cl₂ solution is dried (Na₂SO₄), filtered, and evaporated. The residue is purified by silica chromatography
- 10 (heptane/EtOAc) to give **Preparation Pa**: ¹H NMR (300 MHz, CDCl₃) δ 8.14 (1H), 7.61 (2H), 7.42 (1H), 7.35-7.2 (1H), 4.59 (2H), 2.28 (3H), 1.51 (3H).

- A mixture of **Preparation Pa** (440 mg, 1.6 mmol) and 5-cyanoanthranilic acid (260 mg, 1.6 mmol) and 3 equiv of NaH (192 mg of 60% NaH in mineral oil) in DMF (3
- 15 mL) at rt under N₂ is stirred overnight. The reaction mixture is added dropwise to 0.1 L of aq 1 N HCl. The precipitated solid is collected and washed with water, heptane and iPrOH. It is recrystallized from EtOH to give a white solid: ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.94 (1H), 8.45 (1H), 8.28 (1H), 8.18 (1H), 7.91 (1H), 7.56 (1H), 7.40-7.25 (4H) 2.24 (3H); MS (ESI-) *m/z* 396.22; Anal. C 69.19, H 3.85, N 10.64.


20

Example 6.53: 5-Cyano-2-([6-(3,5-dimethylisoxazol-4-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid




This example, prepared from ethyl 6-(3,5-dimethyl)-3-isoxazolecarboxylate and 1,1-dimethyl 5-cyanoanthranilate as described for **Example 6.53**, is isolated as a solid: ^1H NMR (300 MHz, DMSO- d_6) δ 8.94 (1H), 8.42 (1H), 8.32 (1H), 8.20 (1H), 8.05 (1H), 7.63 (1H), 2.30 (6H); MS (ESI-) m/z 401.14; H_2O 4.19% (0.98 equiv); Anal. C 59.89, H 3.86, N 13.27.

Example 6.54: 5-Cyano-2-[(5-[4-(morpholin-4-ylcarbonyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



Preparation Pb:



1,1-Dimethylethyl 2-[(6-bromobenzoisoxazole-3-carbonyl)amino]-5-cyanobenzoate.

To a mixture of ethyl 6-bromobenzoisoxazole-3-carboxylate (2.0 g, 7.4 mmol) and *t*-butyl 5-cyanoanthranilate (1.62 g, 7.4 mmol) in toluene (27 mL) is added NaH (1.5 g of a 60% mineral oil dispersion, 3.8 mmol) under N_2 . The reaction mixture is stirred

overnight at rt. This mixture is diluted with aq 1 N HCl, extracted with EtOAc (0.2 L). The EtOAc solution is dried and concentrated to give **Preparation Pb** as a solid: ^1H NMR (300 MHz, CDCl_3) δ 12.8 (1H), 9.05 (1H), 8.38 (1H), 8.18 (1H), 7.92 (1H), 7.82 (1H), 7.61 (1H), 1.69 (9H).

5


Preparation Pc:

1,1-Dimethylethyl 2-[(5-bromobenzoisoxazole-3-carbonyl)amino]-5-cyanobenzoate.

This Preparation is made from ethyl 5-bromobenzoisoxazole-3-carboxylate and t-butyl 5-cyanoanthranilate by the procedure given for **Preparation Pb**.

10

Preparation Pd:




1,1-Dimethylethyl 5-cyano-2-[(5-{4-(morpholin-4-carbonyl)phenyl}benzo[d]isoxazole-3-carbonyl)amino]benzoate. A mixture of **Preparation Pc** (615 mg, 1.39 mmol), 4-(morpholin-4-ylcarbonyl)phenylboronic acid (536 mg, 1.5 equiv), $\text{Pd}(\text{PPh}_3)_4$ (118 mg, 0.08 equiv), toluene (15 mL), EtOH (2 mL), and 1 M aq Na_2CO_3 (2 mL) is stirred at reflux for 2.75 h. The reaction mixture is diluted with CH_2Cl_2 . The reaction mixture is filtered through Celite. The CH_2Cl_2 solution is dried (Na_2SO_4), filtered, and evaporated. The residue is triturated with hot MeOH (50 mL). After cooling to rt a solid is collected by filtration. The solid is washed with MeOH and heptane, and dried to give **Preparation Pd** as an off-white solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.85 (1H), 8.43 (1H), 8.39 (1H), 8.11 (1H), 8.09 (1H), 8.02 (1H), 7.81 (2H), 7.57 (2H), 3.8-3.4 (8H), 1.65 (9H).

25


This Example, made by TFA deprotection of **Preparation Pd** is isolated as a solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.97 (1H), 8.94 (1H), 8.41 (1H), 8.10 (6H), 7.80

(1H), 7.53 (1H), 3.7 (8H); MS (CI) m/z (rel intensity) 497; Anal. C 65.33, H 4.04, N 11.28.

Example 6.55: 2-({[5-(2-Acetylphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid



Preparation Pe:



10



1,1-Dimethylethyl 2-({[5-(2-acetylphenyl)benzo[d]isoxazole-3-carbonyl]amino}-5-cyano-benzoate. This Preparation, made from Preparation Pc and 2-acetylphenylboronic acid by the procedure given for Preparation Pd, is isolated as a solid: ^1H NMR (300 MHz, CDCl_3) δ 12.86 (1H), 9.04 (1H), 8.49 (1H), 8.39 (1H), 7.82 (1H), 7.72 (1H), 7.67 (1H), 7.4-7.6 (4H), 2.19 (3H), 1.69 (9H).

15

This Example, made by TFA deprotection of Preparation Pe is isolated as solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.85 (1H), 8.95 (1H), 8.41 (1H), 8.15 (1H), 8.07 (1H), 7.99 (1H), 7.6 (5H), 2.25 (3H); MS (ESI-) m/z 424.25 (calcd $[\text{M}-\text{H}]^-$ 424.09);

20

Example 6.56: 5-Cyano-2-({[5-(2,5-dimethoxyphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid

**Preparation Pf:**


- 5 **1,1-Dimethylethyl 5-cyano-2-({[5-(2,5-dimethoxyphenyl)benzo[d]isoxazole-3-carbonyl]-amino}benzoate.** This Preparation, made from **Preparation Pc** and 2,5-dimethoxyphenylboronic acid by the procedure given for **Preparation Pd**, is isolated as a solid: ^1H NMR (300 MHz, CDCl_3) δ 12.83 (1H), 9.04 (1H), 8.51 (1H), 8.45 (1H), 7.8-7.9 (2H), 7.70 (1H), 6.85-7.0 (3H), 3.78 (3H), 3.82 (3H), 1.69 (9H).

10

This Example, made by TFA deprotection of **Preparation Pf** is isolated as solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.93 (1H), 8.92 (1H), 8.43 (1H), 8.35 (1H), 8.10 (1H), 7.95 (1H), 7.86 (1H), 7.10 (1H), 6.94 (1H), 3.75 (3H), 3.70 (3H); MS (ESI-) m/z 442.24; Anal. C 64.93, H 3.90, N 9.52.

15


Example 6.57: 5-Cyano-2-({[5-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid

Preparation Pg:


1,1-Dimethylethyl 5-cyano-2-[[5-(2-methylphenyl)benzoxazol-3-yl]carbonyl]amino}-benzoate. This Preparation, made from Preparation Pc and 2-methylphenylboronic acid by the procedure given for Preparation Pd, is isolated as a solid: ^1H NMR (300 MHz, CDCl_3) δ 12.80 (1H), 9.03 (1H), 8.36 (1H), 8.24 (1H), 7.81 (1H), 7.72 (1H), 7.61 (1H), 7.2-7.35 (4H), 2.28 (3H), 1.66 (9H).

This Example, made by TFA deprotection of Preparation Pg is isolated as solid: MS (ESI-) m/z 396.23; MS (FAB+) m/z 397.1070; H_2O 1.98% (0.45 equiv); Anal. C 68.96, H 3.86, N 10.52.

Example 6.58: 5-Cyano-2-[[5-[4-(methylsulfonyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid



Preparation Ph:




1,1-Dimethylethyl 5-cyano-2-[[5-(4-methylsulfonyl)phenyl]benzoxazol-3-yl]-carbonyl]-amino}benzoate. This Preparation, made from Preparation Pc and 4-methylsulfonyl-phenylboronic acid by the procedure given for Preparation Pd, is isolated as a solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.82 (1H), 8.48 (1H), 8.40 (1H), 8.25-7.9 (7H), 3.32 (3H), 1.62 (9H).


This Example, made by TFA deprotection of Preparation Ph is isolated as solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 13.00 (1H), 8.92 (1H), 8.51 (1H), 8.45 (1H), 8.0-8.23

(7H), 3.32 (3H); MS (ESI-) m/z 460.24; MS (FAB+) m/z 461.0700; H₂O 1.12% (0.31 equiv); Anal. C 58.74, H 3.56, N 8.96.

Example 6.59: 2-[[6-[3-(Acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid



Preparation Pi:





1,1-Dimethylethyl 2-[[6-(2-acetylaminophenyl)benzoisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoate. This Preparation, made from Preparation Pb and 2-acetylaminophenylboronic acid by the procedure given for Preparation Pd, is isolated as a solid: ¹H NMR (300 MHz, CDCl₃) δ 12.82 (1H), 9.05 (1H), 8.35-8.4 (2H), 8.18 (1H), 7.84 (1H), 7.70 (1H), 7.55-7.40 (2H), 7.35-7.20 (2H), 7.05 (1H), 2.06 (3H), 1.70 (9H).

15

This Example, made by TFA deprotection of Preparation Pi is isolated as solid: ¹H NMR (300 MHz, DMSO-d₆) δ 9.25 (1H), 8.82 (1H), 8.31 (1H), 8.15 (1H), 8.00 (1H), 7.80 (1H), 7.5-7.2 (4H), 1.75 (3H); MS (ESI-) m/z 439.10.


Example 6.60: 2-[[6-(3-Acetylaminophenyl)benzoisoxazole-3-carbonyl]amino]-5-cyano-benzoic acid.

**Preparation Pj:**

1 **1,1-Dimethylethyl 2-([6-(3-acetylaminophenyl)benzo[d]isoxazole-3-carbonyl]-**
 5 **amino)-5-cyanobenzoate.** This Preparation, made from Preparation Pb and 3-
 acetamido-phenylboronic acid by the procedure given for Preparation Pd, is isolated
 as a solid: ^1H NMR (300 MHz, CDCl_3) δ 12.9 (1H), 9.10 (1H), 8.38 (1H), 8.32 (2H),
 7.95 (1H), 7.9-7.8 (2H), 7.72 (1H), 7.5-7.4 (3H), 2.25 (3H), 1.72 (9H).

10 This Example, made by TFA deprotection of Preparation Pj is isolated as solid: ^1H
 NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.95 (1H), 8.78 (1H), 8.31 (1H), 8.15 (1H), 8.05 (2H),
 7.90 (1H), 7.70 (1H), 7.54 (1H), 7.4-7.3 (2H), 1.93 (3H); MS (ESI-) m/z 439.09.

15 **Example 6.61: 2-([(5-[2-(Acetylaminophenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid**




Preparation Pk:

1,1-Dimethylethyl 2-[(5-[2-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate. This Preparation, made from Preparation Pc and 2-acetylamino phenylboronic acid by the procedure as given for Preparation Pd, is isolated as a solid.

This Example, made by TFA deprotection of **Preparation Pk** is isolated as solid: ¹H NMR (300 MHz, DMSO-d₆) δ12.89 (1H), 9.36 (1H), 8.87 (1H), 8.41 (1H), 8.15 (1H), 8.11 (1H), 7.97 (1H), 7.72 (1H), 7.5-7.25 (4H), 1.9 (3H).

Example 6.62: 2-[(5-[3-(Acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid




Preparation Pl:


1,1-Dimethylethyl 2-[(5-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate. This Preparation, made from Preparation Pc and 3-acetylamino phenylboronic acid by the procedure given for Preparation Pd, is isolated as a solid.

This Example, made by TFA deprotection of **Preparation Pl** is isolated as solid: ¹H NMR (300 MHz, DMSO-d₆) δ12.95 (1H), 10.12 (1H), 8.91 (1H), 8.49 (1H), 8.39 (1H), 8.19 (1H), 8.1-7.9 (2H), 7.67 (1H), 7.72 (1H), 7.5-7.4 (2H), 2.08 (3H).

Example 6.63: Benzyl 5-cyano-2-([(5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino)benzoate



Preparation of 5-(Chlorosulfonyl)-1,2-benzisoxazole-3-carboxylic acid




5

Ethyl 1,2-benzisoxazole-3-carboxylate (586 mg, 3.1 mmol) was dissolved in chlorosulfonic acid (10 mL, Aldrich) under N₂ and heated to 80 °C for 15 hours. The dark brown solution was carefully poured into a flask with crushed ice. The resultant tan precipitate was collected by vacuum filtration and washed thoroughly with water.

- 10 Air-drying yielded 382 mg (49%) of a tan solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.83 (d, *J*=8.71 Hz, 1 H) 7.96 (dd, *J*=8.71, 1.66 Hz, 1 H) 8.32 (d, *J*=1.66 Hz, 1 H) 14.23 (s, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 109.61, 118.89, 119.99, 129.17, 145.98, 151.49, 160.70, 163.42.

- 15 Preparation of *tert*-Butyl 2-((5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoate




- 20 5-(Chlorosulfonyl)-1,2-benzisoxazole-3-carboxylic acid (346 mg, 1.32 mmol) was dissolved in dry CH₂Cl₂ (10 mL) under N₂ and treated with DMF (50 μL) followed by oxalyl chloride (0.231 mL, 2.64 mmol). Gas was evolved, and the mixture was stirred

for 1 hour. The solvent and excess oxalyl chloride were evaporated, and the residue was combined with *tert*-butyl 2-amino-5-cyanobenzoate (218 mg, 1.00 mmol) in 15 mL of dry CH₂Cl₂. The solution was refluxed for 30 minutes and then diluted to 100 mL with CH₂Cl₂. The organic solution was washed with 1.0 M HCl, with water, and with brine (75 mL each). The organic layer was dried over Na₂SO₄, filtered, and evaporated. The crude product was purified on a Biotage Flash 40M+ silica cartridge using 95% CH₂Cl₂ in heptane. Evaporation of solvent from the product fractions followed by drying under high vacuum afforded 162 mg (35%) of an off-white solid.

¹H NMR (400 MHz, CDCl₃) δ ppm 1.68 (s, 9 H) 7.88 (dd, *J*=8.81, 1.97 Hz, 1 H) 7.94 (d, *J*=9.12 Hz, 1 H) 8.34 (dd, *J*=9.02, 1.97 Hz, 1 H) 8.38 (d, *J*=1.87 Hz, 1 H) 9.03 (d, *J*=8.91 Hz, 1 H) 9.10 (d, *J*=1.87 Hz, 1 H) 12.98 (s, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ ppm 28.13, 84.80, 107.30, 111.88, 117.90, 118.09, 120.49, 121.24, 125.27, 129.02, 135.70, 137.15, 141.75, 143.39, 152.76, 156.86, 165.75, 166.19.

15 **Preparation of Benzyl 2-([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate**




5-(Chlorosulfonyl)-1,2-benzisoxazole-3-carboxylic acid (1.25 g, 4.78 mmol) was dissolved in dry CH₂Cl₂ (15 mL) under N₂ and treated with DMF (50 μL) followed by oxalyl chloride (0.83 mL, 9.56 mmol). Gas was evolved, and the mixture was stirred for 1 hour. The solvent and excess oxalyl chloride were evaporated, and the residue was combined with benzyl 2-amino-5-cyanobenzoate (1.13 g, 4.48 mmol) in 15 mL of dry CH₂Cl₂. The solution was refluxed for 20 minutes and then stirred at room temperature overnight. The reaction mixture was diluted with CH₂Cl₂ and filtered through a plug of silica. Evaporation of the solvent followed by drying under high vacuum afforded 1.87 g (84%) of a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 5.49 (s, 2 H) 7.46 (m, 5 H) 7.91 (dd, *J*=8.81, 1.97 Hz, 1 H) 7.95 (d, *J*=8.91 Hz, 1

H) 8.34 (dd, $J=9.02$, 1.97 Hz, 1 H) 8.47 (d, $J=1.87$ Hz, 1 H) 9.06 (d, $J=8.71$ Hz, 1 H) 9.10 (d, $J=1.45$ Hz, 1 H) 12.90 (s, 1 H). ^{13}C NMR (100 MHz, DMSO- d_6) δ ppm 67.47, 106.41, 109.81, 117.61, 117.88, 118.47, 119.99, 121.46, 128.31, 128.38, 128.55, 129.60, 135.14, 135.22, 138.02, 142.73, 146.32, 152.22, 157.54, 163.71, 165.72.

Benzyl 2-([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate (410 mg, 0.83 mmol) was dissolved in dry CH_2Cl_2 (10 mL) and treated with pyrrolidine (0.145 mL, 1.74 mmol, Aldrich) resulting in a cream colored precipitate. After 15 minutes, the reaction mixture was diluted to 200 mL with CH_2Cl_2 and washed 2x with 1.0 M HCl and 1x with brine (175 mL each). The golden organic solution was dried over Na_2SO_4 and filtered. Evaporation of the solvent followed by drying under high vacuum afforded 432 mg (98%) of white solid.


^1H NMR (400 MHz, DMSO- d_6) δ ppm 2.50 (m, 4 H) 3.20 (m, 4 H) 5.45 (s, 2 H) 7.38 (m, 3 H) 7.52 (d, $J=6.63$ Hz, 2 H) 8.21 (m, 3 H) 8.49 (d, $J=1.87$ Hz, 1 H) 8.56 (s, 1 H) 8.76 (d, $J=8.92$ Hz, 1 H) 12.43 (s, 1 H). ^{13}C NMR (100 MHz, DMSO- d_6 , CDCl_3) δ ppm 24.64, 47.51, 67.52, 106.62, 110.76, 115.93, 117.09, 119.54, 120.75, 123.48, 128.00, 128.23, 128.28, 129.20, 134.02, 134.27, 134.87, 137.21, 142.96, 151.81, 156.69, 165.01, 165.56. IR (diffuse reflectance) 2498 (w), 2470 (w), 2395 (w), 2351 (w), 2230, 1709 (s), 1583 (s), 1519 (s), 1348 (s), 1316, 1294, 1268 (s), 1236 (s), 1199, 741, cm^{-1} . Anal. Calc. for $\text{C}_{27}\text{H}_{22}\text{N}_4\text{O}_6\text{S}$: C, 61.12; H, 4.18; N, 10.56; S, 6.04. Found: C, 61.00; H, 4.31; N, 10.54.

Example 6.64: 5-Cyano-2-([5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid



To a mixture of benzyl 5-cyano-2-([5-(pyrrolidin-1-ylsulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoate (336 mg, 0.63 mmol) and 10% palladium on carbon (84 mg, Aldrich) was added dry, inhibitor-free THF (15 mL). The mixture was placed under 1 ATM of H₂, and the reaction was stirred vigorously for 15 minutes. The reaction was filtered through powdered cellulose to remove the catalyst, and the solvent was evaporated. The crude product was re-crystallized from hot EtOH/THF and dried under high vacuum to afford 189 mg (68%) of white, crystalline solid. ¹H NMR (400 MHz, DMSO- *d*₆) δ ppm 1.67 (m, 4 H) 3.21 (m, 4 H) 8.17 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.20 (m, 2 H) 8.44 (d, *J*=2.07 Hz, 1 H) 8.57 (s, 1 H) 8.88 (d, *J*=8.91 Hz, 1 H) 12.95 (s, 1 H).


Example 6.65: 5-Cyano-2-([5-[(dipropylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid




tert-Butyl 5-cyano-2-([5-[(dipropylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoate (249 mg, 0.47 mmol) was dissolved in CH₂Cl₂ (10 mL) and treated with TFA (10 mL, Aldrich). After 3 hours, the solvent and excess TFA were evaporated, and the product was dried under vacuum at 100 °C overnight to afford 182 mg (quantitative) of off-white solid. ¹H NMR (400 MHz, DMSO- *d*₆) δ ppm 0.82 (t, *J*=7.36 Hz, 6 H) 1.50 (septet, *J*=7.41 Hz, 4 H) 3.09 (t, *J*=7.46 Hz, 4 H) 8.18 (m, 3 H) 8.44 (d, *J*=2.07 Hz, 1 H) 8.57 (s, 1 H) 8.89 (d, *J*=8.71 Hz, 1 H) 12.96 (s, 1 H).

Example 6.66:

2-([5-(Anilinosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid



Preparation of *tert*-Butyl 2-((5-(anilinosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino-5-cyanobenzoate




- 5 Prepared from aniline and *tert*-butyl 2-((5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino-5-cyanobenzoate in 49% yield according to the general procedure except that CH_2Cl_2 was replaced by pyridine as the solvent. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.59 (s, 9 H) 7.04 (t, $J=7.26$ Hz, 1 H) 7.11 (d, $J=7.46$ Hz, 2 H) 7.23 (t, $J=7.88$ Hz, 2 H) 8.09 (dd, $J=8.91$, 1.66 Hz, 1 H) 8.14 (d, $J=9.12$ Hz, 1 H) 8.17 (dd, $J=8.91$, 1.87 Hz, 1 H) 8.40 (d, $J=2.07$ Hz, 1 H) 8.62 (d, $J=1.24$ Hz, 1 H) 8.73 (d, $J=8.71$ Hz, 1 H) 10.53 (s, 1 H) 12.42 (s, 1 H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ ppm 27.64, 83.97, 106.50, 111.84, 117.92, 119.22, 119.59, 120.50, 121.49, 123.14, 124.56, 129.30, 135.31, 137.17, 137.21, 137.50, 142.32, 152.36, 156.99, 164.84, 165.18; IR (diffuse reflectance) 2351 (w), 2309 (w), 2227, 2176 (w), 2113 (w), 1698, 1599, 1519 (s), 1498, 1330, 1295, 1276, 1259, 1161 (s), 1150 (s), cm^{-1} ; HRMS (FAB) Calc. for $\text{C}_{26}\text{H}_{22}\text{N}_4\text{O}_6\text{S}+\text{H}$ 519.1338, found 519.1323.
- 10
- 15


Prepared from the *t*-butyl ester in 40% yield according to general procedure. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 7.04 (t, $J=7.26$ Hz, 1 H) 7.12 (d, $J=7.46$ Hz, 2 H) 7.24 (t, $J=7.88$ Hz, 2 H) 8.08 (dd, $J=8.91$, 1.66 Hz, 1 H) 8.12 (t, $J=9.23$ Hz, 1 H) 8.17 (dd, $J=8.92$, 2.07 Hz, 1 H) 8.44 (d, $J=2.07$ Hz, 1 H) 8.63 (d, $J=1.04$ Hz, 1 H) 8.86 (d, $J=8.91$ Hz, 1 H) 10.53 (s, 1 H) 12.93 (s, 1 H).

20

Example 6.67: 5-Cyano-2-[(5-[(diethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



5 Preparation of Benzyl 5-cyano-2-[(5-[(diethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate




Prepared from diethylamine and benzyl 2-[(5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoate in 44% yield according to the general procedure.

- 10 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.07 (t, *J*=7.05 Hz, 6 H) 3.23 (q, *J*=7.19 Hz, 4 H) 5.44 (s, 2 H) 7.35 (m, 3 H) 7.51 (d, *J*=1.24 Hz, 1 H) 7.53 (d, *J*=1.66 Hz, 1 H) 8.19 (d, *J*=1.04 Hz, 2 H) 8.22 (d, *J*=2.07 Hz, 1 H) 8.49 (d, *J*=2.07 Hz, 1 H) 8.56 (s, 1 H) 8.75 (d, *J*=8.71 Hz, 1 H) 12.42 (s, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 14.12, 41.94, 67.46, 106.72, 112.02, 117.78, 118.00, 119.63, 121.66, 122.79, 128.26, 128.34, 128.49, 129.47, 135.14, 137.54, 137.94, 142.37, 152.37, 157.07, 164.83, 165.69; IR (diffuse reflectance) 2394 (w), 2351 (w), 2328 (w), 2271 (w), 2232, 1705 (s), 1590 (s), 1525 (s), 1346 (s), 1330, 1315, 1297 (s), 1272 (s), 1199 (s), 1153 (s), cm⁻¹; HRMS (ESI) Calc. for C₂₇H₂₄N₄O₆S+H 533.1495, found 533.1492. Anal. Calc. for C₂₇H₂₄N₄O₆S: C, 60.89; H, 4.54; N, 10.52; S, 6.02. Found: C, 60.92; H, 4.67; N, 10.43.
- 20


The benzyl ester was converted to the acid according to the general procedure. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.08 (t, $J=7.15$ Hz, 6 H) 3.23 (q, $J=7.05$ Hz, 4 H) 8.18 (m, 3 H) 8.44 (d, $J=2.07$ Hz, 1 H) 8.58 (s, 1 H) 8.88 (d, $J=8.71$ Hz, 1 H) 12.95 (s, 1 H).

5

Example 6.68: 5-Cyano-2-([5-(morpholin-4-ylsulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid



Preparation of *tert*-Butyl 5-cyano-2-([5-(morpholin-4-ylsulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoate




Prepared from morpholine and *tert*-butyl 2-([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate in 90% yield according to the general procedure. ^1H NMR (400 MHz, CDCl_3) δ ppm 1.67 (s, 9 H) 3.06 (m, 4 H) 3.76 (m, 4 H) 7.85 (dd, $J=8.91$, 2.07 Hz, 2 H) 8.04 (dd, $J=8.92$, 1.87 Hz, 1 H) 8.36 (d, $J=1.87$ Hz, 1 H) 8.77 (d, $J=1.04$ Hz, 1 H) 9.01 (d, $J=8.91$ Hz, 1 H) 12.93 (s, 1 H).


The *t*-butyl ester was converted to the acid according to the general procedure. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 2.95 (m, 4 H) 3.65 (m, 4 H) 8.11 (dd, $J=8.92$, 1.87 Hz, 1 H) 8.17 (dd, $J=8.81$, 1.97 Hz, 1 H) 8.23 (d, $J=8.71$ Hz, 1 H) 8.45 (d, $J=2.07$ Hz, 1 H) 8.53 (d, $J=1.24$ Hz, 1 H) 8.88 (d, $J=8.71$ Hz, 1 H) 12.96 (s, 1 H).

20

Example 6.69: 5-Cyano-2-[(5-[(dimethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid




Preparation of tert-Butyl 5-cyano-2-[(5-[(dimethylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate



Prepared from dimethylamine and *tert*-butyl 2-([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate in 76% yield according to the general procedure except that CH₂Cl₂ was replaced by THF as the solvent. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.68 (s, 9 H) 2.79 (s, 6 H) 7.85 (dd, *J*=8.81, 0.73 Hz, 1 H) 7.86 (dd, *J*=8.81, 1.97 Hz, 1 H) 8.09 (dd, *J*=8.81, 1.76 Hz, 1 H) 8.37 (d, *J*=2.07 Hz, 1 H) 8.80 (d, *J*=1.24 Hz, 1 H) 9.03 (d, *J*=8.91 Hz, 1 H) 12.92 (s, 1 H).

The *t*-butyl ester was converted to the acid according to the general procedure. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.68 (s, 6 H) 8.14 (dd, *J*=8.91, 1.66 Hz, 1 H) 8.17 (dd, *J*=8.92, 2.07 Hz, 1 H) 8.22 (d, *J*=8.71 Hz, 1 H) 8.45 (d, *J*=2.07 Hz, 1 H) 8.54 (d, *J*=1.24 Hz, 1 H) 8.88 (d, *J*=8.71 Hz, 1 H) 12.94 (s, 1 H).


Example 6.70:

tert-Butyl 5-cyano-2-[(5-[(diisopropylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate


- 5 Prepared from dipropylamine and *tert*-butyl 2-[(5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoate according to the general procedure.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.82 (t, *J*=7.36 Hz, 6 H) 1.50 (septet, *J*=7.26 Hz, 4 H) 1.61 (s, 9 H) 3.09 (t, *J*=7.46 Hz, 4 H) 8.19 (m, 3 H) 8.40 (d, *J*=2.07 Hz, 1 H) 8.56 (s, 1 H) 8.73 (d, *J*=8.71 Hz, 1 H) 12.44 (s, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 10.98, 21.61, 27.64, 49.65, 83.94, 106.56, 111.99, 117.91, 119.40, 119.65, 121.62, 122.83, 129.55, 135.27, 137.30, 137.47, 142.24, 152.48, 157.07, 164.80, 165.18; IR (diffuse reflectance) 2403 (w), 2292 (w), 2232, 2182 (w), 1926 (w), 1705, 1585, 1520 (s), 1350, 1330, 1295, 1278, 1155 (s), 820, 610, cm⁻¹; Anal. Calc. for C₂₆ H₃₀ N₄ O₆ S: C, 59.30; H, 5.74; N, 10.64; S, 6.09. Found: C, 59.21; H, 5.78; N, 10.52.

Example 6.71: 2-[(5-[(5-Chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid



Preparation of




tert-Butyl 2-([(5-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoate


- 5 Prepared from 5-chloroindoline and *tert*-butyl 2-([(5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate in 45% yield according to the general procedure. ¹H NMR (DMSO-*d*₆) δ ppm 1.60 (s, 9 H) 2.92 (t, *J*=8.40 Hz, 2 H) 3.99 (t, *J*=8.50 Hz, 2 H) 7.24 (d, *J*=1.87 Hz, 1 H) 7.29 (dd, *J*=8.50, 2.28 Hz, 1 H) 7.53 (d, *J*=8.50 Hz, 1 H) 8.16 (br s, 2 H) 8.17 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.40 (d, *J*=2.07 Hz, 1 H) 8.60 (br s, 1 H) 8.73 (d, *J*=8.71 Hz, 1 H) 12.42 (s, 1 H).

The *t*-butyl ester was converted to the acid according to the general procedure. ¹H NMR (DMSO-*d*₆) δ ppm 2.92 (t, *J*=8.40 Hz, 2 H) 3.99 (t, *J*=8.40 Hz, 2 H) 7.24 (s, 1 H) 7.30 (dd, *J*=8.60, 2.18 Hz, 1 H) 7.54 (d, *J*=8.71 Hz, 1 H) 8.15 (br d, 2 H) 8.17 (dd, *J*=8.91, 2.07 Hz, 1 H) 8.44 (d, *J*=2.07 Hz, 1 H) 8.61 (s, 1 H) 8.87 (d, *J*=8.71 Hz, 1 H) 12.95 (s, 1 H)

Example 6.72: N,N-Diethylammonium 5-cyano-2-([(5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoate



Preparation of

**tert-Butyl 5-cyano-2-[(5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-****yl]carbonyl]amino]benzoate** Prepared from methylamine and *tert*-butyl 2-([5-

5 (chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl]amino)-5-cyanobenzoate in 99% yield according to the general procedure except that CH₂Cl₂ was replaced by THF as the solvent. Product was used without purification due to very poor solubility in organic solvents. ¹H NMR (DMSO-*d*₆) δ ppm 1.60 (s, 9 H) 2.44 (d, *J*=4.98 Hz, 3 H) 7.75 (q, *J*=4.98 Hz, 1 H) 8.16 (m, 3 H) 8.41 (d, *J*=2.07 Hz, 1 H) 8.61 (d, *J*=1.04 Hz, 1 H) 8.76 (d, *J*=8.92 Hz, 1 H) 12.46 (s, 1 H).

tert-Butyl 5-cyano-2-[(5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-**yl]carbonyl]amino]benzoate** (225 mg, 0.49 mmol) was dissolved in CH₂Cl₂ (10 mL)


and treated with TFA (10 mL, Aldrich). A pinkish precipitate formed. After stirring

15 overnight, the solvent and excess TFA were evaporated, and the residue was triturated in CH₃OH. The product was impure but would not dissolve for purification, so it was heated at 80 °C in a sealed tube with a mixture of diethylamine and THF to form the salt. The solvent was evaporated, and the crude salt was re-crystallized from a hot mixture of EtOH and 1,2-DCE. The crystals were washed with CH₃OH followed by


20 heptane and then dried several days under vacuum at 100 °C to afford 64 mg (28%) of tan solid. ¹H NMR (DMSO-*d*₆) δ ppm 1.18 (t, *J*=7.26 Hz, 6 H) 2.45 (d, *J*=4.98 Hz, 3 H) 2.94 (br s, 4 H) 7.73 (q, *J*=4.77 Hz, 1 H) 7.92 (dd, *J*=8.50, 2.07 Hz, 1 H) 8.12 (dd, *J*=8.91, 1.87 Hz, 1 H) 8.17 (d, *J*=8.91 Hz, 1 H) 8.37 (d, *J*=2.07 Hz, 1 H) 8.43 (br s, 2 H) 8.65 (d, *J*=1.66 Hz, 1 H) 8.81 (d, *J*=8.71 Hz, 1 H).

25

Example 6.73: 2-[(5-[(Bis(2-hydroxyethyl)amino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino}-5-cyanobenzoic acid



Preparation of




Benzyl 2-((5-((bis(2-hydroxyethyl)amino)sulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoate Prepared from diethanolamine and benzyl 2-
 5 (([5-(chlorosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoate in 49% yield according to the general procedure except that triethylamine (1.1 eq) was added.
¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.24 (t, *J*=6.32 Hz, 4 H) 3.53 (br s, 4 H) 4.84 (s, 2 H) 5.45 (s, 2 H) 7.36 (m, 3 H) 7.52 (d, *J*=6.63 Hz, 2 H) 8.20 (m, 3 H) 8.49 (d,
 10 *J*=2.07 Hz, 1 H) 8.58 (s, 1 H) 8.76 (d, *J*=8.92 Hz, 1 H) 12.43 (s, 1 H).


The benzyl ester was converted to the acid according to the general procedure.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.24 (t, *J*=6.32 Hz, 4 H) 3.54 (t, *J*=6.22 Hz, 4 H) 4.86 (s, 2 H) 8.18 (m, 3 H) 8.45 (d, *J*=2.07 Hz, 1 H) 8.61 (s, 1 H) 8.89 (d, *J*=8.91
 15 Hz, 1 H) 13.16 (s, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ ppm 50.82, 59.63, 106.11, 111.85, 118.00, 118.32, 119.61, 120.69, 123.16, 129.65, 135.51, 137.00, 137.54, 143.14, 152.61, 157.07, 164.88, 168.01; IR (diffuse reflectance) 2250, 2250, 2227 (w), 2198 (w), 1965 (w), 1915 (w), 1704, 1591, 1520 (s), 1339, 1297, 1179, 1150 (s), 987, 731, cm⁻¹; Anal. Calc. for C₂₀H₁₈N₄O₈S: C, 50.63; H, 3.82; N, 11.81; S, 6.76.
 20 Found: C, 50.50; H, 3.76; N, 11.75.

Example 6.74: 5-Cyano-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



Preparation of



5 **Ethyl (4-bromo-2-fluorophenyl)(hydroxy)acetate** Trimethylsilyl cyanide (15.1 mL, 113 mmol, Aldrich) was added to a solution of DABCO (0.40 g, 3.6 mmol, Fluka) and 4-bromo-2-fluorobenzaldehyde (23.1 g, 114 mmol, Fluka) in CH_2Cl_2 (350 mL) with cooling in an ice bath. The reaction mixture was stirred at 0 °C for 30 minutes and


10 then at room temperature for 2 hours. The mixture was washed with water (2 X 200 mL) and brine (200 mL), dried over Na_2SO_4 , and evaporated leaving the silylated cyanohydrin as 34.4 g of cloudy oil. This material was treated with water (25 mL) and concentrated HCl (75 mL) and then heated at reflux for 1.7 hours. The mixture was diluted with water (300 mL) and made basic with 6 M NaOH. This solution was

15 washed with CH_2Cl_2 (2 X 250 mL) and then acidified with concentrated HCl. The carboxylic acid was extracted into CH_2Cl_2 (2 X 250 mL). The CH_2Cl_2 was dried over Na_2SO_4 and evaporated yielding 21.3 g of white solid. This carboxylic acid (20.1 g) was dissolved in DMF (300 mL). Cesium carbonate (27.7 g, 85.0 mmol, Aldrich) and iodoethane (6.25 mL, 78.1 mmol, Aldrich) were added, and the reaction was stirred at

20 room temperature for 3 hours and then at 60 °C for 2.5 hours. The mixture was diluted with MTBE (1 L) and washed with water (500 mL), saturated NaHCO_3 (500 mL), water (2 X 500 mL), and brine (500 mL). The organics were dried over Na_2SO_4 , filtered through a 1" plug of silica gel, and evaporated yielding the ethyl ester as 19.8 g of off-white solid.


¹H NMR (400 MHz, DMSO-*d*₆, ¹⁹F decoupled) δ ppm 1.13 (t, *J*=7.15 Hz, 3 H) 4.10 (m, 2 H) 5.29 (d, *J*=5.60 Hz, 1 H) 6.32 (d, *J*=5.60 Hz, 1 H) 7.44 (m, 2 H) 7.56 (d, *J*=1.45 Hz, 1 H).

5 Preparation of



- Ethyl (4-bromo-2-fluorophenyl)(oxo)acetate** Acetic anhydride (10 mL, 110 mmol) was added dropwise to a solution of ethyl (4-bromo-2-fluorophenyl)(hydroxy)acetate (18.5 g, 66.8 mmol) in DMSO (50 mL) at 100 °C. Heat was removed after 2.3 hours.
- 10 The mixture was diluted with MTBE (250 mL) and washed with brine (3 X 250 mL). The organics were filtered through a 1" plug of silica gel and evaporated leaving a golden oil. This material was purified on a Biotage Flash 75M silica gel cartridge using 50% CH₂Cl₂ in heptane as eluent. Yield was 17.0 g of golden oil.
- ¹H NMR (400 MHz, DMSO-*d*₆, ¹⁹F decoupled) δ ppm 1.31 (t, *J*=7.05 Hz, 3 H) 4.39 (q, *J*=7.19 Hz, 2 H) 7.69 (dd, *J*=8.29, 1.66 Hz, 1 H) 7.85 (d, *J*=8.29 Hz, 1 H) 7.89 (d, *J*=1.66 Hz, 1 H).
- 15


Preparation of



- 20 **Ethyl (4-bromo-2-fluorophenyl)(hydroxyimino)ethanoate** Hydroxylamine hydrochloride (4.77 g, 68.6 mmol, Mallinckrodt) and sodium acetate (6.11 g, 74.5 mmol) were added to a solution of ethyl (4-bromo-2-fluorophenyl)(oxo)acetate (15.8 g, 57.5 mmol) in ethanol (45 mL), and the mixture was stirred at room temperature overnight. After removal of the ethanol by rotary evaporation, the residue was
- 25 dissolved in ethyl acetate (250 mL). This solution was washed with water (250 mL), brine (250 mL), and saturated NaHCO₃ (2 X 250 mL). The organics were dried over Na₂SO₄ and evaporated yielding 15.9 g of white solid (mixture of 2 oxime isomers).

¹H NMR (400 MHz, DMSO-*d*₆, ¹⁹F decoupled, major isomer) δ ppm 1.24 (t, *J*=7.26 Hz, 3 H) 4.23 (q, *J*=7.12 Hz, 2 H) 7.36 (d, *J*=8.29 Hz, 1 H) 7.50 (dd, *J*=8.19, 1.76 Hz, 1 H) 7.66 (d, *J*=1.66 Hz, 1 H) 12.93 (s, 1 H).


5 Preparation of



Ethyl 6-bromo-1,2-benzisoxazole-3-carboxylate Potassium carbonate (10.5 g, 76.0 mmol) was added to a solution of ethyl (4-bromo-2-fluorophenyl)(hydroxyimino)ethanoate (15.4 g, 53.0 mmol, mixture of isomers) in DMSO (50 mL) at 75 °C. Heat was removed after 5 hours, and the mixture was diluted with water (300 mL). Product was extracted into CH₂Cl₂ (2 X 250 mL). The combined CH₂Cl₂ was washed with water (250 mL) and brine (250 mL). The organics were filtered through a 1" plug of silica gel and evaporated leaving a white solid. This material was purified on a Biotage Flash 75 M silica gel cartridge using 50% CH₂Cl₂ in heptane as eluent. Yield was 11.2 g of white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.40 (t, *J*=7.15 Hz, 3 H) 4.49 (q, *J*=7.05 Hz, 2 H) 7.73 (dd, *J*=8.50, 1.45 Hz, 1 H) 8.00 (d, *J*=8.50 Hz, 1 H) 8.33 (d, *J*=1.66 Hz, 1 H).


Preparation of



Ethyl 6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-carboxylate Toluene (40 mL) was added to a flask containing ethyl 6-bromo-1,2-benzisoxazole-3-carboxylate (3.15 g, 11.7 mmol), tetrakis(triphenylphosphine)palladium(0) (835 mg, 0.723 mmol, Strem), cesium carbonate (4.12 g, 12.6 mmol, Aldrich), and 2-(trifluoromethyl)phenylboronic acid (2.38 g, 12.5 mmol, Aldrich) under argon. This mixture was heated in a 100 °C oil bath for 35 hours. The mixture was diluted with EtOAc (250 mL) and washed with 4:1 water:brine (250 mL) followed by brine (250 mL). The organics were filtered through a 1" plug of silica gel and evaporated. Product was split in two, adsorbed onto silica gel, and purified on Biotage Flash 40 M+ silica cartridges using 20% EtOAc in heptane. Yield was 2.08 g of orange solid.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.42 (t, $J=7.15$ Hz, 3 H) 4.51 (q, $J=7.05$ Hz, 2 H) 7.52 (d, $J=7.46$ Hz, 1 H) 7.51 (d, $J=8.09$ Hz, 1 H) 7.71 (t, $J=7.57$ Hz, 1 H) 7.79 (t, $J=7.36$ Hz, 1 H) 7.91 (d, $J=7.67$ Hz, 1 H) 7.93 (s, 1 H) 8.14 (d, $J=8.09$ Hz, 1 H).

5 Preparation of



Ethyl 5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-


carboxylate Nitric acid (5.0 mL, Mallinckrodt, 69%) was added dropwise to a suspension of ethyl 6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-carboxylate

10 (2.80 g, 8.61 mmol) in sulfuric acid (20 mL, Mallinckrodt, 96%) with stirring in an ice bath. The mixture was allowed to warm slowly to room temperature overnight. The mixture was poured over ice, and the product was extracted into CH_2Cl_2 (2 X 100 mL). The product precipitated from the CH_2Cl_2 , so EtOAc (200 mL) was added. The organics were washed with saturated NaHCO_3 , filtered through a plug of silica gel, and

15 evaporated. Product was purified on a Biotage Flash 40 M+ cartridge using 25% EtOAc in heptane. Yield was 2.37 g of white solid that was used without further purification despite only being approximately 80% pure.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.44 (t, $J=7.05$ Hz, 3 H) 4.56 (q, $J=7.12$ Hz, 2 H) 7.92 (d, $J=8.29$ Hz, 1 H) 8.31 (s, 1 H) 8.63 (d, $J=2.28$ Hz, 1 H) 8.66 (dd, $J=8.29$,
20 2.28, 1 H) 8.92 (s, 1 H).

Preparation of



***tert*-Butyl 5-cyano-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate** Sulfuric acid (25 mL, 80% in water) was added to a flask containing ethyl 5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-carboxylate (2.33 g, 5.48 mmol), and the mixture was stirred in a 75 °C oil bath for 2 hours. (Additional heating or higher temperatures can cause extensive hydrolysis of the trifluoromethyl group). The mixture was poured over ice and extracted with CH₂Cl₂ (2 X 100 mL). The CH₂Cl₂ was dried over Na₂SO₄ and evaporated. The residue was suspended in CH₂Cl₂ (50 mL) and treated with DMF (50 μL) followed by oxalyl chloride (6 mL). An additional 1 mL portion of oxalyl chloride was added after 14.5 hours, but no bubbles were observed, so the solvent and excess oxalyl chloride were removed by rotary evaporation. Heptane (50 mL) was added and then removed by rotary evaporation to remove the residual oxalyl chloride. The residue was dissolved in CH₂Cl₂ (30 mL) and treated with *t*-butyl 2-amino-5-cyanobenzoate (1.18 g, 5.41 mmol) in pyridine (15 mL). After 2 hours, the reaction was diluted with CH₂Cl₂ (100 mL) and THF (20 mL). The mixture was washed with 1 M HCl (100 mL). The solids were filtered away, washed with heptane, and dried under vacuum yielding 1.15 g of white solid that was used without further purification.


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.62 (s, 9 H) 7.94 (d, *J*=8.50 Hz, 1 H) 8.21 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.35 (s, 1 H) 8.44 (d, *J*=1.87 Hz, 1 H) 8.64 (d, *J*=2.28 Hz, 1 H) 8.66 (dd, *J*=8.48, 2.28 Hz, 1 H) 8.77 (d, *J*=8.71 Hz, 1 H) 9.04 (s, 1 H) 12.49 (s, 1 H).

5-Cyano-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid


Trifluoroacetic acid (15 mL) was added to a slurry of the corresponding *t*-butyl ester (366 mg, 0.613 mmol) in CH₂Cl₂ (20 mL). The resulting solution was stirred for 5.5 hours. The solvents were removed by rotary evaporation. Methanol was added and then removed by rotary evaporation. The residue was recrystallized from hot ethanol (10 mL) with a few drops of THF added. The crystals were washed with methanol followed by heptane and then dried at 100 °C yielding 177 mg of off-white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.93 (d, *J*=8.29 Hz, 1 H) 8.20 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.34 (s, 1 H) 8.47 (d, *J*=2.07 Hz, 1 H) 8.64 (d, *J*=2.07 Hz, 1 H) 8.66 (dd, *J*=8.29, 2.07 Hz, 1 H) 8.89 (d, *J*=8.71 Hz, 1 H) 9.05 (s, 1 H) 13.04 (s, 1 H).

5 **Example 6.75: 2-[(5-(Acetylamino)-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid**



Preparation of



10

***tert*-Butyl 2-[(5-(acetylamino)-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoate** Tin (II) chloride dihydrate (5.25 g, 23.3 mmol, Aldrich) was added to a suspension of *tert*-butyl 5-cyano-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-

15 yl]carbonyl]amino]benzoate (1.08 g, 1.81 mmol) in a mixture of DMF (40 mL) and THF (40 mL). The mixture was stirred for 7 days and then diluted with MTBE (250 mL). It was washed with 1 M NaOH (3 X 100 mL) and brine (100 mL). The organics were filtered through a plug of silica and evaporated yielding 826 mg of orange solid. This material was dissolved in CH₂Cl₂ (25 mL) and treated with triethylamine (560 μL, 4.03 mmol, Aldrich) followed by acetyl chloride (250 μL, 3.52 mmol, Aldrich). The mixture was stirred for 15 hours and then treated with an additional portion of acetyl chloride (100 μL). After an additional 30 minutes, the mixture was filtered through a

20


plug of silica. Product was adsorbed onto silica and purified on a Biotage Flash 40 M+ using a gradient from 60% to 80% EtOAc in CH₂Cl₂. Yield was 455 mg of white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.62 (s, 9 H) 1.87 (s, 3 H) 2.12 (s, 3 H) 7.30 (d, *J*=8.50 Hz, 1 H) 7.80 (s, 1 H) 7.84 (dd, *J*=8.50, 1.66 Hz, 1 H) 8.17 (dd, *J*=8.71, 2.07 Hz, 1 H) 8.21 (d, *J*=1.87 Hz, 1 H) 8.41 (d, *J*=2.07 Hz, 1 H) 8.45 (s, 1 H) 8.80 (d, *J*=8.71 Hz, 1 H) 9.01 (s, 1 H) 10.41 (s, 1 H) 12.42 (s, 1 H).


Trifluoroacetic acid (10 mL) was added to a slurry of the corresponding *t*-butyl ester in CH₂Cl₂ (15 mL), and the resulting solution was stirred overnight. Solvents were removed by rotary evaporation, and the product was triturated with methanol.

Product was washed with heptane and dried at 100 °C under vacuum yielding 298 mg of tan solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.88 (s, 3 H) 2.12 (s, 3 H) 7.30 (d, *J*=8.29 Hz, 1 H) 7.79 (s, 1 H) 7.84 (dd, *J*=8.60, 1.14 Hz, 1 H) 8.18 (dd, *J*=8.71, 1.87 Hz, 1 H) 8.21 (d, *J*=1.66 Hz, 1 H) 8.46 (m, 2 H) 8.91 (d, *J*=8.71 Hz, 1 H) 9.02 (s, 1 H) 10.41 (s, 1 H) 12.92 (s, 1 H).

Example 7.76: 2-[(5-(Acetylamino)-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonylamino]-5-bromobenzoic acid




Preparation of



tert-Butyl 5-bromo-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate Sulfuric acid (25 mL, 80% in water) was added to ethyl 6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-carboxylate (2.04 g, 6.27 mmol), and the mixture was stirred in a 75 °C oil bath for 2.25 hours while monitoring the reaction to avoid hydrolysis of the trifluoromethyl group. The mixture was poured over ice, and the product was extracted into EtOAc (2 X 75 mL). The organics were dried over Na₂SO₄ and evaporated leaving a brown solid. This material was suspended in H₂SO₄ (20 mL, 96%) and treated with nitric acid (5 mL, 69%) with stirring in an ice bath. The mixture was allowed to warm to room temperature overnight and was then poured over ice. Product was extracted into EtOAc (2 X 100 mL). The organics were dried over Na₂SO₄ and evaporated. Toluene (2 X 100 mL) was added and then evaporated to help rid the material of acetic acid. The resulting orange solid (2.52 g) was suspended in CH₂Cl₂ (50 mL) and treated with DMF (20 µL) followed by oxalyl chloride (6 mL). An additional portion of oxalyl chloride (1 mL) was added after 1 hour, and the mixture was stirred for an additional 1 hour. Solvent and excess oxalyl chloride were removed by rotary evaporation. The residue was dissolved in CH₂Cl₂ (30 mL) and treated with *t*-butyl 2-amino-5-bromobenzoate (1.44 g, 5.29 mmol) in pyridine (10 mL). The mixture was stirred for 70 minutes and then added to a separatory funnel with CH₂Cl₂ (100 mL). The organics were washed with 1 M HCl (2 X 100 mL) and brine (100 mL). Product was adsorbed onto silica and purified on a Biotage Flash 40 M+ silica cartridge using a gradient from 60% to 80% CH₂Cl₂ in heptane yielding 1.61 g of white solid. This material was further purified by recrystallization from hot toluene (approximately 75 mL). Yield was 830 mg of white solid that could not be completely freed from residual toluene, even after extended heating at 100 °C under vacuum.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.60 (s, 9 H) 7.95 (m, 2 H) 8.09 (d, *J*=2.49 Hz, 1 H) 8.33 (s, 1 H) 8.52 (d, *J*=8.91 Hz, 1 H) 8.63 (d, *J*=2.07 Hz, 1 H) 8.66 (dd, *J*=8.28, 2.28 Hz, 1 H) 9.03 (s, 1 H) 12.20 (s, 1 H).

Preparation of



***tert*-Butyl 2-[(5-(acetylamino)-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-bromobenzoate** Tin (II) chloride dihydrate

5 (4.05 g, 17.9 mmol, Aldrich) was added to a mixture of *tert*-butyl 5-bromo-2-[(5-nitro-6-[4-nitro-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoate (715 mg, 1.10 mmol) in a mixture of THF (40 mL) and DMF (40 mL). The mixture was stirred for 6 days and then diluted with MTBE (250 mL). The organics were washed with 1 M NaOH (3 X 100 mL) and brine (100 mL).
 10 It was then filtered through a plug of silica and evaporated. The resulting orange solid was dissolved in CH₂Cl₂ (25 mL) and treated with triethylamine (560 μ L) and acetyl chloride (250 μ L). After 5 hours, the mixture was filtered through a plug of silica gel. Product was then adsorbed onto silica gel and purified on a Biotage Flash 40 M+ using a gradient from 50% EtOAc to 75% EtOAc in CH₂Cl₂. Yield was 161 mg of light
 15 yellow solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.59 (s, 9 H) 1.87 (s, 3 H) 2.12 (s, 3 H) 7.29 (d, *J*=8.50 Hz, 1 H) 7.78 (s, 1 H) 7.84 (dd, *J*=8.40, 1.76 Hz, 1 H) 7.92 (dd, *J*=8.91, 2.49 Hz, 1 H) 8.08 (d, *J*=2.49 Hz, 1 H) 8.21 (d, *J*=1.87 Hz, 1 H) 8.43 (s, 1 H) 8.56 (d, *J*=8.91 Hz, 1 H) 9.01 (s, 1 H) 10.40 (s, 1 H) 12.11 (s, 1 H).


20

A slurry of the *t*-butyl ester (137 mg, 0.203 mmol) in CH₂Cl₂ (12 mL) was treated with TFA (8 mL), and the resulting solution was stirred overnight. Solvents were removed by rotary evaporation, and the product was triturated with methanol. The acid product was washed with heptane and dried at 100 °C under vacuum yielding 49 mg of tan


25 solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.87 (s, 3 H) 2.12 (s, 3 H) 7.29 (d, *J*=8.50 Hz, 1 H) 7.78 (s, 1 H) 7.84 (dd, *J*=8.19, 1.35 Hz, 1 H) 7.93 (dd, *J*=9.02, 2.38

Hz, 1 H) 8.17 (d, $J=2.49$ Hz, 1 H) 8.21 (d, $J=1.45$ Hz, 1 H) 8.45 (s, 1 H) 8.71 (d, $J=9.12$ Hz, 1 H) 9.01 (s, 1 H) 10.40 (s, 1 H) 12.63 (s, 1 H).

Example 6.77: 5-Cyano-2-[(6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid



Preparation of



tert-Butyl 5-cyano-2-[(6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoate Sulfuric acid (40 mL, 75% in water) was added to a flask containing ethyl 6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazole-3-carboxylate (1.12 g, 3.35 mmol), and the mixture was stirred in a 60-80°C oil bath for 80-110 minutes. The mixture was diluted to 120 mL with water, and the resulting precipitate was collected and air dried yielding 862 mg of yellow solid. This material was suspended in CH₂Cl₂ (100 mL) and treated with DMF (30 μL) followed by oxalyl chloride (2 mL). Solvent and excess oxalyl chloride were removed by rotary evaporation after 1 hour. The residue was dissolved in CH₂Cl₂ (75 mL) and treated with *t*-butyl 2-amino-5-cyanobenzoate (552 mg, 2.53 mmol) in pyridine (20 mL). The mixture was stirred for 16.5 hours and then diluted with CH₂Cl₂ (100 mL). It was washed with 1 M HCl (2 X 150 mL) followed by brine (150 mL). Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M+ silica cartridge using a gradient from 50% to 75% CH₂Cl₂ in heptane. Yield was 446 mg of white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.62 (s, 9 H) 7.53 (d, $J=8.29$ Hz, 2 H) 7.71 (t, $J=7.57$ Hz, 1 H) 7.80 (t, $J=7.36$ Hz, 1 H) 7.92 (d, $J=7.67$ Hz, 1 H) 7.97 (s, 1 H) 8.18




(dd, $J=8.71$, 2.07 Hz, 1 H) 8.26 (d, $J=8.09$ Hz, 1 H) 8.41 (d, $J=2.07$ Hz, 1 H) 8.80 (d, $J=8.71$ Hz, 1 H) 12.43 (s, 1 H).




A solution of the corresponding *t*-butyl ester (371 mg, 0.731 mmol) in CH_2Cl_2 (15 mL) was treated with TFA (10 mL) and stirred for 3 hours. Solvents were removed by rotary evaporation. To remove residual TFA, the residue was suspended in CH_2Cl_2 , and the solvent was removed by rotary evaporation. This was repeated with methanol and with heptane. The acid product was then triturated with methanol, washed with heptane, and dried at 100°C under vacuum yielding 310 mg of white solid.




^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 7.53 (d, $J=8.09$ Hz, 2 H) 7.71 (t, $J=7.57$ Hz, 1 H) 7.80 (t, $J=7.36$ Hz, 1 H) 7.92 (d, $J=7.46$ Hz, 1 H) 7.96 (s, 1 H) 8.18 (dd, $J=8.71$, 2.07 Hz, 1 H) 8.27 (d, $J=8.09$ Hz, 1 H) 8.46 (d, $J=2.07$ Hz, 1 H) 8.92 (d, $J=8.91$ Hz, 1 H) 12.92 (s, 1 H).




Example 6.78: Other examples of R_4 as optionally substituted benzisoxazole




Compound No., Structure	Compound Name
	2-[[[5-[2-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[[[5-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[4-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[(5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid
	2-[(5-[4-(acetilamino)-2-methylphenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid
	2-[(5-[2-(acetilamino)phenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[(5-[3-(acetylamino)phenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonylamino]-5-cyanobenzoic acid
	2-[(5-[4-(acetylamino)phenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonylamino]-5-cyanobenzoic acid
	2-[(5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonylamino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-([(5-[4-(acetylamino)-2-methylphenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid
	2-([(5-[5-(acetylamino)-2-methoxyphenyl]-6-cyano-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid
	2-([(5-[2-(acetylamino)phenyl]-6-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5-(2-methoxyphenyl)-6-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-{4-[acetyl(methyl)amino]phenyl}-6-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-acetyl-5-[2-(acetilamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-[[[6-acetyl-5-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-acetyl-5-[4-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-acetyl-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[(6-acetyl-5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[(6-acetyl-5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[(6-acetyl-5-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-([6-acetyl-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid
	2-([6-acetyl-5-[4-(acetylamino)-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid
	2-([6-acetyl-5-[4-[(methoxycarbonyl)amino]-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((6-acetyl-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-acetyl-5-[5-(acetylamino)-2-methoxyphenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-acetyl-5-(2-methoxy-5-((methoxycarbonyl)amino)phenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-(((6-acetyl-5-(2-methoxy-5-((methoxycarbonyl)(methyl)amino)phenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[2-(acetylamino)phenyl]-6-propionyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-propionyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-([(6-(acetylamino)-5-phenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid
	2-([(6-(acetylamino)-5-[2-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid
	2-([(6-(acetylamino)-5-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[6-(acetamido)-5-[4-(acetamido)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetamido)-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetamido)-5-[4-(acetamido)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>





Compound No., Structure	Compound Name
	<p>2-[[[6-(acetamido)-5-[4-(acetamido)(methylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetamido)-5-[4-[(methoxycarbonyl)(methylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetamido)-5-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-([6-(acetylamino)-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid
	2-([6-(acetylamino)-5-[4-(acetylamino)-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid
	2-([6-(acetylamino)-5-[4-(acetyl(methyl)amino)-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[6-(acetylamino)-5-{4-[(methoxycarbonyl)amino]-2-methylphenyl]-1,2-benzisoxazol-3-yl}carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetylamino)-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetylamino)-5-{4-[acetyl(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl}carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[[6-(acetylamino)-5-{4-[(methoxycarbonyl)(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetylamino)-5-{4-[(methoxycarbonyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-(acetylamino)-5-[5-(acetylamino)-2-methoxyphenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-(((6-(acetamino)-5-(2-methoxy-5- [(methoxycarbonyl)amino]phenyl)-1,2- benzisoxazol-3-yl)carbonyl)amino)-5- cyanobenzoic acid
	2-(((6-(acetamino)-5-pyridin-2-yl-1,2- benzisoxazol-3-yl)carbonyl)amino)-5- cyanobenzoic acid
	2-(((6-(acetamino)-5-pyridin-3-yl-1,2- benzisoxazol-3-yl)carbonyl)amino)-5- cyanobenzoic acid




Compound No., Structure	Compound Name
	2-({[6-(acetylamino)-5-pyridin-4-yl]-1,2-benzisoxazol-3-yl}carbonyl)amino)-5-cyanobenzoic acid
	2-({[6-(acetylamino)-5-pyrazin-2-yl]-1,2-benzisoxazol-3-yl}carbonyl)amino)-5-cyanobenzoic acid
	2-({[6-(acetylamino)-5-pyridazin-3-yl]-1,2-benzisoxazol-3-yl}carbonyl)amino)-5-cyanobenzoic acid
	2-({[6-(acetylamino)-5-pyridazin-4-yl]-1,2-benzisoxazol-3-yl}carbonyl)amino)-5-cyanobenzoic acid





Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5-phenyl-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-[2-(acetylamino)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[3-(acetylamino)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-({[5-[4-(acetylamino)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid</p>
	<p>5-cyano-2-({[6-(propionylamino)-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid</p>
	<p>2-({[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-((5-([4-(acetyl(methyl)amino)-2-(trifluoromethyl)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>5-cyano-2-((5-([4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-((5-([2-(2-methylphenyl)-6-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-((5-([4-(acetamido)-2-methylphenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>5-cyano-2-((5-([4-((methoxycarbonyl)amino)-2-methylphenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-((5-([2-methoxyphenyl]-6-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5-{4- [(methoxycarbonyl)(methyl)amino]phenyl}-6- (propionylamino)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-{4- [(methoxycarbonyl)amino]phenyl}-6- (propionylamino)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-{2-methoxy-5- [(methoxycarbonyl)amino]phenyl}-6- (propionylamino)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-([(6-(propionylamino)-5-pyridin-2-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid
	5-cyano-2-([(6-(propionylamino)-5-pyridin-3-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid
	5-cyano-2-([(6-(propionylamino)-5-pyridin-4-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid
	5-cyano-2-([(6-(propionylamino)-5-pyridazin-3-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((6-(propionylamino)-5-pyridazin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-[2-(acetylamino)phenyl]-6-(butyrylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-(butyrylamino)-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-([5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-(butyrylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid</p>
	<p>2-([6-(butyrylamino)-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid</p>
	<p>2-([5-[4-(acetylamino)-2-methylphenyl]-6-(butyrylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid</p>

Compound No., Structure	Compound Name
	2-[[[6-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[acetyl(methyl)amino]-5-phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[2-(acetylamino)phenyl]-6-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[5-[4-(acetylamino)phenyl]-6-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[acetyl(methyl)amino]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[[6-[acetyl(methyl)amino]-5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[acetyl(methyl)amino]-5-[4-[(methoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[acetyl(methyl)amino]-5-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-(((6-[acetyl(methyl)amino]-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-[4-(acetylamino)-2-methylphenyl]-6-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[acetyl(methyl)amino]-5-{4-[acetyl(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-{methyl(propionyl)amino}-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-[[[5-[4-(acetylamino)-2-methylphenyl]-6-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[butyryl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	5-cyano-2-[[[6-[(methoxycarbonyl)amino]-5-phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid




Compound No., Structure	Compound Name
	2-[[[5-[2-(acetylamino)phenyl]-6-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[3-(acetylamino)phenyl]-6-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-[4-(acetylamino)phenyl]-6-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid





Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-((methoxycarbonyl)amino)-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-((methoxycarbonyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[4-(acetyl(methyl)amino)-2-(trifluoromethyl)phenyl]-6-((methoxycarbonyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-((methoxycarbonyl)amino)-5-[4-((methoxycarbonyl)(methyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((6-((methoxycarbonyl)amino)-5-[4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((6-((methoxycarbonyl)amino)-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	2-(((5-[4-(acetamido)-2-methylphenyl]-6-((methoxycarbonyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-{4-((methoxycarbonyl)(methyl)amino)-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-{4-((methoxycarbonyl)amino)-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((6-[(methoxycarbonyl)amino]-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-[(methoxycarbonyl)amino]-5-{4-[(methoxycarbonyl)(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-[(methoxycarbonyl)amino]-5-{4-[(methoxycarbonyl)amino]phenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[5-[5-(acetylamino)-2-methoxyphenyl]-6-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[6-[(methoxycarbonyl)amino]-5-(2-methoxy-5-[(methoxycarbonyl)amino]phenyl)-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>5-cyano-2-[[[6-[(methoxycarbonyl)amino]-5-(2-methoxy-5-[(methoxycarbonyl)(methyl)amino]phenyl)-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-pyridin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-pyridin-3-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-pyridin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((6-((methoxycarbonyl)amino)-5-pyrazin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-[[[6-[(methoxycarbonyl)amino]-5-pyridazin-3-yl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	5-cyano-2-[[[6-[(methoxycarbonyl)amino]-5-pyridazin-4-yl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	5-cyano-2-[[[6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid




Compound No., Structure	Compound Name
	<p>5-cyano-2-[[[6-[(methoxycarbonyl)(methyl)amino]-5-phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>2-[[[5-[2-(acetylamino)phenyl]-6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-[4-(acetylamino)phenyl]-6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-[(6-[(methoxycarbonyl)(methyl)amino]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid</p>
	<p>2-[(5-[4-(acetamido)-2-(trifluoromethyl)phenyl]-6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[(5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5-[4- [(methoxycarbonyl)amino]-2- (trifluoromethyl)phenyl]-6- [(methoxycarbonyl)(methyl)amino]-1,2- benzisoxazol-3-yl]carbonyl)amino]benzoic acid</p>
	<p>5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-(2- methylphenyl)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-(4- [(methoxycarbonyl)(methyl)amino]-2- methylphenyl)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5-{4-[(methoxycarbonyl)amino]-2-methylphenyl}-6-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((6-[(methoxycarbonyl)(methyl)amino]-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((6-[(methoxycarbonyl)(methyl)amino]-5-{4-[(methoxycarbonyl)(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-(((5-(4- [(methoxycarbonyl)amino]phenyl)-6- [(methoxycarbonyl)(methyl)amino]-1,2- benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-(2- methoxy-5- [(methoxycarbonyl)amino]phenyl)-1,2- benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-(2- methoxy-5- [(methoxycarbonyl)(methyl)amino]phenyl)- 1,2-benzisoxazol-3- yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-pyridin- 3-yl)-1,2-benzisoxazol-3- yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5-pyridin- 4-yl)-1,2-benzisoxazol-3- yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((6- [(methoxycarbonyl)(methyl)amino]-5- pyridazin-4-yl)-1,2-benzisoxazol-3- yl)carbonyl)amino]benzoic acid





Compound No., Structure	Compound Name
	2-[(5-[2-(acetylamino)phenyl]-6-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid
	5-cyano-2-[(6-methoxy-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	2-[(5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	5-cyano-2-(((6-methoxy-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-[4-(acetilamino)-2-methylphenyl]-6-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[(5-{4-[acetyl(methyl)amino]-2-methylphenyl}-6-methoxy-1,2-benzisoxazol-3-yl)carbonyl]amino-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[6-methoxy-5-{4-[(methoxycarbonyl)(methyl)amino]-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid</p>
	<p>5-cyano-2-[[[6-methoxy-5-{4-[(methoxycarbonyl)amino]-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl]amino}benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-((6-methoxy-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-((methoxycarbonyl)(methyl)amino)phenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-(4-((methoxycarbonyl)amino)phenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[5-[5-(acetylamino)-2-methoxyphenyl]-6-methoxy-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[6-methoxy-5-{2-methoxy-5-[(methoxycarbonyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>5-cyano-2-[[[6-methoxy-5-{2-methoxy-5-[(methoxycarbonyl)(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-(((6-methoxy-5-pyridin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-pyridin-3-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-pyridin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-pyrazin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((6-methoxy-5-pyridazin-3-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((6-methoxy-5-pyridazin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-[4-(acetamino)-2-(trifluoromethyl)phenyl]-6-methyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((5-((5-(acetyl(methyl)amino)-2-methoxyphenyl)-6-methyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-((5-(4-(acetylamino)-2-(trifluoromethyl)phenyl)-6-isopropyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-((5-(4-(acetylamino)-2-(trifluoromethyl)phenyl)-6-isopropoxy-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-([(5-[2-(acetylamino)phenyl]-6-(aminocarbonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
	2-([(6-(aminocarbonyl)-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]-5-cyanobenzoic acid
	2-([(5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-(aminocarbonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid

Compound No., Structure	Compound Name
	<p>2-(((5-[4-(acetyl(methyl)amino)-2-(trifluoromethyl)phenyl]-6-(aminocarbonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-(aminocarbonyl)-5-[4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-[4-(acetylamino)-2-methylphenyl]-6-(aminocarbonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>





Compound No., Structure	Compound Name
	2-[(5-[2-(acetylamino)phenyl]-6-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino-5-cyanobenzoic acid
	5-cyano-2-[(6-[(methylamino)carbonyl]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]benzoic acid
	2-[(5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino-5-cyanobenzoic acid





Compound No., Structure	Compound Name
	<p>2-[[5-[[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[5-[[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-6-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>5-cyano-2-[[6-[[6-[(dimethylamino)carbonyl]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>





Compound No., Structure	Compound Name
	2-[[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[(dimethylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	5-cyano-2-[[6-[(ethylamino)carbonyl]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	2-[[5-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-6-[(ethylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[5-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-6-[(ethylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[5-[4-(acetylamino)-2-methylphenyl]-6-[(ethylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[6-[[ethyl(methyl)amino]carbonyl]-5-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	2-(((5-([4-(acetyl(methyl)amino)-2-(trifluoromethyl)phenyl]-6-[[ethyl(methyl)amino]carbonyl]-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
	2-(((6-(aminosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid
	2-(((6-(aminosulfonyl)-5-phenyl-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((6-(aminosulfonyl)-5-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-(aminosulfonyl)-5-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-(aminosulfonyl)-5-pyridin-3-yl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-(aminosulfonyl)-5-pyridin-4-yl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-[[[6-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	5-cyano-2-[[[6-[(dimethylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	5-cyano-2-[[[6-[(ethylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	5-cyano-2-[[[6-[(diethylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-[[[6-[[ethyl(methyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	2-[[[6-[[bis(2-hydroxyethyl)amino]sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-(aminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	5-cyano-2-[[[5-[[ethylamino]sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((5- [[ethyl(methyl)amino]sulfonyl]-1,2- benzisoxazol-3-yl)carbonyl]amino)benzoic acid
	2-(((5-(acetamino)-6-phenyl-1,2- benzisoxazol-3-yl)carbonyl]amino)-5- cyanobenzoic acid
	2-(((5-[acetyl(methyl)amino]-6-phenyl-1,2- benzisoxazol-3-yl)carbonyl]amino)-5- cyanobenzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((5-((methoxycarbonyl)amino)-6-phenyl-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-(aminosulfonyl)-6-phenyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	5-cyano-2-(((5-((methylamino)sulfonyl)-6-phenyl-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid




Compound No., Structure	Compound Name
	5-cyano-2-(((5-((ethylamino)sulfonyl)-6-phenyl-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-cyano-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[[5-acetyl-6-[2-(acetamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[5-(acetamino)-6-[2-(acetamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[6-[2-(acetamino)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((6-[2-(acetylamino)phenyl]-5-(butyrylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-(((6-[2-(acetamino)phenyl]-5- [(methoxycarbonyl)amino]-1,2-benzisoxazol- 3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[2-(acetamino)phenyl]-5-methoxy- 1,2-benzisoxazol-3-yl)carbonyl)amino)-5- cyanobenzoic acid</p>
	<p>2-(((6-[2-(acetamino)phenyl]-5- (aminocarbonyl)-1,2-benzisoxazol-3- yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-(((6-[2-(acetylamino)phenyl]-5-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-(aminosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[2-(acetylamino)phenyl]-5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-(((5-acetyl-6-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-(acetylamino)-6-[3-(acetylamino)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[3-(acetylamino)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-([(6-[3-(acetylamino)phenyl]-5-(aminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
	2-([(6-[3-(acetylamino)phenyl]-5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
	2-([(6-[4-(acetylamino)phenyl]-5-(trifluoromethyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[[[5-acetyl-6-[4-(acetilamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-(acetilamino)-6-[4-(acetilamino)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[4-(acetilamino)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	2-[[[6-[4-(acetylamino)phenyl]-5-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[4-(acetylamino)phenyl]-5-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[4-(acetylamino)phenyl]-5-methoxy-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-([6-[4-(acetamido)phenyl]-5-(aminosulfonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid</p>
	<p>2-([6-[4-(acetamido)phenyl]-5-[(methylamino)sulfonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino-5-cyanobenzoic acid</p>
	<p>5-cyano-2-([5-cyano-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-[[[5-(trifluoromethyl)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid
	2-[[[5-acetyl-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[5-(acetylamino)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid

Compound No., Structure	Compound Name
	5-cyano-2-(((5-(propionylamino)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-(butylamino)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-[acetyl(methyl)amino]-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>5-cyano-2-[[[5-[methyl(propionyl)amino]-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>2-[[[5-[butyryl(methyl)amino]-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[5-[(methoxycarbonyl)amino]-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((5- [(methoxycarbonyl)(methyl)amino]-6-[2- (trifluoromethyl)phenyl]-1,2-benzisoxazol-3- yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-methoxy-6-[2- (trifluoromethyl)phenyl]-1,2-benzisoxazol-3- yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-(aminocarbonyl)-6-[2- (trifluoromethyl)phenyl]-1,2-benzisoxazol-3- yl)carbonyl)amino)-5-cyanobenzoic acid</p>

Compound No., Structure	Compound Name
	5-cyano-2-(((5-((methylamino)carbonyl)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((5-((dimethylamino)carbonyl)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid
	5-cyano-2-(((5-((ethylamino)carbonyl)-6-[2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]benzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-acetyl-6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-propionyl-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-(((6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-(butyrylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-(pentanoylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[butyryl(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[(methoxycarbonyl)(methyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-[[[6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-methyl-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-isopropyl-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid
	2-[[[6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-(methylthio)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-(((6-[4-(acetamino)-2-(trifluoromethyl)phenyl]-5-(aminocarbonyl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-(acetamino)-2-(trifluoromethyl)phenyl]-5-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-(acetamino)-2-(trifluoromethyl)phenyl]-5-[(dimethylamino)carbonyl]-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-(((6-[4-(acetylamino)-2-(trifluoromethyl)phenyl]-5-[(ethylamino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-acetyl-6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-propionyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-(((5-(acetylamino)-6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-(butyrylamino)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[(5-[acetyl(methyl)amino]-6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>
	<p>2-[(6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl)carbonyl)amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-((methoxycarbonyl)(methyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-methoxy-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-(aminocarbonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>

Compound No., Structure	Compound Name
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-[(methylamino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-[acetyl(methyl)amino]-2-(trifluoromethyl)phenyl]-5-[(ethyl(methyl)amino)carbonyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-(acetylamino)-6-[4-((methoxycarbonyl)(methyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[[5-[acetyl(methyl)amino]-6-[4-[(methoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[5-[(methoxycarbonyl)amino]-6-[4-[(methoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>
	<p>5-cyano-2-[[[5-cyano-6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[[5-acetyl-6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-(acetylamino)-6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[[6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[5-(butyrylamino)-6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[5-[acetyl(methyl)amino]-6-[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>5-cyano-2-[[5-[[4-[(methoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]benzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-[4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-5-((methoxycarbonyl)(methyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-methoxy-6-[4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-(aminocarbonyl)-6-[4-((methoxycarbonyl)amino)-2-(trifluoromethyl)phenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-[4- [(methoxycarbonyl)amino]-2- (trifluoromethyl)phenyl]-5- [(methylamino)carbonyl]-1,2-benzisoxazol-3- yl]carbonyl)amino]benzoic acid</p>
	<p>2-(((5-(acetylamino)-6-(2-methylphenyl)-1,2- benzisoxazol-3-yl]carbonyl)amino)-5- cyanobenzoic acid</p>
	<p>5-cyano-2-(((6-(2-methylphenyl)-5- (propionylamino)-1,2-benzisoxazol-3- yl]carbonyl)amino)benzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-({[5-[acetyl(methyl)amino]-6-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid</p>
	<p>5-cyano-2-({[5-[(methoxycarbonyl)amino]-6-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)benzoic acid</p>
	<p>2-({[5-(aminosulfonyl)-6-(2-methylphenyl)-1,2-benzisoxazol-3-yl]carbonyl}amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-(((5-[(methylamino)sulfonyl]-6-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((5-[(ethylamino)sulfonyl]-6-(2-methylphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((6-[4-(acetamido)-2-methylphenyl]-5-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[5-acetyl-6-[4-(acetylamino)-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-(acetylamino)-6-[4-(acetylamino)-2-methylphenyl]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[4-(acetylamino)-2-methylphenyl]-5-(propionylamino)-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-[[[6-[4-(acetylamino)-2-methylphenyl]-5-[acetyl(methyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[4-(acetylamino)-2-methylphenyl]-5-[methyl(propionyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[6-[4-(acetylamino)-2-methylphenyl]-5-[(methoxycarbonyl)amino]-1,2-benzisoxazol-3-yl]carbonyl]amino]-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-(((6-[4-(acetylamino)-2-methylphenyl]-5-ethoxy-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[4-(acetylamino)-2-methylphenyl]-5-(aminocarbonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[4-(acetylamino)-2-methylphenyl]-5-((methylamino)carbonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-(((6-[4-(acetamino)-2-methylphenyl]-5-((ethylamino)carbonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((6-[4-(acetamino)-2-methylphenyl]-5-(aminosulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-(acetamino)-6-[4-(acetyl(methyl)amino)-2-methylphenyl]-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>2-([(6-{4-[acetyl(methyl)amino]-2-methylphenyl}-5-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid</p>
	<p>2-([(5-[acetyl(methyl)amino]-6-{4-[acetyl(methyl)amino]-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid</p>
	<p>2-([(5-(acetilamino)-6-{4-[(methoxycarbonyl)amino]-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl]amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	<p>5-cyano-2-((5-((methoxycarbonyl)amino)-6-{4-((methoxycarbonyl)amino)-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-methoxy-6-{4-((methoxycarbonyl)amino)-2-methylphenyl}-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((5-(acetamino)-6-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	5-cyano-2-(((6-(2-methoxyphenyl)-5-(propionylamino)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	2-(((5-[acetyl(methyl)amino]-6-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-(aminosulfonyl)-6-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>5-cyano-2-(((6-(2-methoxyphenyl)-5-((methylamino)sulfonyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>5-cyano-2-(((5-((ethylamino)sulfonyl)-6-(2-methoxyphenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid</p>
	<p>2-(((6-(4-(acetyl(methyl)amino)phenyl)-5-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>




Compound No., Structure	Compound Name
	2-[[5-acetyl-6-{4-[acetyl(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoic acid
	2-[[5-(acetylamino)-6-{4-[acetyl(methyl)amino]phenyl}-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoic acid
	2-[[6-{4-[acetyl(methyl)amino]phenyl}-5-methoxy-1,2-benzisoxazol-3-yl]carbonyl]amino-5-cyanobenzoic acid




Compound No., Structure	Compound Name
	<p>2-[[[5-(acetylamino)-6-(4-[(methoxycarbonyl)amino]phenyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-(aminosulfonyl)-6-(4-[(methoxycarbonyl)amino]phenyl)-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>
	<p>2-[[[5-(acetylamino)-6-[5-(acetylamino)-2-methoxyphenyl]-1,2-benzisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid</p>



Compound No., Structure	Compound Name
	2-(((6-[5-(acetylamino)-2-methoxyphenyl]-5-((methoxycarbonyl)amino)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[5-(acetylamino)-2-methoxyphenyl]-5-methyl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((6-[5-(acetyl(methyl)amino)-2-methoxyphenyl]-5-(trifluoromethyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid

Compound No., Structure	Compound Name
	<p>2-(((5-(acetamino)-6-(2-methoxy-5-((methoxycarbonyl)amino)phenyl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-(acetamino)-6-pyridin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>
	<p>2-(((5-(aminosulfonyl)-6-pyridin-3-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid</p>


Compound No., Structure	Compound Name
	5-cyano-2-([(5-[(methylamino)sulfonyl]-6-pyridin-3-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
	5-cyano-2-([(5-[(ethylamino)sulfonyl]-6-pyridin-3-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino]benzoic acid
	2-([(5-(acetamido)-6-pyridin-4-yl)-1,2-benzisoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid

Compound No., Structure	Compound Name
	2-(((5-(aminosulfonyl)-6-pyridin-4-yl-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	5-cyano-2-(((5-((methylamino)sulfonyl)-6-pyridin-4-yl-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid
	5-cyano-2-(((5-((ethylamino)sulfonyl)-6-pyridin-4-yl-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid

Compound No., Structure	Compound Name
	2-(((5-(acetamino)-6-pyrazin-2-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-(acetamino)-6-pyridazin-3-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	2-(((5-(acetamino)-6-pyridazin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid

Compound No., Structure	Compound Name
	2-(((5-(aminosulfonyl)-6-pyridazin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)-5-cyanobenzoic acid
	5-cyano-2-(((5-((methylamino)sulfonyl)-6-pyridazin-4-yl)-1,2-benzisoxazol-3-yl)carbonyl)amino)benzoic acid

Compounds of the invention may also be prepared via a direct coupling shown below.



5

A 50 mL 3-neck round bottom flask was equipped with a J-Kem thermocouple, septum, stir bar and a nitrogen inlet. The flask was heated with a heat gun under nitrogen, cooled to room temperature and tert-butyl 2-amino-5-cyanobenzoate was charged. A 100 mL 3-neck round bottom flask was equipped with a J-Kem

10

thermocouple, septum, stir bar and a nitrogen inlet. The flask was heated with a heat gun under nitrogen, cooled to room temperature and ethyl 5-bromo-1,2-benzisoxazole-3-carboxylate was charged. Anhydrous DMF was added to the flask containing tert-butyl 2-amino-5-cyanobenzoate yielding an orange solution. This solution was cooled with an ice water bath to less than 5 °C and KOtBu was added in 5 portions keeping the temperature below 5 °C. The KOtBu additions resulted in a darkening of the solution.


	<u>Initial T</u>	<u>KOtBu added</u>	<u>Final T</u>
1 st addition	1.4 °C	about 250 mg	2.6 °C
2 nd addition	2.5 °C	about 800 mg	4.4 °C
3 rd addition	2.1 °C	about 800 mg	4.3 °C
4 th addition	2.0 °C	about 800 mg	3.7 °C
5 th addition	--	about 100 mg	3.7 °C

After the KOtBu addition was complete, the solution was allowed to warm to > 20 °C, and the solution was held at >20 °C for 1 hour before re-cooling with an ice water bath to < 5 °C. Anhydrous DMF was added to ethyl 5-bromo-1,2-benzisoxazole-3-carboxylate to yield a pale yellow solution, which was cooled to < 5 °C with an ice water bath. Keeping both solutions < 5 °C, the tert-butyl 2-amino-5-cyanobenzoate solution was transferred via cannula over 5 to 10 minutes to the ester solution and a mild exotherm was noted (T_{max} 4.5 °C). After the addition was complete, the flask was rinsed with DMF, and the mixture was stirred at < 5 °C. The reaction was assayed by HPLC after 1 hour, and it showed 87% conversion to the desired product (1.8% starting material). The reaction was called complete at this point and workup was conducted by quenching the reaction into 1N HCl and CH₂Cl₂. The CH₂Cl₂ layer was removed, and the aqueous was back extracted with CH₂Cl₂. The combined organics were washed two times with water and dried over MgSO₄. The crude organic was filtered and concentrated on the roto vap at 40 °C to an orange semisolid, which after 1 hour at room temperature on high vacuum weighed 20.97 g, 200 wt%. The assay by ¹H NMR showed a significant amount of DMF in the crude. The sample was purified by adding MeOH and heating the slurry between 50 and 55 °C for 30 minutes followed by cooling to < 5 °C. The slurry was held at this temperature for 1 hour before isolating the product via filtration using a medium frit. The white product cake was

rinsed with MeOH, precooled to <5 °C, and dried to constant weight of 8.02 g on high vacuum, 76.4% yield (98.4 area% by HPLC).

Example 7: R₄ as Isoxazol and Derivatives Thereof

Example 7.1: Methyl 5-cyano-2-[(E)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoate




Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-cyanobenzoate (1.7 g mg, 3.46 mmol) in DMSO (20 mL) followed by the addition of NaH (140 mg, 3.4 mmol). Gas evolution was observed, the reaction was heated to 60 °C for 2h, then cooled to rt and 5-phenylisoxazole-3-carbaldehyde (500 mg, 2.8 mmol) was added and the reaction was stirred at rt for 2 h. The mixture was diluted with MTBE, washed with H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel plug (DCM) to afford 996 mg of a Z/E mixture. The solid was dissolved in toluene (40 mL) followed by the addition of thiophenol (32 µL, 0.28 mmol) and AIBN (14 mg, 0.08 mmol). The reaction was heated at reflux for 12 h, then concentrated in vacuo. The residue was recrystallized from MeOH to afford 686 mg (72%) of the title compound.

Analytical data

¹H NMR (300 MHz, CDCl₃) δ 8.32 (s, 1 H), 8.20 (d, *J* = 16.4 Hz, 1 H), 7.87-7.68 (m, 4 H), 7.52-7.50 (m, 3 H), 7.26 (d, *J* = 16.4 Hz, 1 H), 5.68 (s, 1 H), 4.00 (s, 3 H).

Example 7.2: 5-Cyano-2-[(E)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoic acid




The compound of example 7.1 (250 mg, 0.75 mmol) was dissolved in THF (10 mL) and 6N NaOH (5 mL) was added, the resulting mixture was stirred for 16h at rt, then diluted with MTBE, washed with 1N HCl, H₂O, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was recrystallized from MeOH to afford 177 mg (74%) of the title compound.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 13.80 (s, 1 H), 8.27 (d, *J* = 1.6 Hz, 1 H), 8.14-8.04 (m, 3 H), 7.93 (dd, *J* = 1.7, 8.0 Hz, 2 H), 7.59-7.51 (m, 3 H), 7.44 (s, 1 H), 7.36 (d, *J* = 16.4 Hz, 1 H).


5

Example 7.3: Methyl 5-chloro-2-[(*E*)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoate

Methyl 2-[[bromo(triphenyl)phosphoranyl]methyl]-5-chlorobenzoate (3.6 g mg, 6.7 mmol) in DMSO (40 mL) followed by the addition of NaH (270 mg, 6.7 mmol). Gas evolution was observed, the reaction was heated to 60 °C for 2h, then cooled to rt and 5-phenylisoxazole-3-carbaldehyde (838 mg, 4.8 mmol) was added and the reaction was stirred at rt for 2 h. The mixture was diluted with MTBE, washed with H₂O, brine, dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel plug (DCM) to afford 996 mg of a *Z/E* mixture. The solid was dissolved in toluene (40 mL) followed by the addition of thiophenol (100 μL) and AIBN (14 mg). The reaction was heated at reflux for 12 h, then concentrated in vacuo. The residue was recrystallized from MeOH to afford 1.07 g (69%) of the title compound.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.01-7.92 (m, 4 H), 7.88 (d, *J* = 2.3 Hz, 1 H), 7.72 (dd, *J* = 2.2, 8.4 Hz, 1 H), 7.59-7.53 (m, 3 H), 7.43 (s, 1 H), 7.25 (d, *J* = 16.4 Hz, 1 H), 3.91 (s, 3 H).

Example 7.4: 5-Chloro-2-[(*E*)-2-(5-phenylisoxazol-3-yl)ethenyl]benzoic acid


25

The compound of example 7.3 (312 mg, 0.92 mmol) was dissolved in THF (20 mL) and 6N NaOH (5 mL) was added, the resulting mixture was stirred for 18h at rt, then diluted with MTBE, washed with 1N HCl, H₂O, brine, dried (MgSO₄) filtered and concentrated in vacuo. The residue was recrystallized from MeOH to afford 264 mg (88%) of the title compound.

30

Analytical data


¹H NMR (400 MHz, DMSO-*d*₆) δ 13.50 (s, 1 H), 8.04 (d, *J* = 16.4 Hz, 1 H), 8.02-7.88 (m, 4 H), 7.70-7.67 (m, 1 H), 7.58-7.52 (m, 3 H), 7.40 (s, 1 H), 7.20 (d, *J* = 16.4 Hz, 1 H).

Preparation of 5-(2-Fluorophenyl)isoxazole-3-carboxylic acid

General method A: 1-ethynyl-2-fluorobenzene (1 g, 8.33 mmol) and dimethyl 2-nitromalonate (1.34 g, 7.58 mmol) were dissolved in mesitylene (10 ml). The solution was heated at 150°C for about 12 h. Mesitylene was removed in vacuo and the residue was recrystallized from ethanol. 1.22 g (73%) of methyl 5-(2-fluorophenyl)isoxazole-3-carboxylate was yielded as a light brown solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (0.7 g, 16.6 mmol) to afford 0.8 g (70%) of the title compound as a light brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.01 (dt, *J* = 1.7, 7.7 Hz, 1 H), 7.84 (m, 1 H), 7.49 (m, 1 H), 7.43 (dt, *J* = 1.3, 7.7 Hz, 1 H), 7.16 (d, *J* = 3.1 Hz, 1 H)

Example 7.5: 5-Cyano-2-([5-(2-fluorophenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid

General method B: 5-(2-fluorophenyl)isoxazole-3-carboxylic acid (300 mg, 1.46 mmol), DCM (10 ml) and oxyl chloride (0.5 ml) were placed in a flask, followed by the

addition of on drop of DMF. The solution was stirred at room temperature for about 50 min. Then the solvent was removed and the residue was pumped high vacuum for 5 min. The residue was dissolved in DCM (5 ml). Tert-butyl-2-amino-5-cyano benzoate (289 mg, 1.32 mmol) was added and followed by the addition of pyridine (0.4 ml). The resulting solution was stirred overnight, then diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, brine, dried (MgSO₄), filtered, and concentrated in vacuo. The residue was recrystallized from MeOH to afford 320 mg (59%) of t-butyl ester as a white solid, 300 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 225 mg (87%) of a white solid.

10

General method C: 5-(2-fluorophenyl)isoxazole-3-carboxylic acid (4000 mg, 19.4 mmol) was dissolved in thionyl chloride (40 ml) and the resulting mixture was heated at refluxing temperature overnight. Toluene (30 ml) was added and the solution was concentrated in vacuo. The residue was re-dissolved in DCM (40 ml) followed by the addition of tert-butyl-2-amino-5-cyano benzoate (3530 mg, 16.2 mmol) and pyridine (5.2 ml) and the mixture was stirred overnight. The resulting solution was diluted with MTBE (200 ml), washed with 1N HCl, 1N NaOH, brine and dried (MgSO₄). The solution was concentrated in vacuo and the residue was washed with MeOH to afford 5800 mg (88%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (6 ml) in DCM (10 ml) to afford 5000 mg (100%) of a white solid.


20

Analytical data

¹H NMR (300 MHz, CDCl₃) δ 12.75 (s, *J* = Hz, 1 H), 8.84 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 1.9 Hz, 1 H), 8.14 (dd, *J* = 1.9, 8.7 Hz, 1 H), 8.05 (t, *J* = 7.7 Hz, 1 H), 7.65 (m, 1 H), 7.47 (m, 2 H), 7.32 (d, *J* = 2.8 Hz, 1 H)

25

Example 7.6: 5-Bromo-2-([5-(2-fluorophenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid




Prepared according to the General method C: 5-(2-fluorophenyl)isoxazole (300 mg, 1.46 mmol) and tert-butyl-2-amino-5-bromobenzoate (329 mg, 1.21 mmol) afforded 360 mg (54%) of *t*-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in
 5 DCM (8 ml) to afford 330 mg (100%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.44 (s, 1 H), 8.64 (d, *J* = 9.0 Hz, 1 H), 8.13 (d, *J* = 2.5 Hz, 1 H), 8.04 (dt, *J* = 1.3, 7.7 Hz, 1 H), 7.89 (dd, *J* = 2.5, 9.0 Hz, 1 H), 7.64
 10 (m, 1 H), 7.16 (m, 2 H), 7.27 (d, *J* = 2.8 Hz, 1 H)


Example 7.7: 5-Chloro-2-({[5-(2-fluorophenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid



15 Prepared according to the General method C making non-critical variations.


Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.69 (d, *J* = 9.1 Hz, 1 H), 8.04 (dt, *J* = 1.7, 7.7 Hz, 1 H), 8.00 (d, *J* = 2.8 Hz, 1 H), 7.78 (dd, *J* = 2.6, 8.9 Hz, 1 H), 7.65 (m, 1 H), 7.46
 20 (m, 2 H), 7.29 (d, *J* = 2.8 Hz, 1 H).

Preparation of 1-Ethynyl-2-methylbenzene

General procedure D: 1-iodo-2-methylbenzene (2000 mg, 9.2 mmol), CuI (699 mg, 3.7 mmol), and dichlorobis(triphenylphosphine) palladium(0) (644 mg, 0.92 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. THF (30 ml) and triethylamine (30 ml) were added, followed by the addition of ethynyl(trimethyl)silane (9.0 g, 92 mmol). The mixture was stirred at refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO₄). The solution was concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 2.2 g of crude trimethyl[(2-methylphenyl)ethynyl]silane as a brown oil. The TMS group was removed by KF (2.0 g, 35 mmol) in MeOH (10 ml) to afford a 310 mg (29% in 2 steps) of 1-ethynyl-2-methylbenzene as brown oil.


15

Preparation of 5-(2-Methylphenyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-ethynyl-2-methylbenzene (310 mg, 2.67 mmol) and dimethyl 2-nitromalonate (430 mg, 2.43 mmol) to afford 200 mg (38%) of methyl 5-(2-methylphenyl)isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (116 mg, 2.76 mmol) to afford 150 mg (80%) of a light yellow solid.

Example 7.8: 5-Cyano-2-([5-(2-methylphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid

25



Prepared according to the General method C making non-critical variations with 5-(2-methylphenyl)isoxazole-3-carboxylic acid (140 mg, .7 mmol) and tert-butyl-2-amino-5-cyano benzoate (125 mg, 0.6mmol).


5

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.78 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.82 (d, *J* = 7.7 Hz, 1 H), 7.45 (m, 3 H), 7.34 (s, 1 H), 2.53 (s, 3 H).

10

Example 7.9: 5-Chloro-2-[[5-(phenylisoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to the General method C making non-critical variations.

15

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.43 (s, 1 H), 8.73 (d, *J* = 9.0 Hz, 1 H), 8.02 (d, *J* = 2.6 Hz, 2 H), 7.99 (dd, *J* = 2.1, 5.5 Hz, 1 H), 7.78 (dd, *J* = 2.8, 9.0 Hz, 1 H), 7.68 (m, 4 H).


20

Example 7.10: 5-Cyano-2-[[[(5-methylisoxazol-3-yl)carbonyl]amino]benzoic acid

Prepared according to the general method B: 5-methylisoxazole-3-carbonyl chloride (300 mg, 2.1 mmol) and tert-butyl-2-amino-5-cyano benzoate (409 mg, 1.9 mmol) afforded 98 mg (16%) of a white solid, 90 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 52 mg (74%) of the title compound as a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.64 (s, 1 H), 8.82 (d, *J* = 8.9 Hz, 1 H), 8.42 (d, *J* = 1.9 Hz, 1 H), 8.13 (dd, *J* = 2.1, 8.9 Hz, 1 H), 6.76 (s, 1 H), 2.52 (s, 3 H).


Preparation of 5-[4-(Trifluoromethyl)phenyl]isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-ethynyl-2-trifluoromethylbenzene (3.2 g, 18.8 mmol) and dimethyl 2-nitromalonate (3.03 g, 17.0 mmol) to afford 1.9 g (43%) of methyl 5-(2-trifluoromethylphenyl)isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (40 ml) and water (20 ml) by LiOH•H₂O (883 mg, 21 mmol) to afford 1.8 g (100%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 14.17 (s, 1 H), 8.19 (d, *J* = 8.3 Hz, 2 H), 7.94 (d, *J* = 8.5 Hz, 2 H), 7.64 (s, 1 H).

Example 7.11: 5-Cyano-2-[(5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to the General method B: 5-[4-(trifluoromethyl)phenyl]isoxazole-3-carboxylic acid (256 mg, .1 mmol) and tert-butyl-2-amino-5-cyano benzoate (196 mg, 0.9 mmol) afforded 190 mg (46%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 160 mg (96%) of a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.79 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.23 (d, *J* = 8.1 Hz, 2 H), 8.15 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.97 (d, *J* = 8.3 Hz, 2 H), 7.83 (s, 1 H).

Example 7.12: 5-Bromo-2-[(5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to the General method C making non-critical variations.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.47 (s, 1 H), 8.65 (d, *J* = 8.9 Hz, 1 H), 8.23 (d, *J* = 8.1 Hz, 2 H), 8.14 (d, *J* = 2.5 Hz, 1 H), 7.95 (d, *J* = 8.3 Hz, 2 H), 7.90 (dd, *J* = 2.5, 8.9 Hz, 1 H), 7.79 (s, 1 H).

5

Example 7.13: 5-Chloro-2-[(5-[4-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid



Prepared according to the General method C making non-critical variations.


10

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.47 (s, 1 H), 8.72 (d, *J* = 8.9 Hz, 1 H), 8.23 (d, *J* = 8.1 Hz, 2 H), 8.01 (d, *J* = 2.7 Hz, 1 H), 7.96 (d, *J* = 8.5 Hz, 2 H), 7.79 (s, 1 H), 7.78 (dd, *J* = 2.7, 8.9 Hz, 1 H).

15

Preparation of 4-Ethynyl-3,5-dimethylisoxazole [36306-jl-69]



20


General procedure D: 4-iodo-3,5-dimethylisoxazole (2230 mg, 10 mmol), CuI (720 mg, 3.8 mmol), and dichlorobis(triphenylphosphine) palladium(0) (310 mg, 0.47 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. THF (30 ml) and triethylamine (30 ml) were added, followed by the addition of ethynyl(trimethyl)silane 11 ml, 150 mmol. The mixture was stirred at refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO₄). The solution was

concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 1.7 g of trimethyl[(2-methylphenyl)ethynyl]silane as a brown oil. The TMS group was removed by KF (1.5 g, 26 mmol) in MeOH (10 ml) to afford a 690 mg (57% in 2 steps) of 4-Ethynyl-3,5-dimethylisoxazole as brown solid.

Analytical data

^1H NMR (300 MHz, CDCl_3) δ 3.21 (s, 1 H), 2.47 (s, 3 H), 2.31 (s, 3 H);

10 **Preparation of 3,5-Dimethyl-4,5'-biisoxazole-3'-carboxylic acid**




Prepared according to the general method A: 4-Ethynyl-3,5-dimethylisoxazole (690 mg, 5.7 mmol) and dimethyl 2-nitromalonate (918 mg, 8.2 mmol) to afford 770 mg (67%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (40 ml) and water (20 ml) by $\text{LiOH}\cdot\text{H}_2\text{O}$ (437 mg, 10.4 mmol) to afford 730 mg (100%) of a white solid.

Analytical data

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.08 (s, 1 H), 2.65 (s, 3 H), 2.42 (s, 3 H).

20

Example 7.14: 5-Cyano-2-[(3,5-dimethyl-4,5'-biisoxazol-3'-yl)carbonyl]amino}benzoic acid




Prepared according to the General method C: 3,5-dimethyl-4,5'-biisoxazole-3'-carboxylic acid (350 mg, 1.68 mmol) and tert-butyl-2-amino-5-cyano benzoate (306 mg, 1.4 mmol) afforded 380 mg (55%) of t-butyl ester as a white solid, 375 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 290 mg (90%) of a
5 white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.74 (s, 1 H), 8.84 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.25 (s, 1 H), 2.69 (s, 3 H), 2.46 (s, 3
10 H).

Preparation of 5-(4-Methoxyphenyl)isoxazole-3-carboxylic acid




Prepared according to the general method A: 1-ethynyl-4-methoxybenzene (1000 mg, 7.6 mmol) and dimethyl 2-nitromalonate (1220 mg, 6.9 mmol) to afford 1100 mg
15 (68%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (40 ml) and water (20 ml) by LiOH•H₂O (594 mg, 14.2 mmol) to afford 1000 mg (97%) of a brown solid.

20 Analytical data

¹H NMR (300 MHz, CD₃OD) δ 7.73 (m, 2 H), 6.98 (m, 2 H), 6.81 (s, 1 H), 3.85 (s, 3 H).

Example 7.15: 5-Cyano-2-({[5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid
25




Prepared according to the General method B: 5-(4-methoxyphenyl)isoxazole-3-carboxylic acid (300 mg, 1.37 mmol) and tert-butyl-2-amino-5-cyano benzoate (271 mg, 1.25 mmol) afforded 240 mg (46%) of t-butyl ester as a white solid, which was
 5 hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 200 mg (96%) of a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.70 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.42 (d, *J* = 1.9 Hz, 1 H), 8.14 (dd, *J* = 1.9, 8.7 Hz, 1 H), 7.94 (d, *J* = 8.9 Hz, 2 H), 7.45 (s, 1
 10 H), 7.13 (d, *J* = 8.9 Hz, 2 H), 3.85 (s, 3 H).

Example 7.16: 5-Bromo-2-({[5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




15 Prepared according to the General method C: 5-(4-methoxyphenyl)isoxazole-3-carboxylic (300 mg, 1.37 mmol) and tert-butyl-2-amino-5-bromo benzoate (309 mg, 1.14 mmol) afforded 450 mg (69%) of t-butyl ester as a white solid, 440mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 330 mg (85%) of a white solid.

20

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.39 (s, 1 H), 8.66 (d, J = 8.9 Hz, 1 H), 8.14 (d, J = 2.5 Hz, 1 H), 7.92 (m, 3 H), 7.42 (s, 1 H), 7.12 (d, J = 8.9 Hz, 2 H), 3.85 (s, 3 H).

Example 7.17: 5-Chloro-2-([5-(4-methoxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid




Prepared according to the General method C: making non-critical variations.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.41 (s, 1 H), 8.72 (d, *J* = 8.9 Hz, 1 H), 8.02 (d, *J* = 2.7 Hz, 1 H), 7.94 (d, *J* = 8.7 Hz, 2 H), 7.78 (dd, *J* = 2.7, 8.9 Hz, 1 H), 7.43 (s, 1 H), 7.12 (d, *J* = 8.9 Hz, 2 H), 3.85 (s, 3 H).


5

Preparation of 5-(2-Chlorophenyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-ethynyl-2-chlorobenzene (2000 mg, 14.6 mmol) and dimethyl 2-nitromalonate (2356 mg, 13.2 mmol) to afford 1850 mg (59%) of methyl ester as a orange solid, which was hydrolyzed in MeOH (40 ml) and water (20 ml) by LiOH•H₂O (980 mg, 23.4 mmol) to afford 1500 mg (86%) of a orange solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.97 (m, 1 H), 7.71 (m, 1 H), 7.58 (m, 2 H), 7.34 (s, 1 H).

Example 7.18: 2-([5-(2-Chlorophenyl)isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid

20


Prepared according to the General method B: making non-critical variations.

Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 12.75 (s, 1 H), 8.84 (d, $J = 8.9$ Hz, 1 H), 8.43 (d, $J = 1.9$ Hz, 1 H), 8.15 (dd, $J = 1.7, 8.9$ Hz, 1 H), 8.01 (dd, $J = 1.7, 6.8$ Hz, 1 H), 7.73 (d, $J = 7.4$ Hz, 1 H), 7.60 (m, 2 H), 7.50 (s, 1 H).

5

Example 7.19: 5-Bromo-2-([5-(2-chlorophenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid



Prepared according to the General method C: making non-critical variations.


10

Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 12.46 (s, 1 H), 8.64 (d, $J = 8.9$ Hz, 1 H), 8.14 (d, $J = 2.5$ Hz, 1 H), 8.00 (m, 1 H), 7.90 (dd, $J = 2.5, 9.1$ Hz, 1 H), 7.73 (m, 1 H), 7.60 (m, 2 H), 7.46 (s, 1 H).

15

Example 7.20: 5-Chloro-2-([5-(2-chlorophenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid




Prepared according to the General method C: making non-critical variations.

20

Analytical data


^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.40 (s, 1 H), 8.70 (d, $J = 9.1$ Hz, 1 H), 8.00 (m, 2 H), 7.63 (dd, $J = 2.6, 9.0$ Hz, 1 H), 7.72 (m, 1 H), 7.60 (m, 2 H), 7.47 (s, 1 H).

5 **Preparation of 1-Ethynyl-2-(trifluoromethyl)benzene**

General procedure D: 1-iodo-2-(trifluoromethyl)benzene (2720 mg, 10 mmol), CuI (720 mg, 3.8 mmol), and dichlorobis(triphenylphosphine) palladium(0) (310 mg, 0.47 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. THF (30 ml) and triethylamine (30 ml) were added, followed by the addition of ethynyl(trimethyl)silane 11 ml, 150 mmol. The mixture was stirred at refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO_4). The solution was concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 2.6 g of trimethyl[(2-methylphenyl)ethynyl]silane as a brown oil. The TMS group was removed by KF (1.9 g, 32 mmol) in MeOH (30 ml) to afford a 1.6 g (94% in 2 steps) of 1-Ethynyl-2-(trifluoromethyl)benzene as a brown oil.

20 Analytical data

^1H NMR (300 MHz, CDCl_3) δ 7.56 (t, $J = 6.8$ Hz, 2 H), 7.40 (t, $J = 7.3$ Hz, 1 H), 7.34 (t, $J = 7.7$ Hz, 1 H), 3.27 (s, 1 H);

Preparation of 5-[2-(Trifluoromethyl)phenyl]isoxazole-3-carboxylic acid

25


Prepared according to the general method A: 1-Ethynyl-2-(trifluoromethyl)benzene (1600mg, 9.4 mmol) and dimethyl 2-nitromalonate (1514 mg, 8.56 mmol) to afford 1340 mg (52%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (40

ml) and water (20 ml) by LiOH•H₂O (623mg, 14.8 mmol) to afford 1180 mg (93%) of a brown solid.

Analytical data

- 5 ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.41 (s, 1 H), 7.99 (d, *J* = 7.4 Hz, 1 H), 7.85 (m, 3 H), 7.18 (s, 1 H).

Example 7.21: 5-Cyano-2-[(5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonylamino]benzoic acid



10


Prepared according to the General method C: 5-[2-(trifluoromethyl)phenyl]isoxazole-3-carboxylic acid (300 mg, 1.17 mmol) and tert-butyl-2-amino-5-cyanobenzoate (212 mg, 1.0 mmol) afforded 420 mg (79%) of t-butyl ester as a white solid, 355 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 250 mg (80%) of a

15 white solid.

Analytical data

- 20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.78 (s, 1 H), 8.83 (d, *J* = 8.7 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.16 (dd, *J* = 2.1, 8.7 Hz, 1 H), 8.02 (d, *J* = 7.7 Hz, 1 H), 7.91 (m, 3 H), 7.38 (s, 1 H)

Example 7.22: 5-Bromo-2-[(5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonylamino]benzoic acid




Prepared according to the General method C: making non-critical variations.

Analytical data

- 5 ^1H NMR (400 MHz, DMSO- d_6) δ 12.47 (s, 1 H), 8.64 (d, J = 8.9 Hz, 1 H), 8.15 (d, J = 2.5 Hz, 1 H), 8.02 (d, J = 7.7 Hz, 1 H), 7.90 (m, 3 H), 7.34 (s, 1 H).

Example 7.23: 5-Chloro-2-[(5-[2-(trifluoromethyl)phenyl]isoxazol-3-yl)carbonylamino]benzoic acid




10

Prepared according to the General method C: making non-critical variations.

Analytical data

- 15 ^1H NMR (400 MHz, DMSO- d_6) δ 12.47 (s, 1 H), 8.70 (d, J = 9.1 Hz, 1 H), 8.02 (dd, J = 5.2, 2.7 Hz, 2 H), 7.91 (m, 4 H), 7.35 (s, 1 H).

Preparation of 4-Methyl-5-phenylisoxazole-3-carboxylic acid




Prepared according to the general method A: prop-1-ynylbenzene (2000mg, 17.2 mmol) and dimethyl 2-nitromalonate (2770 mg, 15.7 mmol) to afford 930 mg (25%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (20 ml) and water (10
5 ml) by LiOH•H₂O (540mg, 12.9 mmol) to afford 910 mg (10%) of a brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76 (dd, *J* = 1.7, 8.3 Hz, 2 H), 7.59 (m, 3 H), 2.36 (s, 3 H);

10

Example 7.24: 5-Cyano-2-[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino}benzoic acid




Prepared according to the General method C: 4-methyl-5-phenylisoxazole-3-carboxylic
15 acid (300 mg, 1.48 mmol) and tert-butyl-2-amino-5-cyano benzoate (268 mg, 1.2 mmol) afforded 360 mg (60%) of t-butyl ester as a white solid, 355 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 290 mg (95%) of a white solid.

Analytical data

20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.68 (s, 1 H), 8.86 (d, *J* = 8.7 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.13 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.80 (dd, *J* = 1.7, 8.3 Hz, 2 H), 7.61 (m, 3 H), 2.45 (s, 3 H).

Example 7.25: 5-Bromo-2-[[[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino]benzoic acid



Prepared according to the General method C: making non-critical variations.


5

Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 12.37 (s, 1 H), 8.67 (d, J = 8.9 Hz, 1 H), 8.14 (d, J = 2.5 Hz, 1 H), 7.89 (dd, J = 2.6, 9.1 Hz, 1 H), 7.81 (m, 2 H), 7.60 (m, 3 H), 2.44 (s, 3 H);

10

Example 7.26: 5-Chloro-2-[[[(4-methyl-5-phenylisoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to the General method C: making non-critical variations.


15

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.36 (s, 1 H), 8.72 (d, J = 8.9 Hz, 1 H), 8.01 (d, J = 2.7 Hz, 1 H), 7.79 (m, 3 H), 7.60 (m, 3 H), 2.44 (s, 3 H).

Preparation of 1-Ethynyl-2-methoxybenzene

General procedure D: 1-iodo-2-methoxybenzene (2000 mg, 8.6 mmol), CuI (651 mg, 3.4 mmol), and dichlorobis(triphenylphosphine) palladium(0) (600 mg, 0.86 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. THF (30 ml) and triethylamine (30 ml) were added, followed by the addition of ethynyl(trimethyl)silane (8.38 g, 86 mmol). The mixture was stirred at refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO₄). The solution was concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 2.1 g of trimethyl[(2-methoxyphenyl)ethynyl]silane as a brown oil. The TMS group was removed by KF (0.94 g, 16 mmol) in MeOH (10 ml) to afford 1.5 g of crude 1-Ethynyl-2-methoxybenzene as brown oil.


Preparation of 5-(2-Methoxyphenyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-Ethynyl-2-methoxybenzene (1500mg, 11.4 mmol) and dimethyl 2-nitromalonate (1830 mg, 10.3 mmol) to afford 1100 mg (42%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (20 ml) and water (10 ml) by LiOH•H₂O (600mg, 14.2 mmol) to afford 850 mg (82%) of a brown solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.91 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.55 (m, 1 H), 7.26 (d, *J* = 7.9 Hz, 1 H), 7.14 (t, *J* = 7.7 Hz, 1 H), 7.10 (s, 1 H), 3.98 (s, 3 H).

Example 7.27: 5-Cyano-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




Prepared according to the General method C: 5-(2-methoxyphenyl)isoxazole-3-carboxylic acid (300 mg, 1.37 mmol) and tert-butyl-2-amino-5-cyano benzoate (249 mg, 1.14 mmol) afforded 140 mg (24%) of t-butyl ester as a brown solid, 130 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 90 mg (80%) of a white solid.

10 Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.71 (s, 1 H), 8.84 (d, J = 8.7 Hz, 1 H), 8.12 (d, J = 2.1 Hz, 1 H), 8.14 (dd, J = 2.1, 8.7 Hz, 1 H), 7.94 (dd, J = 1.5, 7.8 Hz, 1 H), 7.57 (m, 1 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.24 (s, 1 H), 7.16 (t, J = 8.1 Hz, 1 H), 4.00 (s, 3 H).

15 Example 7.28: 5-Bromo-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




Prepared according to the General method C: making non-critical variations.

20 Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 12.42 (s, 1 H), 8.66 (d, J = 9.0 Hz, 1 H), 8.14 (d, J = 2.5 Hz, 1 H), 7.95 (dd, J = 1.5, 7.7 Hz, 1 H), 7.90 (dd, J = 2.4, 8.9 Hz, 1 H), 7.67 (m, 1 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.22 (s, 1 H), 7.16 (t, J = 7.7 Hz, 1 H), 4.00 (s, 3 H).

Example 7.29: 5-Chloro-2-({[5-(2-methoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




- 5 Prepared according to the General method C: making non-critical variations.

Analytical data


- ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.43 (s, 1 H), 8.72 (d, *J* = 8.9 Hz, 1 H), 8.02 (d, *J* = 2.7 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.79 (dd, *J* = 2.7, 8.9 Hz, 1 H), 7.67 (m, 1 H), 7.28 (d, *J* = 8.3 Hz, 1 H), 7.23 (s, 1 H), 7.16 (t, *J* = 7.3 Hz, 1 H), 4.00 (s, 3 H).
- 10

Preparation of 2-Ethynyl-3-methylthiophene



- 15 General procedure D: 2-bromo-3-methylthiophene (2000 mg, 11.3 mmol), CuI (861 mg, 4.5 mmol), and dichlorobis(triphenylphosphine) palladium(0) (793 mg, 1.1 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. THF (30 ml) and triethylamine (30 ml) were added, followed by the addition of ethynyl(trimethyl)silane (11 g, 113 mmol). The mixture was stirred at
- 20 refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO₄). The solution was concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 4.4 g brown oil. The TMS group was removed by KF (3.9 g, 68 mmol) in MeOH (10 ml) to afford 0.7 g (25% in two steps)
- 25 of crude 2-Ethynyl-3-methylthiophene as brown oil.

Preparation of 5-(3-methylthien-2-yl)isoxazole-3-carboxylic acid




Prepared according to the general method A: 2-ethynyl-3-methylthiophene (700mg, 5.7 mmol) and dimethyl 2-nitromalonate (923 mg, 5.2 mmol) to afford 120 mg (9%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (68mg, 1.6 mmol) to afford 80 mg (71%) of a brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.18 (d, *J* = 5.0 Hz, 1 H), 6.75 (d, *J* = 5.2 Hz, 1 H), 6.57 (s, 1 H), 2.27 (s, 3 H).


Example 7.30: 5-Cyano-2-({[5-(3-methylthien-2-yl)isoxazol-3-yl]carbonyl}amino)benzoic acid



Prepared according to the General method C: 5-(3-methyl-thien-2-yl)isoxazole-3-carboxylic acid (80 mg, 0.38 mmol) and tert butyl-2-amino-5-cyano benzoate (76 mg, 0.35 mmol) afforded 100 mg (64%) of t-butyl ester as a brown solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 60 mg (70%) of a gray solid.

Analytical data


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.73 (s, 1 H), 8.84 (d, *J* = 8.7 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.81 (d, *J* = 5.0 Hz, 1 H), 7.16 (m, 2 H), 2.48 (s, 3 H).

Example 7.31: 2-[[[(5-*t*-Butylisoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid

Prepared according to the General method C: 5-(*t*-butyl)isoxazole-3-carboxylic acid (280 mg, 1.66 mmol) and tert-butyl-2-amino-5-cyano benzoate (301 mg, 1.38 mmol) afforded 301 mg (49%) of *t*-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 180 mg (71%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.64 (s, 1 H), 8.82 (d, *J* = 8.92 Hz, 1 H), 8.42 (d, *J* = 2.1 Hz, 1 H), 8.12 (dd, *J* = 2.1, 8.7 Hz, 1 H), 6.78 (s, 1 H), 1.36 (s, 9 H).


Preparation of 5-(3-Cyclohexylpropyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: pent-4-ynylcyclohexane (2000mg, 13.3 mmol) and dimethyl 2-nitromalonate (2145 mg, 12.1 mmol) to afford 1600 mg (48%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (20 ml) and water (10ml) by LiOH•H₂O (800mg, 19.1 mmol) to afford 1100mg (72%) of a brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 13.87 (s, 1 H), 6.60 (s, 1 H), 2.78 (t, *J* = 7.5 Hz, 2 H), 1.65 (m, 7 H), 1.18 (m, 6 H), 0.85 (m, 2 H).

Example 7.32: 5-Cyano-2-({[5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




Prepared according to the General method C: 5-(3-cyclohexylpropyl)isoxazole-3-carboxylic acid (300 mg, 1.27 mmol) and tert butyl-2-amino-5-cyano benzoate (230 mg, 1.05 mmol) afforded 500 mg (90%) of t-butyl ester as a brown solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 150 mg (34%) of a brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.62 (s, 1 H), 8.82 (d, *J* = 8.9 Hz, 1 H), 8.41 (d, *J* = 2.1 Hz, 1 H), 8.12 (dd, *J* = 2.1, 8.9 Hz, 1 H), 6.78 (s, 1 H), 2.83 (t, *J* = 7.5 Hz, 2 H), 1.67 (m, 7 H), 1.18 (m, 6 H), 0.85 (m, 2 H).

Example 7.33: 5-Bromo-2-({[5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




Prepared according to the General method C: making non-critical variations.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.32 (s, 1 H), 8.62 (d, *J* = 8.9 Hz, 1 H), 8.13 (d, *J* = 2.5 Hz, 1 H), 7.88 (dd, *J* = 2.5, 8.9 Hz, 1 H), 6.75 (s, 1 H), 2.83 (t, *J* = 7.5 Hz, 2 H), 1.66 (m, 7 H), 1.18 (m, 6 H), 0.85 (m, 2 H).

Example 7.34: 5-Chloro-2-([5-(3-cyclohexylpropyl)isoxazol-3-yl]carbonyl)amino)benzoic acid



Prepared according to the General method C: making non-critical variations.


5

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.31 (s, 1 H), 8.68 (d, J = 8.9 Hz, 1 H), 8.00 (d, J = 2.7 Hz, 1 H), 7.76 (dd, J = 2.5, 8.9 Hz, 1 H), 6.75 (s, 1 H), 2.83 (t, J = 7.5 Hz, 2 H), 1.65 (m, 7 H), 1.18 (m, 6 H), 0.85 (m, 2 H).

10

Preparation of 5-(3-Phenylpropyl)isoxazole-3-carboxylic acid



Prepared according to the general method A: pent-4-ynylbenzene (3000mg, 20.8 mmol) and dimethyl 2-nitromalonate (3347 mg, 18.9 mmol) to afford 3800 mg (82%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (20 ml) and water (10ml) by LiOH \cdot H $_2$ O (1540mg, 36.7 mmol) to afford 2600mg (92%) of a brown solid.


15

Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 13.98 (s, 1 H), 7.26 (m, 5 H), 6.64 (s, 1 H), 2.81 (t, J = 7.7 Hz, 2 H), 2.64 (t, J = 7.3 Hz, 2 H), 1.98 (pent, J = 7.5 Hz, 2 H).

20

Example 7.35: 5-Cyano-2-([5-(3-phenylpropyl)isoxazol-3-yl]carbonyl)amino)benzoic acid



25

Prepared according to the General method C: 5-(3-phenylpropyl)isoxazole-3-carboxylic acid (300 mg, 1.30 mmol) and tert-butyl-2-amino-5-benzoate (236 mg, 1.08 mmol) afforded 320 mg (57%) of t-butyl ester as a white solid, 310mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 170 mg (63%) of a white solid.


5

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.71 (s, 1 H), 8.84 (d, J = 8.7 Hz, 1 H), 8.12 (d, J = 2.1 Hz, 1 H), 8.14 (dd, J = 2.1, 8.7 Hz, 1 H), 7.94 (dd, J = 1.5, 7.8 Hz, 1 H), 7.57 (m, 1 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.24 (s, 1 H), 7.16 (t, J = 8.1 Hz, 1 H), 4.00 (s, 3 H).

10

Example 7.36: 5-Bromo-2-({[5-(3-phenylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




15 Prepared according to the General method C: making non-critical variations.

Analytical data

^1H NMR (300 MHz, DMSO- d_6) δ 12.32 (s, 1 H), 8.63 (d, J = 9.0 Hz, 1 H), 8.13 (d, J = 2.5 Hz, 1 H), 7.88 (dd, J = 2.5, 8.9 Hz, 1 H), 7.25 (m, 5 H), 6.79 (s, 1 H), 2.87 (t, J = 7.3 Hz, 2 H), 2.66 (t, J = 7.9 Hz, 2 H), 2.00 (pent, J = 7.5 Hz, 2 H).

20

Example 7.37: 5-Chloro-2-({[5-(3-phenylpropyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




25 Prepared according to the General method C: making non-critical variations.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.31 (s, 1 H), 8.68 (d, *J* = 9.1 Hz, 1 H), 8.00 (d, *J* = 2.7 Hz, 1 H), 7.77 (dd, *J* = 2.7, 9.1 Hz, 1 H), 7.26 (m, 5 H), 6.80 (s, 1 H), 2.86 (t, *J* = 7.5 Hz, 2 H), 2.66 (t, *J* = 7.9 Hz, 2 H), 2.00 (pent, *J* = 7.7 Hz, 2 H).

5


Preparation of N-(2-ethynylphenyl)-4-(trifluoromethoxy)benzenesulfonamide

- 2-[(trimethylsilyl)ethynyl]aniline (2000 mg, 10.6 mmol) and 4-(trifluoromethoxy)benzenesulfonyl chloride (2500 mg, 9.6 mmol) were dissolved in DCM (10 ml). Pyridine (0.4 ml) was added. And the n the solution was stirred at room temperature over night. The resulting solution was stirred overnight, then diluted with MTBE (200 ml) and washed with 1N HCl, 1N NaOH, brine, dried (MgSO₄), filtered, and concentrated in vacuo. The residue was recrystallized from MeOH to afford 3340 mg (76%) of 4-(trifluoromethoxy)-N-{2-[(trimethylsilyl)ethynyl]phenyl} benzenesulfonamide as a white solid, which was de-protected by KF (1410 mg, 24.3 mmol) in MeOH (20 ml) to afford 2440 mg (99%) of N-(2-ethynylphenyl)-4-(trifluoromethoxy)benzenesulfonamide as a yellow solid.

Analytical data

- ¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 2 H), 7.45 (d, *J* = 8.3 Hz, 1 H), 7.19 (m, 2 H), 7.08 (m, 2 H), 6.92 (dt, *J* = 1.2, 7.7 Hz, 1 H), 3.18 (s, 1 H);

Example 7.38: 5-[2-({[4(Trifluoromethoxy)phenyl]sulfonyl}amino)phenyl]-isoxazole-3-carboxylic acid



Prepared according to the general method A: N-(2-ethynylphenyl)-4-


- 5 (trifluoromethoxy)benzenesulfonamide (2440mg, 7.16 mmol) and dimethyl 2-nitromalonate (1150 mg, 6.5mmol) to afford 1800 mg (57%) of methyl ester as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5ml) by LiOH•H₂O (513 mg, 12.22 mmol) to afford 1500mg (86%) of a brown solid.

10 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.26 (s, 1 H), 7.82 (dd, *J* = 1.5, 7.1 Hz, 1 H), 7.74 (d, *J* = 8.7 Hz, 2 H), 7.49 (m, 4 H), 7.14 (s, 1 H), 7.08 (d, *J* = 7.3 Hz, 1 H).

Example 7.39: 5-Cyano-2-[(5-[2-({[4(trifluoromethoxy)phenyl]sulfonyl}amino)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid

- 15




- Prepared according to the General method C: 5-[2-({[4(Trifluoromethoxy)phenyl]-sulfonyl} amino)phenyl]isoxazole-3-carboxylic acid (300 mg, 0.7 mmol) and tert-butyl-2-amino-5-cyano benzoate (127mg, 0.58 mmol) afforded 62 mg (17%) of t-butyl ester as a white solid, 310mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 36 mg (40%) of a yellow solid.
- 20

Analytical data

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.76 (s, 1 H), 10.32 (s, 1 H), 8.87 (d, $J = 8.7$ Hz, 1 H), 8.45 (d, $J = 2.1$ Hz, 1 H), 8.17 (2.1, $J = 8.7$ Hz, 1 H), 7.86 (m, 1 H), 7.72 (m, 2 H), 7.50 (m, 4 H), 7.31 (s, 1 H), 7.12 (m, 1 H).

5

Example 7.40: 5-Chloro-2-[(5-[2-[(4-(trifluoromethoxy)phenyl)sulfonyl]amino)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to the General method C: making non-critical variations.

10

Analytical data

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.40 (s, 1 H), 10.32 (s, 1 H), 8.73 (d, $J = 9.0$ Hz, 1 H), 8.04 (d, $J = 2.6$ Hz, 1 H), 7.86 (dd, $J = 1.7, 6.8$ Hz, 1 H), 7.80 (dd, $J = 2.6, 9.0$ Hz, 1 H), 7.72 (d, $J = 8.9$ Hz, 2 H), 7.50 (m, 4 H), 7.28 (s, 1 H), 7.11 (dd, $J = 1.7, 7.2$ Hz, 1 H).

15

Preparation of 5-Ethynyl-1,3-benzodioxole


Prepared according to the general method D: 5-iodo-1,3-benzodioxole (5 g, 20.3 mmol) and ethynyl(trimethyl)silane (2.6 g, 26.42 mmol) afforded 4.4 g (99%) of (1,3-benzodioxol-5-ylethynyl)(trimethyl)silane as a yellow oil, which was de-protected by KF (3.5 g, 60.6 mmol) to afford 3.2 g (100%) yellow oil.

20

Analytical data

^1H NMR (300 MHz, CDCl_3) δ 7.05 (dd, $J = 1.5, 7.9$ Hz, 1 H), 6.95 (d, $J = 1.5$ Hz, 1 H), 6.77 (d, $J = 8.1$ Hz, 1 H), 6.00 (s, 2 H), 2.99 (s, 1 H);


25

Preparation of 5-(1,3-Benzodioxol-5-yl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 5-ethynyl-1,3-benzodioxole (3200mg, 21.9 mmol) and dimethyl 2-nitromalonate (3527 mg, 19.9 mmol) to afford 3600 mg (72%) of methyl ester as a brown solid, 2000 mg of which was hydrolyzed in MeOH (10 ml) and water (5ml) by LiOH•H₂O (1020 mg, 24.3 mmol) to afford 1500mg (80%) of a white solid.

10 Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.52 (d, *J* = 1.3 Hz, 1 H), 7.49 (d, *J* = 8.1 Hz, 1 H), 7.80 (s, 1 H), 7.09 (d, *J* = 8.1 Hz, 1 H), 6.13 (s, 2 H);


Example 7.41: 2-([5-(1,3-Benzodioxol-5-yl)isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid

Prepared according to the General method C: 5-(1,3-Benzodioxol-5-yl)isoxazole-3-carboxylic acid (300 mg, 1.28 mmol) and tert-butyl-2-amino-5-cyano-benzoate (233 mg, 1.07 mmol) afforded 220 mg (47%) of t-butyl ester as a white solid, 310mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 120 mg (63%) of a brown solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.68 (s, 1 H), 8.84 (d, *J* = 8.7 Hz, 1 H), 8.42 (d, *J* = 1.9 Hz, 1 H), 8.13 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.67 (d, *J* = 1.5 Hz, 1 H), 7.63 (dd, *J* = 1.7, 8.1 Hz, 1 H), 7.48 (s, 1 H), 7.11 (d, *J* = 8.10 Hz, 1 H), 6.15 (s, 2 H).

Example 7.42: 2-([5-(1,3-Benzodioxol-5-yl)isoxazol-3-yl]carbonyl)amino)-5-bromobenzoic acid




Prepared according to the General method C: making non-critical variations.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.38 (s, 1 H), 8.65 (d, *J* = 9.1 Hz, 1 H), 8.14 (d, *J* = 2.5 Hz, 1 H), 7.89 (dd, *J* = 2.6, 9.0 Hz, 1 H), 7.67 (d, *J* = 1.7 Hz, 1 H), 7.63 (dd, *J* = 1.7, 8.1 Hz, 1 H), 7.45 (s, 1 H), 7.11 (d, *J* = 8.1 Hz, 1 H), 6.15 (s, 2 H).

Preparation of 5-(4-[(5-Methylisoxazol-3-yl)amino]sulfonyl)phenyl)isoxazole-3-carboxylic acid




Prepared according to the general method A: 4-ethynyl-N-(5-methyl-3-

isoxazolyl)benzenesulfonamide (1000mg, 3.8 mmol) and dimethyl 2-nitromalonate (613 mg, 3.47 mmol) to afford 1200 mg (53%) of methyl ester as a brown solid, which was hydrolyzed in MeOH (20 ml) and water (10 ml) by LiOH•H₂O (416 mg, 9.9 mmol) to afford 940mg (82%) of a brown solid.

Analytical data

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 11.64 (s, 1 H), 8.19 (d, $J = 8.5$ Hz, 2 H), 8.01 (d, $J = 8.5$ Hz, 2 H), 7.61 (s, 1 H), 6.18 (s, 1 H), 2.30 (s, 3 H).


5 **Example 7.43: 5-Bromo-2-({[5-(4-{{[5-methylisoxazol-3-yl]amino]sulfonyl}phenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid**



Prepared according to the General method C: 5-(4-{{[5-Methylisoxazol-3-yl]amino]sulfonyl}phenyl)isoxazole-3-carboxylic acid (300 mg, 0.86 mmol) and tert-butyl-2-amino-5-bromo benzoate (194mg, 0.72 mmol) afforded 60 mg (12 %) of t-butyl ester as a brown solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 30 mg (55%) of a brown solid.

Analytical data


15 ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.47 (s, 1 H), 11.66 (s, 1 H), 8.65 (d, $J = 8.9$ Hz, 1 H), 8.24 (d, $J = 8.7$ Hz, 2 H), 8.15 (d, $J = 2.7$ Hz, 1 H), 8.03 (d, $J = 8.7$ Hz, 2 H), 7.91 (dd, $J = 2.5, 9.1$ Hz, 1 H), 7.76 (s, 1 H), 2.31 (s, 3 H).

Preparation of 5-(3-Methoxyphenyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-ethynyl-3-methoxybenzene (5000 mg, 37.9 mmol) and diethyl 2-nitromalonate (7060 mg, 34.4 mmol) to afford 4100 mg (48%) of ethyl ester as a brown solid, 1000 mg of which was hydrolyzed in MeOH (20 ml) and water (10ml) by LiOH•H₂O (1000 mg, 23.8 mmol) to afford 860mg (92%) of a brown solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.50 (m, 4 H), 7.12 (ddd, *J* = 1.0, 2.5, 8.1 Hz, 1 H), 3.85 (s, 3 H).

Example 7.45: 5-Cyano-2-([5-(3-methoxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid

15


Prepared according to the General method C: 5-(3-methoxyphenyl)isoxazole-3-carboxylic acid (340 mg, 1.55 mmol) and tert butyl-2-amino-5-cyano benzoate (372mg, 1.71 mmol) afforded 510 mg (87%) of t-butyl ester as a white solid, 500 mg of which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 320 mg (100%) of a white solid.

20

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.73 (s, 1 H), 8.85 (d, *J* = 8.7 Hz, 1 H), 8.42 (d, *J* = 1.3 Hz, 1 H), 8.14 (dd, *J* = 1.5, 8.7 Hz, 1 H), 7.66 (s, 1 H), 7.65 (m, 2 H), 7.49 (t, *J* = 7.9 Hz, 1 H), 7.13 (d, *J* = 7.9 Hz, 1 H), 3.86 (s, 3 H).

5


Preparation of 5-(2-Bromophenyl)isoxazole-3-carboxylic acid

Prepared according to the general method A: 1-bromo-2-ethynylbenzene (2000 mg, 11.0 mmol) and diethyl 2-nitromalonate (2050 mg, 10.0 mmol) to afford 2800 mg (96%) of ethyl ester as a brown oil, which was hydrolyzed in MeOH (20 ml) and water (10ml) by LiOH·H₂O (1000 mg, 23.8 mmol) to afford 1700mg (93%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.87 (dd, *J* = 1.5, 8.3 Hz, 2 H), 7.59 (dt, *J* = 1.5, 7.5 Hz, 1 H), 7.51 (m, 1 H), 7.34 (s, 1 H).

15

Example 7.46: 2-([5-(2-Bromophenyl)isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid

Prepared according to the General method C: 5-(2-bromophenyl)isoxazole-3-carboxylic acid (1900 mg, 7.1 mmol) and tert-butyl-2-amino-5-cyano benzoate (1700mg, 7.8 mmol) afforded 690 mg (20%) of t-butyl ester which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 38 mg (87%) of a white solid.


20

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.81 (s, 1 H), 8.85 (d, *J* = 8.7 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.16 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.91 (m, 2 H), 7.63 (dt, *J* = 1.3, 7.5 Hz, 1 H), 7.65 (dd, *J* = 1.7, 7.5 Hz, 1 H), 7.61 (s, 1 H).

5

Example 7.47: 2-([5-(1,1'-Biphenyl-2-yl)isoxazol-3-yl]carbonyl)amino)-5-cyanobenzoic acid



5-(2-bromophenyl)isoxazole-3-carboxylic acid (300 mg, 0.64 mmol), sodium carbonate (259 mg, 2.44 mmol), benzyl boronic acid (86mg, 0.71 mmol) and tetrakis(triphenylphosphine) palladium(0) (37 mg, 0.032 mmol) were placed in a 100 ml one-necked flask. The system was evacuated and filled with argon several times. Then THF (50 ml) and distilled water (5 ml) were added. The mixture was stirred at refluxing temperature overnight. Then the resulting solution was loaded directly on silica gel and purified by silica gel chromatography (EtOAc/Heptane=1/10) to afford 210 mg (70%) of the advanced t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (8 ml) to afford 140 mg (76%) of a white solid.


15

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.61 (s, 1 H), 8.76 (d, *J* = 8.9 Hz, 1 H), 8.40 (d, *J* = 2.1 Hz, 1 H), 8.11 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.91 (dd, *J* = 1.1, 7.4 Hz, 1 H), 7.64 (m, 2 H), 7.49 (dd, *J* = 1.5, 7.5 Hz, 1 H), 7.44 (m, 1 H), 7.43 (d, *J* = 2.1 Hz, 2 H), 7.29 (m, 2 H), 6.45 (s, 1 H).

25

Preparation of 1-Ethynyl-2-[(4-methoxybenzyl)oxy]benzene




2-ethynylphenol (75 g, 341 mmol), NaI (90 g, 682 mmol) and K₂CO₃ (63 g, 682 mmol) were placed in a 1 L flask. Acetonitrile (500 ml) was added, followed by the addition of 4-methoxy benzyl chloride (50 g, 319 mmol). The mixture was stirred at room temperature for about 12h. After filtration, the solution was washed with 1N NaOH, 1N HCl, and dried (MgSO₄). The solution was concentrated to yield 101 g (87%) of 1-iodo-2-[(4-methoxybenzyl)oxy]benzene as a yellow solid.

1-iodo-2-[(4-methoxybenzyl)oxy]benzene (61 g, 180 mmol), CuI (6.85 g, 35.9 mmol), and dichlorobis(triphenylphosphine) palladium(0) (12.6 g, 18.0 mmol) were placed in a 1000 ml one-necked flask. The system was evacuated and filled with argon several times. THF (250 ml) and diethylamine (250 ml) were added, followed by the addition of ethynyl(trimethyl)silane (22.8 g, 233 mmol). The mixture was stirred at refluxing temperature overnight. Then the resulting mixture was diluted with MTBE (1000 ml) and washed with 1N HCl, 1N NaOH, and dried (MgSO₄). The solution was concentrated and the residue was purified by flash chromatography (Heptane/EtOAc=1000/0, 1000/10) to afford 42 g (76%) of crude (2-[(4-methoxybenzyl)oxy]phenyl)ethynyl(trimethyl)silane as a yellow oil. The TMS group was removed by KF (12.0 g, 203 mmol) in MeOH (100 ml) to afford a 28 g (87%) of 1-Ethynyl-2-[(4-methoxybenzyl)oxy]benzene as a yellow solid.

Analytical data

¹H NMR (300 MHz, CDCl₃) δ 7.50 (dd, *J* = 1.9, 7.9 Hz, 1 H), 7.42 (d, *J* = 8.7 Hz, 2 H), 7.29 (m, 1 H), 6.93 (m, 5 H), 5.15 (s, 2 H), 3.83 (s, 3 H), 3.32 (s, 1 H).

Preparation of Ethyl 5-(2-hydroxyphenyl)isoxazole-3-carboxylate




1-Ethynyl-2-[(4-methoxybenzyl)oxy]benzene (28 g, 118 mmol) and diethyl 2-nitromalonate (22.3 g, 107 mmol) were dissolved in mesitylene (20 ml). The solution was heated at 150°C for about 12 h. Mesitylene was removed in vacuo and the residue was recrystallized from ethanol. 36 g (87%) of ethyl 5-{2-[(4-methoxybenzyl)oxy]phenyl}isoxazole-3-carboxylate was yielded as a light brown solid, 16 g of which was hydrolyzed in DCM (50 ml) TFA (6 mmol) to afford 10.6 g (100%) of a white solid.

10 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.81 (s, 1 H), 8.83 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.88 (m, 1 H), 7.14 (s, 1 H), 7.07 (dd, *J* = 0.8, 8.3 Hz, 1 H), 6.99 (m, 1 H), 4.40 (tetra, *J* = 7.1 Hz, 2 H), 1.35 (t, *J* = 7.3 Hz, 3 H).

15 **Preparation of 5-(2-Isopropoxyphenyl)isoxazole-3-carboxylic acid**




General method A: Ethyl 5-(2-hydroxyphenyl)isoxazole-3-carboxylate (300 mg, 1.3 mmol) and triphenylphosphine (337 mg, 1.3 mmol) were dissolved in THF (5 ml). Propan-2-ol (77 mg, 1.3 mmol) was added, followed by the addition of DEAD (224 mg, 1.3 mmol). The mixture was shaken over night. The resulting solution was loaded on silica gel and purified by flashing chromatography ((Heptane/EtOAc=1000/10, 1000/20) to afford 300 mg (51%) of ethyl 5-(2-isopropoxyphenyl)isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (137 mg, 3.3 mmol) to afford 270 mg (100%) of 5-(2-isopropoxyphenyl)isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 14.05 (s, 1 H), 7.91 (dd, *J* = 1.5, 7.9 Hz, 1 H), 7.51 (m, 1 H), 7.26 (d, *J* = 8.3 Hz, 1 H), 7.11 (d, *J* = 7.5 Hz, 1 H), 7.08 (s, 1 H), 4.86 (hept, *J* = 6.0 Hz, 1 H), 1.37 (d, *J* = 6.0 Hz, 6 H).

5

Example 7.48: 5-Cyano-2-({[5-(2-isopropoxyphenyl)isoxazol-3-yl]carbonyl}amino)benzoic acid




General method B: 5-(2-Isopropoxyphenyl)isoxazole-3-carboxylic acid (270 mg, 1.1 mmol) was dissolved in thionyl chloride (20 ml) and the resulting mixture was heated at refluxing temperature overnight. Toluene (30 ml) was added and the solution was concentrated in vacuo. The residue was re-dissolved in DCM (40 ml) followed by the addition of tert-butyl-2-amino-5-cyano benzoate (218 mg, 1.0 mmol) and pyridine (0.4 ml) and the mixture was stirred overnight. The resulting solution was diluted with MTBE (200 ml), washed with 1N HCl, 1N NaOH, brine and dried (MgSO₄). The solution was concentrated in vacuo and the residue was washed with MeOH to afford 170 mg (38%) of t-butyl ester as a light yellow solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 90 mg (60%) of a white solid.

20 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.64 (m, 1 H), 7.30 (d, *J* = 8.5 Hz, 1 H), 7.22 (s, 1 H), 7.13 (m, 1 H), 4.89 (hept, *J* = 6.0 Hz, 1 H), 1.40 (d, *J* = 6.0 Hz, 6 H).

25

Preparation of 5-{2-[2-(2-Ethoxyethoxy)ethoxy]phenyl}isoxazole-3-carboxylic acid



Prepared according to General method A: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 2-(2-ethoxyethoxy)ethanol (288 mg, 2.15 mmol) afforded 410 mg (55%) of ethyl 5-{2-[2-(2-ethoxyethoxy)ethoxy]phenyl}isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (148mg, 3.5 mmol) to afford 360 mg (95%) of 5-{2-[2-(2-ethoxyethoxy)ethoxy]phenyl}isoxazole-3-carboxylic acid as a yellow solid.


10

Analytical data

¹H NMR (300 MHz, DMSO-d₆) δ 8.02 (dd, J = 1.7, 7.8 Hz, 1 H), 7.44 (m, 1 H), 7.37 (s, 1 H), 7.11 (dt, J = 0.9, 7.7 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1 H), 4.32 (m, 2 H), 3.99 (m, 2 H), 3.80 (m, 2 H), 3.73 (m, 2 H), 3.58 (m, 2 H), 1.22 (t, J = 7.0 Hz, 3 H).

15

Example 7.49: 5-Cyano-2-[[5-{2-[2-(2-ethoxyethoxy)ethoxy]phenyl}isoxazol-3-yl]carbonyl]amino}benzoic acid




Prepared according to General method B: 5-{2-[2-(2-

ethoxyethoxy)ethoxy]phenyl}isoxazole-3-carboxylic acid (360 mg, 1.1 mmol) and tert-butyl-2-amino-5-cyano benzoate (284 mg, 1.3 mmol) afforded 170 mg (29%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 120 mg (79%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.77 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.55 (m, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.22 (s, 1 H), 7.15 (t, *J* = 7.9 Hz, 1 H), 4.20 (t, *J* = 6.4 Hz, 2 H), 1.85 (pent, *J* = 6.2 Hz, 2 H), 1.60 (pent, *J* = 7.0 Hz, 2 H), 1.35 (m, 4 H), 0.88 (t, *J* = 7.0 Hz, 3 H).

10 **Preparation of 5-[2-(2,3-Dihydro-1,4-benzodioxin-2-ylmethoxy)phenyl]isoxazole-3-carboxylic acid**



Prepared according to General method A: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and 2,3-dihydro-1,4-benzodioxin-2-ylmethanol (348 mg, 2.15 mmol) afforded 550 mg (68%) of ethyl 5-[2-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (148mg, 3.5 mmol) to afford 470 mg (92%) of 5-[2-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)phenyl]isoxazole-3-carboxylic acid as a white solid.


20

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 14.05 (s, 1 H), 7.94 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.55 (m, 1 H), 7.36 (s, 1 H), 7.32 (d, *J* = 8.1 Hz, 1 H), 7.18 (m, 1 H), 7.01 (m, 1 H), 6.92 (m, 1 H), 6.86 (m, 2 H), 4.74 (m, 1 H), 4.67 (dd, *J* = 3.5, 10.6 Hz, 1 H), 4.46 (dd, *J* = 2.5, 11.6 Hz, 1 H), 4.33 (dd, *J* = 7.5, 10.6 Hz, 1 H), 4.18 (dd, *J* = 6.9, 11.6 Hz, 1 H).

25

Example 7.50: 5-Cyano-2-[(5-[2-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid



Prepared according to General method B: 5-[2-(2,3-dihydro-1,4-benzodioxin-2-


5 ylmethoxy)phenyl]isoxazole-3-carboxylic acid (470 mg, 1.4 mmol) and tert-butyl-2-amino-5-cyano benzoate (267 mg, 1.2 mmol) afforded 360 mg (54%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 290 mg (89%) of a white solid.

10 Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.74 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.13 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.98 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.57 (m, 1 H), 7.48 (s, 1 H), 7.34 (d, *J* = 8.3 Hz, 1 H), 7.20 (t, *J* = 7.7 Hz, 1 H), 7.04 (m, 1 H), 6.90 (m, 3 H), 4.76 (m, 1 H), 4.59 (dd, *J* = 3.8, 10.7 Hz, 1 H), 4.47 (dd, *J* = 2.3,

15 11.5 Hz, 1 H), 4.35 (dd, *J* = 7.4, 10.6 Hz, 1 H), 4.20 (dd, *J* = 6.6, 11.3 Hz, 1 H).

Preparation of 5-[2-(Hexyloxy)phenyl]isoxazole-3-carboxylic acid




General method C: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 1.3 mmol), K₂CO₃ (455 mg, 4.29 mmol) and n-Iodohexane were placed in acetonitrile (20 ml). The mixture was stirred overnight. The resulting solution was loaded on silica gel and purified by flashing chromatography ((Heptane/EtOAc=1000/10, 1000/20) to afford 590 mg (87%) of ethyl 5-[2-(hexyloxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O

(137 mg, 3.3 mmol) to afford 528 mg (98%) of 5-[2-(hexyloxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.91 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.52 (m, 1 H), 7.24 (d, *J* = 8.1 Hz, 1 H), 7.12 (m, 1 H), 7.08 (s, 1 H), 4.17 (t, *J* = 6.2 Hz, 2 H), 1.82 (m, 2 H), 1.48 (m, 2 H), 1.32 (m, 4 H), 0.87 (t, *J* = 7.1 Hz, 3 H).

Example 7.51: 5-Cyano-2-[(5-[2-(hexyloxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(hexyloxy)phenyl]isoxazole-3-carboxylic acid (528 mg, 1.8 mmol) and tert-butyl-2-amino-5-cyano benzoate (362 mg, 1.7 mmol) afforded 430 mg (53%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 290 mg (76%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.77 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.55 (m, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.22 (s, 1 H), 7.15 (t, *J* = 7.9 Hz, 1 H), 4.20 (t, *J* = 6.4 Hz, 2 H), 1.85 (pent, *J* = 6.2 Hz, 2 H), 1.60 (pent, *J* = 7.0 Hz, 2 H), 1.35 (m, 4 H), 0.88 (t, *J* = 7.0 Hz, 3 H).

Preparation of 5-[2-(Allyloxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method C: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 1.3 mmol) and allyl bromide (286 mg, 2.4 mmol) afforded 540 mg (92%) of 5-[2-(allyloxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (137 mg, 3.3 mmol) to afford 480 mg (99%) of 5-[2-(allyloxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 14.12 (s, 1 H), 7.92 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.53 (m, 1 H), 7.26 (d, *J* = 8.1 Hz, 1 H), 7.14 (m, 1 H), 7.10 (s, 1 H), 6.15 (m, 1 H), 5.48 (dd, *J* = 1.7, 17.2 Hz, 1 H), 5.35 (dd, *J* = 1.7, 10.6 Hz, 1 H), 4.90 (dt, *J* = 1.2, 5.4 Hz, 2 H)


Example 7.52: 2-[(5-[2-(Allyloxy)phenyl]isoxazol-3-yl)carbonyl]amino]-5-cyanobenzoic acid



Prepared according to General method B: 5-[2-(allyloxy)phenyl]isoxazole-3-carboxylic acid (480 mg, 2.0 mmol) and tert-butyl-2-amino-5-cyano benzoate (388 mg, 1.8 mmol) afforded 330 mg (42%) of t-butyl ester as a white solid, 100 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 60 mg (69%) of a white solid.

Analytical data


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.76 (s, 1 H), 8.85 (d, *J* = 8.7 Hz, 1 H), 8.33 (d, *J* = 1.9 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.96 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.65 (m, 1 H), 7.29 (d, *J* = 8.5 Hz, 1 H), 7.25 (s, 1 H), 7.17 (t, *J* = 7.7 Hz, 1 H), 6.17 (m, 1 H), 5.48 (dd, *J* = 1.5, 17.2 Hz, 1 H), 5.37 (dd, *J* = 1.5, 10.6 Hz, 1 H), 4.82 (d, *J* = 5.5 Hz, 2 H).

Preparation of 5-(2-Ethoxyphenyl)isoxazole-3-carboxylic acid

Prepared according to General method A: ethyl 5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and tetrahydro-2H-pyran-2-ylmethanol (249 mg, 2.15 mmol) afforded 110 mg (25%) of ethyl 5-(2-ethoxyphenyl)isoxazole-3-carboxylate as a white solid, which (plus another 110 mg from 36831-jl-34) was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (148mg, 3.5 mmol) to afford 200 mg (100%) of 5-(2-ethoxyphenyl)isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.92 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.52 (m, 1 H), 7.24 (d, *J* = 8.3 Hz, 1 H), 7.12 (t, *J* = 7.7 Hz, 1 H), 7.08 (s, 1 H), 4.24 (tetra, *J* = 7.0 Hz, 2 H), 1.45 (t, *J* = 7.0 Hz, 3 H).


Example 7.53: 5-Cyano-2-([5-(2-ethoxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid

Prepared according to General method B: 5-(2-ethoxyphenyl)isoxazole-3-carboxylic acid (200 mg, 0.86 mmol) and tert-butyl-2-amino-5-cyano benzoate (170 mg, 0.78 mmol) afforded 130 mg (38%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 98 mg (87%) of a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.77 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 1.9 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.96 (dd, *J* = 1.5, 7.9 Hz, 1 H), 7.55 (m, 1 H), 7.26 (d, *J* = 8.3 Hz, 1 H), 7.23 (s, 1 H), 7.15 (t, *J* = 7.7 Hz, 1 H), 4.27 (tetra, *J* = 7.0 Hz, 2 H), 1.48 (t, *J* = 7.0 Hz, 3 H).

Preparation of 5-[2-(tetrahydro-2H-pyran-2-ylmethoxy)phenyl]isoxazole-3-carboxylic acid



10

General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and triphenylphosphine (562 mg, 2.15 mmol) were dissolved in THF (5 ml). tetrahydro-2H-pyran-2-ylmethanol (249 mg, 2.15 mmol) was added, followed by the addition of Di-tert-butylazocarboxylate (DIAD) (495 mg, 2.15 mmol). The mixture was shaken over night. The resulting solution was loaded on silica gel and purified by flashing chromatography ((Heptane/EtOAc=1000/10, 1000/20) to afford 380 mg (54%) of ethyl 5-[2-(tetrahydro-2H-pyran-2-ylmethoxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (137 mg, 3.3 mmol) to afford 360 mg (100%) of 5-[2-(tetrahydro-2H-pyran-2-ylmethoxy)phenyl]isoxazole-3-carboxylic acid as a yellow oil.


20

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.02 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.53 (s, 1 H), 7.44 (m, 1 H), 7.10 (t, *J* = 7.7 Hz, 1 H), 7.02 (d, *J* = 8.5 Hz, 1 H), 4.14 (m, 3 H), 3.86 (m, 1 H), 3.61 (m, 1 H), 1.97 (m, 1 H), 1.65 (m, 5 H).

25

Example 7.54: 5-Cyano-2-[(5-[2-(tetrahydro-2H-pyran-2-ylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(tetrahydro-2H-pyran-2-

- 5 ylmethoxy)phenyl]isoxazole-3-carboxylic acid (360 mg, 1.2 mmol) and tert-butyl-2-amino-5-cyano benzoate (235 mg, 1.1 mmol) afforded 270 mg (50%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 200 mg (83%) of a white solid.

10 Analytical data

- ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.87 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.96 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.65 (s, 1 H), 7.54 (m, 1 H), 7.25 (d, *J* = 8.3 Hz, 1 H), 7.16 (m, 1 H), 4.21 (dd, *J* = 3.1, 10.2 Hz, 1 H), 4.11 (dd, *J* = 6.0, 10.2 Hz, 1 H), 4.03 (d, *J* = 11.0 Hz, 1 H), 3.76 (m, 1 H), 3.50 (m, 1 H), 1.86 (m, 1 H), 1.66 (d, *J* = 11.2 Hz, 1 H), 1.67 (m, 4 H).

Preparation of 5-[2-(3-Phenoxypropoxy)phenyl]isoxazole-3-carboxylic acid




- Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and 3-phenoxypropan-1-ol (327 mg, 2.15 mmol) afforded 660 mg (88%) of ethyl 5-[2-(3-phenoxypropoxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5

ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 540 mg (88%) of 5-[2-(3-phenoxypropoxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Analytical data

¹H NMR (300 MHz, CD₃OD) δ 7.94 (dd, *J* = 1.9, 8.3 Hz, 1 H), 7.43 (m, 1 H), 7.24 (m, 2 H), 7.15 (s, 1 H), 7.08 (d, *J* = 7.9 Hz, 2 H), 6.91 (m, 3 H), 4.35 (t, *J* = 6.2 Hz, 2 H), 4.19 (t, *J* = 5.8 Hz, 2 H), 3.88 (pent, *J* = 6.0 Hz, 2 H).

Example 7.55: 5-Cyano-2-[(5-[2-(3-phenoxypropoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(3-phenoxypropoxy)phenyl]isoxazole-3-carboxylic acid (540 mg, 1.7 mmol) and tert-butyl-2-amino-5-cyano benzoate (331 mg, 1.5 mmol) afforded 500 mg (63%) of t-butyl ester as a yellow solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 410 mg (89%) of a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.73 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.95 (dd, *J* = 1.5, 7.9 Hz, 1 H), 7.55 (m, 1 H), 7.32 (d, *J* = 8.9 Hz, 1 H), 7.26 (m, *J* = 3 Hz, 1 H), 7.16 (t, *J* = 7.5 Hz, 1 H), 6.94 (m, 3 H), 4.38 (t, *J* = 6.0 Hz, 2 H), 4.20 (t, *J* = 6.2 Hz, 2 H), 2.82 (pent, *J* = 6.2 Hz, 2 H).

Preparation of 5-(2-[(1*S*)-1-phenylethyl]oxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 1 (1S)-1-phenylethanol (262 mg, 2.15 mmol) afforded 440 mg (57%) of ethyl 5-(2-((1S)-1-

- 5 phenylethyl]oxy}phenyl)isoxazole-3-carboxylate as a green oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (200 mg, 4.8mmol) to afford 380 mg (100%) of 5-(2-((1S)-1-phenylethyl]oxy}phenyl)isoxazole-3-carboxylic acid as a yellow solid.

10 Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.90 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.37 (m, 5 H), 7.28 (m, 1 H), 7.23 (s, 1 H), 7.06 (m, 2 H), 5.78 (tetra, *J* = 6.4 Hz, 1 H), 1.68 (d, *J* = 6.2 Hz, 3 H);

15 **Example 7.56: 5-Cyano-2-((5-(2-hydroxyphenyl)isoxazol-3-yl]carbonyl)amino)benzoic acid**




- Prepared according to General method B: 5-(2-((1S)-1-phenylethyl]oxy}phenyl)isoxazole-3-carboxylic acid (380 mg, 1.2 mmol) and tert-butyl-2-amino-5-cyano benzoate (244 mg, 1.1 mmol) afforded 45 mg (8%) of tert-butyl 5-cyano-2-((5-(2-((1S)-1-phenylethyl]oxy}phenyl)isoxazol-3-
- 20

yl]carbonyl}amino)benzoate as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 18 mg (58%) of a white solid.

Analytical data

- 5 ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.70 (s, 1 H), 10.87 (s, 1 H), 8.86 (d, *J* = 8.7 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.87 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.89 (m, 1 H), 7.26 (s, 1 H), 7.09 (d, *J* = 7.7 Hz, 1 H), 7.01 (t, *J* = 7.0 Hz, 1 H).

10 **Preparation of 5-[2-(Cyclobutyloxy)phenyl]isoxazole-3-carboxylic acid**




- Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and cyclobutanol (155 mg, 2.15 mmol) afforded 260 mg (42%) of ethyl 5-[2-(cyclobutyloxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH·H₂O (300 mg, 7.1 mmol) to afford 200 mg (82%) of 5-[2-(cyclobutyloxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Analytical data

- 20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.91 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.50 (m, 1 H), 7.10 (s, 1 H), 7.09 (m, 2 H), 4.90 (m, 1 H), 2.54 (m, 1 H), 2.14 (m, 2 H), 1.81 (m, 1 H), 1.71 (m, 1 H), 1.37 (d, *J* = 6.0 Hz, 1 H);

- Example 7.57: 5-Cyano-2-[(5-[2-(cyclobutyloxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid**




Prepared according to General method B: 5-[2-(cyclobutyloxy)phenyl]isoxazole-3-carboxylic acid (200 mg, 0.77 mmol) and tert-butyl-2-amino-5-cyano benzoate (154 mg, 0.7 mmol) afforded 140 mg (44%) of t-butyl ester as a white solid, which was
 5 hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 67 mg (55%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 1.9 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.52
 10 (m, 1 H), 7.24 (s, 1 H), 7.14 (t, *J* = 7.7 Hz, 1 H), 7.10 (d, *J* = 8.1 Hz, 1 H), 4.92 (pent, *J* = 7.1 Hz, 1 H), 2.55 (m, 1 H), 2.18 (m, 2 H), 1.87 (tetra, *J* = 10.4 Hz, 1 H), 1.71 (m, 1 H), 1.40 (d, *J* = 6.0 Hz, 1 H).


Preparation of 5-[2-(Tetrahydrofuran-3-yloxy)phenyl]isoxazole-3-carboxylic acid



15

Prepared according to General method D: ethyl 5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and tetrahydrofuran-3-ol (155 mg, 2.15 mmol) afforded 1000 mg (100%) of ethyl 5-[2-(tetrahydrofuran-3-yloxy)phenyl]isoxazole-3-carboxylate as a yellow solid, which was hydrolyzed in MeOH (10 ml) and water (5
 20 ml) by LiOH·H₂O (300 mg, 7.1 mmol) to afford 810 mg (89%) of crude 5-[2-(tetrahydrofuran-3-yloxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Example 7.58: 5-Cyano-2-[(5-[2-(tetrahydrofuran-3-yloxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(tetrahydrofuran-3-yloxy)phenyl]isoxazole-3-carboxylic acid (810 mg, 3.0 mmol) and tert-butyl-2-amino-5-cyano benzoate (584 mg, 2.7 mmol) afforded 440 mg (35%) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 410 mg (100%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.71 (s, 1 H), 8.84 (d, *J* = 8.7 Hz, 1 H), 8.42 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.96 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.55 (m, 1 H), 7.28 (d, *J* = 8.3 Hz, 1 H), 7.18 (s, 1 H), 7.17 (t, *J* = 7.3 Hz, 1 H), 5.82 (m, 1 H), 3.94 (m, 3 H), 3.82 (m, 1 H), 2.33 (m, 1 H), 2.07 (m, 1 H).

Preparation of 5-[2-(Tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and tetrahydro-2H-pyran-4-ol (219 mg, 2.15 mmol) afforded 1000 mg (100%) of ethyl 5-[2-(tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 780 mg (85%) of 5-[2-(tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.88 (s, 1 H), 7.92 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.51 (m, 1 H), 7.35 (d, *J* = 8.3 Hz, 1 H), 7.12 (t, *J* = 7.3 Hz, 1 H), 7.10 (s, 1 H), 4.77 (m, 1 H), 3.86 (m, 2 H), 3.54 (m, 2 H), 2.07 (m, 2 H), 1.68 (m, 2 H).

5

Example 7.59: 5-Cyano-2-[(5-[2-(tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(tetrahydro-2H-pyran-4-yloxy)phenyl]isoxazole-3-carboxylic acid (780 mg, 2.7 mmol) and tert-butyl-2-amino-5-cyano benzoate (535 mg, 2.5 mmol) afforded 950 mg (79%) of t-butyl ester as a brown solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 350 mg (42%) of a white solid.

15 Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.96 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.54 (m, 1 H), 7.38 (d, *J* = 8.3 Hz, 1 H), 7.24 (s, 1 H), 7.15 (t, *J* = 7.5 Hz, 1 H), 4.88 (hept, *J* = 4.2 Hz, 1 H), 3.90 (t, *J* = 4.1 Hz, 1 H), 3.86 (t, *J* = 4.5 Hz, 1 H), 3.55 (m, 2 H), 2.09 (m, 2 H), 1.72 (m, 2 H).

Preparation of 5-(2-[(1S,2R)-2-methylcyclopentyl]oxy}phenyl)isoxazole-3-carboxylic acid




Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (500 mg, 2.15 mmol) and (1R,2R)-2-methylcyclopentanol (215 mg, 2.15 mmol) afforded 430 mg (64%) of ethyl 5-(2-((1S,2R)-2-methylcyclopentyl)oxy}phenyl)isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 360 mg (91 %) of 5-(2-((1S,2R)-2-methylcyclopentyl)oxy}phenyl)isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.90 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.60 (m, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.10 (m, 1 H), 7.08 (s, 1 H), 4.92 (dt, *J* = 1.5, 4.5 Hz, 1 H), 2.19 (m, 1 H), 2.03 (m, 1 H), 1.90 (m, 1 H), 1.73 (m, 2 H), 1.62 (m, 1 H), 1.60 (m, 1 H), 1.05 (d, *J* = 6.8 Hz, 3 H).

Example 7.60: 5-Cyano-2-((5-(2-((1S,2R)-2-methylcyclopentyl)oxy}phenyl)isoxazol-3-yl)carbonyl)amino)benzoic acid




Prepared according to General method B: 5-(2-((1S,2R)-2-methylcyclopentyl)oxy}phenyl)isoxazole-3-carboxylic acid (360 mg, 1.3 mmol) and tert-butyl-2-amino-5-cyano benzoate (249 mg, 1.1 mmol) afforded 270 mg (49 %) of tert-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 250 mg (42%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.77 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 8.1 Hz, 1 H), 8.13 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.95 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.53 (m, 1 H), 7.30 (d, *J* = 8.3 Hz, 1 H), 7.22 (s, 1 H), 7.13 (m, 1 H), 4.95 (m, 1 H), 2.21 (m, 1 H), 2.05 (m, 1 H), 1.93 (m, 1 H), 1.76 (m, 2 H), 1.65 (m, 1 H), 1.54 (m, 1 H), 1.07 (d, *J* = 6.8 Hz, 3 H).

Preparation of 5-[2-(2-Methoxy-1-methylethoxy)phenyl]isoxazole-3-carboxylic acid




- 5 Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate acid (500 mg, 2.15 mmol) and 1-methoxypropan-2-ol (194 mg, 2.15 mmol) afforded 570 mg (87%) of ethyl 5-[2-(2-methoxy-1-methylethoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 430 mg
 10 (83 %) of 5-[2-(2-methoxy-1-methylethoxy)phenyl]isoxazole-3-carboxylic acid as a white solid.

Analytical data

- ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.91 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.50 (m, 1 H), 7.30
 15 (d, *J* = 8.3 Hz, 1 H), 7.21 (s, 1 H), 7.11 (m, 1 H), 4.86 (m, 1 H), 3.59 (d, *J* = 4.5 Hz, 2 H), 3.32 (s, 3 H), 1.31 (d, *J* = 6.2 Hz, 3 H).

Example 7.61: 5-Cyano-2-[(5-[2-(2-methoxy-1-methylethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid



20


Prepared according to General method B: 5-[2-(2-methoxy-1-methylethoxy)phenyl]isoxazole-3-carboxylic acid (430 mg, 1.6 mmol) and tert-butyl-2-amino-5-cyano benzoate (308 mg, 1.4 mmol) afforded 360 mg (54 %) of t-butyl ester

as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 160 mg (50 %) of a white solid.

Analytical data

- 5 ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.75 (s, 1 H), 8.86 (d, $J = 8.9$ Hz, 1 H), 8.43 (d, $J = 2.1$ Hz, 1 H), 8.14 (dd, $J = 2.1, 8.7$ Hz, 1 H), 7.96 (dd, $J = 1.7, 7.9$ Hz, 1 H), 7.53 (m, 1 H), 7.36 (s, 1 H), 7.33 (d, $J = 8.5$ Hz, 1 H), 7.14 (t, $J = 7.1$ Hz, 1 H), 4.88 (m, 1 H), 3.63 (d, $J = 4.4$ Hz, 2 H), 3.35 (s, 3 H), 1.34 (d, $J = 6.3$ Hz, 3 H).

10 **Preparation of 5-[2-(1-Methylbutoxy)phenyl]isoxazole-3-carboxylic acid**




Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate acid (500 mg, 2.15 mmol) and pentan-2-ol (189 mg, 2.15 mmol) afforded 530 mg (82%) of ethyl 5-[2-(1-methylbutoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by $\text{LiOH}\cdot\text{H}_2\text{O}$ (300 mg, 7.1 mmol) to afford 450 mg (93%) of 5-[2-(1-methylbutoxy)phenyl]isoxazole-3-carboxylic acid as a colorless oil.

Analytical data

- 20 ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.91 (dd, $J = 1.7, 7.9$ Hz, 1 H), 7.50 (m, 1 H), 7.27 (d, $J = 8.3$ Hz, 1 H), 7.10 (m, 1 H), 7.06 (s, 1 H), 4.73 (hex, $J = 6.0$ Hz, 1 H), 1.69 (m, 2 H), 1.41 (m, 2 H), 1.32 (d, $J = 6.0$ Hz, 3 H), 0.91 (t, $J = 7.4$ Hz, 3 H).

Example 7.62: 5-Cyano-2-[(5-[2-(1-methylbutoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(1-methylbutoxy)phenyl]isoxazole-3-carboxylic acid (450 mg, 1.6 mmol) and tert-butyl-2-amino-5-cyano benzoate (324 mg, 1.5 mmol) afforded 320 mg (45 %) of t-butyl ester as a white solid, which was
 5 hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 170 mg (60%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.79 (s, *J* = 1 Hz, H), 8.86 (d, *J* = 8.7 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.96 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.64 (m, 1 H), 7.30 (d, *J* = 8.5 Hz, 1 H), 7.21 (s, 1 H), 7.12 (t, *J* = 7.3 Hz, 1H), 4.76 (hex, *J* = 6.2 Hz, 1 H), 1.79 (m, 1 H), 1.68 (m, 1 H), 1.45 (m, 2 H), 1.34 (d, *J* = 6.0 Hz, 3 H), 0.92 (t, *J* = 7.3 Hz, 3 H).

Preparation of 5-[2-(Cyclobutylmethoxy)phenyl]isoxazole-3-carboxylic acid



15


Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate acid (500 mg, 2.15 mmol) and cyclobutylmethanol (185 mg, 2.15 mmol) afforded 420 mg (65%) of ethyl 5-[2-(cyclobutylmethoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml)
 20 by LiOH•H₂O (300 mg, 7.1 mmol) to afford 360 mg (94 %) of 5-[2-(cyclobutylmethoxy)phenyl]isoxazole-3-carboxylic acid as a white solid.

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 7.92 (dd, $J = 1.7, 7.9$ Hz, 1 H), 7.52 (m, 1 H), 7.24 (d, $J = 8.3$ Hz, 1 H), 7.13 (t, $J = 7.7$ Hz, 1 H), 7.07 (s, 1 H), 4.14 (d, $J = 6.6$ Hz, 2 H), 2.86 (m, 1 H), 2.12 (m, 2 H), 1.95 (m, 4 H).

5

Example 7.63: 5-Cyano-2-[(5-[2-(cyclobutylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(cyclobutylmethoxy)phenyl]isoxazole-3-carboxylic acid (360 mg, 1.3 mmol) and tert-butyl-2-amino-5-cyano benzoate (261 mg, 1.2 mmol) afforded 470 mg (83 %) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 340 mg (82%) of a white solid.

Analytical data

^1H NMR (400 MHz, DMSO- d_6) δ 12.73 (s, 1 H), 8.85 (d, $J = 8.7$ Hz, 1 H), 8.42 (d, $J = 2.1$ Hz, 1 H), 8.12 (dd, $J = 2.1, 8.7$ Hz, 1 H), 7.95 (dd, $J = 1.7, 7.7$ Hz, 1 H), 7.54 (m, 1 H), 7.26 (d, $J = 8.3$ Hz, 1 H), 7.20 (s, 1 H), 7.15 (m, 1 H), 4.16 (d, $J = 6.6$ Hz, 2 H), 2.89 (m, 1 H), 2.14 (m, 2 H), 1.97 (m, 4 H).

20 Preparation of 5-[2-(Cyclohex-2-en-1-ylmethoxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and cyclobutylmethanol (241 mg, 2.15 mmol) afforded 390 mg (56%) of ethyl 5-[2-(cyclohex-2-en-1-ylmethoxy)phenyl]isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 370 mg (100 %) of 5-[2-(cyclohex-2-en-1-ylmethoxy)phenyl]isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.92 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.52 (m, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.13 (t, *J* = 7.5 Hz, 1 H), 7.08 (s, 1 H), 5.71 (s, 2 H), 4.09 (d, *J* = 6.2 Hz, 2 H), 2.19 (m, 2 H), 2.08 (m, 2 H), 1.89 (m, 2 H), 1.41 (m, 1 H).

Example 7.64: 5-Cyano-2-[(5-[2-(cyclobutylmethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid



15

Prepared according to General method B: 5-[2-(cyclohex-2-en-1-ylmethoxy)phenyl]isoxazole-3-carboxylic acid (370 mg, 1.2 mmol) and tert-butyl-2-amino-5-cyano benzoate (299 mg, 1.4 mmol) afforded 200 mg (32 %) of t-butyl ester as a white solid, 190 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 158 mg (94%) of a white solid.


20

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.76 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.3, 8.9 Hz, 1 H), 7.76 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.55 (m, 1 H), 7.30 (d, *J* = 8.3 Hz, 1 H), 7.22 (s, 1 H), 7.16 (m, 1 H), 5.72 (s, 2 H), 4.12 (d, *J* = 6.2 Hz, 2 H), 2.21 (m, 2 H), 2.10 (m, 2 H), 1.92 (m, 2 H), 1.43 (m, 1 H).

25

Preparation of 5-[2-(Carboxymethoxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method C: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 4-(chloroacetyl)morpholine (529 mg, 3.2 mmol) afforded 450 mg (56%) of ethyl 5-[2-(2-morpholin-4-yl-2-oxoethoxy)phenyl]isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 380 mg (100 %) of 5-[2-(carboxymethoxy)phenyl]isoxazole-3-carboxylic acid as a white solid.

10 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.95 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.62 (m, 1 H), 7.61 (s, 1 H), 7.17 (m, 2 H), 4.92 (s, 2 H).


15 Example 7.65: 2-({[2-(3-{{(2-Carboxy-4-cyanophenyl)amino}carbonyl}isoxazol-5-yl)phenoxy]acetyl}amino)-5-cyanobenzoic acid



Prepared according to General method B: 5-[2-(carboxymethoxy)phenyl]isoxazole-3-carboxylic acid (380 mg, 1.4 mmol) and tert-butyl-2-amino-5-cyano benzoate (693 mg, 3.2 mmol) afforded 780 mg (89 %) of t-butyl ester as a light yellow solid, 290 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 260 mg (99%) of a white solid.

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.72 (s, 1 H), 12.05 (s, 1 H), 8.84 (dd, *J* = 3.0, 8.9 Hz, 2 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.30 (2.1, *J* = 1 Hz, H), 8.15 (dd, *J* = 1.9, 8.9 Hz, 1 H), 8.09 (dd, *J* = 2.1, 8.9 Hz, 1 H), 8.01 (dd, *J* = 1.3, 7.7 Hz, 1 H), 7.56 (t, *J* = 8.3 Hz, 1 H), 7.53 (s, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.23 (t, *J* = 7.7 Hz, 1 H), 5.19 (s, 2 H).

Preparation of 5-[2-(1-Ethylpropoxy)phenyl]isoxazole-3-carboxylic acid

10 Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-carboxylate (500 mg, 2.15 mmol) and pentan-3-ol (189 mg, 2.15 mmol) afforded 330 mg (51%) of ethyl 5-[2-(1-ethylpropoxy)phenyl]isoxazole-3-carboxylate as a white
soild, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300
mg, 7.1 mmol) to afford 240 mg (80%) of 5-[2-(1-ethylpropoxy)phenyl]isoxazole-3-
15 carboxylic acid as a yellow oil.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.92 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.50 (m, 1 H), 7.26 (d, *J* = 8.3 Hz, 1 H), 7.10 (t, *J* = 7.2 Hz, 1 H), 7.05 (s, 1 H), 4.55 (pent, *J* = 5.7 Hz, 1
20 H), 1.72 (m, 4 H), 0.91 (t, *J* = 7.4 Hz, 6 H).

Example 7.66: 5-Cyano-2-[(5-[2-(1-ethylpropoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid

Prepared according to General method B: 5-[2-(1-ethylpropoxy)phenyl]isoxazole-3-carboxylic acid (240 mg, 0.9 mmol) and tert-butyl-2-amino-5-cyano benzoate (299 mg, 1.0 mmol) afforded 150 mg (36 %) of t-butyl ester as a yellow solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 120 mg (91%) of a white solid.


5

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.78 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.96 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.53 (m, 1 H), 7.30 (d, *J* = 8.5 Hz, 1 H), 7.20 (s, 1 H), 7.12 (m, 1 H), 4.58 (pent, *J* = 5.8 Hz, 1 H), 1.74 (m, 4 H), 0.93 (t, *J* = 7.3 Hz, 6 H).

10

Preparation of 5-{2-[2-(4-Methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazole-3-carboxylic acid




15 Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 2-(4-methyl-1,3-thiazol-5-yl)ethanol (307 mg, 2.15 mmol) afforded 470 mg (62%) of ethyl 5-{2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazole-3-carboxylate as a white solid, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH·H₂O (300 mg, 7.1 mmol) to afford 90 mg
20 (21 %) of 5-{2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.82 (s, 1 H), 7.90 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.53 (m, 1 H), 7.28 (d, *J* = 8.3 Hz, 1 H), 7.14 (t, *J* = 7.4 Hz, 1 H), 6.96 (s, 1 H), 4.39 (t, *J* = 6.0 Hz, 2 H), 3.35 (t, *J* = 6.0 Hz, 2 H), 2.36 (s, 3 H).

25

Example 7.67: 5-Cyano-2-[[5-{2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazol-3-yl]carbonyl]amino}benzoic acid




Prepared according to General method B: 5-{2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl}isoxazole-3-carboxylic acid (90 mg, 0.27 mmol) and tert-butyl-2-amino-5-cyano benzoate (66 mg, 0.3 mmol) afforded 60 mg (42 %) of t-butyl ester as a yellow solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 48 mg (89%) of a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.78 (s, 1 H), 8.86 (d, *J* = 8.7 Hz, 1 H), 8.82 (s, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.94 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.56 (m, 1 H), 7.31 (d, *J* = 8.3 Hz, 1 H), 7.17 (t, *J* = 7.1 Hz, 1 H), 7.12 (s, 1 H), 4.42 (t, *J* = 6.2 Hz, 2 H), 1.38 (t, *J* = 6.0 Hz, 2 H), 2.38 (s, 3 H).

Preparation of 5-[2-(1-Cyclohexylethoxy)phenyl]isoxazole-3-carboxylic acid



15


Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 1-cyclohexylethanol (275 mg, 2.15 mmol) afforded 340 mg (47%) of ethyl 5-[2-(1-cyclohexylethoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH·H₂O (300 mg, 7.1 mmol) to afford 280 mg (89 %) of 5-[2-(1-cyclohexylethoxy)phenyl]isoxazole-3-carboxylic acid as a yellow oil.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.90 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.50 (m, 1 H), 7.27 (d, *J* = 8.3 Hz, 1 H), 7.09 (m, 1 H), 7.08 (s, 1 H), 4.55 (m, 1 H), 1.88 (d, *J* = 11.8 Hz, 1 H), 1.69 (m, 4 H), 1.26 (d, *J* = 6.2 Hz, 3 H), 1.16 (m, 6 H).

5

Example 7.68: 5-Cyano-2-[(5-[2-(1-cyclohexylethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




Prepared according to General method B: 5-[2-(1-cyclohexylethoxy)phenyl]isoxazole-3-carboxylic acid (280 mg, 0.9 mmol) and tert-butyl-2-amino-5-cyano benzoate (215 mg, 1.0 mmol) afforded 190 mg (42 %) of t-butyl ester as a yellow solid, 80 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 61 mg (86%) of a white solid.

15 Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.86 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.14 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.94 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.53 (m, 1 H), 7.30 (d, *J* = 8.5 Hz, 1 H), 7.23 (s, 1 H), 7.11 (m, 1 H), 4.59 (pent, *J* = 5.8 Hz, 1 H), 1.91 (d, *J* = 12.0 Hz, 1 H), 1.73 (m, 4 H), 1.28 (d, *J* = 6.2 Hz, 3 H), 1.16 (m, 6 H).

20

Preparation of 5-[2-(2-Oxobutoxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method C: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 1-bromobutan-2-one (649 mg, 4.30 mmol) afforded 650 mg (100%) of ethyl 5-[2-(2-oxobutoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, 580 mg of which was hydrolyzed in MeOH (10 ml) and water (5 ml) by
5 LiOH•H₂O (300 mg, 7.1 mmol) to afford 520 mg (99 %) of 5-[2-(2-oxobutoxy)phenyl]isoxazole-3-carboxylic acid as a yellow oil.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.95 (dd, *J* = 1.7, 8.1 Hz, 1 H), 7.55 (s, 1 H), 7.61
10 (m, 1 H), 7.15 (m, 2 H), 5.11 (s, 2 H), 2.55 (tetra, *J* = 7.4 Hz, 2 H), 1.02 (t, *J* = 7.4 Hz, 3 H).

Example 7.69: 5-Cyano-2-[(5-[2-(2-oxobutoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid




15

Prepared according to General method B: 5-[2-(2-oxobutoxy)phenyl]isoxazole-3-carboxylic acid (520 mg, 1.9 mmol) and tert-butyl-2-amino-5-cyano benzoate (453 mg, 2.1 mmol) afforded 470 mg (52 %) of t-butyl ester as a yellow solid, 170 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 140 mg (93%) of a yellow
20 solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 12.75 (s, 1 H), 8.87 (d, *J* = 8.9 Hz, 1 H), 8.43 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.7 Hz, 1 H), 7.98 (dd, *J* = 1.7, 8.1 Hz, 1 H), 7.68
25 (s, 1 H), 7.63 (m, 1 H), 7.18 (m, 2 H), 5.14 (s, 2 H), 2.56 (tetra, *J* = 7.5 Hz, 2 H), 1.03 (t, *J* = 7.3 Hz, 3 H).

Preparation of 5-[2-(2-Oxo-2-phenylethoxy)phenyl]isoxazole-3-carboxylic acid




Prepared according to General method C: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 2-bromo-1-phenylethanone (513 mg, 2.58 mmol) afforded 650 mg (86 %) of ethyl 5-[2-(2-oxo-2-phenylethoxy)phenyl]isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (300 mg, 7.1 mmol) to afford 610mg (100 %) of 5-[2-(2-oxo-2-phenylethoxy)phenyl]isoxazole-3-carboxylic acid as a yellow solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.11 (d, *J* = 7.2 Hz, 2 H), 7.99 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.75 (s, 1 H), 7.71 (d, *J* = 7.4 Hz, 1 H), 7.6 (m, 2 H), 7.53 (m, 1 H), 7.37 (d, *J* = 8.1 Hz, 1 H), 7.18 (t, *J* = 7.7 Hz, 1 H), 5.84 (s, 2 H).


Example 7.70: 5-Cyano-2-[(5-[2-(2-oxo-2-phenylethoxy)phenyl]isoxazol-3-yl)carbonyl]amino]benzoic acid



Prepared according to General method B: 5-[2-(2-oxo-2-phenylethoxy)phenyl]isoxazole-3-carboxylic acid (610 mg, 1.9 mmol) and tert-butyl-2-amino-5-cyano benzoate (453 mg, 2.1 mmol) afforded 600 mg (61 %) of t-butyl ester as a yellow solid, 300 mg of which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 190 mg (100 %) of a white solid.

Analytical data

¹H NMR (300 MHz, DMSO-*d*₆) δ 12.78 (s, 1 H), 8.89 (d, *J* = 8.7 Hz, 1 H), 8.44 (d, *J* = 1.9 Hz, 1 H), 8.16 (dd, *J* = 2.1, 8.7 Hz, 1 H), 8.12 (tetra, *J* = 7.2 Hz, 2 H), 8.03 (dd, *J* = 1.7, 7.9 Hz, 1 H), 7.88 (s, 1 H), 7.73 (m, 1 H), 7.61 (t, *J* = 7.7 Hz, 2 H), 7.56 (m, 1 H), 7.39 (d, *J* = 8.3 Hz, 1 H), 7.20 (t, *J* = 7.7 Hz, 1 H), 5.88 (s, 2 H).


Preparation of 5-{2-[(5-Hydroxypentyl)oxy]phenyl}isoxazole-3-carboxylic acid

Prepared according to General method D: ethyl-5-(2-hydroxyphenyl)isoxazole-3-carboxylate (500 mg, 2.15 mmol) and 5-[[tert-butyl(dimethyl)silyl]oxy]pentan-1-ol (469 mg, 2.15 mmol) afforded 640 mg (69 %) of ethyl 5-{2-[(5-[[tert-butyl(dimethyl)silyl]oxy]pentyl)oxy]phenyl}isoxazole-3-carboxylate as a yellow oil, which was hydrolyzed in MeOH (10 ml) and water (5 ml) by LiOH•H₂O (500 mg, 11.9 mmol) to afford 210mg (44 %) of 5-{2-[(5-hydroxypentyl)oxy]phenyl}isoxazole-3-carboxylic acid as a white solid.

Analytical data

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.85 (dd, *J* = 1.7, 7.7 Hz, 1 H), 7.46 (m, 1 H), 7.20 (d, *J* = 8.1 Hz, 1 H), 7.09 (dt, *J* = 0.8, 7.5 Hz, 1 H), 6.91 (s, 1 H), 4.14 (t, *J* = 6.3 Hz, 2 H), 3.41 (t, *J* = 6.0 Hz, 2 H), 1.84 (pent, *J* = 6.8 Hz, 2 H), 1.61 (pent, *J* = 3.1 Hz, 4 H).

Example 7.71: 2-[[5-{2-[(5-Chloropentyl)oxy]phenyl}isoxazol-3-yl]carbonyl]amino}-5-cyanobenzoic acid




Prepared according to General method B: 5-{2-[(5-hydroxypentyl)oxy]phenyl}isoxazole-3-carboxylic acid (251 mg, 0.79 mmol) and tert-butyl-2-amino-5-cyano benzoate (206 mg, 0.94 mmol) afforded 90 mg (21 %) of t-butyl ester as a white solid, which was hydrolyzed by TFA (2 ml) in DCM (10 ml) to afford 62 mg (79%) of a white solid.

Analytical data


¹H NMR (300 MHz, DMSO-*d*₆) δ 12.76 (s, 1 H), 8.85 (d, *J* = 8.9 Hz, 1 H), 8.44 (d, *J* = 2.1 Hz, 1 H), 8.15 (dd, *J* = 2.1, 8.9 Hz, 1 H), 7.95 (dd, *J* = 1.5, 7.7 Hz, 1 H), 7.55 (m, 1 H), 7.29 (d, *J* = 8.5 Hz, 1 H), 7.22 (s, 1 H), 7.15 (t, *J* = 7.4 Hz, 1 H), 4.21 (t, *J* = 6.2 Hz, 2 H), 3.68 (t, *J* = 6.6 Hz, 2 H), 1.83 (m, 4 H), 1.61 (m, 2 H).

Example 8: R4 as Benzoxazole and derivatives thereof


Preparation of 2-Amino-5-cyanobenzoic acid



To a slurry of methyl 2-amino-5-cyanobenzoate (9.55 g, 54.2 mmol) in methanol (200 mL) was added aqueous sodium hydroxide (30 mL, 6.0 molar, 180 mmol). This mixture was stirred at room temperature and became a solution after 1 hour. After a total of 27.5 hours, the solvent was evaporated, and the residue was dissolved in water (300 mL). This solution was washed with methylene chloride (2 X 200 mL) and then acidified with concentrated HCl. The product was extracted into ethyl acetate (500 mL). The organics were dried over MgSO₄ and evaporated leaving the product as 8.57 g (97.5%) of yellow solid that was used without further purification.

Preparation of Benzyl 2-amino-5-cyanobenzoate


To a flask containing 2-amino-5-cyanobenzoic acid (8.57 g, 52.9 mmol) and cesium carbonate (17.2 g, 52.8 mmol) was added DMF (150 mL). Benzyl bromide (6.00 mL, 50.4 mmol) was added, resulting in the rapid formation of a precipitate. The mixture was stirred at room temperature for 6 hours and then added to a separatory funnel with methyl *tert*-butyl ether (500 mL). This mixture was washed with water (250 mL), saturated aqueous sodium bicarbonate (2 X 250 mL), and brine (250 mL). The organics were then filtered through a 1" plug of silica gel. The plug was rinsed with methylene chloride, and the combined organics were evaporated leaving the product as 12.5 g of yellow solid (98.0% from benzyl bromide, 93.6% from acid). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.09 (d, *J* = 2.1 Hz, 1 H), 7.59 (dd, *J* = 8.7, 2.1 Hz, 1 H), 7.45-7.53 (m, 4 H), 7.41 (t, *J* = 7.2 Hz, 2 H), 7.36 (t, *J* = 7.1 Hz, 1 H), 6.88 (d, *J* = 8.9 Hz, 1 H), 5.32 (s, 2 H).

Preparation of Benzyl 1,3-benzoxazole-2-carboxylate

To a stirred solution of benzoxazole (1.32 g, 11.1 mmol, Aldrich) in THF (20 mL) at -40 °C was added *n*-BuLi (6.5 mL of 1.6 M in hexanes, 10.4 mmol, Aldrich). The solution was stirred for 40 minutes at -40 °C and then added by cannula to a solution of benzyl cyanoformate (1.67 g, 10.4 mmol, Aldrich) in THF (20 mL) at -78 °C. The resulting mixture was stirred at -78 °C for 10 minutes, at -40 °C for 10 minutes, and then at room temperature for 20 minutes. It was then added to a separatory funnel with 200 mL of saturated aqueous NaHCO₃. Product was extracted into 200 mL of EtOAc. The EtOAc was washed with another 200 mL of saturated NaHCO₃ and 200 mL of brine. The EtOAc was dried over Na₂SO₄ and evaporated leaving an orange oil. Product was purified by two successive chromatography runs using a Biotage Flash 40

M silica cartridge with 60% CH₂Cl₂ in heptane as eluent. Yield was 473 mg of yellow solid.


Example 8.1: 2-[(1,3-Benzoxazol-2-ylcarbonyl)amino]-5-cyanobenzoic acid



To a solution of benzyl 1,3-benzoxazole-2-carboxylate (233 mg, 0.920 mmol) in 1:1 ethanol/THF (20 mL) was added palladium on carbon (56 mg of 5%, Aldrich) and triethylamine (180 μ L, 1.29 mmol, Aldrich). The mixture was stirred under 1 ATM of hydrogen for 2 hours and then filtered through a plug of celite. Removal of the solvent left the triethylamine salt as an orange oil (the protonated form of the acid rapidly decarboxylates and should be avoided). This oil was dissolved in CH₂Cl₂ (20 mL) and treated with DMF (20 μ L) followed by oxalyl chloride (220 μ L, 2.52 mmol, Aldrich). Solvent and excess oxalyl chloride were removed by rotary evaporation after 76 hours. The residue was dissolved in CH₂Cl₂ (20 mL), and benzyl 2-amino-5-cyanobenzoate (250 mg, 0.991 mmol) in pyridine (8 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 of 1.0 M HCl and 100 mL of brine. Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using CH₂Cl₂ as eluent. Product was collected as 218 mg of white solid as the benzyl ester. A mixture of benzyl 2-[(1,3-benzoxazol-2-ylcarbonyl)amino]-5-cyanobenzoate (168 mg, 0.423 mmol) and palladium on carbon (33 mg of 5%, Aldrich) in 2:1 THF/ethanol (30 mL) was stirred under 1 ATM of hydrogen for 25 minutes. The mixture was filtered through a plug of celite and then evaporated. The residue was dried at 100 °C under vacuum yielding 116 mg of white solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 7.56 (t, *J*=7.67 Hz, 1 H) 7.63 (t, *J*=7.88 Hz, 1 H) 7.94 (d, *J*=8.29 Hz, 1 H) 8.00 (d, *J*=7.67 Hz, 1 H) 8.16 (dd, *J*=8.81, 1.97 Hz, 1 H) 8.45 (d, *J*=2.07 Hz, 1 H) 8.87 (d, *J*=8.71 Hz, 1 H) 13.16 (s, 1 H).


Example 9: R₄ as Pyrazine and Derivatives Thereof

Example 9.1: 5-Cyano-2-([5-(2-phenylethyl)pyrazin-2-yl]carbonyl)amino)benzoic acid



To a slurry of 5-[(E)-2-phenylethenyl]pyrazine-2-carboxylic acid (146 mg, 0.645 mmol, from RCC) in CH₂Cl₂ (15 mL) was added DMF (10 μL) followed by oxalyl chloride (100 μL, 1.15 mmol, Aldrich). An orange solution quickly resulted. Solvent and excess oxalyl chloride were removed by rotary evaporation after stirring overnight. The residue was dissolved in CH₂Cl₂ (15 mL), and benzyl 2-amino-5-cyanobenzoate (155 mg, 0.614 mmol) in pyridine (8 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 of 1.0 M HCl and 100 mL of brine. Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using a gradient from CH₂Cl₂ to 2% EtOAc in CH₂Cl₂ as eluent. Product was collected as 138 mg of yellow solid as the benzyl ester. A mixture of benzyl 5-cyano-2-[(5-[(E)-2-phenylethenyl]pyrazin-2-yl]carbonyl)amino]benzoate (118 mg, 0.256 mmol) and palladium on carbon (46 mg of 5%, Aldrich) in 1:1 THF/ethanol (40 mL) was stirred under 1 ATM of hydrogen for 6.5 hours. The mixture was filtered through a plug of celite and then evaporated. The residue was recrystallized from ethanol/THF. The solids were washed with ethanol followed by heptane and then dried at 100 °C under vacuum yielding 37 mg of tan solid. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 3.08 (t, J=7.88 Hz, 2 H) 3.25 (t, J=7.77 Hz, 2 H) 7.24 (m, 5 H) 8.12 (dd, J=8.81, 1.97 Hz, 1 H) 8.42 (d, J=1.87 Hz, 1 H) 8.70 (d, J=1.04 Hz, 1 H) 8.98 (d, J=8.71 Hz, 1 H) 9.28 (d, J=1.24 Hz, 1 H) 13.28 (s, 1 H).


25 Preparation of 5-(Hexyloxy)pyrazine-2-carboxylic acid



Hexyl alcohol (30 mL, Aldrich) was added to a flask containing sodium (423 mg, 18.4 mmol), and the mixture was heated in a 60 °C oil bath for 45 minutes to dissolve the

sodium. Methyl 5-chloropyrazine-2-carboxylate (1.62 g, 9.39 mmol, Lonza) was added, and the mixture was stirred in a 50 °C oil bath for 35 minutes. The mixture was added to a separatory funnel with 100 mL of CH₂Cl₂. This was washed with 100 mL of water, but solid material was present in the CH₂Cl₂ that would not dissolve. The CH₂Cl₂ was then washed with 100 mL of 1.0 M aqueous HCl, and everything dissolved. The CH₂Cl₂ was washed with another 100 mL of water, dried over MgSO₄, and evaporated. The residual hexanol was distilled away, and the residue was purified on a Biotage Flash 40 M silica cartridge. Hexyl 5-hexyloxy pyrazine-2-carboxylate eluted with CH₂Cl₂ followed by methyl 5-hexyloxy pyrazine-2-carboxylate. Addition of methanol to the eluent resulted in the elution of 5-(hexyloxy)pyrazine-2-carboxylic acid followed by 5-chloropyrazine-2-carboxylic acid. The hexyloxy acid was isolated as 137 mg of white solid. Hexyl 5-hexyloxy pyrazine-2-carboxylate was isolated as 1.64 g of colorless oil.

Example 9.2: 5-Cyano-2-([5-(hexyloxy)pyrazin-2-yl]carbonyl)amino)benzoic acid




To a mixture of 5-(hexyloxy)pyrazine-2-carboxylic acid (271 mg, 1.21 mmol) in CH₂Cl₂ (15 mL) was added DMF (10 µL) followed by oxalyl chloride (160 µL, 1.83 mmol, Aldrich). Solvent and excess oxalyl chloride were removed by rotary evaporation after 2 hours. The residue was dissolved in CH₂Cl₂ (15 mL), and benzyl 2-amino-5-cyanobenzoate (288 mg, 1.14 mmol) in pyridine (6 mL) was added. The mixture was stirred overnight and then added to a separatory funnel with 100 mL of CH₂Cl₂. This solution was washed with 2 X 100 of 1.0 M HCl and 100 mL of brine. Product was adsorbed onto silica gel and purified on a Biotage Flash 40 M silica gel cartridge using CH₂Cl₂ as eluent. Product was collected as 205 mg of white solid as the benzyl ester. A mixture of benzyl 5-cyano-2-([5-(hexyloxy)pyrazin-2-yl]carbonyl)amino)benzoate (169 mg, 0.369 mmol) and palladium on carbon (25 mg of 5%, Aldrich) in 6:1 THF/ethanol (35 mL) was stirred under 1 ATM of hydrogen for 1


hour. The mixture was filtered through a plug of celite and then evaporated. The residue was twice suspended in methanol and evaporated. It was then suspended in CH_2Cl_2 and evaporated. It was then dried at 100 °C under vacuum yielding 122 mg of tan solid. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 0.88 (t, $J=7.05$ Hz, 3 H) 1.32 (m, 4 H) 1.42 (m, 2 H) 1.77 (m, 2 H) 4.40 (t, $J=6.63$ Hz, 2 H) 8.11 (dd, $J=8.81, 2.18$ Hz, 1 H) 8.40 (d, $J=2.07$ Hz, 1 H) 8.42 (d, $J=1.24$ Hz, 1 H) 8.93 (d, $J=1.24$ Hz, 1 H) 8.98 (d, $J=8.91$ Hz, 1 H) 13.07 (s, 1 H).

Example 10: R_4 as Oxazoles and Derivatives Thereof

SCHEME I
Synthesis of Oxazole Esters/Acids




SCHEME II
Synthesis of Anthranilates




SCHEME III
Two Methods for Preparing the Targets

(A) - utilization of oxazole acids and tert-butyl anthranilates




(B) - Direct coupling of oxazole esters with anthranilic acids



PREPARATION OF PHENACYL HALIDES

5 Method A - bromination of methyl ketones

2-Bromo-3',4'-methylenedioxyacetophenone (PH-k):




10

3,4-Methylenedioxyacetophenone (20.0 g, 121.2 mmol) was dissolved in $\text{CHCl}_3/\text{EtOAc}$ (700 mL/700 mL) followed by the addition of CuBr_2 (40.6 g, 181.8 mmol, 1.5 eq). The reaction mixture was heated at reflux for 3 days. TLC (1/1 Hept/EtOAc) showed about 80% completion (product and S.M. have close R_f). Solid

was removed by filtration, washed with CHCl_3 . The filtrate was concentrated on a rotavap to give an orange solid (27.77 g, 94 % yield, containing 21% unreacted starting material). The material was carried to the next step without further purification. ^1H NMR (300 MHz, CDCl_3) δ 7.60 (d, 1H), 7.40 (s, 1H), 6.85 (d, 1H), 6.20 (s, 2H), 4.40 (s, 2H).


Yield: 94%

2-Bromo-2'-(trifluoromethyl)acetophenone (PH-g):



^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.45–7.82 (m, 4H), 4.42 (s, 2 H). 92% yield (70% conversion)


4-(2-Bromo-acetyl)-benzonitrile (PH-l):



^1H NMR (300 MHz, CDCl_3) δ 8.19 (d, 1H), 7.80 (d, 1H), 4.45 (s, 2H).


Yield: 65%

3-(2-Bromo-acetyl)-benzonitrile (PH-m):



^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.53 (s, 1H), 8.29 (d, 1H), 8.14 (d, 1H), 7.74 (t, 1 H), 5.03 (s, 2 H). 92% yield (75% conversion).

Method B – acylation of a aromatic heterocycle with bromoacetyl bromide

2-Bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone (PH-s):

N-methylpyrrole (10g, 123mmol) was dissolved in 400 mL of dichloromethane.


Bromoacetyl bromide (1 eq) was added, and the solution stirred at 0°C for 4.5 h. The

5 reaction mixture was washed with 10% NaHCO₃ (2x1 L) and H₂O (2x100 mL). The organic layer was dried over Na₂SO₄ and concentrated under vacuum.

Chromatography gave 4.9 g. ¹H NMR (300 MHz, CDCl₃) δ 7.15 (d, 1H), 6.90 (d, 1H), 6.18 (d, 1H), 4.30 (s, 2H), 3.98 (s, 3H).

Yield: 20%

10

PREPARATION OF PHENACYL AMINES***Method A – using diformylimide sodium salt*****2-Amino-1-(4-methoxy-phenyl)-ethanone hydrochloride(PA-b):**

15

To a stirred solution of 2-Bromo-4'-methoxyacetophenone (20.0 g, 87.3 mmol) in CH₃CN (90 mL), was added sodium diformylamide (9.95 g, 104.76 mmol, 1.2 eq).

The resulting mixture was stirred for 2h at RT, and heated for 2 h at 70 °C (monitored by TLC). Solvent was removed under reduced pressure. Then EtOH (250 mL) and


20 Conc. HCl (40 mL) were added. The reaction mixture was refluxed for 1h. Solvent

was removed by rotavap. The crude product was suspended in iPr-OH (100 mL) and

stirred at RT O/N. The off-white pure product was obtained by filtration (17.28 g, 98%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.4 (br), 8.0 (d, 2H), 7.1 (d, 2H), 4.5 (s, 2H), 3.9 (s, 3H).


25 MS (APCI⁺) m/z 166 (M-HCl).

Yield: 98%

2-Amino-3'-methoxyacetophenone hydrochloride (PA-a):


¹HNMR (300 MHz, DMSO-d₆) δ 8.50 (bs), 7.65 (d, 1H), 7.50 (m, 2 H), 7.32 (dd, 1 H), 4.59 (bs, 2H), 3.83 (s, 3 H). 86% yield

5

2-Amino-4'-fluoroacetophenone hydrochloride (PA-d):


¹HNMR (300 MHz, DMSO-d₆) δ 8.50 (bs) (8.15 (m, 2 H), 7.44 (m, 2 H), 4.65 (m, 2 H). 76% yield

10

2-Amino-acetophenone hydrochloride (PA-f):


¹HNMR (300 MHz, DMSO-d₆) δ 8.59 (bs), 8.06 (d, 2 H), 7.67 (t, 1H), 7.55 (t, 2 H), 4.53 (s, 2 H). 72% yield.

15

2-Amino-2'-(trifluoromethyl)-acetophenone hydrochloride (PA-g):


¹HNMR (300 MHz, DMSO-d₆) δ 8.64 (bs), 7.88-8.11 (m, 4 H), 4.35 (s, 2 H). 18% yield

20

2-Amino-1-furan-2-yl-ethanone hydrochloride (PA-h):

^1H NMR (300 MHz, DMSO- d_6) δ 8.35 (bs), 8.15 (d, 1H), 7.67 (d, 1H), 6.82 (d, 1H), 4.32 (s, 2 H). 82% yield.


1 2-AMINO-2'-METHOXYACETOPHENONE HYDROCHLORIDE (PA-l):



^1H NMR (300 MHz, DMSO- d_6) δ 8.31 (br), 7.85 (d, 1H), 7.70 (t, 1H), 7.27 (d, 1H), 7.12 (t, 1H), 4.35 (s, 2H), 3.95 (s, 3H).

Yield: 83%


10 2-Amino-3',4'-methylenedioxyacetophenone hydrochloride (PA-k):



^1H NMR (300 MHz, DMSO- d_6) δ 8.39 (br), 7.65 (d, 1H), 7.55 (d, 1H), 7.13 (d, 1H), 6.20 (s, 2H), 4.5 (s, 2H).

Yield: 90%


15 2-Amino-4'-cyanoacetophenone hydrochloride (PA-l):



^1H NMR (300 MHz, DMSO- d_6) δ 8.60 (br), 8.17 (d, 2H), 8.10 (d, 2H), 4.70 (s, 2H).


Yield: 59%

20 2-Amino-3'-cyanoacetophenone hydrochloride (PA-m):



¹H NMR (300 MHz, DMSO-d₆) δ 8.71 (bs), 8.47 (s, 1H), 8.29 (d, 1H), 8.20 (d, 1H), 7.82 (t, 1 H), 4.65 (d, 2 H). 77% yield.

2-Amino-1-(1-methyl-1H-pyrrol-2-yl)-ethanone hydrochloride (PA-s):




LC/MS: MS (APCI⁺) m/z 139(M-HCl-1).

Yield: 88%

PREPARATION OF AMIDE ESTERS

Ethyl [2-(4-methoxyphenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-b):




To a solution of 2-Amino-4'-methoxyacetophenone hydrochloride (17.28 g, 85.7 mmol) in DCM, was added triethylamine (25.1 mL, 179.97 mmol, 2.1 eq) followed by the addition of ethylchlorooxoacetate (9.7 mL, 86.6 mmol) slowly at 0°C under N₂. The resulting mixture was stirred at 0°C for another 2.5 h. The reaction was quenched with H₂O (200 mL). The organic phase was separated and the aqueous layer was extracted with DCM (2X50 mL). The combined organic layers were dried over MgSO₄. Solid was removed by filtration, and filtrate was concentrated to dryness under reduced pressure. The pure product was obtained by washing with Heptane/iPr-OH (200 mL/20 mL) in the yield of 96%.

¹H NMR (300 MHz, CDCl₃) δ 8.1 (br), 8.0 (d, 2H), 7.0 (d, 2H), 4.8 (d, 2H), 4.4 (q, 2H), 3.9 (s, 3H), 1.4 (t, 3H).


MS (APCI⁺) m/z 266 (M + 1).

Yield: 96%

Ethyl [2-(4-fluorophenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-d):


¹H NMR (300 MHz, CDCl₃) δ 9.18 (bs), 8.14 (m, 1H), 7.41 (m, 2H), 4.71 (d, 2H), 4.35 (q, 2H), 1.32 (t, 3 H).

5 MS (APCI⁺) m/z 254(M + 1). 80% yield

Ethyl [2-(2-trifluoromethylphenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-g):


¹H NMR (300 MHz, CDCl₃) δ 9.38 (bs), 7.70-7.95 (m, 4H), 4.55 (d, 2H), 4.35 (q, 2H), 1.32 (t, 3 H). 90% yield.

10

N-(2-Furan-2-yl-2-oxo-ethyl)-oxalamic acid ethyl ester (AE-h):


¹H NMR (300 MHz, CDCl₃) δ 9.15 (bs), 8.09 (d, 1H), 7.62 (d, 1H), 6.79 (d, 1H),

15 4.52 (d, 2H), 4.35 (q, 2H), 1.34 (t, 3 H). 85% yield.

Ethyl [2-(2-methoxyphenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-i):


20 ¹H NMR (300 MHz, CDCl₃) δ 8.15 (br), 7.98 (d, 1H), 7.60 (t, 1H), 7.30 (s, 1H), 7.05 (m, 1H), 4.80 (d, 2H), 4.45 (q, 2H), 4.00 (s, 3H), 1.45 (t, 3H).

Yield: 88%

Ethyl [2-(3,4-methylenedioxyphenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-k):


¹H NMR (300 MHz, CDCl₃) δ 8.10 (br), 7.60 (d, 1H), 7.45 (s, 1H), 6.90 (d, 1H), 6.10 (s, 2H), 4.75 (d, 2H), 4.40 (q, 2H), 1.40 (t, 3H). Yield: 96%

5

Ethyl [2-(4-cyanophenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-l):


¹H NMR (300 MHz, CDCl₃) δ 8.10 (d, 2H), 7.85 (d, 2H), 4.85 (d, 2H), 4.40 (q, 2H), 1.45 (t, 3H).

10 Yield: 66%

Ethyl [2-(3-cyanophenyl)-2-oxoethyl]amino-2-oxoethanoate (AE-m):


¹H NMR (300 MHz, CDCl₃) δ 9.24 (bs), 8.52 (s, 1H), 8.29 (d, 1H), 8.14 (d, 1H), 7.74 (t, 1H), 4.78 (d, 2H), 4.35 (q, 2H), 1.32 (t, 2H). 81% yield.

15

N-[2-(1-Methyl-1H-pyrrol-2-yl)-2-oxo-ethyl]-oxalamic acid ethyl ester (AE-s):

¹H NMR (300 MHz, DMSO-d₆) δ 9.01 (bs), 7.22 (m, 2H), 6.18 (m, 1H), 4.40 (d, 2H), 4.30 (q, 2H), 3.87 (s, 3H), 1.25 (t, 3H). 83% yield.


20

5-phenyl-oxazole-2-carboxylic acid ethyl ester (OE-f):

Ethyl [2-phenyl-2-oxoethyl]amino-2-oxoethanoate (16.5 g, 71 mmol) was dissolved in 200 mL of anhydrous toluene in a 1 L Parr bottle. To the solution was added 21 mL (225 mmol, 3.15 eq) of POCl₃. The Parr bottle was sealed, and the reaction mixture heated at an oil bath temperature of 110°C for 48 h. The solvent and POCl₃ were removed under reduced pressure to give a brown oil. To the brown oil was added 300 mL H₂O. The aqueous solution was extracted twice with 150 mL of dichloromethane. The combined organics were dried over MgSO₄, filtered and the solvent removed *in vacuo*. The resulting brown solid was recrystallized from 50 mL of EtOH to give 12.5 g of an orange solid (80% yield).


¹H NMR (300 MHz, DMSO) δ 8.10 (s, 1H), 7.82 (d, 2 H), 7.55 (m, 3 H), 4.43 (q, 2H), 1.35 (t, 3H).

MS (APCI⁺) m/z 218(M + 1)

5-(3-methoxyphenyl)-oxazole-2-carboxylic acid ethyl ester (OE-a):

MS (APCI⁺) m/z 248(M + 1).

Yield: 50%


5-(4-methoxyphenyl)-oxazole-2-carboxylic acid ethyl ester (OE-b):

¹H NMR (300 MHz, CDCl₃) δ 7.7 (d, 2H), 7.4 (s, 1H), 7.0 (d, 2H), 4.5 (q, 2H), 3.8 (s, 3H), 1.5 (t, 3H).

MS (APCI⁺) m/z 248 (M + 1).

Yield: 43%


5-(4-fluorophenyl)-oxazole-2-carboxylic acid ethyl ester (OE-d):



5

¹H NMR (300 MHz, DMSO) δ 8.05 (s, 1H), 7.85 (m, 2H), 7.41 (m, 2H), 4.42 (q, 2H), 1.35 (t, 3H). Yield: 59%


5-(2-trifluoromethylphenyl)-oxazole-2-carboxylic acid ethyl ester (OE-g):



10

¹H NMR (300 MHz, DMSO) δ 7.67-8.05 (m, 5 H), 4.43 (q, 2H), 1.35 (t, 3H).
MS (APCI⁺) m/z 286(M + 1). 41% yield


5-furan-2-yl-oxazole-2-carboxylic acid ethyl ester (OE-h):



15

¹H NMR (300 MHz, DMSO) δ 7.95 (s, 1H), 7.72 (d, 1H), 7.14 (d, 1H), 6.79 (d, 1H), 4.37 (q, 2H), 1.38 (t, 3H).
MS (APCI⁺) m/z 208(M + 1). 35% yield

20 **5-(2-Methoxyphenyl)-oxazole-2-carboxylic acid ethyl ester (OE-i):**




¹H NMR (300 MHz, CDCl₃) δ 7.90 (d, 1H), 7.70 (s, 1H), 7.38 (m, 1H), 7.10 (d, 1H), 7.04 (t, 1H), 4.50 (q, 2H), 4.00 (s, 3H), 1.48 (t, 3H).

MS (APCI⁺) m/z 248(M + 1).

Yield: 68%

5-(3,4-Methylenedioxyphenyl)-oxazole-2-carboxylic acid ethyl ester (OE-k):

5




¹H NMR (300 MHz, CDCl₃) δ 7.42 (s, 1H), 7.27 (dd, 1H), 7.20 (d, 1H), 6.90 (d, 1H), 6.06 (s, 2H), 4.50 (q, 2H), 1.48 (t, 3H).

MS (APCI⁺) m/z 262(M + 1).

10 Yield: 61%

5-(4-Cyanophenyl)-oxazole-2-carboxylic acid ethyl ester (OE-l):




15 ¹H NMR (300 MHz, CDCl₃) δ 7.90 (d, 2H), 7.78 (d, 2H), 7.68 (s, 1H), 4.55 (q, 2H), 1.50 (t, 3H).

MS (APCI⁺) m/z 243(M + 1). Yield: 24%


5-(3-cyanophenyl)-oxazole-2-carboxylic acid ethyl ester (OE-m):

20



¹H NMR (300 MHz, DMSO) δ 8.39 (s, 1H), 8.18 (m, 2 H), 7.92 (d, 1H), 7.74 (t, 1 H), 4.41 (q, 2 H), 1.32 (t, 3 H).


25 MS (APCI⁺) m/z 243(M + 1). 35% yield

5-(1-methyl-1H-pyrrol-2-yl)-oxazole-2-carboxylic acid ethyl ester (OE-s):

¹H NMR (300 MHz, DMSO) δ 7.58 (s, 1H), 7.05 (s, 1 H), 6.58 (d, 1H), 6.15 (d, 1 H),
5 4.41 (q, 2H), 3.83 (s, 3 H), 1.32 (t, 3 H). 14% yield

PREPARATION OF OXAZOLE ACIDS (as triethyl ammonium salts)**5-(4-fluorophenyl)-oxazole-2-carboxylic acid triethyl ammonium salt (OA-d):**

10




5-(4-fluorophenyl)-oxazole-2-carboxylic acid ethyl ester (3.56 g, 15.1 mmol) was
dissolved in 140 mL of THF/H₂O (2.5 : 1). To this solution was added 3.3 g (5.2 eq)
15 of LiOH H₂O. The resulting solution was stirred at ambient temperature overnight.
The reaction mixture was adsorbed onto 18 g of silica gel and placed on a pad of silica
gel. The triethyl ammonium salt was eluted off the pad with 200 mL of 10%
MeOH/10% Et₃N/80% CH₂Cl₂. After concentrating the filtrate, 4.4 g of a brown oil
was obtained (93% yield)

20

¹H NMR (300 MHz, DMSO) δ 7.78 (m, 2 H), 7.60 (s, 1 H), 7.35 (m, 2 H), 3.15 (q,
6 H), 1.18 (t, 9 H). MS (APCI⁺) m/z 208(M + 1).

5-(4-methoxyphenyl)-oxazole-2-carboxylic acid triethyl ammonium salt (OA-b):


25



^1H NMR (300 MHz, CDCl_3) δ 7.7 (d, 2H), 7.3 (s, 1H), 6.9 (d, 2H), 3.9 (s, 3H), 3.2 (q, 6H), 1.4 (t, 9H). MS (APCI $^+$) m/z 220 [M (free acid) + 1].

Yield: 94%

5 **5-(4-Methoxyphenyl)-oxazole-2-carboxylic acid triethyl ammonium salt (OA-i):**




10 ^1H NMR (300 MHz, CDCl_3) δ 8.00 (d, 1H), 7.65 (s, 1H), 7.30 (t, 1H), 6.95 (m, 2H), 3.97 (s, 3H), 3.15 (q, 6H), 1.35 (t, 9H).

MS (APCI $^+$) m/z 220 [M (free acid) + 1]. Yield: 99%

PREPARATION OF ANTHRANILATES


15 **tert-Butyl 2-nitrobenzoate:**



To a mixture of 2-nitrobenzoic acid (80.2 g, 0.48 mol) in DCM (2 L) was added
 20 DMF (4 mL) followed by the dropwise (55 min) addition of a solution of oxalyl
 chloride (100 mL, 1.15 mol) in DCM (0.4 L). After stirring at RT for 6 h, the
 reaction mixture was evaporated to dryness using heptane to aid in the chasing off of
 residual oxalyl chloride. This process was repeated and the two residue acid chlorides
 combined. To a stirred and cooled (0°C) solution of the combined acid chloride in dry
 25 THF (2 L) was added a solution of potassium tert-butoxide (130 g, 1.16 mol) in dry
 THF (1.4 L). The reaction mixture was stirred (~1 h), concentrated to one-fifth the
 original volume, dissolved in TBME (2 L) and then washed with 1 N NaOH (4 x 1.5
 L), dried (Na_2SO_4), and evaporated to dryness (rotovap, then high vacuum) to give
 194.8 g (yield of 91%) of the tert-butyl ester as a brown oil.

¹H NMR (300 MHz, CDCl₃) δ 7.86 (dd, 1H), 7.73 (dd, 1H), 7.55-7.70 (m, 2 H), 1.58 (s, 9 H).


5 **tert-Butyl 2-aminobenzoate:**



To a mixture of tert-butyl 2-nitrobenzoate (194.8 g, 0.873 mol) in EtOH (2.5 L) in a
10 5 L Parr bottle was added 72 g of Raney Nickel 2800 (washed 5 times with ethanol).
The system was degassed (suction) three times, each time replenishing the system
with nitrogen gas. The system was then pressurized with hydrogen gas (30 psi) and
1.5 h later was repressurized to 50 psi of hydrogen. After overnight stirring, the
pressure of the system had fallen to 30 psi and was repressurized to 50 psi. At the
15 end of the day, the reaction was found to be complete. The reaction mixture was
filtered thru Celite and evaporated to give 160.8 g (yield of 95%) of the aniline ester
as a brown oil.

¹H NMR (300 MHz, CDCl₃) δ 7.82 (dd, 1H), 7.22 (ddd, 1H), 6.55-6.65 (m, 2 H), 5.7
20 (br s), 1.58 (s, 9 H).

tert-Butyl 2-amino-5-bromobenzoate:




To a stirred and cooled (0°C) solution of tert-butyl 2-aminobenzoate (23.37 g, 120.9
25 mmol) in DMF (20 mL) was added a mixture of NBS (21.50 g, 120.8 mmol) in DMF
(20 mL) over a period of 3-5 min (an additional 10 mL of DMF used to rinse the NBS
container was added as well). After stirring for 4 h (0°C to RT), the reaction mixture
was diluted with EtOAc (500 mL) and then washed with 1 N NaOH (3 x 300 mL),

dried (Na_2SO_4), filtered, evaporated on to silica gel (48 g), and applied to a column of silica gel (620 g) packed in 80:1 heptane/TBME. Elution was effected with 80:1, 70:1, and then 60:1 heptane/TBME to give (after evaporation of fractions) 25.99 g (yield of 79%) of the title product as a yellowish-white solid.

5

^1H NMR (300 MHz, CDCl_3) δ 7.91 (d, 1H), 7.30 (dd, 1H), 6.53 (d, 1 H), 5.72 (br s), 1.58 (s, 9 H).

tert-Butyl 2-amino-5-iodobenzoate:



10


To a stirred and cooled (0°C) solution of tert-butyl 2-aminobenzoate (71.3 g, 369 mmol) in DMF (25 mL) was added (dropwise) a mixture of NIS (87.0 g, 387 mmol) in DMF (150 mL). After removing the ice bath, the mixture was stirred for 4 h (RT), diluted with EtOAc (1500 mL), washed with 1 N NaOH (3 x 500 mL), dried (Na_2SO_4), filtered, evaporated on to silica gel (~150 g), and applied to a column of silica gel (1500 g) packed in 80:1 heptane/TBME. Elution was effected with 80:1, 70:1, and then 60:1 heptane/ TBME to give (after evaporation of desired fractions) 72.8 g (yield of 62%) of the title product as a solid.

15

^1H NMR (300 MHz, CDCl_3) δ 8.06 (d, 1H), 7.44 (dd, 1H), 6.43 (d, 1 H), 5.75 (br s), 1.58 (s, 9 H).

20

tert-Butyl 2-amino-5-cyanobenzoate:



25

To a stirred and hot (internal temperature of 80-90°C) solution of tert-butyl 2-amino-5-iodobenzoate (60.4 g, 189 mmol) in pyridine (125 mL) was added CuCN (20.5 g, 229 mmol). The resulting reaction mixture was then stirred at a gentle reflux (internal temperature of 120°C) for 16 h, then allowed to cool to RT and diluted with EtOAc (150 mL) and heptane (25 mL). The copper salts were filtered off and the filtrate was then evaporated on to silica gel (80 g) and applied to a column of silica gel (1.2 Kg) packed in 8:1 heptane/ EtOAc. Elution was effected beginning with 8:1 and ending with 4:1 heptane/EtOAc. Evaporation of fractions gave 36.1 g (yield of 87%) of cyanoanthranilate as a light yellow fluffy solid.


¹H NMR (300 MHz, CDCl₃) δ 8.13 (d, 1H), 7.42 (dd, 1H), 6.65 (d, 1 H), ~6.8 (very br s), 1.60 (s, 9 H).

Methyl 2-Amino-5-cyanobenzoate (methyl 5-cyanoanthranilate):



Methyl 2-amino-5-bromobenzoate (24.0 g, 104 mmol), zinc cyanide (8.02 g, 68.3 mmol), and Pd(PPh₃)₄ (2.02 g) were weighed into a three-necked flask, which was then purged with nitrogen. After adding DMF (130 mL), the reaction mixture was stirred in a hot oil bath (90°C) for 8 h. Because TLC revealed no change during the last 3 h, additional catalyst (2.00 g) was added and stirred in the hot oil bath overnight. Additional catalyst (1.00 g) and heating at 100°C was required to drive reaction to near completion. Reaction was poured into water (400 mL), extracted with EtOAc (700 mL), and the two-phase mixture filtered. The organic layer was removed, washed with saturated brine (4 x 200 mL), dried, filtered, and evaporated on to silica gel, and applied to a column of silica gel. Elution was effected using 4:1 heptane/EtOAc to give 15.60 g (yield of 85%) of the methyl 5-cyanoanthranilate as a pale yellow solid.

¹H NMR (300 MHz, CDCl₃) δ 8.19 (d, 1H), 7.45 (dd, 1H), 6.68 (d, 1 H), ~6.3 (very br s), 3.90 (s, 3 H).

2-Amino-5-cyanobenzoic acid (5-cyanoanthranilic acid):

Methyl 2-amino-5-cyanobenzoate (5.0 g, 28.41 mmol) was dissolved in MeOH (105 mL). Then 6M NaOH (14 mL) was added. The resulting mixture was stirred at RT
 5 O/N. The reaction mixture was diluted with H₂O (143 mL), washed with DCM to remove any unreacted S.M. The product was precipitated from aqueous layer by addition of conc. HCl to pH 1 and extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over MgSO₄. Solid was removed by filtration, and filtrate was concentrated to dryness under reduced pressure. The light yellow product was
 10 obtained in the yield of 94%.


¹H NMR (300 MHz, DMSO-d₆) δ 8.08 (d, 1H), 7.56 (dd, 1H), 7.50 (br), 6.85 (d, 1H).

15 ***Method B – Through a two step process:***

(1) Coupling Of An Oxazole Acid Chloride With A Tert-Butyl Anthranilate

***t*-Butyl {5-cyano-2-[5-(4-fluorophenyl)-oxazole-2-carbonyl]amino}benzoate**

20 **(PRE(CN)-d):**




5-(4-fluorophenyl)-oxazole-2-carboxylic acid triethyl ammonium salt (1 g, 3.25 mmol) was dissolved in 25 mL of CH₂Cl₂. To this solution was added 3 drops of DMF, followed by 1 mL (3.5 eq) of oxalyl chloride dropwise. The resultant brown/orange
 25 solution was stirred at ambient temperature overnight. The solvent and excess oxalyl chloride were removed *in vacuo* to give an orange solid. The solid was dissolved in 12.5 mL of CH₂Cl₂ and added dropwise to a solution of 2-amino-5-cyano-benzoic acid

(0.65 g, 0.94 eq), pyridine (5 mL) in 12.5 mL of CH₂Cl₂. The reaction was stirred at ambient temperature for 5 h. The reaction mixture was diluted with 25 mL of TBME and washed with 50 mL of 1 N HCl, followed by 50 mL of brine solution. The organic layer was dried (MgSO₄), filtered, and the solvent removed *in vacuo*. The resulting solid was dissolved in 20 mL of MeOH and CH₂Cl₂ added until precipitation occurred (15 mL). The solution was placed in the freezer overnight to aid in crystal formation. The white solid was collected by filtration to give 1.38 g (36% yield).


¹H NMR (300 MHz, DMSO-d₆) δ 8.84 (d, 1H), 8.39 (d, 1H), 8.15 (d, 1H), 8.10 (s, 1H), 7.95 (m, 2H), 7.42 (m, 2H), 2.05 (s, 9 H).

***t*-Butyl {5-cyano-2-[5-(3-methoxyphenyl)-oxazole-2-carbonyl]amino}benzoate (PRE(CN)-a):**



¹H NMR (300 MHz, CDCl₃) δ 12.59 (br), 8.78 (d, 1H), 8.40 (s, 1H), 8.20 (dd, 1H), 8.17 (s, 1H), 7.40 (m, 3H), 7.05 (m, 1H), 3.85 (s, 3H), 1.70 (s, 9H). Yield: 15%


***t*-butyl{5-cyano-2-[5-(4-methoxyphenyl)-oxazole-2-carbonyl]amino}benzoate (PRE(CN)-b):**



¹H NMR (300 MHz, CDCl₃) δ 12.82 (br), 9.05 (d, 1H), 8.35 (d, 1H), 7.85 (dd, 1H), 7.75 (dd, 2H), 7.45 (s, 1H), 7.00 (d, 2H), 3.90 (s, 3H), 1.70 (s, 9H).

Yield: 41%

t-Butyl {5-cyano-2-[5-(2-methoxyphenyl)-oxazole-2-carbonyl]amino}benzoate
(PRE(CN)-i):



¹H NMR (300 MHz, CDCl₃) δ 12.89 (br), 9.05 (d, 1H), 8.35 (s, 1H), 8.03 (dd, 1H),
 5 7.85 (dd, 1H), 7.80 (s, 1H), 7.40 (m, 1H), 7.10 (t, 1H), 7.00 (d, 1H), 4.00 (s, 3H),
 1.70 (s, 9H).


MS (APCI⁺) m/z 420(M + 1).

Yield: 55%

10

(2) Deprotection of the Tert-Butyl Ester

5-Cyano-2-[5-(4-fluorophenyl)-oxazole-2-carbonyl]amino}benzoic acid (TI(CN)-
d):




15 t-Butyl {5-cyano-2-[5-(4-fluorophenyl)-oxazole-2-carbonyl]amino}benzoate (480 mg,
 1.1 mmol) was dissolved in 22 mL of CH₂Cl₂. To this solution was added 7 mL of
 trifluoroacetic acid. The resultant mixture was stirred at room temperature overnight,
 followed by 40°C (oil bath temperature) for 3 h. The solvent was removed *in vacuo* to
 give 420 mg of a light brown solid. This solid was heated in 50 mL of MeOH to
 20 boiling in a 2 L erlenmeyer flask. Dichloromethane was added dropwise to the
 solution (maintaining the boil) until the solid had mostly dissolved. The solution was
 filtered hot to remove the insoluble impurities. The clear filtrate was then heated until
 the solution became quite cloudy. The solution was cooled to room temperature and
 the placed in the freezer overnight. The white solid that formed was collected by
 25 filtration to give 230 mg (57% yield).

^1H NMR (300 MHz, DMSO- d_6) δ 13.50 (br), 8.82 (d, 1H), 8.41 (s, 1H), 8.13 (dd, 1H), 8.05 (s, 1H), 7.92 (m, 2H), 7.42 (m, 2H).

5 5-Cyano-2-([5-(3-methoxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid

(TI(CN)-a):




^1H NMR (300 MHz, DMSO- d_6) δ 12.95 (br), 8.85 (d, 1H), 8.43 (s, 1H), 8.14 (d, 1H), 8.09 (s, 1H), 7.45 (m, 3H), 7.04 (m, 1H), 3.84 (s, 3H).

10

5-Cyano-2-([5-(4-methoxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid

(TI(CN)-b):




^1H NMR (300 MHz, DMSO- d_6) δ 13.1 (br), 8.83 (d, 1H), 8.45 (d, 1H), 8.12 (dd, 1H), 7.92 (s, 1H), 7.80 (d, 2H), 7.10 (d, 2H), 3.86 (s, 3H).

15

5-Cyano-2-([5-(2-methoxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid


(TI(CN)-i):



^1H NMR (300 MHz, DMSO- d_6) δ 12.95 (br), 8.85 (d, 1H), 8.45 (s, 1H), 8.13 (dd, 1H), 7.90 (s, 1H), 7.85 (d, 1H), 7.45 (m, 1H), 7.25 (d, 1H), 7.15 (t, 1H), 4.00 (s, 3H).

20


5-Bromo-2-[(5-(4-fluorophenyl)-oxazole-2-carbonyl)amino]benzoic acid (TI(Br)-d):



- 5 ^1H NMR (300 MHz, DMSO- d_6) δ 12.60 (br), 8.69 (d, 1H), 8.14 (d, 1 H), 8.05 (s, 1H), 7.92 (m, 3 H), 7.42 (m, 2H).

Method B – Direct Coupling Of Oxazole Esters With Anthranilic Acids


- 10 **5-cyano-2-[(5-(2-furanyl)-oxazole-2-carbonyl)amino]benzoic acid (TI(CN)-h):**



- To a solution of 2-amino-5-cyano-benzoic acid (0.389 g, 2.4 mmol) and oxazole ester (1 eq) in DMF (5 mL) was added NaH (3 eq). The solution was allowed to stir at room temperature overnight. The reaction mixture was added dropwise to 100 mL of
15 1 N HCl with stirring. The carboxylic acid precipitated out and was collected by filtration. The tan solid was recrystallized from boiling EtOH to give 230 mg of an off white solid (yield of 32%).


- ^1H NMR (300 MHz, DMSO- d_6) δ 12.91 (bs), 8.86 (d, 1H), 8.45 (s, 1H), 8.18 (dd,
20 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.12 (d, 1H), 6.78 (d, 1 H).

5-Cyano-2-[(5-phenyl)-oxazole-2-carbonyl]aminobenzoic acid (TI(CN)-f):



^1H NMR (300 MHz, DMSO- d_6) δ 12.71 (br), 8.84 (d, 1H), 8.41 (s, 1H), 8.14 (dd, 1H), 8.10 (s, 1H), 7.88 (d, 2H), 7.50 (m, 3H).


5 **5-Cyano-2-([5-(2-trifluoromethylphenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(CN)-g):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.71 (br), 8.82 (d, 1H), 8.41 (s, 1H), 8.14 (m, 3H), 7.88 (m, 2H), 7.74 (t, 1H).

10


5-Cyano-2-([5-(3,4-methylenedioxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(CN)-k):



^1H NMR (300 MHz, DMSO- d_6) δ 12.95 (br), 8.87 (d, 1H), 8.45 (d, 1H), 8.13 (dd, 1H), 7.95 (s, 1H), 7.40-7.47 (m, 2H), 7.10 (d, 1H), 6.17 (s, 2H).


15

5-Cyano-2-([5-(4-cyanophenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(CN)-D):



^1H NMR (300 MHz, DMSO- d_6) δ 13.00 (br), 8.82 (d, 1H), 8.43 (d, 1H), 8.28 (s, 1H), 8.12 (dd, 1H), 8.04 (s, 4H).


5 **5-Cyano-2-([5-(3-cyanophenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(CN)-m):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.96 (br), 8.82 (d, 1H), 8.37 (d, 2H), 8.25 (s, 1H), 8.12 (dd, 2H), 7.93 (d, 1H), 7.74 (t, 1H).


10

5-Cyano-2-([5-(1-methyl-1H-pyrrol-2-yl)-oxazole-2-carbonyl]amino)benzoic acid (TI(CN)-s):




15 ^1H NMR (300 MHz, DMSO- d_6) δ 12.65 (br), 8.85 (d, 1H), 8.41 (s, 1H), 8.19 (dd, 1H), 7.62 (s, 1H), 7.10 (s, 1H), 6.65 (dd, 1H), 6.18 (t, 1H).

5-Bromo-2-([5-(4-methoxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(Br)-b):




^1H NMR (300 MHz, DMSO- d_6) δ 12.60 (br), 8.65 (d, 1H), 8.20 (s, 1H), 7.90 (m, 2H), 7.80 (d, 2H), 7.10 (d, 2H), 3.80 (s, 3H).

5 **5-Bromo-2-[(5-phenyl-oxazole-2-carbonyl)amino]benzoic acid (TI(Br)-f):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.65 (br), 8.65 (d, 1H), 8.19 (d, 1H), 8.10 (s, 1H), 7.90 (m, 3H), 7.50 (m, 3H).


10 **5-Bromo-2-[(5-(2-trifluoromethylphenyl)-oxazole-2-carbonyl)amino]benzoic acid (TI(Br)-g):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.67 (br), 8.65 (d, 1H), 8.13 (d, 1H), 7.76-7.98 (m, 6H).

15


5-Bromo-2-[(5-(2-furanyl)-oxazole-2-carbonyl)amino]benzoic acid (TI(Br)-h):



^1H NMR (300 MHz, DMSO- d_6) δ 8.67 (d, 1H), 8.16 (s, 1H), 7.97 (s, 1H), 7.92 (d, 1H), 7.81 (s, 1H), 7.09 (d, 1H), 6.77 (d, 1H).


5-Bromo-2-([5-(2-methoxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid

5 **(TI(Br)-i):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.65 (br), 8.64 (d, 1H), 8.13 (d, 1H), 7.84 (m, 3H), 7.44 (m, 1H), 7.10 (m, 2H), 3.98 (s, 3H).


10 **5-Bromo-2-([5-(3,4-methylenedioxyphenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(Br)-k):**



^1H NMR (300 MHz, DMSO- d_6) δ 12.63 (br), 8.63 (d, 1H), 8.15 (d, 1H), 7.89 (s, 1H), 7.85 (dd, 1H), 7.40 (d, 1H), 7.34 (dd, 1H), 7.10 (d, 1H), 6.15 (s, 2H).

15


5-Bromo-2-([5-(4-cyanophenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(Br)-l):



^1H NMR (300 MHz, DMSO- d_6) δ 12.68 (br), 8.62 (d, 1H), 8.24 (s, 1H), 8.12 (d, 1H), 8.01 (s, 4H), 7.86 (dd, 1H).


20

5-Bromo-2-([5-(3-cyanophenyl)-oxazole-2-carbonyl]amino)benzoic acid (TI(Br)-m):



¹H NMR (300 MHz, DMSO-d₆) δ 12.71 (br), 8.64 (d, 1H), 8.37 (s, 1H), 8.14 (m, 3H), 7.88 (m, 2H), 7.74 (t, 1H).

5-Bromo-2-([5-(1-methyl-1H-pyrrol-2-yl)-oxazole-2-carbonyl]amino)benzoic acid (TI(Br)-s):



¹H NMR (300 MHz, DMSO-d₆) δ 12.59 (br), 8.65 (d, 1H), 8.14 (d, 1H), 7.88 (dd, 1H), 7.64 (s, 1H), 7.04 (d, 1H), 6.63 (dd, 1H), 6.17 (dd, 1H).

Example 11: Activity Data

MIC Test Method

The *in vitro* MICs of test compounds were determined by a standard agar dilution method. A stock drug solution of each analog was prepared in the preferred solvent, usually DMSO:H₂O (1:3). Serial 2-fold dilutions of each sample are made using 1.0 ml aliquots of sterile distilled water. To each 1.0 ml aliquot of drug was added 9 ml of molten Mueller Hinton agar medium. The drug-supplemented agar was mixed, poured into 15 x 100 mm petri dishes, and allowed to solidify and dry prior to inoculation.








Vials of each of the test organisms are maintained frozen in the vapor phase of a liquid nitrogen freezer. Test cultures are grown overnight at 35°C on the medium appropriate for the organism. Colonies are harvested with a sterile swab, and cell suspensions are prepared in Trypticase Soy broth (TSB) to equal the turbidity of a 0.5 McFarland standard. A 1:20 dilution of each suspension was made in TSB. The plates containing the drug supplemented agar are inoculated with a 0.001 ml drop of the cell










suspension using a Steers replicator, yielding approximately 10^4 to 10^5 cells per spot.










The plates are incubated overnight at 35°C.









Following incubation the Minimum Inhibitory Concentration (MIC $\mu\text{g/ml}$), the lowest concentration of drug that inhibits visible growth of the organism, was read and













5 recorded.













COMPOUND	SAUR 9218 MIC
	64
	8
	>128
	16
	16
	32
	>128












COMPOUND	SAUR 9218 MIC
	>128
	>128
	>128
	>128
	>128
	>128
	>128
	128
	16










COMPOUND	SAUR 9218 MIC
	64
	128
	8
	64
	32
	64
	16
	2
	2











COMPOUND	SAUR 9218 MIC
	16
	16
	8
	64
	64
	8
	1
	>128














COMPOUND	SAUR 9218 MIC
	>128
	16
	>128
	64
	>128
	>128
	>128
	64
	>128
	4
	16
	8













COMPOUND	SAUR 9218 MIC
	>128
	>128
	>128
	64
	8
	>128
	>128
	8
	8
	32
	128
	4













COMPOUND	SAUR 9218 MIC
	16
	>128
	16
	>128
	64
	64
	32
	32
	16
	64
	32












COMPOUND	SAUR 9218 MIC
	64
	4
	>128
	16
	8
	32
	>128
	8
	>128











COMPOUND	SAUR 9218 MIC
	2
	8
	0.25
	>128
	0.25
	4
	0.5
	16
	1
	>128












COMPOUND	SAUR 9218 MIC
	4
	32
	>128
	>128
	32
	>128
	16
	8
	8
	8
	8
	8
	16














COMPOUND	SAUR 9218 MIC
	>128
	4
	8
	2
	32
	>128
	0.5
	2
	2
	128
	8
	0.25













COMPOUND	SAUR 9218 MIC
	2
	64
	0.25
	0.25
	0.5
	>128
	8
	0.125
	16
	>128
	16
	8













COMPOUND	SAUR 9218 MIC
	16
	64
	8
	32
	64
	64
	16
	8
	32
	128
	32












COMPOUND	SAUR 9218 MIC
	4
	8
	2
	64
	8
	16
	128
	32
	8
	8












COMPOUND	SAUR 9218 MIC
	16
	32
	8
	32
	4
	8
	32
	2
	64
	64
	16











COMPOUND	SAUR 9218 MIC
	>128
	128
	128
	16
	32
	128
	16
	16
	>128
	>128
	16
	>128
	16












COMPOUND	SAUR 9218 MIC
	1
	4
	64
	4
	4
	8
	32
	32
	32
	64
	4
	>128











COMPOUND	SAUR 9218 MIC
	16
	2
	8
	4
	64
	8
	16
	4
	32
	0.25
	0.125
	1











COMPOUND	SAUR 9218 MIC
	4
	0.25
	0.125
	0.5
	1
	0.125
	2
	4
	0.25
	0.5
	0.125











COMPOUND	SAUR 9218 MIC
	1
	0.125
	0.125
	0.5
	0.125
	0.5
	0.125
	1
	1
	0.25
	0.5











COMPOUND	SAUR 9218 MIC
	2
	8
	1
	0.125
	0.5
	0.125
	8
	0.125
	1
	64











COMPOUND	SAUR 9218 MIC
	16
	1
	1
	8
	0.25
	4
	16
	0.25
	1
	1
	1











COMPOUND	SAUR 9218 MIC
	0.5
	2
	32
	2
	4
	4
	4
	16
	0.5
	1










COMPOUND	SAUR 9218 MIC
	8
	4
	16
	2
	4
	4
	4
	4
	4
	4











COMPOUND	SAUR 9218 MIC
	2
	4
	2
	2
	4
	4
	4
	4
	4
	4












COMPOUND	SAUR 9218 MIC
	4
	0.5
	>128
	0.5
	32
	64
	0.5
	0.25
	1
	32











COMPOUND	SAUR 9218 MIC
	8
	0.5
	1
	0.125
	0.125
	0.25
	4
	2
	0.125
	0.125










COMPOUND	SAUR 9218 MIC
	0.125
	1
	1
	2
	0.25
	0.25
	1
	1
	0.25
	0.5









COMPOUND	SAUR 9218 MIC
	1
	1
	0.5
	1
	32
	0.5
	0.5
	0.5
	0.25










COMPOUND	SAUR 9218 MIC
	0.125
	0.125
	1
	2
	2
	0.125
	0.125
	1
	0.125
	2









COMPOUND	SAUR 9218 MIC
	2
	2
	1
	0.125
	1
	4
	0.25
	0.125
	4
	0.5
	0.125









COMPOUND	SAUR 9218 MIC
	0.125
	0.25
	0.125
	0.5
	1
	1
	1
	0.25
	0.5
	0.25








COMPOUND	SAUR 9218 MIC
	0.5
	2
	1
	2
	2
	0.25
	0.25
	1
	0.5










COMPOUND	SAUR 9218 MIC
	1
	2
	2
	0.5
	2
	0.25
	0.5
	0.5










COMPOUND	SAUR 9218 MIC
	0.25
	4
	0.5
	1
	0.5
	1
	4
	2
	0.5









COMPOUND	SAUR 9218 MIC
	8
	0.125
	1
	0.5
	16
	0.5
	0.5
	0.5









COMPOUND	SAUR 9218 MIC
	0.5
	1
	0.25
	1
	1
	1
	0.125
	0.5










COMPOUND	SAUR 9218 MIC
	8
	>128
	0.5
	0.25
	0.125
	1
	0.25












COMPOUND	SAUR 9218 MIC
	0.5
	1
	0.125
	0.125
	0.5
	0.25
	0.25
	0.125
	0.25












COMPOUND	SAUR 9218 MIC
	0.25
	0.125
	0.5
	0.5
	0.5
	0.25
	0.5
	0.5
	0.5












COMPOUND	SAUR 9218 MIC
	0.25
	0.125
	1
	0.25
	0.5
	0.25
	0.125
	0.25











COMPOUND	SAUR 9218 MIC
	1
	2
	2
	0.5
	0.25
	0.5
	2
	0.5












COMPOUND	SAUR 9218 MIC
	1
	0.25
	4
	0.25
	0.5
	0.5
	2
	0.5
	8












COMPOUND	SAUR 9218 MIC
	4
	2
	0.5
	1
	0.5
	64
	64
	32
	>128
	>128
	0.25










COMPOUND	SAUR 9218 MIC
	1
	2
	0.25
	0.5
	0.25
	2
	2
	128
	0.5
	4
	1











COMPOUND	SAUR 9218 MIC
	1
	>128
	2
	2
	>128
	2
	4
	0.125
	2
	2
	8










COMPOUND	SAUR 9218 MIC
	8
	0.125
	0.125
	0.25
	16
	1
	0.125
	2
	0.125
	1










COMPOUND	SAUR 9218 MIC
	0.125
	1
	0.125
	0.125
	0.5
	2
	0.25
	2
 single enantiomer	>128
	1
	0.125












COMPOUND	SAUR 9218 MIC
	0.125
	0.5
	0.125
	8
	1
	1
 single enantiomer, 3	>128
	16
	32
	0.125
	0.25











COMPOUND	SAUR 9218 MIC
	8
	0.125
	4
	32
	0.125
	0.5
	0.5
	0.125
	0.25










COMPOUND	SAUR 9218 MIC
	0.125
	0.125
	8
	0.125
	2
	0.5
	4
	1
	0.125
	0.125












COMPOUND	SAUR 9218 MIC
	2
	0.125
	0.5
	0.125
	0.25
	0.5
	0.125
	0.25
	0.125











COMPOUND	SAUR 9218 MIC
	0.25
	0.125
	0.25
	0.125
	0.125
	0.125
	0.125
	0.125
	0.125













COMPOUND	SAUR 9218 MIC
	1
	1
	2
	128
	4
	128
	1
	16
	16
	0.125
	32











COMPOUND	SAUR 9218 MIC
	1
	0.5
	0.125
	0.125
	0.5
	0.25
	0.25
	4
	8
	0.125











COMPOUND	SAUR 9218 MIC
	1
	1
	0.25
	0.125
	0.5
	0.125
	4
	16
	0.125













COMPOUND	SAUR 9218 MIC
	1
	0.125
	16
	0.125
	32
	>128
	0.25
	0.25
	0.125
	0.125
	2










COMPOUND	SAUR 9218 MIC
	8
	4
	2
	0.25
	4
	0.06
	32
	>128
	64
	64











COMPOUND	SAUR 9218 MIC
	8
	1
	0.03
	0.5
	>128
	64
	0.5
	>128
	>128
	1
	128
	2












COMPOUND	SAUR 9218 MIC
	2
	0.5
	0.5
	0.125
	16
	8
	8
	0.125
	0.25
	4











COMPOUND	SAUR 9218 MIC
	0.125
	0.125
	0.5
	0.5
	1
	8
	0.5
	0.015
	0.25
	1













COMPOUND	SAUR 9218 MIC
	32
	0.5
	0.125
	0.015
	128
	1
	0.5
	0.5
	0.5
	16
	>128
	8












COMPOUND	SAUR 9218 MIC
	2
	1
	1
	>128
	2
	0.25
	0.5
	0.25
	0.5











COMPOUND	SAUR 9218 MIC
	1
	0.5
	4
	128
	1
	0.015
	0.125
	0.5
	8
	0.06












COMPOUND	SAUR 9218 MIC
	0.03
	1
	2
	1
	0.5
	0.125
	1
	2
	0.03
	2
	1











COMPOUND	SAUR 9218 MIC
	0.03
	0.125
	4
	2
	2
	0.5
	1
	2
	0.5
	0.25









COMPOUND	SAUR 9218 MIC
	16
	0.5
	128
	>128
	0.5
	0.5
	0.25
	0.06
	0.25
	4
	0.5
	4











COMPOUND	SAUR 9218 MIC
	>128
	>128
	8
	2
	0.5
	0.5
	8
	0.25
	0.25
	0.125
	0.25









COMPOUND	SAUR 9218 MIC
	2
	0.25
	0.5
	0.5
	1
	1
	2
	>128
	2
	0.5










COMPOUND	SAUR 9218 MIC
	0.5
	16
	0.125
	0.06
	0.5
	0.125
	128
	0.06
	0.25
	0.03
	32









COMPOUND	SAUR 9218 MIC
	0.03
	0.5
	0.5
	0.5
	2
	0.5
	0.06
	0.5
	1
	0.06











COMPOUND	SAUR 9218 MIC
	0.25
	0.25
	0.06
	0.0075
	0.5
	0.5
	0.25
	0.125

COMPOUND	SAUR 9218 MIC
	0.25
	4
	0.25
	0.5
	0.25
	0.03
	0.5
	0.06
	64
	0.125









COMPOUND	SAUR 9218 MIC
	0.5
	0.5
	0.125
	0.5
	0.125
	0.25
	0.125
	0.25










COMPOUND	SAUR 9218 MIC
	0.03
	0.5
	1
	0.5
	2
	0.5
	0.5
	2
	0.5










COMPOUND	SAUR 9218 MIC
	0.5
	0.5
	2
	0.5
	0.25
	0.125
	0.5
	0.5



COMPOUND	SAUR 9218 MIC
	0.5
	0.015
	1
	1
	0.25
	1
	>128
 A	0.5
 A	1
 A	1

mixture of diastereomers

COMPOUND	SAUR 9218 MIC
A 	0.5
A 	0.125
A 	1
	1
	>128
	1
	0.5
	0.25


COMPOUND	SAUR 9218 MIC
	0.25
B 	1
	0.5
	0.125
	0.125
	0.125
	8
	8
	2

COMPOUND	SAUR 9218 MIC
	16
	>128
	2
	8
	4
	>128
	2
	1
	8

COMPOUND	SAUR 9218 MIC
	2
	16

What is claimed is:

1. A compound of formula I,



- 5 or a pharmaceutically acceptable salt thereof,
wherein

X = NH

Y = CO, CS, -C(=N-CN) or


X and Y together form an alkene, or C₃-C₅ cycloalkyl;

- 10 R₁ is -COOH;

R₂ is an electron withdrawing group; and

R₄ is an optionally substituted HET, provided that the HET is not
simultaneously substituted with a sulfonamide and a urea or thiourea.

- 15 2. The compound of claim 1 having a formula II



or a pharmaceutically acceptable salt thereof,
wherein

X = NH

- 20 Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

R₅ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-

- 25 (CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R_6 is selected from H, halo, HET, -CN, NH_2 , NO_2 , alkyl, substituted alkyl, alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-N(Q_{15})_2$, HET, and substituted HET;

5 R_8 is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, $-OQ_{16}$, $-SQ_{16}$, $-S(O)_2Q_{16}$, $-S(O)Q_{16}$, $-OS(O)_2Q_{16}$, -

10 $C(=NQ_{16})Q_{16}$, $-S(O)_2-N=S(O)(Q_{16})_2$, $-S(O)_2-N=S(Q_{16})_2$, $-SC(O)Q_{16}$, $-NQ_{16}Q_{16}$, $-C(O)Q_{16}$, $-C(S)Q_{16}$, $-C(O)OQ_{16}$, $-OC(O)Q_{16}$, $-C(O)NQ_{16}Q_{16}$, $-C(S)NQ_{16}Q_{16}$, $-C(O)C(Q_{16})_2OC(O)Q_{16}$, -CN, $-NQ_{16}C(O)Q_{16}$, $-NQ_{16}C(S)Q_{16}$, $-NQ_{16}C(O)NQ_{16}Q_{16}$, $-NQ_{16}C(S)NQ_{16}Q_{16}$, $-S(O)_2NQ_{16}Q_{16}$, $-NQ_{16}S(O)_2Q_{16}$, $-NQ_{16}S(O)Q_{16}$, $-NQ_{16}SQ_{16}$, -
 15 NO_2 , and $-SNQ_{16}Q_{16}$. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S;

Each Q_{16} is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

W is O, S, $-(CZ_2)-$, or $-(CHZ_3)-$;

Z_1 is O;


20 Z_2 is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z_3 is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

k is 0, 1, or 2.

25 3. The compound of claim 1 having a formula III



or a pharmaceutically acceptable salt thereof,

wherein

X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

5 R₂ is an electron withdrawing group;

R₃ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-(CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, HET, -CN, NH₂, NO₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

10 R₇ is selected from alkyl, substituted alkyl, aryl, substituted aryl, -N(Q₁₅)₂, HET, and substituted HET;

R₈ is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q₁₅ is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, 15 phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, -OQ₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆, -C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Q₁₆)₂, -S(O)₂-N=S(Q₁₆)₂, -SC(O)Q₁₆, -NQ₁₆Q₁₆, | -C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆, -C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆, 20 -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

25 W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z₁ is O;


Z₂ is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z₃ is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

30 k is 0, 1, or 2.

4. The compound of claim 1 having a formula IV



or a pharmaceutically acceptable salt thereof,

wherein

X = NH

5 Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

R₅ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-
10 (CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, HET, -CN, NH₂, NO₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

R₇ is selected from alkyl, substituted alkyl, aryl, substituted aryl, -N(Q₁₅)₂, HET, and substituted HET;

15 R₈ is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q₁₅ is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, -OQ₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆,
20 -C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Q₁₆)₂, -S(O)₂-N=S(Q₁₆)₂, -SC(O)Q₁₆, -NQ₁₆Q₁₆, -C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆, -C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆, -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally
25 substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z_1 is O;


Z_2 is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z_3 is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

5 k is 0, 1, or 2.

5. The compound of claim 1 having a formula V



10 or a pharmaceutically acceptable salt thereof,
wherein

$X = NH$

$Y = CO, CS, -C(=N-CN)$ or

X and Y together form an alkene, or C_3 - C_5 cycloalkyl;

15 R_1 is $-COOH$;

R_2 is an electron withdrawing group;

R_3 is $-(CH_2)_k-S(O)_i-R_7$, $-NH-SO_2-R_7$, $-(CH_2)_k-W-R_8$, $-NH-(CZ_1)-R_8$, $-NH-(CZ_1)-NR_8$, substituted aryl, substituted C_{1-4} alkyl, or substituted C_{1-4} alkenyl;

20 R_6 is selected from H, halo, HET, -CN, NH_2 , NO_2 , alkyl, substituted alkyl, alkoxy, substituted alkoxy, $-NH-CO-HET$, and $-NH-CO-aryl$;

R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-N(Q_{15})_2$, HET, and substituted HET;

R_8 is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

25 Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, $-OQ_{16}$, $-SQ_{16}$, $-S(O)_2Q_{16}$, $-S(O)Q_{16}$, $-OS(O)_2Q_{16}$, $-C(=NQ_{16})Q_{16}$, $-S(O)_2-N=S(O)(Q_{16})_2$, $-S(O)_2-N=S(Q_{16})_2$, $-SC(O)Q_{16}$, $-NQ_{16}Q_{16}$,

-C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆,
 -C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆,
 -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆,
 -NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally
 5 substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z₁ is O;


10 Z₂ is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z₃ is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

k is 0, 1, or 2.

15 6. The compound of claim 1 having a formula XX.



XX

or a pharmaceutically acceptable salt thereof,
 wherein

20 X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

25 R₃ is H, halo, NO₂, CN, -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈-NH-
 (CZ₁)-R₈, -(CZ₁)-NH-R₈, -NH-(CZ₁)-NR₈R₈, -(CH₂)_k-NR₈R₈, substituted aryl,
 substituted HET, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R_6 is selected from H, halo, aryl, substituted aryl, HET, substituted HET, -CN, NH_2 , NO_2 , alkyl, substituted alkyl, alkoxy, substituted alkoxy, $-(CH_2)_k-S(O)_i-R_7$, -NH- SO_2-R_7 , $-(CH_2)_k-W-R_8$, -NH-(CZ_1)- R_8 , -(CZ_1)-NH- R_8 , -NH-(CZ_1)- NR_8R_8 , or substituted C_{1-4} alkenyl;

5 R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-N(Q_{15})_2$, HET, and substituted HET;

Each R_8 is independently H, alkyl, substituted alkyl, $-OQ_{16}$, aryl, substituted aryl, HET, substituted HET, cycloalkyl, and substituted cycloalkyl, or two R_8 substituents when attached to the same atom may be taken together to form a 5-8
10 membered ring, wherein the ring includes the atom to which the two R_8 substituents attach;

Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, $-OQ_{16}$, $-SQ_{16}$, $-S(O)_2Q_{16}$, $-S(O)Q_{16}$, $-OS(O)_2Q_{16}$,
15 $-C(=NQ_{16})Q_{16}$, $-S(O)_2-N=S(O)(Q_{16})_2$, $-S(O)_2-N=S(Q_{16})_2$, $-SC(O)Q_{16}$, $-NQ_{16}Q_{16}$, $-C(O)Q_{16}$, $-C(S)Q_{16}$, $-C(O)OQ_{16}$, $-OC(O)Q_{16}$, $-C(O)NQ_{16}Q_{16}$, $-C(S)NQ_{16}Q_{16}$, $-(O)C(Q_{16})_2OC(O)Q_{16}$, -CN, $-NQ_{16}C(O)Q_{16}$, $-NQ_{16}C(S)Q_{16}$, $-NQ_{16}C(O)NQ_{16}Q_{16}$, $-NQ_{16}C(S)NQ_{16}Q_{16}$, $-S(O)_2NQ_{16}Q_{16}$, $-NQ_{16}S(O)_2Q_{16}$, $-NQ_{16}S(O)Q_{16}$, $-NQ_{16}SQ_{16}$, $-NO_2$, and $-SNQ_{16}Q_{16}$. The alkyl, cycloalkyl, and
20 cycloalkenyl being further optionally substituted with =O or =S;

Each Q_{16} is independently selected from -H, alkyl, cycloalkyl, phenyl, benzyl, $-CH_2$ -substituted phenyl, and Het in which each of alkyl, cycloalkyl, phenyl, and Het optionally include 1-3 halos;

W is O, S, $-(CZ_2)-$, or $-(CHZ_3)-$, provided that W is not S or O when R_5 or R_6
25 are $-(CH_2)_k-W-OR_{16}$;

Z_1 is =O;

Z_2 is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z_3 is -OH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;


i is 0, 1, or 2; and

30 k is 0, 1, or 2.

7. The compound of claim 6, wherein at least one of R_5 and R_6 is a substituted phenyl or substituted HET.


8. The compound of claim 7, wherein at least one of R_5 and R_6 is pyridine, pyrimidine, pyridazine, or pyrazine, each of which is optionally substituted with the substituents described for substituted HET.

5 9. The compound of claim 7, wherein the substituted phenyl has the formula



R_{11} , wherein each R_{10} and R_{11} is selected from -F, -Cl, -Br, -I, -OQ₁₆, -Q₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆, -SC(O)Q₁₆, -NQ₁₆Q₁₆, -C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆, -(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆, -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -NO₂, and -SNQ₁₆Q₁₆.

10. The compound of claim of claim 8, wherein the substituted phenyl has the formula



11. The compound of claim 6, wherein one of R_5 or R_6 is -NH-(CZ₁)-NR₈R₈.

12. The compound of claim 11, wherein -NR₈R₈ forms a 5-8 membered ring.

13. The compound of claim 12, wherein the ring is morpholino, pyrrolidinyl, or piperidinyl.

14. The compound of claim 11, wherein at least one of the R_8 substituents is benzyl or $-CH_2$ -substituted phenyl.

5 15. The compound of claim 6, wherein one of R_5 or R_6 is $-(CH_2)_k-S(O)_i-R_7$ or $-NH-SO_2-R_7$.

16. The compound of claim 15, wherein R_7 is het, substituted het, alkyl, or substituted alkyl.

10


17. The compound of claim 16, wherein het is indoliny, pyrrolindiny, or indolyl, pyrrolyl.

18. The compound of claim 16, wherein substituted het includes a het substituent substituted with 1-3 of halo or CN.

15

19. The compound of claim 16, wherein substituted alkyl is an alkyl substituted with 1-3 of OH, NH_2 , NHQ_{16} , $-NR_8R_8$.

20 20. The compound of claim 1 having a formula XXX



XXX

or a pharmaceutically acceptable salt thereof,

wherein

25

X = NH

Y = CO, CS, $-C(=N-CN)$ or

X and Y together form an alkene, or C_3-C_5 cycloalkyl;

R_1 is $-\text{COOH}$;

R_2 is an electron withdrawing group;

R_3 is H, halo, NO_2 , CN, $-(\text{CH}_2)_k-\text{S}(\text{O})_i-\text{R}_7$, $-\text{NH}-\text{SO}_2-\text{R}_7$, $-(\text{CH}_2)_k-\text{W}-\text{R}_8$, $-\text{NH}-(\text{CZ}_1)-\text{R}_8$, $-(\text{CZ}_1)-\text{NH}-\text{R}_8$, $-\text{NH}-(\text{CZ}_1)-\text{NR}_8\text{R}_8$, $-(\text{CH}_2)_k-\text{NR}_8\text{R}_8$, substituted aryl,

5 substituted HET, substituted C_{1-4} alkyl, or substituted C_{1-4} alkenyl;

R_6 is selected from H, halo, aryl, substituted aryl, HET, substituted HET, $-\text{CN}$, NH_2 , NO_2 , alkyl, substituted alkyl, alkoxy, substituted alkoxy, $-(\text{CH}_2)_k-\text{S}(\text{O})_i-\text{R}_7$, $-\text{NH}-\text{SO}_2-\text{R}_7$, $-(\text{CH}_2)_k-\text{W}-\text{R}_8$, $-\text{NH}-(\text{CZ}_1)-\text{R}_8$, $-(\text{CZ}_1)-\text{NH}-\text{R}_8$, $-\text{NH}-(\text{CZ}_1)-\text{NR}_8\text{R}_8$, or substituted C_{1-4} alkenyl;

10 R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-\text{N}(\text{Q}_{15})_2$, HET, and substituted HET;

Each R_8 is independently H, alkyl, substituted alkyl, $-\text{OQ}_{16}$, aryl, substituted aryl, HET, substituted HET, cycloalkyl, and substituted cycloalkyl, or two R_8 substituents when attached to the same atom may be taken together to form a 5-8
15 membered ring, wherein the ring includes the atom to which the two R_8 substituents attach;

Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{OQ}_{16}$, $-\text{SQ}_{16}$, $-\text{S}(\text{O})_2\text{Q}_{16}$, $-\text{S}(\text{O})\text{Q}_{16}$, $-\text{OS}(\text{O})_2\text{Q}_{16}$,
20 $-\text{C}(=\text{NQ}_{16})\text{Q}_{16}$, $-\text{S}(\text{O})_2-\text{N}=\text{S}(\text{O})(\text{Q}_{16})_2$, $-\text{S}(\text{O})_2-\text{N}=\text{S}(\text{Q}_{16})_2$, $-\text{SC}(\text{O})\text{Q}_{16}$, $-\text{NQ}_{16}\text{Q}_{16}$, $-\text{C}(\text{O})\text{Q}_{16}$, $-\text{C}(\text{S})\text{Q}_{16}$, $-\text{C}(\text{O})\text{OQ}_{16}$, $-\text{OC}(\text{O})\text{Q}_{16}$, $-\text{C}(\text{O})\text{NQ}_{16}\text{Q}_{16}$, $-\text{C}(\text{S})\text{NQ}_{16}\text{Q}_{16}$, $-(\text{O})\text{C}(\text{Q}_{16})_2\text{OC}(\text{O})\text{Q}_{16}$, $-\text{CN}$, $-\text{NQ}_{16}\text{C}(\text{O})\text{Q}_{16}$, $-\text{NQ}_{16}\text{C}(\text{S})\text{Q}_{16}$, $-\text{NQ}_{16}\text{C}(\text{O})\text{NQ}_{16}\text{Q}_{16}$, $-\text{NQ}_{16}\text{C}(\text{S})\text{NQ}_{16}\text{Q}_{16}$, $-\text{S}(\text{O})_2\text{NQ}_{16}\text{Q}_{16}$, $-\text{NQ}_{16}\text{S}(\text{O})_2\text{Q}_{16}$, $-\text{NQ}_{16}\text{S}(\text{O})\text{Q}_{16}$, $-\text{NQ}_{16}\text{SQ}_{16}$, $-\text{NO}_2$, and $-\text{SNQ}_{16}\text{Q}_{16}$. The alkyl, cycloalkyl, and
25 cycloalkenyl being further optionally substituted with $=\text{O}$ or $=\text{S}$;

Each Q_{16} is independently selected from $-\text{H}$, alkyl, cycloalkyl, phenyl, benzyl, $-\text{CH}_2$ -substituted phenyl, and Het in which each of alkyl, cycloalkyl, phenyl, and Het optionally include 1-3 halos;

W is O, S, $-(\text{CZ}_2)-$, or $-(\text{CHZ}_3)-$, provided that W is not S or O when R_5 or R_6
30 are $-(\text{CH}_2)_k-\text{W}-\text{OR}_{16}$;

Z_1 is $=\text{O}$;

Z_2 is $=\text{O}$, $=\text{S}$, $=\text{N}-\text{OH}$, $=\text{N}-\text{O}-\text{alkyl}$, or $=\text{N}-\text{O}-\text{substituted alkyl}$;

Z_3 is $-\text{OH}$, $-\text{N}=\text{N}-\text{alkyl}$, $-\text{NH}-\text{alkyl}$, or $-\text{NH}-\text{substituted alkyl}$;

i is 0, 1, or 2; and


k is 0, 1, or 2.

21. The compound of claim 20, wherein at least one of R_5 and R_6 is a substituted
5 phenyl or substituted HET.

22. The compound of claim 21, wherein at least one of R_5 and R_6 is pyridine,
pyrimidine, pyridazine, or pyrazine, each of which is optionally substituted with the
substituents described for substituted HET.


10

23. The compound of claim 21, wherein the substituted phenyl has the formula




R_{11} , wherein each R_{10} and R_{11} is selected from -F, -Cl, -Br, -I,
-O Q_{16} , - Q_{16} , -S Q_{16} , -S(O) $_2Q_{16}$, -S(O) Q_{16} , -OS(O) $_2Q_{16}$, -SC(O) Q_{16} , -N $Q_{16}Q_{16}$, -
C(O) Q_{16} , -C(S) Q_{16} , -C(O)O Q_{16} , -OC(O) Q_{16} , -C(O)N $Q_{16}Q_{16}$, -C(S)N $Q_{16}Q_{16}$, -
15 (O)C(Q_{16}) $_2$ OC(O) Q_{16} , -CN, -N Q_{16} C(O) Q_{16} , -N Q_{16} C(S) Q_{16} , -N Q_{16} C(O)N $Q_{16}Q_{16}$, -
N Q_{16} C(S)N $Q_{16}Q_{16}$, -S(O) $_2$ N $Q_{16}Q_{16}$, -N Q_{16} S(O) $_2Q_{16}$, -N Q_{16} S(O) Q_{16} , -N Q_{16} S Q_{16} , -NO $_2$,
and -SN $Q_{16}Q_{16}$.

24. The compound of claim of claim 23, wherein the substituted phenyl has the
20 formula



25. The compound of claim 20, wherein one of R_5 or R_6 is -NH-(CZ $_1$)-NR $_8R_8$.

26. The compound of claim 25, wherein $-NR_8R_8$ forms a 5-8 membered ring.
27. The compound of claim 26, wherein the ring is morpholino, pyrrolidinyl, or piperdinyl.
- 5 28. The compound of 26, wherein at least one of the R_8 substituents is benzyl or $-CH_2$ -substituted phenyl.
29. The compound of claim 20, wherein one of R_5 or R_6 is $-(CH_2)_k-S(O)_i-R_7$ or -
- 10 $NH-SO_2-R_7$.
30. The compound of claim 29, wherein R_7 is het, substituted het, alkyl, or substituted alkyl.
- 15 31. The compound of claim 30, wherein het is indolinyl, pyrrolindinyl, or indolyl, pyrrolyl.
32. The compound of claim 30, wherein substituted het includes a het substituent substituted with 1-3 of halo or CN.
- 20 33. The compound of claim 30, wherein substituted alkyl is an alkyl substituted with 1-3 of OH, NH_2 , NHQ_{16} , $-NR_8R_8$.
34. The compound of claim 1 having a formula VII
- 25



VII

or a pharmaceutically acceptable salt thereof,
wherein

X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₃ cycloalkyl;

R₁ is -COOH;

5 R₂ is an electron withdrawing group;

R₃ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-(CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, HET, -CN, NH₂, NO₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

10 R₇ is selected from alkyl, substituted alkyl, aryl, substituted aryl, -N(Q₁₅)₂, HET, and substituted HET;

R₈ is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q₁₅ is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl,
15 phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, -OQ₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆, -C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Q₁₆)₂, -S(O)₂-N=S(Q₁₆)₂, -SC(O)Q₁₆, -NQ₁₆Q₁₆, -C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆, -C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆, -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

25 W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z₁ is O;


Z₂ is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z₃ is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

30 k is 0, 1, or 2.

35. The compound of claim 1 having a formula VIII



VIII

or a pharmaceutically acceptable salt thereof,

wherein

5 X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

10 R₅ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-(CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, C₁-C₄ alkyl, -CN, NH₂, NO₂;

R₇ is selected from alkyl, substituted alkyl, aryl, substituted aryl, -N(Q₁₅)₂, HET, and substituted HET;

15 R₈ is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q₁₅ is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, -OQ₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆, -

20 C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Q₁₆)₂, -S(O)₂-N=S(Q₁₆)₂, -SC(O)Q₁₆, -NQ₁₆Q₁₆, -

C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆,

-C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆,

-NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -

NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally

25 substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z_1 is O;


Z_2 is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z_3 is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

5 k is 0, 1, or 2.

36. The compound of claim 1 having a formula IX



IX

10 or a pharmaceutically acceptable salt thereof,
wherein

$X = NH$

$Y = CO, CS, -C(=N-CN)$ or

X and Y together form an alkene, or C_3-C_5 cycloalkyl;

15 R_1 is $-COOH$;

R_2 is an electron withdrawing group;

R_5 is $-(CH_2)_k-S(O)_i-R_7$, $-NH-SO_2-R_7$, $-(CH_2)_k-W-R_8$, $-NH-(CZ_1)-R_8$, $-NH-(CZ_1)-NR_8$, substituted aryl, substituted C_{1-4} alkyl, or substituted C_{1-4} alkenyl;

R_6 is selected from H, halo, $-CN$, NH_2 , NO_2 , alkyl;

20 R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-N(Q_{15})_2$,
HET, and substituted HET;

R_8 is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET,
cycloalkyl, substituted cycloalkyl;

Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl,
25 phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently
selected from $-F$, $-Cl$, $-Br$, $-I$, $-OQ_{16}$, $-SQ_{16}$, $-S(O)_2Q_{16}$, $-S(O)Q_{16}$, $-OS(O)_2Q_{16}$, $-C(=NQ_{16})Q_{16}$, $-S(O)_2-N=S(O)(Q_{16})_2$, $-S(O)_2-N=S(Q_{16})_2$, $-SC(O)Q_{16}$, $-NQ_{16}Q_{16}$, $-C(O)Q_{16}$, $-C(S)Q_{16}$, $-C(O)OQ_{16}$, $-OC(O)Q_{16}$, $-C(O)NQ_{16}Q_{16}$, $-C(S)NQ_{16}Q_{16}$,

-C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆,
 -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆, -
 NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally
 substituted with =O or =S;

5 Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl
 and cycloalkyl optionally including 1-3 halos;

W is O, S, -(CZ₂)-, or -(CHZ₃)-;

Z₁ is O;


Z₂ is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

10 Z₃ is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

k is 0, 1, or 2.

37. The compound of claim 1 having a formula X



15

or a pharmaceutically acceptable salt thereof,

wherein

X = NH

20 Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

25 R₅ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-
 (CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, HET, -CN, NH₂, NO₂, alkyl, substituted alkyl,
 alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

R_7 is selected from alkyl, substituted alkyl, aryl, substituted aryl, $-N(Q_{15})_2$, HET, and substituted HET;

R_8 is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

5 Each Q_{15} is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from -F, -Cl, -Br, -I, $-OQ_{16}$, $-SQ_{16}$, $-S(O)_2Q_{16}$, $-S(O)Q_{16}$, $-OS(O)_2Q_{16}$, $-C(=NQ_{16})Q_{16}$, $-S(O)_2N=S(O)(Q_{16})_2$, $-S(O)_2N=S(Q_{16})_2$, $-SC(O)Q_{16}$, $-NQ_{16}Q_{16}$, $-C(O)Q_{16}$, $-C(S)Q_{16}$, $-C(O)OQ_{16}$, $-OC(O)Q_{16}$, $-C(O)NQ_{16}Q_{16}$, $-C(S)NQ_{16}Q_{16}$,
 10 $-C(O)C(Q_{16})_2OC(O)Q_{16}$, -CN, $-NQ_{16}C(O)Q_{16}$, $-NQ_{16}C(S)Q_{16}$, $-NQ_{16}C(O)NQ_{16}Q_{16}$, $-NQ_{16}C(S)NQ_{16}Q_{16}$, $-S(O)_2NQ_{16}Q_{16}$, $-NQ_{16}S(O)_2Q_{16}$, $-NQ_{16}S(O)Q_{16}$, $-NQ_{16}SQ_{16}$, - NO_2 , and $-SNQ_{16}Q_{16}$. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S;

Each Q_{16} is independently selected from -H, alkyl, and cycloalkyl. The alkyl
 15 and cycloalkyl optionally including 1-3 halos;

W is O, S, $-(CZ_2)-$, or $-(CHZ_3)-$;

Z_1 is O;


Z_2 is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z_3 is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

20 i is 0, 1, or 2; and

k is 0, 1, or 2.

38. The compound of claim 1 having a formula XI



25 XI

or a pharmaceutically acceptable salt thereof,

wherein

X = NH

Y = CO, CS, -C(=N-CN) or

X and Y together form an alkene, or C₃-C₅ cycloalkyl;

R₁ is -COOH;

R₂ is an electron withdrawing group;

5 R₅ is -(CH₂)_k-S(O)_i-R₇, -NH-SO₂-R₇, -(CH₂)_k-W-R₈, -NH-(CZ₁)-R₈, -NH-(CZ₁)-NR₈, substituted aryl, substituted C₁₋₄alkyl, or substituted C₁₋₄alkenyl;

R₆ is selected from H, halo, HET, -CN, NH₂, NO₂, alkyl, substituted alkyl, alkoxy, substituted alkoxy, -NH-CO-HET, and -NH-CO-aryl;

10 R₇ is selected from alkyl, substituted alkyl, aryl, substituted aryl, -N(Q₁₅)₂, HET, and substituted HET;

R₈ is H, alkyl, substituted alkyl, aryl, substituted aryl, HET, substituted HET, cycloalkyl, substituted cycloalkyl;

Each Q₁₅ is independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently
 15 selected from -F, -Cl, -Br, -I, -OQ₁₆, -SQ₁₆, -S(O)₂Q₁₆, -S(O)Q₁₆, -OS(O)₂Q₁₆,
 -C(=NQ₁₆)Q₁₆, -S(O)₂-N=S(O)(Q₁₆)₂, -S(O)₂-N=S(Q₁₆)₂, -SC(O)Q₁₆, -NQ₁₆Q₁₆,
 -C(O)Q₁₆, -C(S)Q₁₆, -C(O)OQ₁₆, -OC(O)Q₁₆, -C(O)NQ₁₆Q₁₆, -C(S)NQ₁₆Q₁₆,
 -C(O)C(Q₁₆)₂OC(O)Q₁₆, -CN, -NQ₁₆C(O)Q₁₆, -NQ₁₆C(S)Q₁₆, -NQ₁₆C(O)NQ₁₆Q₁₆,
 -NQ₁₆C(S)NQ₁₆Q₁₆, -S(O)₂NQ₁₆Q₁₆, -NQ₁₆S(O)₂Q₁₆, -NQ₁₆S(O)Q₁₆, -NQ₁₆SQ₁₆,
 20 -NO₂, and -SNQ₁₆Q₁₆. The alkyl, cycloalkyl, and cycloalkenyl being further optionally substituted with =O or =S;

Each Q₁₆ is independently selected from -H, alkyl, and cycloalkyl. The alkyl and cycloalkyl optionally including 1-3 halos;

W is O, S, -(CZ₂)-, or -(CHZ₃)-;

25 Z₁ is O;

Z₂ is =O, =S, =N-OH, =N-O-alkyl, or =N-O-substituted alkyl;

Z₃ is -OH, -N=NH, -N=N-alkyl, -NH-alkyl, or -NH-substituted alkyl;

i is 0, 1, or 2; and

k is 0, 1, or 2.

30

39. The compound of claim 1, wherein Y is -CO-.

40. The compound of claim 1, wherein R_2 is halo, -CN, -NO₂, HET, substituted HET, aryl, substituted aryl, -(CO)-alkyl, -(CO)-substituted alkyl, -(CO)-aryl, -(CO)-substituted aryl, -(CO)-O-alkyl, -(CO)-O-substituted alkyl, -(CO)-O-aryl, -(CO)-O-substituted aryl, -OC(Z_n)₃, -C(Z_n)₃, -C(Z_n)₂-O-C(Z_m)₃, -SO₂-C(Z_n)₃, -SO₂-aryl, -CN(Q₁₇)₂, -C(NQ₁₇)Q₁₇, -CH=C(Q₁₇)₂, -C≡C-Q₁₇, in which each Z_n and Z_m is independently H, halo, -CN, -NO₂, -OH, or C₁₋₄alkyl optionally substituted with 1-3 halo, -OH, NO₂, provided that at least one of Z_n is halo, -CN, or NO₂.
41. The compound of claim 40, wherein R_2 is Br, Cl, F, I, -CN, formyl, methoxyimino, hydroxyimino, -CH₂-halo, CH₂-CN, phenyl, thienyl, pyrazinyl, 1-methyl-1H-pyrrol-2-yl, pyridin-2-yl, chlorophenyl, nitrophenyl, cyanophenyl, chlorothienyl, methylthienyl, fluorophenyl, (trifluoromethyl)phenyl, di(trifluoromethyl)phenyl, difluorophenyl, dimethylisoxazolyl, dimethoxypyrimidinyl.
42. The compound of claim 1, wherein R_5 is -NH₂, -SO₂-NH-alkyl, -SO₂-NH-substituted alkyl, -SO₂-NH-aryl, -NH-SO₂-aryl, -SO₂-NH-substituted aryl, -NH-SO₂-substituted aryl, -SO₂-NH-HET, -SO₂-NH-substituted HET, -SO₂-N(alkyl)(substituted alkyl), -SO₂-N(alkyl)(aryl), -SO₂-N(alkyl)(substituted aryl), -SO₂-N(alkyl)(HET), -SO₂-N(alkyl)(substituted HET), -S-alkyl, -S-substituted alkyl, -O-alkyl, -O-aryl, -S-substituted alkyl, -CH₂-S-alkyl, -CH₂-S-substituted alkyl, -(CH₂)₂-S-alkyl, -(CH₂)₂-S-substituted alkyl, -C(O)-aryl, -C(O)H, -C(OH)-aryl, -C(N-OCH₃)-aryl, -C(N-OH)-aryl, -C(O)-C₁₋₆cycloalkyl, -NH-C(O)-O-C₁₋₄alkyl, -NH-C(O)-aryl, -NH-C(O)-substituted aryl, -NH-C(O)-HET, -NH-C(O)-substituted HET, -NHC(O)NH-aryl, -NHC(O)NH-substituted aryl, -NHC(O)NH-het, -NHC(O)NH-substituted het.
43. The compound of claim 42, wherein R_5 is (diethylamino)sulfonyl, (1H-indol-5-yl)aminosulfonyl, (furylmethylamino)sulfonyl, (ethoxycarbonyl)-1-piperazinylsulfonyl, pyridinylethylaminosulfonyl, (benzylamino)sulfonyl, (2-hydroxy-1-methylethyl)aminosulfonyl, (4-carboxyanilino)sulfonyl, (3,4-dihydro-1(2H)-quinolinyl)sulfonyl, [2-(3,5-dimethoxyphenyl)ethyl]aminosulfonyl, [(3S)-3-hydroxypyrrolidinyl]sulfonyl, (ethylanilino)sulfonyl, (3,5-dimethoxyanilino)sulfonyl, (2-hydroxy-2-phenylethyl)(methyl)amino]sulfonyl, (2,3-dihydro-1H-indol-1-yl)sulfonyl, (5-methoxy-2,3-dihydro-1H-indol-1-yl)sulfonyl, (5-fluoro-2,3-dihydro-1H-indol-1-

yl)sulfonyl, (1H-benzimidazol-1-yl)sulfonyl, (5-fluoro-1H-indol-1-yl)sulfonyl, (1H-indol-1-yl)sulfonyl, (6-fluoro-1H-indol-1-yl)sulfonyl, (5-chloro-1H-indol-1-yl)sulfonyl, (6-chloro-1H-indol-1-yl)sulfonyl, (6-chloro-5-fluoro-1H-indol-1-yl)sulfonyl, (1H-pyrrol-1-yl)sulfonyl, (5-methoxy-1H-indol-1-yl)sulfonyl, (1H-pyrrolo[2,3-b]pyridin-1-yl)sulfonyl, (5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl, (3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)sulfonyl, (4-chlorophenyl)(methyl)amino]sulfonyl, benzylthio, methyl(pyridin-2-yl)amino]sulfonyl, (1H-indol-1-yl)sulfonyl, (pyrrolidin-1-yl)sulfonyl, (2-methylpyrrolidin-1-yl)sulfonyl, (morpholin-4-yl)sulfonyl, (piperidin-1-yl)sulfonyl, (methoxy-1H-indol-1-yl)sulfonyl, {methyl[(1R)-1-phenylethyl]amino} sulfonyl, {methyl[(1S)-1-phenylethyl]amino} sulfonyl, [(2-aminophenyl)(methyl)amino]sulfonyl, (dipropylamino)sulfonyl, benzylsulfanyl, (dipropylamino)sulfanyl, (dipropylamino)sulfinyl, [4-chloro(methyl)anilino]sulfonyl, (phenylthio)methyl, benzyloxy, 3-(ethylthio), (pyridin-4-ylmethyl)thio, phenoxy, phenylthio, (pyridin-4-ylmethyl)thio, benzylthio, (1-phenylethyl)thio, cyclopentylthio, cyclopentylsulfinyl, benzoyl, hydroxy(phenyl)methyl, (methoxyimino)(phenyl)methyl, (hydroxyimino)(phenyl)methyl, cyclopentylcarbonyl, benzoylamino, furoylamino, (thien-2-ylacetyl)amino, (mesitylcarbonyl)amino, (1,3-benzodioxol-5-ylcarbonyl)amino, 3-(2,4-dimethoxybenzoyl)amino, (phenylthio)acetylamino, (anilino)carbonyl)amino, (2,4-difluorophenyl)amino carbonylamino, (3-cyanophenyl)aminocarbonylamino, (3-acetylphenyl)aminocarbonylamino, - (trifluoromethoxy)phenylsulfonylamino, (thien-2-ylacetyl)amino, (5-nitro-2-furoyl)amino, (5-chloro-2-methoxyphenyl)aminocarbonylamino, (4-phenoxyphenyl)aminocarbonylamino, (4-acetylphenyl)aminocarbonylamino, phenylethynyl, 2-phenylethyl, 4-Chlorophenyl, benzyloxy, phenoxy, alkylthio, phenyl, dihalophenyl, amino, acetylamino, benzoylamino, phenylacetylamino, methylsulfonylamino, phenylsulfonylamino, benzylsulfonylamino, benzyloxy, hydroxy, 3-phenoxypropoxy, (2,3-dihydro-1,4-benzodioxin-2-yl)methoxy, cyclobutylmethoxy, (2,2-dimethyl-1,3-dioxolan-4-yl)methoxy, 2,3-dihydroxypropoxy, cyclobutylmethoxy, 2-methoxy-1-methylethoxy, isopropoxy, cyclopropylmethoxy, cyclohexylmethoxy, 2-methoxyethoxy, tetrahydro-2H-pyran-2-yl-methoxy, (oxiran-2-yl)methoxy, 2-hydroxy-3-isopropoxypropoxy, furylmethoxy, pentylmethoxy, phenylacetylamino, Benzoylamino, Acetyloxyacetylamino, cyclopentylcarbonylamino, 6-Chloropyridin-3-ylcarbonylamino, isoxazol-5-ylcarbonylamino, 2,4-difluorobenzoylamino, fluoroacetylamino,

- Acetylamino, 4-Chlorophenylacetylamino, 4-methoxyphenylacetylamino, cyclopentylacetylamino, 3-fluorobenzoylamino, 3-cyanophenylacetylamino, cyclohexylcarbonylamino, propionylamino, 5-methoxy-5-oxopentanoylamino, Butyrylamino, 4-Bromobenzoylamino, 3-phenylpropanoylamino, phenoxyacetylamino,
- 5 3-cyclopentylpropanoylamino, 3-methoxy-3-oxopropanoylamino, 2-ethylhexanoylamino, 3,4-dimethoxyphenylacetylamino, 3,5,5-trimethylhexanoylamino, cyclopropylcarbonylamino, methoxyacetylamino, 3-methylbutanoylamino, pentanoylamino, 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]hept-1-ylcarbonylamino, Chloro(phenyl)acetylamino, Benzyloxyacetylamino, 3-ethoxy-3-oxopropanoylamino,
- 10 1-Adamantylcarbonylamino, hexanoylamino, 2-phenylcyclopropanoylamino, 2-phenylbutanoylamino, heptanoylamino, Acetyloxyphenylacetylamino, thien-2-ylcarbonylamino, 2-methylbutanoylamino, 8-methoxy-8-oxooctanoylamino, 2-ethylbutanoylamino, octanoylamino, cyclobutylcarbonylamino, 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl, Benzylthio, morpholin-4-ylsulfonylbzoylamino, 1H-indol-2-
- 15 ylcabonylamino, 1-methyl-1H-indol-2-ylcarbonylamino, 5-phenylisoxazol-3-ylcarbonylamino, 5-phenylpentanoylamino, 4-phenylbutanoylamino, 4-(4-methoxyphenyl)butanoylamino, 2-Chlorophenylacetylamino, 2,4-dichlorophenylacetylamino, 3,4-dichlorophenylacetylamino, 3-Chlorophenylacetylamino, 3-(trifluoromethyl)phenylacetylamino, 3-
- 20 methylphenylacetylamino, 4-tert-Butylphenylacetylamino, 3-methoxyphenylacetylamino, 2-methoxyphenylacetylamino, 2-methylphenylacetylamino, 4-(trifluoromethyl)phenylacetylamino, 4-isopropylphenylacetylamino, 4-methylphenylacetylamino, 4-fluorophenylacetylamino, 2-(trifluoromethyl)phenylacetylamino, 3-fluorophenylacetylamino,
- 25 phenylthioacetylamino, naphthylacetylamino, naphthyloxyacetylamino, 2-propoxybenzoylamino, tetrahydrofuran-3-ylcarbonylamino, 1-methylcyclopropylcarbonylamino, 4-ethoxyphenylacetylamino, 1-Benzothien-3-ylacetylamino, 1,1'-Biphenyl-4-ylcarbonylamino, 4-Butoxybenzoylamino, 2-(2-phenylethyl)benzoylamino, 1,1'-Biphenyl-2-ylcarbonylamino, 4-
- 30 (ethylthio)benzoylamino, 2-(methylsulfonyl)benzoylamino, 2,6-dichlorophenylacetylamino, 1,1'-Biphenyl-4-ylacetylamino, 1,3-Benzodioxol-5-ylacetylamino, 3,3-dimethylbutanoylamino, thien-2-ylacetylamino, 3-methyl-5-phenylisoxazol-4-ylcarbonylamino, [2-(2-methoxyethoxy)ethoxy]acetylamino, (2-

hydroxybenzoyl)amino, prolylamino, (3-methylisoxazol-5-yl)acetylamino, and 4-Azido-3-iodobenzoylamino.

44. The compound of claim 1, wherein R_6 is H, halo, -CN, NH_2 , NO_2 , methyl, methoxy, $-(CH_2)_2-OH$, morpholinyl, and $-(CH_2)_2-O-CO-CH_3$.

45. A compound selected from
- 5-cyano-2-[(1H-indol-2-ylcarbonyl)amino]benzoic acid;
 - 5-cyano-2-{[(5-methoxy-1H-indol-2-yl)carbonyl]amino} benzoic acid;
 - 2-([5-(benzyloxy)-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 5-cyano-2-{[(1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
 - 2-([6-(benzyloxy)-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 2-([7-chloro-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 5-cyano-2-{[(4-methoxy-1H-indol-2-yl)carbonyl]amino} benzoic acid;
 - 5-bromo-2-{[(1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
 - 2-([6-chloro-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 2-([1-benzyl-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 5-cyano-2-{[(1-ethyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
 - 5-cyano-2-([7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 2-([1-allyl-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 5-cyano-2-([1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 5-cyano-2-([1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 5-cyano-2-([1-pentyl-1H-indol-2-yl]carbonyl)amino} benzoic acid;
 - 2-([1-butyl-1H-indol-2-yl]carbonyl)amino)-5-cyanobenzoic acid;
 - 5-cyano-2-([1-propyl-1H-indol-2-yl]carbonyl)amino} benzoic acid;
 - 5-chloro-2-([1-propyl-1H-indol-2-yl]carbonyl)amino} benzoic acid;
 - 2-([1-butyl-1H-indol-2-yl]carbonyl)amino)-5-chlorobenzoic acid;
 - 5-chloro-2-([1-pentyl-1H-indol-2-yl]carbonyl)amino} benzoic acid;
 - 5-chloro-2-([1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 5-chloro-2-([1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 2-([1-allyl-1H-indol-2-yl]carbonyl)amino)-5-chlorobenzoic acid;
 - 2-([1-allyl-1H-indol-2-yl]carbonyl)amino)-5-bromobenzoic acid;
 - 5-bromo-2-([1-(cyclohexylmethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;
 - 5-bromo-2-([1-(2-methoxyethyl)-1H-indol-2-yl]carbonyl)amino)benzoic acid;

- 5-bromo-2-{{{(1-pentyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-bromo-2-{{{(1-butyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-bromo-2-{{{(1-propyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 2-{{{(1-benzyl-1H-indol-2-yl)carbonyl}amino}-5-chlorobenzoic acid;
 5 2-{{{(1-benzyl-1H-indol-2-yl)carbonyl}amino}-5-bromobenzoic acid;
 5-bromo-2-{{{(1-isopropyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-cyano-2-{{{(1-isopropyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-chloro-2-{{{(1-methyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-chloro-2-{{{(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 10 5-bromo-2-{{{(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-cyano-2-{{{(1-isobutyl-1H-indol-2-yl)carbonyl}amino}benzoic acid;
 5-cyano-2-({{[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 5-chloro-2-({{[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 5-bromo-2-({{[1-(3-phenylpropyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 15 5-chloro-2-({{[7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 5-bromo-2-({{[7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 5-cyano-2-({{[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic acid;
 5-bromo-2-({{[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic
 acid;
 20 5-chloro-2-({{[1-methyl-7-(phenylsulfonyl)-1H-indol-2-yl]carbonyl}amino)benzoic
 acid;
 5-cyano-2-([{7-[(phenylacetyl)amino]-1H-indol-2-yl}carbonyl]amino)benzoic acid;
 2-([{7-(benzoylamino)-1H-indol-2-yl]carbonyl}amino)-5-cyanobenzoic acid;
 2-([{7-([{acetyloxy}acetyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic
 25 acid;
 5-cyano-2-([{7-[(cyclopentylcarbonyl)amino]-1H-indol-2-yl}carbonyl]amino)benzoic
 acid;
 2-([{7-amino-1H-indol-2-yl}carbonyl]amino)-5-cyanobenzoic acid;
 2-([{7-([{6-chloropyridin-3-yl}carbonyl]amino)-1H-indol-2-yl}carbonyl]amino)-5-
 30 cyanobenzoic acid;
 5-cyano-2-([{7-[(isoxazol-5-ylcarbonyl)amino]-1H-indol-2-yl}carbonyl]amino)benzoic
 acid;

- 5-cyano-2-[(7-[(2,4-difluorobenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(fluoroacetyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 2-[(7-(acetyl)amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 5 2-[(7-[(4-chlorophenyl)acetyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(4-methoxyphenyl)acetyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(cyclopentylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 10 5-cyano-2-[(7-[(3-fluorobenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-(propionylamino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 15 5-cyano-2-[(7-[(5-methoxy-5-oxopentanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 2-[(7-(butyrylamino)-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid;
- 2-[(7-[(4-bromobenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(3-phenylpropanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 20 5-cyano-2-[(7-[(phenoxyacetyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(3-cyclopentylpropanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(3-methoxy-3-oxopropanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 25 5-cyano-2-[(7-[(2-ethylhexanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(3,4-dimethoxyphenyl)acetyl]amino)-1H-indol-2-yl]carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(3,5,5-trimethylhexanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 30 5-cyano-2-[(7-[(cyclopropylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(methoxyacetyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;

- 5-cyano-2-[(7-[(3-methylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-(pentanoylamino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]hept-1-yl)carbonyl]amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 2-[(7-[(chloro(phenyl)acetyl]amino)-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 2-[(7-[(benzyloxy)acetyl]amino)-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(3-ethoxy-3-oxopropanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 2-[(7-[(1-adamantylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-(hexanoylamino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(2-phenylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-(heptanoylamino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 2-[(7-[(acetyloxy)(phenyl)acetyl]amino)-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(2-phenylcyclopropyl)carbonyl]amino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(thien-2-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(2-methylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(8-methoxy-8-oxooctanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(2-ethylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-(octanoylamino)-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-[(cyclobutylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-[(7-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1H-indol-2-yl)carbonyl]amino]benzoic acid;

- 2-([7-([2-(benzylthio)-1,3-thiazol-4-yl]carbonyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 5-cyano-2-([7-([3-(morpholin-4-ylsulfonyl)benzoyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 5 5-cyano-2-([7-([1H-indol-2-ylcarbonyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 5-cyano-2-([7-([1-methyl-1H-indol-2-yl]carbonyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 5-cyano-2-([7-([5-phenylisoxazol-3-yl]carbonyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 10 5-cyano-2-([7-([5-phenylpentanoyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 5-cyano-2-([7-([4-phenylbutanoyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 15 5-cyano-2-([7-([4-(4-methoxyphenyl)butanoyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 2-([7-([2-chlorophenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 5-cyano-2-([7-([2,4-dichlorophenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 20 5-cyano-2-([7-([3,4-dichlorophenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 2-([7-([3-chlorophenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 25 5-cyano-2-([7-([3-(trifluoromethyl)phenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 5-cyano-2-([7-([3-methylphenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;
- 2-([7-([4-tert-butylphenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)-5-cyanobenzoic acid;
- 30 5-cyano-2-([7-([3-methoxyphenyl]acetyl]amino)-1H-indol-2-yl]carbonyl]amino)benzoic acid;

- 5-cyano-2-[[[7-[[[2-methoxyphenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[2-methylphenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5 5-cyano-2-[[[7-[[[4-(trifluoromethyl)phenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[4-isopropylphenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 10 5-cyano-2-[[[7-[[[4-methylphenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[4-fluorophenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[2-(trifluoromethyl)phenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 15 5-cyano-2-[[[7-[[[3-fluorophenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[phenylthio]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[2-naphthylacetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 20 5-cyano-2-[[[7-[[[1-naphthylacetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[2-naphthyloxy]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[2-propoxybenzoyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 25 5-cyano-2-[[[7-[[[tetrahydrofuran-3-ylcarbonyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[1-methylcyclopropyl]carbonyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-[[[7-[[[4-ethoxyphenyl]acetyl]amino]-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 30 2-[[[7-[[[1-benzothien-3-ylacetyl]amino]-1H-indol-2-yl]carbonyl]amino]-5-cyanobenzoic acid;

- 2-[(7-[(1,1'-biphenyl-4-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 2-[(7-[(4-butoxybenzoyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5 5-cyano-2-[(7-[(2-(2-phenylethyl)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 2-[(7-[(1,1'-biphenyl-2-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(4-(ethylthio)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 10 acid;
- 5-cyano-2-[(7-[(2-(methylsulfonyl)benzoyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 5-cyano-2-[(7-[(2,6-dichlorophenyl)acetyl]amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 15 2-[(7-[(1,1'-biphenyl-4-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 2-[(7-[(1,3-benzodioxol-5-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
- 5-cyano-2-[(7-[(3,3-dimethylbutanoyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 20 acid;
- 5-cyano-2-[(7-[(thien-2-ylacetyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 5-cyano-2-[(7-[(3-methyl-5-phenylisoxazol-4-yl)carbonyl]amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 5-cyano-2-[(7-[(2-(2-methoxyethoxy)ethoxy)acetyl]amino)-1H-indol-2-yl]carbonyl}amino}benzoic acid;
- 25 acid;
- 5-cyano-2-[(7-[(2-hydroxybenzoyl)amino]-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 5-cyano-2-[(7-[(4-(trifluoromethoxy)phenyl)sulfonyl]amino)-1H-indol-2-yl]carbonyl}amino}benzoic acid;
- 30 5-cyano-2-[(7-(proplylamino)-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 5-cyano-2-[(7-[(3-methylisoxazol-5-yl)acetyl]amino)-1H-indol-2-yl)carbonyl]amino}benzoic acid;
- 2-[(7-[(benzylsulfonyl)amino]-1H-indol-2-yl)carbonyl]amino]-5-cyanobenzoic acid;

- 5-cyano-2-{{{(1-methyl-7-{{[3-(morpholin-4-ylsulfonyl)benzoyl]amino}-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 5-cyano-2-{{{(7-{{[(4-fluorophenyl)acetyl]amino}-1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 5 5-cyano-2-[[{(7-[(fluoroacetyl)amino]-1-methyl-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-{{{(1-methyl-7-{{[(1-methyl-1H-indol-2-yl)carbonyl]amino}-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 2-([[(6-(benzyloxy)-1-methyl-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid;
- 10 5-cyano-2-[[{(6-methoxy-1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 5-cyano-2-[[{(1-methyl-7-[(morpholin-4-ylcarbonyl)amino]-1H-indol-2-yl)carbonyl]amino]benzoic acid;
- 5-cyano-2-([[(1-methyl-7-([[(tetrahydrofuran-2-ylmethyl)amino]carbonyl]amino)-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 15 5-cyano-2-[[{(7-hydroxy-1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 2-[[{(7-[[[(benzylamino)carbonyl]amino]-1-methyl-1H-indol-2-yl)carbonyl]amino}-5-cyanobenzoic acid;
- 5-cyano-2-([[(7-([[(2,3-dihydroxypropyl)amino]carbonyl]amino)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 20 1-[[[(2-[[[(2-carboxy-4-cyanophenyl)amino]carbonyl]-1-methyl-1H-indol-7-yl)amino]carbonyl](methyl)amino]-1-deoxyhexitol;
- 5-cyano-2-([[(7-(2,3-dihydro-1,4-benzodioxin-2-ylmethoxy)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 2-([[(7-(benzyloxy)-1H-indol-2-yl)carbonyl]amino)-5-cyanobenzoic acid;
- 25 5-cyano-2-([[(1-methyl-7-(3-phenoxypropoxy)-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 5-cyano-2-([[(7-(cyclobutylmethoxy)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 5-cyano-2-([[(7-(2-furylmethoxy)-1-methyl-1H-indol-2-yl)carbonyl]amino)benzoic acid;
- 30 acid;
- 5-cyano-2-[[{(7-[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;

- 5-cyano-2-({[(7-({[(2R)-2,3-dihydroxypropyl]oxy})-1-methyl-1H-indol-2-yl]carbonyl]amino} benzoic acid;
- 5-cyano-2-({[7-(cyclobutyloxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[7-(2-methoxy-1-methylethoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[(7-isopropoxy-1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 2-({[7-(benzyloxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)-5-cyanobenzoic acid;
- 2-({[(6-sec-butoxy-1-methyl-1H-indol-2-yl)carbonyl]amino} -5-cyanobenzoic acid;
- 2-({[(6-butoxy-1-methyl-1H-indol-2-yl)carbonyl]amino} -5-cyanobenzoic acid;
- 5-cyano-2-({[7-(cyclohexylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[7-(cyclopropylmethoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[1-methyl-7-(tetrahydro-2H-pyran-2-ylmethoxy)-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[1-methyl-7-(pentyloxy)-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[7-(2-methoxyethoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-({[7-(2-hydroxy-3-isopropoxypropoxy)-1-methyl-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-cyano-2-([({1-methyl-7-[2-(methylthio)ethoxy]-1H-indol-2-yl} carbonyl)amino]benzoic acid;
- 2-([({7-[(4-azido-3-iodobenzoyl)amino]-1-methyl-1H-indol-2-yl} carbonyl)amino]-5-cyanobenzoic acid;
- 5-cyano-2-([({7-[(3-cyanobenzoyl)amino]-1H-indol-2-yl} carbonyl)amino]benzoic acid;
- 5-cyano-2-([({1-methyl-6-[2-(trifluoromethyl)phenyl]-1H-indol-2-yl} carbonyl)amino]benzoic acid;
- 5-cyano-2-([({1-methyl-6-(2,3,4-trimethoxyphenyl)-1H-indol-2-yl]carbonyl} amino)benzoic acid;
- 5-iodo-2-([({1-methyl-1H-indol-2-yl)carbonyl]amino} benzoic acid;
- 2-([4-(benzylsulfanyl)-2-pyridinyl]carbonyl} amino)-5-bromobenzoic acid;
- 2-([6-(benzylsulfanyl)-2-pyridinyl]carbonyl} amino)-5-bromobenzoic acid;
- 5-bromo-2-([3-chloro-5-(trifluoromethyl)-2-pyridinyl]carbonyl} amino)benzoic acid;

- 5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzoic acid;
5-bromo-2-[[[(5-butylpyridin-2-yl)carbonyl]amino]benzoic acid;
5-bromo-2-[(quinolin-2-ylcarbonyl)amino]benzoic acid;
5-bromo-2-[[[(6-bromopyridin-2-yl)carbonyl]amino]benzoic acid;
5 2-[[[(3-benzoylpyridin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
2-[[[(6-bromopyridin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
5-cyano-2-[(pyridin-2-ylcarbonyl)amino]benzoic acid;
5-cyano-2-[(quinolin-2-ylcarbonyl)amino]benzoic acid;
5-cyano-2-[[[(2-phenylfuro[2,3-c]pyridin-5-yl)carbonyl]amino]benzoic acid;
10 5-cyano-2-[[[(3-methylfuro[2,3-c]pyridin-5-yl)carbonyl]amino]benzoic acid;
2-[[[(4-(benzyloxy)pyridin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
5-bromo-2-[[[(4-chloro-1-oxidopyridin-2-yl)carbonyl]amino]benzoic acid;
2-[[[(4-(benzyloxy)pyridin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
2-[[[(4-(benzyloxy)-1-oxidopyridin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
15 2-[[[(4-(benzylthio)-1-oxidopyridin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
5-cyano-2-[(isoquinolin-3-ylcarbonyl)amino]benzoic acid;
5-bromo-2-[(quinoxalin-2-ylcarbonyl)amino]benzoic acid;
5-bromo-2-[[[(5-methylpyrazin-2-yl)carbonyl]amino]benzoic acid;
5-cyano-2-[(pyrazin-2-ylcarbonyl)amino]benzoic acid;
20 2-[[[(5-(benzylthio)pyrazin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
2-[[[(5-(benzylthio)pyrazin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
2-[[[(6-(benzylthio)pyrazin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
2-[[[(6-(benzylthio)pyrazin-2-yl)carbonyl]amino]-5-bromobenzoic acid;
2-[[[(5-(butylthio)pyrazin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
25 5-bromo-2-[[[(5-(sec-butylthio)pyrazin-2-yl)carbonyl]amino]benzoic acid;
5-bromo-2-[[[(5-(butylthio)pyrazin-2-yl)carbonyl]amino]benzoic acid;
2-[[[(5-(butylthio)pyrazin-2-yl)carbonyl]amino]-5-chlorobenzoic acid;
5-bromo-2-[[[(5-(pentylthio)pyrazin-2-yl)carbonyl]amino]benzoic acid;
5-bromo-2-[[[(5-(hexylthio)pyrazin-2-yl)carbonyl]amino]benzoic acid;
30 2-[[[(5-(sec-butylthio)pyrazin-2-yl)carbonyl]amino]-5-cyanobenzoic acid;
5-cyano-2-[[[(5-(pentylthio)pyrazin-2-yl)carbonyl]amino]benzoic acid;
5-cyano-2-[[[(5-[[3-(2-methoxyethoxy)propyl]thio]pyrazin-2-yl)carbonyl]amino]benzoic acid;

- 5-chloro-2-({[5-(pentylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(hexylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-chloro-2-({[5-(hexylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 2-({[5-(sec-butylthio)pyrazin-2-yl]carbonyl} amino)-5-chlorobenzoic acid;
 5 5-bromo-2-({[5-(methoxypyrazin-2-yl)carbonyl] amino} benzoic acid;
 5-cyano-2-({[5-(2-phenylethyl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-bromo-2-({[5-({(E)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethenyl} pyrazin-2-yl)carbonyl] amino} benzoic acid;
 5-cyano-2-({[5-(isopentylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 10 5-cyano-2-({[5-(isobutylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(methoxypyrazin-2-yl)carbonyl] amino} benzoic acid;
 5-cyano-2-({[5-(hexyloxy)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-[2-(trifluoromethyl)phenyl]pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-[(4-methoxybenzyl)thio]pyrazin-2-yl]carbonyl} amino)benzoic acid;
 15 5-cyano-2-({[5-(2-fluorophenyl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-bromo-2-({[5-({(E)-2-[(2S)-1,4-dioxaspiro[4.5]dec-2-yl]ethenyl} pyrazin-2-yl)carbonyl] amino} benzoic acid;
 5-cyano-2-({[5-(2-methylphenyl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(2,3,4-trimethoxyphenyl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 20 5-cyano-2-({[5-(nonylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(octylthio)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(6-methoxypyridin-3-yl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[5-(phenylpyrazin-2-yl)carbonyl] amino} benzoic acid;
 5-cyano-2-({[5-[4-(methylsulfonyl)phenyl]pyrazin-2-yl]carbonyl} amino)benzoic acid;
 25 5-cyano-2-({[5-(3,5-dimethylisoxazol-4-yl)pyrazin-2-yl]carbonyl} amino)benzoic acid;
 5-cyano-2-({[6-(hexylthio)pyridazin-3-yl]carbonyl} amino)benzoic acid; and
 5-cyano-2-({[6-[2-(trifluoromethyl)phenyl]pyridazin-3-yl]carbonyl} amino)benzoic acid.
- 30 46. A method for the sanitizing or disinfecting including administering an effective amount of the antimicrobial compoundsof claim 1.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/82 C07D209/42 C07D405/12 C07D413/12 C07D401/12
 C07D409/12 C07D417/12 C07D471/04 C07D231/14 A61P31/00
 A61K31/415 A61K31/44 A61K31/4745 C07D261/20 C07D413/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 135 927 A (TOEPFL WERNER ET AL) 4 August 1992 (1992-08-04) compound 3.077 claims	1,46
A	US 5 463 122 A (ELSLAGER EDWARD F ET AL) 31 October 1995 (1995-10-31) the whole document	1,46
X	GB 1 595 467 A (HOECHST AG) 12 August 1981 (1981-08-12) page 3, line 45; claims; table 1	1
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

3 December 2003

Date of mailing of the international search report

12/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D261/08 C07D261/10 C07D241/24 C07D333/38 C07D487/08
C07D495/04 C07D277/68 C07D279/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.-M.BASTIAN ET AL.: "4H-Benzo'4,5!cyclohepta'1,2-b!thiphen" HELVETICA CHIMICA ACTA., vol. 49, no. 26, 1966, pages 214-234, XP002263672 VERLAG HELVETICA CHIMICA ACTA. BASEL., CH ISSN: 0018-019X page 216, compounds VI --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

3 December 2003

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HOLLA, B. SHIVARAMA ET AL: "Studies in biheterocycles: part III. Nitration of 2-(2'furyl)indole and 2-(2'-thienyl)indole" retrieved from STN Database accession no. 89:108924 XP002263673 CAS RN 67446-35-9 abstract & INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY (1978), 16B(3), 240-1 ,</p>	1
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HISANO, TAKUZO ET AL: "A convenient method for synthesis of 4(3H)-quinazolinones" retrieved from STN Database accession no. 84:121768 XP002263674 CAS RN 58668-50-1 abstract & ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL (1975), 7(6), 271-5 ,</p>	1
X	<p>GB 1 084 448 A (SANDOZ LTD) 20 September 1967 (1967-09-20) page 3, column 2, line 55 page 5, column 1, line 1</p>	1
X	<p>DATABASE CHEMCATS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002263675 Order Numbers: VIT019201, VIT010162, VIT008257, VIT007179, VIT005167 & , VITAS-M , CENTRE OF MOLECULAR MEDICINE, ROOM 208, LABORATORY BUILDING "B", MOSCOW, 1192829, RUSSIA</p>	1

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 46 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5135927	A	04-08-1992	AT 82275 T	15-11-1992
			AU 610553 B2	23-05-1991
			AU 1097488 A	04-08-1988
			BR 8800374 A	20-09-1988
			CA 1338418 C	25-06-1996
			DE 3875750 D1	17-12-1992
			EP 0279239 A1	24-08-1988
			ES 2052612 T3	16-07-1994
			IL 85236 A	01-12-1992
			JP 2764265 B2	11-06-1998
			JP 63201178 A	19-08-1988
			KR 9509517 B1	23-08-1995
			US 4992434 A	12-02-1991
			ZA 8800635 A	25-07-1990
US 5463122	A	31-10-1995	AU 710806 B2	30-09-1999
			AU 3008795 A	04-03-1996
			BG 63301 B1	28-09-2001
			BG 101189 A	31-03-1998
			BR 1100148 A3	18-07-2000
			CA 2193845 A1	15-02-1996
			CZ 9700262 A3	17-06-1998
			EP 0775110 A1	28-05-1997
			FI 970417 A	31-01-1997
			HR 950429 A1	30-04-1997
			HU 77653 A2	28-07-1998
			JP 10504292 T	28-04-1998
			MD 970135 A	31-03-1999
			NO 970495 A	02-04-1997
			NZ 300073 A	29-07-1999
			OA 10467 A	05-04-2002
			PL 318540 A1	23-06-1997
			RU 2156236 C2	20-09-2000
			SK 15497 A3	14-01-1998
			TJ 285 B	13-12-2000
			WO 9604242 A1	15-02-1996
			US 5668178 A	16-09-1997
			US 5734081 A	31-03-1998
			US 5668291 A	16-09-1997
			US 5929114 A	27-07-1999
			ZA 9506551 A	25-03-1996
GB 1595467	A	12-08-1981	DE 2655094 A1	15-06-1978
			AT 362788 B	10-06-1981
			AT 866277 A	15-11-1980
			BE 861502 A4	05-06-1978
			CA 1094564 A1	27-01-1981
			CH 614945 A5	28-12-1979
			DK 538577 A	05-06-1978
			ES 464553 A2	01-08-1979
			FR 2372813 A2	30-06-1978
			IE 46102 B1	23-02-1983
			IT 1113801 B	27-01-1986
			JP 53071069 A	24-06-1978
			LU 78626 A1	11-07-1978
			NL 7713148 A	06-06-1978
GB 1084448	A	20-09-1967	CH 477471 A	31-08-1969

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1084448	A	CH 448129 A	15-12-1967
		AT 246130 B	12-04-1966
		AT 247315 B	10-06-1966
		BE 657366 A	18-06-1965
		BE 657367 A	18-06-1965
		DE 1238923 B	20-04-1967
		DK 107488 C	05-06-1967
		FR 4225 M	
		FR 4344 M	
		FR 1430945 A	11-03-1966
		FR 1417838 A	12-11-1965
		GB 1084450 A	20-09-1967
		IL 22640 A	22-08-1968
		LU 47609 A1	18-06-1965
		MC 510 A	27-08-1965
		NL 6414603 A	21-06-1965
		NL 6414607 A	21-06-1965
		NO 115584 B	28-10-1968
		OA 1345 A	15-02-1969
		SE 332178 B	01-02-1971
		SE 323969 B	19-05-1970
		US 3465003 A	02-09-1969
